{"PMC7476647": [["Unmittelbar nach Anamnese und k\u00f6rperlicher Untersuchung durchgef\u00fchrt, erm\u00f6glicht sie auch bei Patienten mit kardiorespiratorischen Erkrankungen fr\u00fchzeitig Entscheidungen \u00fcber weitere diagnostische und erste therapeutisch notwendige Ma\u00dfnahmen [1, 2].EinleitungSo \u00fcberrascht es nicht, dass auch im Rahmen der aktuellen COVID-19-Pandemie bereits zahlreiche Studien und Erfahrungsberichte \u00fcber Anwendung, Befunde und Stellenwert der Lungensonographie (LUS) bei Patienten mit dieser neuen Infektionskrankheit publiziert wurden [3\u201314].EinleitungZiel dieses \u00dcbersichtsartikels ist die Pr\u00e4sentation typischer Ultraschallbefunde dieser Infektionskrankheit und die Diskussion ihres klinischen Stellenwerts.Grundlagen der LungensonographieAufgrund des Rippenthorax k\u00f6nnen nur ca.", [["EinleitungSo \u00fcberrascht es nicht, dass auch im Rahmen der aktuellen COVID-19-Pandemie bereits zahlreiche Studien und Erfahrungsberichte \u00fcber Anwendung, Befunde und Stellenwert der Lungensonographie (LUS) bei Patienten mit dieser neuen Infektionskrankheit publiziert wurden", "SPECIES", 249, 521], ["EinleitungZiel dieses \u00dcbersichtsartikels ist die Pr\u00e4sentation typischer Ultraschallbefunde dieser Infektionskrankheit und die Diskussion ihres klinischen", "SPECIES", 529, 682], ["COVID", "TEST", 317, 322], ["EinleitungZiel", "TREATMENT", 529, 543]]], ["Durch die Luftf\u00fcllung der gesunden Lunge kommt es an der Lungenoberfl\u00e4che zu einer Totalreflexion der Schallwellen mit Entstehung von Reverberationsartefakten, sog.", [["sog", "ANATOMY", 160, 163]]], ["Zu den darstellbaren Befunden geh\u00f6ren nach Mathis [15]:Extrapulmonale Befunde (Pleuraerguss, Pleuraempyem, H\u00e4matothorax, pleurale Tumoren)PneumothoraxVer\u00e4nderungen an der Pleura visceralis und parietalis und subpleurale Ver\u00e4nderungen (Pleuritis)Konsolidierungen (Lungenembolie, Pneumonien, Tumoren)Ver\u00e4nderungen des Lungeninterstitiums (deutliche Zunahme sog.", [["Pleura visceralis", "SPECIES", 171, 188], ["Extrapulmonale Befunde (Pleuraerguss", "TREATMENT", 55, 91], ["Pleuraempyem", "TREATMENT", 93, 105], ["H\u00e4matothorax", "TREATMENT", 107, 119], ["pleurale Tumoren", "TREATMENT", 121, 137], ["Pneumothorax", "PROBLEM", 138, 150], ["an der Pleura visceralis", "TEST", 164, 188], ["Ver\u00e4nderungen (Pleuritis", "PROBLEM", 220, 244], ["Konsolidierungen (Lungenembolie", "TREATMENT", 245, 276], ["Pneumonien", "TREATMENT", 278, 288], ["Tumoren", "TREATMENT", 290, 297], ["Ver\u00e4nderungen des", "TREATMENT", 298, 315], ["Pneumothorax", "OBSERVATION", 138, 150], ["Pleura", "ANATOMY", 171, 177], ["Pleuritis", "OBSERVATION", 235, 244]]], ["B\u2011Linien) undVer\u00e4nderungen der Thoraxwand.Histopathologische Befunde bei\u00a0COVID-19Pathologisch werden bei COVID-19-Pneumonien ein interstitielles \u00d6dem, interstitielle entz\u00fcndliche Infiltrate und gegebenenfalls auch ein intraalveol\u00e4res proteinreiches Exsudat beschrieben.", [["Histopathologische Befunde bei\u00a0COVID-19Pathologisch werden bei COVID-19-Pneumonien ein interstitielles \u00d6dem, interstitielle entz\u00fcndliche Infiltrate und gegebenenfalls auch ein intraalveol\u00e4res proteinreiches Exsudat beschrieben", "SPECIES", 42, 268], ["Histopathologische", "TEST", 42, 60], ["COVID", "TEST", 73, 78], ["bei COVID", "TEST", 101, 110], ["interstitielle entz\u00fcndliche Infiltrate", "PROBLEM", 151, 189], ["Infiltrate", "OBSERVATION", 179, 189]]], ["Je nach Schwere der Erkrankung finden sich segmentale pneumonische Infiltrate bis hin zum diffusen Alveolarschaden mit hyalinen Membranen bei vorliegendem ARDS [16\u201324].", [["ARDS", "DISEASE", 155, 159], ["Infiltrate bis hin zum diffusen", "PROBLEM", 67, 98], ["Alveolarschaden", "PROBLEM", 99, 114], ["ARDS", "PROBLEM", 155, 159]]], ["Weiterhin fallen makroskopisch plaqueartige Ver\u00e4nderungen auf der Pleura visceralis auf und selten eine fettige Proliferation derselben [25].Untersuchungstechnik und protektive Hygienema\u00dfnahmenDie Ultraschalluntersuchung der Lunge wird \u00fcblicherweise mit multifrequenten Konvex- und Linearschallk\u00f6pfen durchgef\u00fchrt.", [["Pleura visceralis auf und selten eine fettige Proliferation derselben", "SPECIES", 66, 135], ["Untersuchungstechnik und protektive Hygienema\u00dfnahmenDie Ultraschalluntersuchung der Lunge wird \u00fcblicherweise mit multifrequenten Konvex- und Linearschallk\u00f6pfen durchgef\u00fchrt", "SPECIES", 141, 313], ["Weiterhin fallen makroskopisch plaqueartige", "TREATMENT", 0, 43], ["Untersuchungstechnik", "TREATMENT", 141, 161], ["Pleura", "ANATOMY", 66, 72]]], ["W\u00e4hrend sich mit Konvexschallk\u00f6pfen sehr gut interstitielle Ver\u00e4nderungen (s. unten) und pneumonische Infiltrate darstellen lassen, k\u00f6nnen mit hochfrequenten Linearschallk\u00f6pfen sehr gut die Pleura und die subpleurale Lunge untersucht werden.", [["W\u00e4hrend sich mit Konvexschallk\u00f6pfen sehr gut interstitielle Ver\u00e4nderungen (s. unten) und pneumonische Infiltrate darstellen lassen, k\u00f6nnen mit hochfrequenten Linearschallk\u00f6pfen sehr gut die Pleura und die subpleurale Lunge untersucht werden", "SPECIES", 0, 240], ["Infiltrate", "PROBLEM", 102, 112], ["Infiltrate", "OBSERVATION", 102, 112], ["Pleura", "ANATOMY", 190, 196], ["Lunge", "ANATOMY", 217, 222]]], ["Diese hochaufl\u00f6sende Darstellung der Pleura ist technisch in vergleichbarer Aufl\u00f6sung und Qualit\u00e4t mit keinem anderen bildgebenden Verfahren m\u00f6glich.", [["Diese hochaufl\u00f6sende Darstellung der Pleura ist technisch in vergleichbarer Aufl\u00f6sung und Qualit\u00e4t mit keinem anderen bildgebenden Verfahren m\u00f6glich", "SPECIES", 0, 148], ["Pleura", "ANATOMY", 37, 43]]], ["Sofern ein anderes Preset verwendet wird, k\u00f6nnen mit Sektorschallk\u00f6pfen auch gr\u00f6\u00dfere pneumonische Infiltrate und ein interstitielles Syndrom dargestellt werden, die Darstellung kleiner (sub-)pleuraler Ver\u00e4nderungen ist mit Sektorschallk\u00f6pfen nicht m\u00f6glich.", [["Sofern ein anderes Preset verwendet wird, k\u00f6nnen mit Sektorschallk\u00f6pfen auch gr\u00f6\u00dfere pneumonische Infiltrate und ein interstitielles Syndrom dargestellt werden, die Darstellung kleiner (sub-)pleuraler Ver\u00e4nderungen ist mit Sektorschallk\u00f6pfen nicht m\u00f6glich", "SPECIES", 0, 255], ["Infiltrate", "PROBLEM", 98, 108], ["Syndrom", "PROBLEM", 133, 140], ["Infiltrate", "OBSERVATION", 98, 108]]], ["In der Praxis empfiehlt es sich, die Untersuchung mit dem Konvexschallkopf (alternativ Sektorschallkopf) zu beginnen und dann auf den Linearschallkopf zu wechseln.", [["Untersuchung mit dem Konvexschallkopf (alternativ Sektorschallkopf) zu beginnen und dann auf den Linearschallkopf zu wechseln", "SPECIES", 37, 162], ["mit dem Konvexschallkopf (alternativ Sektorschallkopf)", "TREATMENT", 50, 104]]], ["Der Farbdoppler kann hilfreich sein bei der Darstellung pulmonal- bzw. bronchialarterieller Gef\u00e4\u00dfe in kleinen Konsolidierungen und kann dann eine Differenzierung zwischen Lungeninfarkten und entz\u00fcndlichen Infiltraten erm\u00f6glichen.", [["Gef\u00e4\u00dfe", "SIMPLE_CHEMICAL", 92, 98], ["Der Farbdoppler kann hilfreich sein bei der Darstellung pulmonal- bzw", "SPECIES", 0, 69], ["bronchialarterieller", "SPECIES", 71, 91], ["Der Farbdoppler", "TEST", 0, 15], ["Gef\u00e4\u00dfe", "TREATMENT", 92, 98], ["kleinen Konsolidierungen", "TREATMENT", 102, 126]]], ["Vor- und Nachteile der verschiedenen Schallk\u00f6pfe bei Anwendung zur Lungensonographie zeigt Tab.", [["Vor", "TEST", 0, 3]]], ["1.Untersuchungstechnik und protektive Hygienema\u00dfnahmenDie deutschsprachigen Ultraschallfachgesellschaften sind \u00fcbereingekommen, den menschlichen Thorax auf jeder Seite in 6 Regionen einzuteilen (Abb.", [["Untersuchungstechnik", "TREATMENT", 2, 22], ["Thorax", "ANATOMY", 145, 151]]], ["Zur besseren Darstellung der Lunge sollte der Patient die Arme \u00fcber den Kopf nehmen (Spreizen der Rippen), die Scapula kann durch Ergreifen der gegen\u00fcberliegenden Schulter \u201eherausgedreht\u201c werden.", [["Kopf nehmen (Spreizen der Rippen)", "TREATMENT", 72, 105], ["Scapula", "ANATOMY", 111, 118]]], ["Ventral und lateral kann sehr gut in R\u00fcckenlage untersucht werden, die Untersuchung der dorsalen Lunge gelingt am besten im Sitzen, weil so auch kleine Pleuraerg\u00fcsse sicher detektiert werden k\u00f6nnen.", [["Ventral und lateral kann sehr", "TREATMENT", 0, 29]]], ["Die vollst\u00e4ndige Lungensonographie dauert bei entsprechender Expertise 5\u201315 min [10].Untersuchungstechnik und protektive Hygienema\u00dfnahmenDa es sich bei der Sonografie um eine patientennahe Untersuchung handelt, muss der Untersucher bei Covid-19-Verdacht umfangreiche Schutzma\u00dfnahmen (mindestens Kopfhaube, Schutzbrille und -kittel, 2 Paar Einmalhandschuhe) ergreifen.", [["Untersuchungstechnik und protektive Hygienema\u00dfnahmenDa es sich bei der Sonografie um eine patientennahe Untersuchung handelt, muss der Untersucher bei Covid-19-Verdacht umfangreiche Schutzma\u00dfnahmen (mindestens Kopfhaube, Schutzbrille und -kittel", "SPECIES", 85, 330], ["Untersuchungstechnik und protektive Hygienema\u00dfnahmenDa", "TREATMENT", 85, 139], ["Covid", "TEST", 236, 241]]], ["Zus\u00e4tzlich sollte der Patient einen Mund-Nasen-Schutz tragen.", [["Zus\u00e4tzlich sollte der Patient einen Mund-Nasen-Schutz tragen", "SPECIES", 0, 60]]], ["Bei Smartphone\u2011/Tablet-basierten Ger\u00e4ten muss darauf geachtet werden, dass deren Displays durch die notwendige Reinigung mit viruziden T\u00fcchern keinen Schaden nehmen.Ultraschallbefunde bei SARS-CoV-2-InfektionDie sonographisch darstellbaren Befunde werden in 3 Kategorien eingeteilt:Ver\u00e4nderungen der Pleura visceralisDurch eine entz\u00fcndliche Alteration der Pleura und der subpleuralen Lunge erscheint die Oberfl\u00e4chenkontur der Pleura visceralis unregelm\u00e4\u00dfig und wirkt kurzstreckig unterbrochen bzw. \u201efragmentiert\u201c.", [["Bei Smartphone\u2011/Tablet-basierten Ger\u00e4ten muss darauf geachtet werden, dass deren Displays durch die notwendige Reinigung mit viruziden T\u00fcchern keinen Schaden nehmen", "SPECIES", 0, 164], ["Ultraschallbefunde bei SARS-CoV", "SPECIES", 165, 196], ["Die sonographisch darstellbaren", "SPECIES", 208, 239], ["Bei Smartphone\u2011", "TREATMENT", 0, 15], ["basierten", "TREATMENT", 23, 32], ["Ultraschallbefunde bei SARS", "TEST", 165, 192], ["CoV", "TEST", 193, 196], ["Ver\u00e4nderungen der Pleura visceralisDurch eine entz\u00fcndliche Alteration der Pleura und der subpleuralen Lunge erscheint", "TREATMENT", 282, 399], ["Pleura", "ANATOMY", 300, 306], ["Pleura", "ANATOMY", 356, 362], ["Pleura", "ANATOMY", 426, 432]]], ["Die gegen\u00fcberliegende Pleura parietalis kann ebenfalls verdickt imponieren.", [["Pleura", "ANATOMY", 22, 28]]], ["Dar\u00fcber hinaus findet sich wenig, ggf. gefangener Pleuraerguss (Abb.", [["ggf", "GENE_OR_GENE_PRODUCT", 34, 37], ["Abb", "GENE_OR_GENE_PRODUCT", 64, 67], ["ggf", "PROTEIN", 34, 37], ["Dar\u00fcber hinaus", "SPECIES", 0, 14]]], ["Gr\u00f6\u00dfere Pleuraerg\u00fcsse sind bei COVID-19 sehr selten und m\u00fcssen den Untersucher an andere Differenzialdiagnosen denken lassen.KonsolidierungenDie entz\u00fcndliche, pneumonische Infiltration der Lunge mit fl\u00fcssigkeitsgef\u00fcllten Alveolen f\u00fchrt zu einem solide, bisweilen leber\u00e4hnlich imponierenden Lungenparenchym.", [["Gr\u00f6\u00dfere Pleuraerg\u00fcsse sind bei COVID-19 sehr selten und m\u00fcssen den Untersucher an andere Differenzialdiagnosen denken lassen", "SPECIES", 0, 124], ["KonsolidierungenDie entz\u00fcndliche", "TREATMENT", 125, 157], ["pneumonische Infiltration", "PROBLEM", 159, 184], ["Infiltration", "OBSERVATION", 172, 184]]], ["Bisweilen findet sich im zuf\u00fchrenden Bronchus noch Luft im Sinne eines Bronchoaerogramms (Abb.", [["Bisweilen findet sich im zuf\u00fchrenden Bronchus", "TREATMENT", 0, 45], ["Bronchus", "ANATOMY", 37, 45]]], ["Wichtigste Differenzialdiagnose ist bei kleineren, dreiecksf\u00f6rmigen Konsolidierungen die Lungenembolie.", [["Wichtigste Differenzialdiagnose ist bei kleineren", "SPECIES", 0, 49], ["Wichtigste Differenzialdiagnose ist bei kleineren", "TREATMENT", 0, 49]]], ["W\u00e4hrend sich \u00fcblicherweise sowohl in gro\u00dfen als auch in kleinen pneumonischen Infiltraten farbdopplersonographisch Gef\u00e4\u00dfe darstellen lassen, gibt es erste Hinweise, dass dies m\u00f6glicherweise bei Infiltraten durch COVID-19 seltener der Fall ist [4].Interstitielles SyndromIm fr\u00fchen Stadium zeichnet sich die COVID-19-Pneumonie durch ein interstitielles \u00d6dem mit vermehrtem Nachweis (>3 pro Schallfeld) von sog.", [["gibt es erste Hinweise, dass dies m\u00f6glicherweise bei Infiltraten durch COVID-19 seltener der Fall ist", "SPECIES", 141, 242], ["Stadium zeichnet sich die COVID-19-Pneumonie durch ein interstitielles \u00d6dem mit vermehrtem Nachweis (>3 pro Schallfeld", "SPECIES", 280, 398], ["sich", "PROBLEM", 8, 12], ["Interstitielles", "TEST", 247, 262], ["COVID", "TEST", 306, 311], ["Pneumonie", "PROBLEM", 315, 324]]], ["B\u2011Linien aus.", [["aus", "OBSERVATION", 9, 12]]], ["Bei Zunahme der interstitiellen Ver\u00e4nderungen verschmelzen diese B\u2011Linien und die A\u2011Linien verschwinden vollst\u00e4ndig.", [["Bei Zunahme der interstitiellen Ver\u00e4nderungen verschmelzen diese B\u2011Linien und die A\u2011Linien verschwinden vollst\u00e4ndig", "SPECIES", 0, 115]]], ["Dar\u00fcber hinaus m\u00fcssen zahlreiche Differenzialdiagnosen bedacht werden (Tab.", [["Dar\u00fcber hinaus m\u00fcssen zahlreiche", "TREATMENT", 0, 32]]], ["Lange Zeit wurden die Begriffe \u201eB-Linien\u201c und \u201eKometenschweifartefakte\u201c synonym verwendet.", [["Lange Zeit wurden die Begriffe \u201eB-Linien\u201c und \u201eKometenschweifartefakte\u201c synonym verwendet", "SPECIES", 0, 89]]], ["Heutzutage wird von \u201eB-Linien\u201c im engeren Sinne nur dann gesprochen, wenn diese vertikalen Artefakte an der unauff\u00e4lligen Pleuraoberfl\u00e4chenkontur entstehen.", [["Heutzutage wird von \u201eB-Linien\u201c im engeren Sinne nur dann gesprochen, wenn diese vertikalen Artefakte an der unauff\u00e4lligen Pleuraoberfl\u00e4chenkontur entstehen", "SPECIES", 0, 155]]], ["Entstehen sie an einer morphologisch ver\u00e4nderten Pleura (Konsolidierung oder Pleuritis), wird von Kometenschweifartefakten gesprochen.", [["Pleuritis", "PROBLEM", 77, 86], ["Pleura", "ANATOMY", 49, 55], ["Pleuritis", "OBSERVATION", 77, 86]]], ["Da bei COVID-19 sowohl interstitielle als auch pleurale Ver\u00e4nderungen vorliegen, kommen beide Formen dieser vertikalen Artefakte vor.", [["Da bei COVID", "TEST", 0, 12]]], ["F\u00fcr die bessere Darstellung dieser Artefakte und auch des Lungengleitens an sich ist es vorteilhaft, am Ultraschallger\u00e4t Artefaktunterdr\u00fcckungsmechanismen (z.", [["an sich ist es vorteilhaft", "TREATMENT", 73, 99]]], ["B. \u201eSono-CT\u201c u. a.) und Verfahren des sog. \u201epost-proceeding\u201c auszuschalten.Verteilung der Ver\u00e4nderungenDie darstellbaren Ver\u00e4nderungen finden sich meistens bilateral und oft multifokal.", [["bilateral", "ANATOMY_MODIFIER", 156, 165]]], ["Dabei sind basale, laterale und dorsale Lungenabschnitte h\u00e4ufiger betroffen als ventral und kranial gelegene Areale.DiskussionBei der neuartigen SARS-CoV-2-Infektion wird zwischen einem asymptomatischen, einem milden, einem moderaten, einem schweren und einem kritischen Verlauf unterschieden (Tab.", [["DiskussionBei der neuartigen SARS", "TEST", 116, 149], ["CoV", "TEST", 150, 153], ["Infektion", "PROBLEM", 156, 165]]], ["Als anzuwendendes bildgebendes Verfahren sprechen sich die nordamerikanischen Fachgesellschaften bei moderatem Verlauf f\u00fcr die Durchf\u00fchrung einer R\u00f6ntgen\u00fcbersichtsaufnahme aus, das chinesische National Health Institute \u00e4u\u00dfert sich nicht dazu, welches Verfahren angewendet werden sollte.DiskussionIn diesem Spannungsfeld der Frage, ob und mit welchem Verfahren eine erg\u00e4nzende Bildgebung bei Patienten mit SARS-CoV-2-Infektion sinnvoll ist, bietet sich die Lungensonographie (LUS) als \u201eFortsetzung der klinischen Untersuchung mit technischen Mitteln\u201c [36] an.DiskussionAls zuverl\u00e4ssiges und kosteng\u00fcnstiges bildgebendes Verfahren kann es auch unter Einhaltung strikter Hygienema\u00dfnahmen ubiquit\u00e4r und bettseitig angewendet werden.", [["DiskussionIn diesem Spannungsfeld der Frage, ob und mit welchem Verfahren eine erg\u00e4nzende Bildgebung bei Patienten mit SARS-CoV-2-Infektion sinnvoll ist, bietet sich die Lungensonographie (LUS) als \u201eFortsetzung der klinischen Untersuchung mit technischen", "SPECIES", 286, 540], ["CoV", "TEST", 410, 413], ["Infektion sinnvoll ist", "TREATMENT", 416, 438], ["DiskussionAls zuverl\u00e4ssiges", "TREATMENT", 558, 585]]], ["Dar\u00fcber hinaus kommt der Ultraschall ohne Strahlenbelastung mit der potenziellen Folge lebensbedrohender Krebserkrankungen im Langzeitverlauf aus [37, 38].DiskussionBei Patienten mit positivem PCR-Nachweis f\u00fcr COVID-19 zeigt sich als Ausdruck einer Pneumonie bei mildem bzw. moderatem Verlauf in der Mehrzahl der F\u00e4lle zun\u00e4chst eine deutliche Zunahme von B\u2011Linien an verschiedenen Arealen der Lunge (\u201einterstitielles Syndrom\u201c).", [["DiskussionBei Patienten mit positivem PCR-Nachweis f\u00fcr COVID-19 zeigt sich als Ausdruck einer Pneumonie bei mildem bzw", "SPECIES", 155, 273], ["PCR", "TEST", 193, 196], ["COVID", "TEST", 210, 215], ["moderatem Verlauf in der Mehrzahl der F\u00e4lle zun\u00e4chst eine deutliche", "TREATMENT", 275, 342], ["an verschiedenen Arealen der Lunge (\u201einterstitielles Syndrom", "TREATMENT", 364, 424]]], ["Verschmelzende B\u2011Linien (\u201ewei\u00dfe Lunge\u201c) mit Verschwinden der A\u2011Linien und solide imponierende Infiltrate mit Nachweis eines Bronchoaerogramms sind Ausdruck schwergradiger pneumonischer Ver\u00e4nderungen [4, 7, 8, 11, 39].DiskussionNach eigenen Erfahrungen und ersten Studien zufolge eignet sich damit der LUS in der zentralen Notaufnahme zusammen mit Anamnese, Klinik, Labor und Blutgasanalyse sehr gut zur Einsch\u00e4tzung, welche COVID-19-Patienten ambulant gef\u00fchrt und welche station\u00e4r aufgenommen werden sollten [40].", [["DiskussionNach eigenen Erfahrungen und ersten Studien zufolge eignet sich damit der LUS in der zentralen Notaufnahme zusammen mit Anamnese, Klinik, Labor und Blutgasanalyse sehr gut zur Einsch\u00e4tzung, welche COVID-19-Patienten ambulant gef\u00fchrt und welche station\u00e4r aufgenommen werden sollten", "SPECIES", 217, 507], ["Verschmelzende B\u2011Linien (\u201ewei\u00dfe Lunge\u201c", "TREATMENT", 0, 38], ["mit Verschwinden der A\u2011Linien und solide imponierende", "TREATMENT", 40, 93], ["Infiltrate", "PROBLEM", 94, 104], ["Bronchoaerogramms", "TEST", 124, 141], ["COVID", "TEST", 424, 429]]], ["Damit bietet sich der LUS auch sehr gut zur Kl\u00e4rung der Frage an, ob \u00fcberhaupt eine erg\u00e4nzende Thorax-CT indiziert ist.", [["sich der LUS", "TEST", 13, 25], ["ob", "ANATOMY", 66, 68], ["Thorax", "ANATOMY", 95, 101]]], ["Weiterhin kann die Sonographie auch Hinweise auf wichtige Differenzialdiagnosen wie die Lungenembolie geben und diesen Verdacht nachfolgend mittels Echokardiographie oder Beinvenensonographie best\u00e4tigen.", [["Sonographie auch Hinweise auf wichtige Differenzialdiagnosen wie die Lungenembolie geben und diesen Verdacht nachfolgend mittels Echokardiographie oder Beinvenensonographie best\u00e4tigen", "SPECIES", 19, 202]]], ["Bei Thrombosenachweis er\u00fcbrigt sich dann beispielsweise die erg\u00e4nzende Durchf\u00fchrung einer Angio-CT, da unabh\u00e4ngig von deren Ergebnis eine harte Indikation zur Antikoagulation vorliegt [41].", [["Bei Thrombosenachweis er\u00fcbrigt sich dann beispielsweise die erg\u00e4nzende Durchf\u00fchrung einer Angio-CT, da unabh\u00e4ngig von deren Ergebnis eine harte Indikation zur Antikoagulation vorliegt", "SPECIES", 0, 183], ["Angio", "TEST", 90, 95], ["CT", "TEST", 96, 98]]], ["Sofern bei Patienten mit sonographisch nachgewiesener Lungenembolie/Thrombose gekl\u00e4rt werden sollte, ob m\u00f6glicherweise zus\u00e4tzlich eine COVID-19-Pneumonie vorliegen k\u00f6nnte, ist die Durchf\u00fchrung einer sog.", [["Sofern bei Patienten mit sonographisch nachgewiesener Lungenembolie/Thrombose gekl\u00e4rt werden sollte, ob m\u00f6glicherweise zus\u00e4tzlich eine COVID-19-Pneumonie vorliegen k\u00f6nnte, ist die Durchf\u00fchrung einer sog", "SPECIES", 0, 202], ["Lungenembolie", "TREATMENT", 54, 67], ["Thrombose gekl\u00e4rt", "TREATMENT", 68, 85]]], ["Low-dose-CT ausreichend.Differenzialdiagnosen und Stellenwert im Vergleich mit anderen bildgebenden VerfahrenStudien, in denen zwischen dem Lungenultraschall und der R\u00f6ntgen\u00fcbersichtsaufnahme bei COVID-19 verglichen wurde, gibt es bislang nicht.", [["Differenzialdiagnosen und Stellenwert im Vergleich mit anderen bildgebenden VerfahrenStudien, in denen zwischen dem Lungenultraschall und der R\u00f6ntgen\u00fcbersichtsaufnahme bei COVID-19 verglichen wurde", "SPECIES", 24, 221], ["Differenzialdiagnosen", "TREATMENT", 24, 45], ["COVID", "TEST", 196, 201]]], ["Verglichen mit dem CT werden allerdings gerade bei moderatem Verlauf im R\u00f6ntgenbild viele Infiltrate \u00fcbersehen [42].", [["Verglichen mit dem CT", "TEST", 0, 21], ["Infiltrate", "PROBLEM", 90, 100], ["Infiltrate", "OBSERVATION", 90, 100]]], ["Die Computertomographie zeigt bei COVID-19-Pneumonie dagegen nicht nur typische Befunde einer Viruspneumonie, sondern h\u00e4ufig auch ein f\u00fcr COVID-19 typisches Verteilungsmuster der Ver\u00e4nderungen [43\u201346].", [["Die Computertomographie zeigt bei COVID-19-Pneumonie dagegen nicht nur typische Befunde einer Viruspneumonie, sondern h\u00e4ufig auch ein f\u00fcr COVID-19 typisches Verteilungsmuster der Ver\u00e4nderungen", "SPECIES", 0, 192], ["Die", "TEST", 0, 3], ["Computertomographie", "TEST", 4, 23], ["zeigt", "TEST", 24, 29], ["COVID", "TEST", 34, 39], ["Pneumonie", "PROBLEM", 43, 52], ["Viruspneumonie", "TEST", 94, 108], ["COVID", "TEST", 138, 143]]], ["Retrospektive Vergleichsstudien mit kleinen Fallzahlen zwischen CT und LUS lassen ahnen, dass die Schweregradeinteilung bei COVID-19-Pneumonie in beiden Verfahren gut korreliert (Tab.", [["Vergleichsstudien mit kleinen Fallzahlen zwischen CT und LUS lassen ahnen, dass die Schweregradeinteilung bei COVID-19-Pneumonie in beiden Verfahren gut korreliert", "SPECIES", 14, 177], ["CT", "TEST", 64, 66], ["COVID", "TEST", 124, 129], ["Pneumonie", "TREATMENT", 133, 142]]], ["Da nur 70 % der Lungenoberfl\u00e4che sonographisch darstellbar sind, k\u00f6nnen sonographisch zentrale und apikale Infiltrate nicht detektiert und somit eine pulmonale Manifestation bei bekannter SARS-CoV-2-Infektion auch nicht ausgeschlossen werden.", [["pulmonale", "DISEASE", 150, 159], ["k\u00f6nnen sonographisch zentrale und apikale Infiltrate nicht detektiert und somit eine pulmonale Manifestation bei bekannter SARS-CoV-2-Infektion auch nicht ausgeschlossen werden", "SPECIES", 65, 241], ["Infiltrate", "PROBLEM", 107, 117], ["SARS", "TEST", 188, 192], ["CoV", "TEST", 193, 196], ["Infektion", "PROBLEM", 199, 208]]], ["Allerdings ist bei fehlendem sonographischem Nachweis entsprechender Ver\u00e4nderungen allenfalls von einer milden pulmonalen Manifestation der Erkrankung auszugehen.Differenzialdiagnosen und Stellenwert im Vergleich mit anderen bildgebenden VerfahrenBei Nachweis eines interstitiellen Syndroms sind zahlreiche Differenzialdiagnosen wie eine Herzinsuffizienz und Ur\u00e4mie zu ber\u00fccksichtigen.", [["Differenzialdiagnosen und Stellenwert im Vergleich mit anderen bildgebenden VerfahrenBei Nachweis eines interstitiellen Syndroms sind zahlreiche Differenzialdiagnosen wie eine Herzinsuffizienz und Ur\u00e4mie zu ber\u00fccksichtigen", "SPECIES", 162, 384], ["Allerdings ist bei fehlendem sonographischem", "TREATMENT", 0, 44], ["Differenzialdiagnosen", "TEST", 162, 183], ["VerfahrenBei", "TEST", 238, 250], ["zahlreiche Differenzialdiagnosen", "TREATMENT", 296, 328]]], ["Hier d\u00fcrfen B\u2011Linien und Kometenschweifartefakte allenfalls dann diagnostisch verwendet werden, wenn das Ausma\u00df dieser Ver\u00e4nderungen bei dem Patienten vorbekannt und es zu einer erheblichen Zunahme dieser Ver\u00e4nderungen gekommen ist.", [["Hier d\u00fcrfen B\u2011Linien und Kometenschweifartefakte allenfalls dann diagnostisch verwendet werden, wenn das Ausma\u00df dieser Ver\u00e4nderungen bei dem Patienten vorbekannt und es zu einer erheblichen Zunahme dieser Ver\u00e4nderungen gekommen", "SPECIES", 0, 227]]], ["Auch wenn hierzu aussagef\u00e4hige Vergleichsstudien fehlen, erscheint es naheliegend, dass bei diesen Patienten die Thorax-CT besser in der Lage ist, eine Viruspneumonie zu erkennen.Differenzialdiagnosen und Stellenwert im Vergleich mit anderen bildgebenden VerfahrenFokal lokalisierte pulmonale und pleurale Ver\u00e4nderungen finden sich auch bei Pneumonien und Pleuritiden durch andere Erreger.", [["pulmonale", "DISEASE", 283, 292], ["Differenzialdiagnosen und Stellenwert im Vergleich mit anderen bildgebenden VerfahrenFokal lokalisierte pulmonale und pleurale Ver\u00e4nderungen finden sich auch bei Pneumonien und Pleuritiden durch andere Erreger", "SPECIES", 179, 388], ["CT besser", "TEST", 120, 129], ["Differenzialdiagnosen", "TREATMENT", 179, 200], ["VerfahrenFokal lokalisierte pulmonale", "TREATMENT", 255, 292], ["Thorax", "ANATOMY", 113, 119]]], ["Finden sich bei bislang gesunden Patienten jedoch alle o. g. typischen Kriterien in Kombination in verschiedenen Arealen, muss der Befund in der aktuellen Pandemiesituation als hoch suggestiv f\u00fcr das Vorliegen einer COVID-19-Pneumonie angesehen werden.Bildgebung zum Screening bei Verdacht auf COVID-19In Phasen der Pandemie, als Notaufnahmen in Wuhan/China, in Italien und in den USA eine sehr gro\u00dfe Anzahl von Patienten mit neu aufgetretenen Atemwegsinfekten zu bew\u00e4ltigen hatten und gleichzeitig PCR-Tests nur begrenzt verf\u00fcgbar und dar\u00fcber hinaus mit Wartezeiten bis zu 30 h verbunden waren, wurde mangels Alternativen die Thorax-CT zum Screening auf Vorliegen einer m\u00f6glichen SARS-CoV-2-Infektion angewendet [47].", [["der aktuellen Pandemiesituation als hoch suggestiv f\u00fcr das Vorliegen einer COVID-19-Pneumonie angesehen werden", "SPECIES", 141, 251], ["Bildgebung zum Screening bei Verdacht auf COVID-19In Phasen der Pandemie, als Notaufnahmen", "SPECIES", 252, 342], ["von Patienten mit neu aufgetretenen Atemwegsinfekten zu bew\u00e4ltigen hatten und gleichzeitig PCR-Tests nur begrenzt verf\u00fcgbar und dar\u00fcber hinaus mit Wartezeiten bis zu 30 h verbunden waren, wurde mangels Alternativen die Thorax-CT zum Screening auf Vorliegen einer m\u00f6glichen SARS-CoV-2-Infektion angewendet", "SPECIES", 408, 712], ["COVID", "TEST", 216, 221], ["Atemwegsinfekten", "TEST", 444, 460], ["gleichzeitig", "TEST", 486, 498], ["PCR", "TEST", 499, 502], ["Tests", "TEST", 503, 508], ["nur", "TEST", 509, 512], ["verf\u00fcgbar", "TEST", 522, 531], ["verbunden waren", "TREATMENT", 579, 594], ["CT zum", "TEST", 634, 640], ["Screening", "TEST", 641, 650], ["SARS", "TEST", 681, 685], ["Thorax", "ANATOMY", 627, 633]]], ["In entsprechenden Studien war die Sensitivit\u00e4t der CT zur Erkennung einer COVID-19-Pneumonie sogar h\u00f6her als die der PCR im ersten durchgef\u00fchrten Nasen-Rachen-Abstrich [48, 49].", [["entsprechenden Studien war die Sensitivit\u00e4t der CT zur Erkennung einer COVID-19-Pneumonie sogar h\u00f6her als die der PCR im ersten durchgef\u00fchrten Nasen-Rachen-Abstrich", "SPECIES", 3, 167], ["COVID", "TEST", 74, 79]]], ["Gerade in der fr\u00fchen Phase der Erkrankung zeigt das CT sowohl bei asymptomatischen als auch bei symptomatischen Patienten in bis zu 56 % einen Normalbefund [50\u201353] und die Befunde sind nicht spezifisch f\u00fcr eine COVID-19-Pneumonie [50, 54, 55].", [["der fr\u00fchen Phase der Erkrankung zeigt das CT sowohl bei asymptomatischen als auch bei symptomatischen Patienten in bis zu 56 % einen Normalbefund [50\u201353] und die Befunde sind nicht spezifisch f\u00fcr eine COVID-19-Pneumonie", "SPECIES", 10, 229], ["CT", "TEST", 52, 54], ["spezifisch", "TEST", 191, 201], ["eine COVID", "TEST", 206, 216]]], ["Daher warnen mittlerweile radiologische Fachgesellschaften [56\u201358] weltweit vor dem Einsatz der CT als \u201escreening tool\u201c zur Detektion einer SARS-CoV-2-Infektion und verweisen \u2013 auch in Hinblick auf die Strahlenbelastung \u2013 darauf, dass eine CT nur eingesetzt werden darf, wenn sich daraus direkt therapeutische Konsequenzen ableiten lassen [59\u201361].Zusammenfassung und AusblickAuch wenn aufgrund der noch kurzen Dauer der aktuellen Pandemie der Stellenwert der Bildgebung bei Patienten mit Verdacht auf SARS-CoV-2-Infektion noch nicht abschlie\u00dfend beurteilt werden kann, bietet sich aus Gr\u00fcnden des Infektions- und Strahlenschutzes der Lungenultraschall als erstes bildgebendes Verfahren unmittelbar nach Anamneseerhebung und klinischer Untersuchung bei der Abkl\u00e4rung von Patienten mit V. a.", [["Daher warnen mittlerweile radiologische Fachgesellschaften [56\u201358] weltweit vor dem Einsatz der CT als \u201escreening tool\u201c zur Detektion einer SARS-CoV-2-Infektion und verweisen \u2013 auch in Hinblick auf die Strahlenbelastung \u2013 darauf", "SPECIES", 0, 228], ["Zusammenfassung und AusblickAuch wenn aufgrund der noch kurzen Dauer der aktuellen Pandemie der Stellenwert der Bildgebung bei Patienten mit Verdacht auf SARS-CoV-2-Infektion noch nicht abschlie\u00dfend beurteilt werden kann, bietet sich aus Gr\u00fcnden des Infektions- und Strahlenschutzes der Lungenultraschall als erstes bildgebendes Verfahren unmittelbar nach Anamneseerhebung und klinischer Untersuchung bei der Abkl\u00e4rung von Patienten mit V. a.", "SPECIES", 347, 789], ["der CT", "TEST", 92, 98], ["Zusammenfassung", "TREATMENT", 347, 362], ["CoV", "TEST", 506, 509], ["Infektion", "PROBLEM", 512, 521], ["bietet sich aus Gr\u00fcnden des", "TREATMENT", 569, 596]]], ["COVID-19-Pneumonie an und ist gut geeignet, die Patienten zu selektionieren, die einer zus\u00e4tzlichen Bildgebung mittels CT bed\u00fcrfen.", [["COVID", "TEST", 0, 5]]], ["Sowohl CT-basierte [62] als auch ultraschallbasierte [40] publizierte Triagealgorithmen m\u00fcssen weiterhin kritisch unter Ber\u00fccksichtigung der lokalen Pandemiesituation und der vorhandenen Infrastruktur gepr\u00fcft werden [63].Zusammenfassung und AusblickAktuell werden internationale Datenbanken und multizentrische Studien eingerichtet, die die verschiedenen bildgebenden Verfahren miteinander vergleichen [39, 64].", [["Sowohl CT", "TEST", 0, 9], ["publizierte Triagealgorithmen", "TREATMENT", 58, 87], ["Zusammenfassung", "TREATMENT", 221, 236]]], ["Mithilfe der daraus gewonnenen Erkenntnisse k\u00f6nnen hoffentlich zuk\u00fcnftig Algorithmen f\u00fcr eine optimierte, individuelle Patientenversorgung in verschiedenen Phasen der Pandemie erarbeitet werden.Fazit f\u00fcr die Praxis", [["Mithilfe der daraus gewonnenen", "TREATMENT", 0, 30]]]], "56afeaf66bbaf1d2e6990bdfb4f7d8a87748fbde": [["BackgroundAcute respiratory distress syndrome (ARDS) is defined as pulmonary compromise with bilateral pulmonary infiltrates associated with moderate to severe hypoxemia [1] .", [["pulmonary", "ANATOMY", 67, 76], ["pulmonary", "ANATOMY", 103, 112], ["BackgroundAcute respiratory distress syndrome", "DISEASE", 0, 45], ["ARDS", "DISEASE", 47, 51], ["hypoxemia", "DISEASE", 160, 169], ["pulmonary", "ORGAN", 67, 76], ["pulmonary", "ORGAN", 103, 112], ["BackgroundAcute respiratory distress syndrome", "PROBLEM", 0, 45], ["ARDS", "PROBLEM", 47, 51], ["pulmonary compromise", "PROBLEM", 67, 87], ["bilateral pulmonary infiltrates", "PROBLEM", 93, 124], ["moderate to severe hypoxemia", "PROBLEM", 141, 169], ["respiratory distress", "OBSERVATION", 16, 36], ["ARDS", "OBSERVATION", 47, 51], ["pulmonary", "ANATOMY", 67, 76], ["compromise", "OBSERVATION", 77, 87], ["bilateral", "ANATOMY_MODIFIER", 93, 102], ["pulmonary", "ANATOMY", 103, 112], ["infiltrates", "OBSERVATION", 113, 124], ["moderate", "OBSERVATION_MODIFIER", 141, 149], ["severe", "OBSERVATION_MODIFIER", 153, 159], ["hypoxemia", "OBSERVATION", 160, 169]]], ["The public health impact of ARDS is considerable, and it is estimated that approximately 75,000 cases of ARDS occur annually in Germany.", [["ARDS", "DISEASE", 28, 32], ["ARDS", "DISEASE", 105, 109], ["ARDS", "PROBLEM", 28, 32], ["ARDS", "PROBLEM", 105, 109], ["ARDS", "OBSERVATION", 28, 32], ["ARDS", "OBSERVATION", 105, 109]]], ["The estimated mortality ranges from 26 to 51% and depends on the severity of the associated hypoxemia [2] .", [["hypoxemia", "DISEASE", 92, 101], ["The estimated mortality", "TEST", 0, 23], ["the associated hypoxemia", "PROBLEM", 77, 101], ["mortality", "OBSERVATION_MODIFIER", 14, 23], ["ranges", "OBSERVATION_MODIFIER", 24, 30], ["hypoxemia", "OBSERVATION", 92, 101]]], ["Patients surviving ARDS treatment also show reduced functional capacity in their everyday life following hospitalization [3, 4] .", [["ARDS", "DISEASE", 19, 23], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["Patients surviving ARDS treatment", "TREATMENT", 0, 33], ["reduced functional capacity", "PROBLEM", 44, 71], ["ARDS", "OBSERVATION", 19, 23]]], ["Therefore, there is a pressing need to develop further ARDS treatment strategies with a view to ultimately improving patient outcomes.BackgroundThe bilateral pulmonary infiltrates that can be identified on chest radiography reflect the diffuse inflammatory changes within the lung that are caused by acute inflammation within the pulmonary tissue and the alveolar space.", [["pulmonary infiltrates", "ANATOMY", 158, 179], ["chest", "ANATOMY", 206, 211], ["lung", "ANATOMY", 276, 280], ["pulmonary tissue", "ANATOMY", 330, 346], ["alveolar space", "ANATOMY", 355, 369], ["ARDS", "DISEASE", 55, 59], ["inflammation", "DISEASE", 306, 318], ["patient", "ORGANISM", 117, 124], ["pulmonary", "ORGAN", 158, 167], ["chest", "ORGANISM_SUBDIVISION", 206, 211], ["lung", "ORGAN", 276, 280], ["pulmonary tissue", "TISSUE", 330, 346], ["alveolar space", "MULTI-TISSUE_STRUCTURE", 355, 369], ["patient", "SPECIES", 117, 124], ["further ARDS treatment strategies", "TREATMENT", 47, 80], ["The bilateral pulmonary infiltrates", "PROBLEM", 144, 179], ["chest radiography", "TEST", 206, 223], ["the diffuse inflammatory changes within the lung", "PROBLEM", 232, 280], ["acute inflammation within the pulmonary tissue and the alveolar space", "PROBLEM", 300, 369], ["ARDS", "OBSERVATION", 55, 59], ["bilateral", "ANATOMY_MODIFIER", 148, 157], ["pulmonary", "ANATOMY", 158, 167], ["infiltrates", "OBSERVATION", 168, 179], ["diffuse", "OBSERVATION_MODIFIER", 236, 243], ["inflammatory", "OBSERVATION", 244, 256], ["lung", "ANATOMY", 276, 280], ["acute", "OBSERVATION_MODIFIER", 300, 305], ["inflammation", "OBSERVATION", 306, 318], ["pulmonary tissue", "ANATOMY", 330, 346], ["alveolar", "ANATOMY_MODIFIER", 355, 363]]], ["The initial inflammatory process is induced by the activation of the innate immune response by the binding of microbial products (pathogen-associated molecular patterns [PAMPs]) or cell injury-associated endogenous molecules (danger-associated molecular patterns [DAMPs] ) to pattern recognition receptors (PRRs).", [["cell", "ANATOMY", 181, 185], ["pathogen-associated molecular patterns", "GENE_OR_GENE_PRODUCT", 130, 168], ["PAMPs", "GENE_OR_GENE_PRODUCT", 170, 175], ["cell", "CELL", 181, 185], ["danger-associated molecular patterns", "GENE_OR_GENE_PRODUCT", 226, 262], ["DAMPs", "GENE_OR_GENE_PRODUCT", 264, 269], ["pattern recognition receptors", "GENE_OR_GENE_PRODUCT", 276, 305], ["microbial products", "PROTEIN", 110, 128], ["pathogen-associated molecular patterns", "PROTEIN", 130, 168], ["PAMPs", "PROTEIN", 170, 175], ["associated endogenous molecules", "PROTEIN", 193, 224], ["danger-associated molecular patterns", "PROTEIN", 226, 262], ["DAMPs", "PROTEIN", 264, 269], ["pattern recognition receptors", "PROTEIN", 276, 305], ["PRRs", "PROTEIN", 307, 311], ["The initial inflammatory process", "PROBLEM", 0, 32], ["cell injury", "PROBLEM", 181, 192], ["endogenous molecules", "PROBLEM", 204, 224], ["inflammatory", "OBSERVATION", 12, 24], ["cell injury", "OBSERVATION", 181, 192], ["endogenous molecules", "OBSERVATION", 204, 224]]], ["Therefore, the common causes of ARDS are trauma, sepsis, pneumonia, blood transfusion, or aspiration into the lungs.", [["blood", "ANATOMY", 68, 73], ["lungs", "ANATOMY", 110, 115], ["ARDS", "DISEASE", 32, 36], ["trauma", "DISEASE", 41, 47], ["sepsis", "DISEASE", 49, 55], ["pneumonia", "DISEASE", 57, 66], ["blood", "ORGANISM_SUBSTANCE", 68, 73], ["lungs", "ORGAN", 110, 115], ["ARDS", "PROBLEM", 32, 36], ["trauma", "PROBLEM", 41, 47], ["sepsis", "PROBLEM", 49, 55], ["pneumonia", "PROBLEM", 57, 66], ["blood transfusion", "TREATMENT", 68, 85], ["aspiration into the lungs", "PROBLEM", 90, 115], ["ARDS", "OBSERVATION", 32, 36], ["trauma", "OBSERVATION", 41, 47], ["sepsis", "OBSERVATION", 49, 55], ["pneumonia", "OBSERVATION", 57, 66], ["blood transfusion", "OBSERVATION", 68, 85], ["aspiration", "OBSERVATION", 90, 100], ["lungs", "ANATOMY", 110, 115]]], ["After the initial activation of the innate immune response, innate immune effector mechanisms, such as the formation of neutrophil extracellular traps (NETs), are activated, which further aggravate the alveolar injury [5] .", [["neutrophil extracellular", "ANATOMY", 120, 144], ["alveolar", "ANATOMY", 202, 210], ["alveolar injury", "DISEASE", 202, 217], ["neutrophil extracellular traps", "GENE_OR_GENE_PRODUCT", 120, 150], ["alveolar", "TISSUE", 202, 210], ["the innate immune response", "TREATMENT", 32, 58], ["innate immune effector mechanisms", "TREATMENT", 60, 93], ["neutrophil extracellular traps", "TREATMENT", 120, 150], ["the alveolar injury", "PROBLEM", 198, 217], ["alveolar", "ANATOMY", 202, 210], ["injury", "OBSERVATION", 211, 217]]], ["The resulting increased permeability of the microvascular barrier results in the extravascular accumulation of protein-rich fluid that accumulates within the alveolar space.", [["microvascular barrier", "ANATOMY", 44, 65], ["extravascular", "ANATOMY", 81, 94], ["alveolar space", "ANATOMY", 158, 172], ["microvascular barrier", "TISSUE", 44, 65], ["extravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 81, 94], ["fluid", "ORGANISM_SUBSTANCE", 124, 129], ["alveolar space", "MULTI-TISSUE_STRUCTURE", 158, 172], ["the microvascular barrier", "PROBLEM", 40, 65], ["the extravascular accumulation of protein-rich fluid", "PROBLEM", 77, 129], ["increased", "OBSERVATION_MODIFIER", 14, 23], ["permeability", "OBSERVATION_MODIFIER", 24, 36], ["microvascular barrier", "OBSERVATION", 44, 65], ["extravascular", "OBSERVATION_MODIFIER", 81, 94], ["accumulation", "OBSERVATION_MODIFIER", 95, 107], ["protein-", "OBSERVATION", 111, 119], ["rich fluid", "OBSERVATION", 119, 129], ["alveolar space", "OBSERVATION", 158, 172]]], ["The increased permeability is also linked to the transfer of leukocytes (mostly neutrophil granulocytes) and erythrocytes into the alveolar space in ARDS, as well as to the presence of proinflammatory-regulated cytokines that increase the inflammatory burden within the lung [5] .", [["leukocytes", "ANATOMY", 61, 71], ["neutrophil granulocytes", "ANATOMY", 80, 103], ["erythrocytes", "ANATOMY", 109, 121], ["alveolar space", "ANATOMY", 131, 145], ["lung", "ANATOMY", 270, 274], ["ARDS", "DISEASE", 149, 153], ["leukocytes", "CELL", 61, 71], ["neutrophil granulocytes", "CELL", 80, 103], ["erythrocytes", "CELL", 109, 121], ["alveolar space", "MULTI-TISSUE_STRUCTURE", 131, 145], ["lung", "ORGAN", 270, 274], ["leukocytes", "CELL_TYPE", 61, 71], ["neutrophil granulocytes", "CELL_TYPE", 80, 103], ["erythrocytes", "CELL_TYPE", 109, 121], ["proinflammatory-regulated cytokines", "PROTEIN", 185, 220], ["The increased permeability", "PROBLEM", 0, 26], ["leukocytes", "TEST", 61, 71], ["neutrophil granulocytes", "TEST", 80, 103], ["erythrocytes into the alveolar space", "PROBLEM", 109, 145], ["ARDS", "PROBLEM", 149, 153], ["proinflammatory-regulated cytokines", "PROBLEM", 185, 220], ["the inflammatory burden within the lung", "PROBLEM", 235, 274], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["permeability", "OBSERVATION", 14, 26], ["leukocytes", "ANATOMY", 61, 71], ["neutrophil granulocytes", "OBSERVATION", 80, 103], ["alveolar", "ANATOMY_MODIFIER", 131, 139], ["ARDS", "OBSERVATION", 149, 153], ["proinflammatory", "OBSERVATION_MODIFIER", 185, 200], ["regulated cytokines", "OBSERVATION", 201, 220], ["increase", "OBSERVATION_MODIFIER", 226, 234], ["inflammatory", "OBSERVATION_MODIFIER", 239, 251], ["burden", "OBSERVATION", 252, 258], ["lung", "ANATOMY", 270, 274]]], ["As a result, dysregulated inflammation, the accumulation of leukocytes and platelets, and altered permeability of alveolar barriers remain the central pathophysiologic problems in ARDS [5, 6] .BackgroundThe treatment of ARDS to date is focused on the prevention of further iatrogenic damage of the lung through lung-protective mechanical ventilation, neuromuscular blockade, and conservative fluid management [7] .", [["leukocytes", "ANATOMY", 60, 70], ["platelets", "ANATOMY", 75, 84], ["alveolar", "ANATOMY", 114, 122], ["lung", "ANATOMY", 298, 302], ["lung", "ANATOMY", 311, 315], ["neuromuscular", "ANATOMY", 351, 364], ["fluid", "ANATOMY", 392, 397], ["inflammation", "DISEASE", 26, 38], ["ARDS", "DISEASE", 180, 184], ["ARDS", "DISEASE", 220, 224], ["neuromuscular blockade", "DISEASE", 351, 373], ["leukocytes", "CELL", 60, 70], ["platelets", "CELL", 75, 84], ["alveolar", "MULTI-TISSUE_STRUCTURE", 114, 122], ["lung", "ORGAN", 298, 302], ["lung", "ORGAN", 311, 315], ["leukocytes", "CELL_TYPE", 60, 70], ["platelets", "CELL_TYPE", 75, 84], ["dysregulated inflammation", "PROBLEM", 13, 38], ["the accumulation of leukocytes", "PROBLEM", 40, 70], ["platelets", "TEST", 75, 84], ["altered permeability of alveolar barriers", "PROBLEM", 90, 131], ["the central pathophysiologic problems", "PROBLEM", 139, 176], ["ARDS", "PROBLEM", 180, 184], ["ARDS", "PROBLEM", 220, 224], ["further iatrogenic damage of the lung", "PROBLEM", 265, 302], ["protective mechanical ventilation", "TREATMENT", 316, 349], ["neuromuscular blockade", "TREATMENT", 351, 373], ["conservative fluid management", "TREATMENT", 379, 408], ["dysregulated", "OBSERVATION_MODIFIER", 13, 25], ["inflammation", "OBSERVATION", 26, 38], ["accumulation of leukocytes", "OBSERVATION", 44, 70], ["altered", "OBSERVATION_MODIFIER", 90, 97], ["permeability", "OBSERVATION_MODIFIER", 98, 110], ["alveolar barriers", "OBSERVATION", 114, 131], ["central", "OBSERVATION_MODIFIER", 143, 150], ["pathophysiologic", "OBSERVATION_MODIFIER", 151, 167], ["problems", "OBSERVATION", 168, 176], ["ARDS", "OBSERVATION", 180, 184], ["ARDS", "OBSERVATION", 220, 224], ["iatrogenic", "OBSERVATION", 273, 283], ["lung", "ANATOMY", 298, 302], ["lung", "ANATOMY", 311, 315], ["mechanical ventilation", "OBSERVATION", 327, 349]]], ["Recent clinical trials have focused on the role of ventilation strategies in the prevention or treatment of ARDS using noninvasive ventilation devices or prone positioning [8, 9] .", [["ARDS", "DISEASE", 108, 112], ["Recent clinical trials", "PROBLEM", 0, 22], ["ventilation strategies", "TREATMENT", 51, 73], ["ARDS", "PROBLEM", 108, 112], ["noninvasive ventilation devices", "TREATMENT", 119, 150], ["prone positioning", "TREATMENT", 154, 171], ["ARDS", "OBSERVATION", 108, 112]]], ["Although these strategies have shown a positive effect on patient oxygenation and symptoms, they do not interfere with the underlying pathophysiological changes of ARDS.", [["ARDS", "DISEASE", 164, 168], ["patient", "ORGANISM", 58, 65], ["patient", "SPECIES", 58, 65], ["a positive effect on patient oxygenation", "PROBLEM", 37, 77], ["symptoms", "PROBLEM", 82, 90], ["ARDS", "PROBLEM", 164, 168], ["positive", "OBSERVATION_MODIFIER", 39, 47], ["effect", "OBSERVATION_MODIFIER", 48, 54], ["ARDS", "OBSERVATION", 164, 168]]], ["Several interventions have tried to use a potential anti-inflammatory strategy for the treatment of the existing intra-alveolar inflammation or to intervene in the development of intra-alveolar inflammation.", [["intra-alveolar", "ANATOMY", 113, 127], ["intra-alveolar", "ANATOMY", 179, 193], ["inflammation", "DISEASE", 128, 140], ["intra-alveolar inflammation", "DISEASE", 179, 206], ["intra-alveolar", "IMMATERIAL_ANATOMICAL_ENTITY", 113, 127], ["intra-alveolar inflammation", "PATHOLOGICAL_FORMATION", 179, 206], ["a potential anti-inflammatory strategy", "TREATMENT", 40, 78], ["the treatment", "TREATMENT", 83, 96], ["the existing intra-alveolar inflammation", "PROBLEM", 100, 140], ["intra-alveolar inflammation", "PROBLEM", 179, 206], ["intra-alveolar", "OBSERVATION_MODIFIER", 113, 127], ["inflammation", "OBSERVATION", 128, 140], ["intra-alveolar", "ANATOMY_MODIFIER", 179, 193], ["inflammation", "OBSERVATION", 194, 206]]], ["For this, patients were treated with aspirin, simvastatin, and surfactant, but the tested treatments failed and did not have any significant effect [10] [11] [12] .IloprostConsiderable evidence in preclinical models shows that the use of iloprost for the treatment of ARDS and pulmonary inflammation might be of significant benefit.", [["pulmonary", "ANATOMY", 277, 286], ["aspirin", "CHEMICAL", 37, 44], ["simvastatin", "CHEMICAL", 46, 57], ["surfactant", "CHEMICAL", 63, 73], ["Iloprost", "CHEMICAL", 164, 172], ["iloprost", "CHEMICAL", 238, 246], ["ARDS", "DISEASE", 268, 272], ["pulmonary inflammation", "DISEASE", 277, 299], ["aspirin", "CHEMICAL", 37, 44], ["simvastatin", "CHEMICAL", 46, 57], ["Iloprost", "CHEMICAL", 164, 172], ["iloprost", "CHEMICAL", 238, 246], ["patients", "ORGANISM", 10, 18], ["aspirin", "SIMPLE_CHEMICAL", 37, 44], ["simvastatin", "SIMPLE_CHEMICAL", 46, 57], ["surfactant", "SIMPLE_CHEMICAL", 63, 73], ["Iloprost", "SIMPLE_CHEMICAL", 164, 172], ["iloprost", "SIMPLE_CHEMICAL", 238, 246], ["pulmonary", "ORGAN", 277, 286], ["patients", "SPECIES", 10, 18], ["aspirin", "TREATMENT", 37, 44], ["simvastatin", "TREATMENT", 46, 57], ["surfactant", "TREATMENT", 63, 73], ["the tested treatments", "TREATMENT", 79, 100], ["Iloprost", "TREATMENT", 164, 172], ["iloprost", "TREATMENT", 238, 246], ["ARDS", "PROBLEM", 268, 272], ["pulmonary inflammation", "PROBLEM", 277, 299], ["ARDS", "OBSERVATION", 268, 272], ["pulmonary", "ANATOMY", 277, 286], ["inflammation", "OBSERVATION", 287, 299]]], ["In small animal models, investigators showed that iloprost improves endothelial barrier function and reduces the detrimental signs of pulmonary edema [13] .", [["endothelial barrier", "ANATOMY", 68, 87], ["pulmonary", "ANATOMY", 134, 143], ["iloprost", "CHEMICAL", 50, 58], ["pulmonary edema", "DISEASE", 134, 149], ["iloprost", "CHEMICAL", 50, 58], ["iloprost", "SIMPLE_CHEMICAL", 50, 58], ["endothelial barrier", "TISSUE", 68, 87], ["pulmonary", "ORGAN", 134, 143], ["iloprost", "TREATMENT", 50, 58], ["endothelial barrier function", "TREATMENT", 68, 96], ["pulmonary edema", "PROBLEM", 134, 149], ["small", "OBSERVATION_MODIFIER", 3, 8], ["animal models", "OBSERVATION_MODIFIER", 9, 22], ["iloprost", "OBSERVATION", 50, 58], ["pulmonary", "ANATOMY", 134, 143], ["edema", "OBSERVATION", 144, 149]]], ["It also reduces the pulmonary sequestration of leukocytes and platelets, which is a central disease mechanism underlying the development of ARDS [14] .", [["pulmonary", "ANATOMY", 20, 29], ["leukocytes", "ANATOMY", 47, 57], ["platelets", "ANATOMY", 62, 71], ["ARDS", "DISEASE", 140, 144], ["pulmonary", "ORGAN", 20, 29], ["leukocytes", "CELL", 47, 57], ["platelets", "CELL", 62, 71], ["leukocytes", "CELL_TYPE", 47, 57], ["platelets", "CELL_TYPE", 62, 71], ["the pulmonary sequestration of leukocytes", "PROBLEM", 16, 57], ["platelets", "TEST", 62, 71], ["a central disease mechanism", "PROBLEM", 82, 109], ["ARDS", "PROBLEM", 140, 144], ["pulmonary", "ANATOMY", 20, 29], ["sequestration", "OBSERVATION", 30, 43], ["leukocytes", "OBSERVATION", 47, 57], ["platelets", "OBSERVATION_MODIFIER", 62, 71], ["central disease", "OBSERVATION", 84, 99], ["ARDS", "OBSERVATION", 140, 144]]], ["This evidence could be transferred into different models of lung injury, showing positive evidence for the reduction of pulmonary inflammation in a pressure-induced model of lung injury [15] .", [["lung", "ANATOMY", 60, 64], ["pulmonary", "ANATOMY", 120, 129], ["lung", "ANATOMY", 174, 178], ["lung injury", "DISEASE", 60, 71], ["pulmonary inflammation", "DISEASE", 120, 142], ["lung injury", "DISEASE", 174, 185], ["lung", "ORGAN", 60, 64], ["pulmonary", "ORGAN", 120, 129], ["lung", "ORGAN", 174, 178], ["lung injury", "PROBLEM", 60, 71], ["pulmonary inflammation", "PROBLEM", 120, 142], ["lung injury", "PROBLEM", 174, 185], ["lung", "ANATOMY", 60, 64], ["injury", "OBSERVATION", 65, 71], ["positive evidence for", "UNCERTAINTY", 81, 102], ["reduction", "OBSERVATION_MODIFIER", 107, 116], ["pulmonary", "ANATOMY", 120, 129], ["inflammation", "OBSERVATION", 130, 142], ["pressure", "OBSERVATION_MODIFIER", 148, 156], ["lung", "ANATOMY", 174, 178], ["injury", "OBSERVATION", 179, 185]]], ["The anti-inflammatory effect was attributed to the cyclooxygenase-2 (COX-2) system and the involvement of lipoxin A4 [16] .", [["lipoxin A4", "CHEMICAL", 106, 116], ["cyclooxygenase-2", "GENE_OR_GENE_PRODUCT", 51, 67], ["COX-2", "GENE_OR_GENE_PRODUCT", 69, 74], ["lipoxin A4", "GENE_OR_GENE_PRODUCT", 106, 116], ["cyclooxygenase-2 (COX-2", "PROTEIN", 51, 74], ["the cyclooxygenase", "TREATMENT", 47, 65], ["lipoxin A4", "TREATMENT", 106, 116], ["anti-inflammatory effect", "OBSERVATION", 4, 28]]], ["Ras-related protein 1 (RAP-1) might also be involved in the protective role of iloprost [17] .", [["iloprost", "CHEMICAL", 79, 87], ["iloprost", "CHEMICAL", 79, 87], ["Ras-related protein 1", "GENE_OR_GENE_PRODUCT", 0, 21], ["RAP-1", "GENE_OR_GENE_PRODUCT", 23, 28], ["iloprost", "SIMPLE_CHEMICAL", 79, 87], ["Ras-related protein 1", "PROTEIN", 0, 21], ["RAP", "PROTEIN", 23, 26], ["Ras-related protein", "TEST", 0, 19], ["RAP", "TEST", 23, 26]]], ["This positive anti-inflammatory effect of iloprost on the pulmonary tissue was also demonstrated in several models of ischemia-reperfusion (IR) injury.", [["pulmonary tissue", "ANATOMY", 58, 74], ["iloprost", "CHEMICAL", 42, 50], ["ischemia-reperfusion (IR) injury", "DISEASE", 118, 150], ["iloprost", "CHEMICAL", 42, 50], ["iloprost", "SIMPLE_CHEMICAL", 42, 50], ["pulmonary tissue", "TISSUE", 58, 74], ["iloprost", "TREATMENT", 42, 50], ["ischemia-reperfusion (IR) injury", "PROBLEM", 118, 150], ["anti-inflammatory effect", "OBSERVATION", 14, 38], ["iloprost", "OBSERVATION", 42, 50], ["pulmonary tissue", "ANATOMY", 58, 74], ["several models", "OBSERVATION_MODIFIER", 100, 114], ["ischemia-reperfusion", "OBSERVATION", 118, 138], ["injury", "OBSERVATION", 144, 150]]], ["Furthermore, IR injury can also result in ARDS and pulmonary failure.", [["pulmonary", "ANATOMY", 51, 60], ["ARDS", "DISEASE", 42, 46], ["pulmonary failure", "DISEASE", 51, 68], ["pulmonary", "ORGAN", 51, 60], ["IR injury", "PROBLEM", 13, 22], ["ARDS", "PROBLEM", 42, 46], ["pulmonary failure", "PROBLEM", 51, 68], ["injury", "OBSERVATION", 16, 22], ["ARDS", "OBSERVATION", 42, 46], ["pulmonary", "ANATOMY", 51, 60], ["failure", "OBSERVATION", 61, 68]]], ["Iloprost was able to reduce this pulmonary compromise in several preclinical studies [18] [19] [20] [21] .", [["pulmonary", "ANATOMY", 33, 42], ["Iloprost", "CHEMICAL", 0, 8], ["Iloprost", "CHEMICAL", 0, 8], ["Iloprost", "SIMPLE_CHEMICAL", 0, 8], ["pulmonary", "ORGAN", 33, 42], ["[18] [19] [20] [21]", "SIMPLE_CHEMICAL", 85, 104], ["Iloprost", "TREATMENT", 0, 8], ["this pulmonary compromise", "PROBLEM", 28, 53], ["several preclinical studies", "TEST", 57, 84], ["pulmonary", "ANATOMY", 33, 42], ["compromise", "OBSERVATION", 43, 53]]], ["The anti-inflammatory effect of iloprost was also shown in large animal models of lung injury using porcine models of ARDS [22] [23] [24] .", [["lung", "ANATOMY", 82, 86], ["iloprost", "CHEMICAL", 32, 40], ["lung injury", "DISEASE", 82, 93], ["ARDS", "DISEASE", 118, 122], ["iloprost", "CHEMICAL", 32, 40], ["iloprost", "SIMPLE_CHEMICAL", 32, 40], ["lung", "ORGAN", 82, 86], ["porcine", "ORGANISM", 100, 107], ["iloprost", "TREATMENT", 32, 40], ["lung injury", "PROBLEM", 82, 93], ["ARDS", "PROBLEM", 118, 122], ["anti-inflammatory", "OBSERVATION_MODIFIER", 4, 21], ["large", "OBSERVATION_MODIFIER", 59, 64], ["lung", "ANATOMY", 82, 86], ["injury", "OBSERVATION", 87, 93]]], ["Here, again, iloprost showed an anti-inflammatory effect.", [["iloprost", "CHEMICAL", 13, 21], ["iloprost", "CHEMICAL", 13, 21], ["iloprost", "SIMPLE_CHEMICAL", 13, 21], ["iloprost", "TREATMENT", 13, 21], ["an anti-inflammatory effect", "PROBLEM", 29, 56], ["anti-inflammatory effect", "OBSERVATION", 32, 56]]], ["In addition, the shunt fraction could be reduced, which resulted in improved oxygenation and improved pulmonary dynamics, which is essential for the reinstitution of spontaneous ventilation during and following ARDS [22, 23, [25] [26] [27] .", [["pulmonary", "ANATOMY", 102, 111], ["ARDS", "DISEASE", 211, 215], ["pulmonary", "ORGAN", 102, 111], ["[25] [26] [27]", "SIMPLE_CHEMICAL", 225, 239], ["the shunt fraction", "TREATMENT", 13, 31], ["spontaneous ventilation", "TREATMENT", 166, 189], ["ARDS", "TEST", 211, 215], ["shunt fraction", "OBSERVATION", 17, 31], ["reduced", "OBSERVATION_MODIFIER", 41, 48], ["improved", "OBSERVATION_MODIFIER", 68, 76], ["oxygenation", "OBSERVATION_MODIFIER", 77, 88], ["improved", "OBSERVATION_MODIFIER", 93, 101], ["pulmonary dynamics", "OBSERVATION", 102, 120]]], ["This shows that the preclinical data identified a beneficial effect of iloprost on ARDS.", [["iloprost", "CHEMICAL", 71, 79], ["ARDS", "DISEASE", 83, 87], ["iloprost", "CHEMICAL", 71, 79], ["iloprost", "SIMPLE_CHEMICAL", 71, 79], ["the preclinical data", "TEST", 16, 36], ["iloprost", "TREATMENT", 71, 79], ["ARDS", "PROBLEM", 83, 87], ["iloprost", "OBSERVATION", 71, 79], ["ARDS", "OBSERVATION", 83, 87]]], ["So far, only one study on inhaled iloprost in adult patients with ARDS has been conducted, although an application of inhaled iloprost is noted in the guidelines of the Association of the Scientific Medical Societies (AWMF) for the treatment of ARDS [28] .", [["iloprost", "CHEMICAL", 34, 42], ["ARDS", "DISEASE", 66, 70], ["iloprost", "CHEMICAL", 126, 134], ["ARDS", "DISEASE", 245, 249], ["iloprost", "CHEMICAL", 34, 42], ["iloprost", "CHEMICAL", 126, 134], ["iloprost", "SIMPLE_CHEMICAL", 34, 42], ["patients", "ORGANISM", 52, 60], ["iloprost", "SIMPLE_CHEMICAL", 126, 134], ["patients", "SPECIES", 52, 60], ["inhaled iloprost", "TREATMENT", 26, 42], ["ARDS", "PROBLEM", 66, 70], ["inhaled iloprost", "TREATMENT", 118, 134], ["ARDS", "PROBLEM", 245, 249], ["ARDS", "OBSERVATION", 66, 70], ["ARDS", "OBSERVATION", 245, 249]]], ["The AWMF guidelines indicate that the use of ARDS can be considered, especially in patients with severe ARDS who are mechanically ventilated and not selfconsenting [7] .Study designThIlo is a multicenter, randomized, single blinded clinical phase II trial assessing the efficacy of inhaled iloprost in the development and progression of ARDS in critically ill patients.", [["ARDS", "DISEASE", 45, 49], ["ARDS", "DISEASE", 104, 108], ["iloprost", "CHEMICAL", 290, 298], ["ARDS", "DISEASE", 337, 341], ["critically ill", "DISEASE", 345, 359], ["iloprost", "CHEMICAL", 290, 298], ["patients", "ORGANISM", 83, 91], ["iloprost", "SIMPLE_CHEMICAL", 290, 298], ["patients", "ORGANISM", 360, 368], ["patients", "SPECIES", 83, 91], ["patients", "SPECIES", 360, 368], ["ARDS", "PROBLEM", 45, 49], ["severe ARDS", "PROBLEM", 97, 108], ["mechanically ventilated", "PROBLEM", 117, 140], ["inhaled iloprost", "TREATMENT", 282, 298], ["ARDS", "PROBLEM", 337, 341], ["ARDS", "OBSERVATION", 45, 49], ["severe", "OBSERVATION_MODIFIER", 97, 103], ["ARDS", "OBSERVATION", 104, 108], ["progression", "OBSERVATION_MODIFIER", 322, 333], ["ARDS", "OBSERVATION", 337, 341]]], ["Based on the risk of pulmonary hemorrhage, which is very rare-especially in patients with ARDS-the study medication was unblended.", [["pulmonary", "ANATOMY", 21, 30], ["pulmonary hemorrhage", "DISEASE", 21, 41], ["ARDS", "DISEASE", 90, 94], ["pulmonary", "ORGAN", 21, 30], ["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["pulmonary hemorrhage", "PROBLEM", 21, 41], ["ARDS", "PROBLEM", 90, 94], ["the study medication", "TREATMENT", 95, 115], ["pulmonary", "ANATOMY", 21, 30], ["hemorrhage", "OBSERVATION", 31, 41], ["ARDS", "OBSERVATION", 90, 94]]], ["For safety reasons, after treatment of 100 patients (day 28 after last dose investigational medicinal product [IMP] Patient 100) within the study, an interim analysis for an increased risk for pulmonary hemorrhage \u2265 grade III according to Common Terminology (Toxicity) Criteria for Adverse Events (CTCAE) Version 5.0 in the treatment (iloprost) arm will be performed and the results discussed with the Data and Safety Monitoring Board (DSMB).", [["pulmonary", "ANATOMY", 193, 202], ["IMP", "CHEMICAL", 111, 114], ["pulmonary hemorrhage", "DISEASE", 193, 213], ["Toxicity", "DISEASE", 259, 267], ["iloprost", "CHEMICAL", 335, 343], ["iloprost", "CHEMICAL", 335, 343], ["patients", "ORGANISM", 43, 51], ["pulmonary", "ORGAN", 193, 202], ["iloprost", "SIMPLE_CHEMICAL", 335, 343], ["patients", "SPECIES", 43, 51], ["treatment", "TREATMENT", 26, 35], ["the study", "TEST", 136, 145], ["an interim analysis", "TEST", 147, 166], ["an increased risk", "PROBLEM", 171, 188], ["pulmonary hemorrhage", "PROBLEM", 193, 213], ["grade III", "PROBLEM", 216, 225], ["Adverse Events", "PROBLEM", 282, 296], ["Version", "TEST", 305, 312], ["the treatment (iloprost) arm", "TREATMENT", 320, 348], ["increased", "OBSERVATION_MODIFIER", 174, 183], ["pulmonary", "ANATOMY", 193, 202], ["hemorrhage", "OBSERVATION", 203, 213], ["arm", "ANATOMY", 345, 348]]], ["The study was ap-PopulationThe target population for this clinical trial is adult critically ill patients with ARDS.", [["critically ill", "DISEASE", 82, 96], ["ARDS", "DISEASE", 111, 115], ["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 97, 105], ["The study", "TEST", 0, 9], ["ARDS", "PROBLEM", 111, 115], ["ARDS", "OBSERVATION", 111, 115]]], ["Patients will be included in the trial if they present with ARDS as defined by the Berlin definition (Table 1 and [1] ) and meet the inclusion criteria.", [["ARDS", "DISEASE", 60, 64], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["ARDS", "PROBLEM", 60, 64], ["ARDS", "OBSERVATION", 60, 64]]], ["The trial population will consist of both sexes.", [["The trial population", "TREATMENT", 0, 20]]], ["One hundred fifty intensive care patients with ARDS will be included in the study at the Department of Anesthesiology, Eberhard Karls University T\u00fcbingen, Germany; the Department of Intensive Care and Intermediate Care, University Hospital RWTH Aachen, Germany; and the Department of Anesthesiology, University Hospital M\u00fcnster (UKM), M\u00fcnster, Germany.Inclusion criteriaPatients meeting the following criteria will be included: age \u2265 18 years, PaO 2 /FiO 2 \u2264 300, bilateral infiltrates consistent with pulmonary edema on frontal chest radiograph, need for positive pressure ventilation via an endotracheal tube or noninvasive ventilation and no clinical signs of left atrial hypertension detected via echocardiography, or if measured, a pulmonary arterial wedge pressure (PAWP) less than or equal to 18 mmHg.", [["pulmonary", "ANATOMY", 502, 511], ["endotracheal", "ANATOMY", 593, 605], ["left atrial", "ANATOMY", 663, 674], ["pulmonary arterial", "ANATOMY", 737, 755], ["ARDS", "DISEASE", 47, 51], ["pulmonary edema", "DISEASE", 502, 517], ["left atrial hypertension", "DISEASE", 663, 687], ["patients", "ORGANISM", 33, 41], ["pulmonary", "ORGAN", 502, 511], ["atrial", "MULTI-TISSUE_STRUCTURE", 668, 674], ["pulmonary arterial", "MULTI-TISSUE_STRUCTURE", 737, 755], ["patients", "SPECIES", 33, 41], ["ARDS", "PROBLEM", 47, 51], ["PaO", "TEST", 444, 447], ["FiO", "TEST", 451, 454], ["bilateral infiltrates", "PROBLEM", 464, 485], ["pulmonary edema", "PROBLEM", 502, 517], ["frontal chest radiograph", "TEST", 521, 545], ["positive pressure ventilation", "TREATMENT", 556, 585], ["an endotracheal tube", "TREATMENT", 590, 610], ["noninvasive ventilation", "TREATMENT", 614, 637], ["left atrial hypertension", "PROBLEM", 663, 687], ["echocardiography", "TEST", 701, 717], ["a pulmonary arterial wedge pressure", "TEST", 735, 770], ["PAWP", "TEST", 772, 776], ["bilateral", "ANATOMY_MODIFIER", 464, 473], ["infiltrates", "OBSERVATION", 474, 485], ["consistent with", "UNCERTAINTY", 486, 501], ["pulmonary", "ANATOMY", 502, 511], ["edema", "OBSERVATION", 512, 517], ["chest", "ANATOMY", 529, 534], ["pressure ventilation", "OBSERVATION", 565, 585], ["endotracheal tube", "OBSERVATION", 593, 610], ["left atrial", "ANATOMY", 663, 674], ["hypertension", "OBSERVATION", 675, 687], ["pulmonary arterial", "ANATOMY", 737, 755], ["wedge pressure", "OBSERVATION", 756, 770]]], ["The term \"acute onset\" is defined as follows: the durations of the hypoxemia criterion and the chest radiograph criterion must be \u226448 h at the time of randomization.", [["chest", "ANATOMY", 95, 100], ["hypoxemia", "DISEASE", 67, 76], ["the hypoxemia criterion", "PROBLEM", 63, 86], ["the chest radiograph criterion", "TEST", 91, 121], ["acute", "OBSERVATION_MODIFIER", 10, 15], ["hypoxemia", "OBSERVATION", 67, 76], ["chest", "ANATOMY", 95, 100]]], ["Patients must be enrolled within 48 h of ARDS onset and no later than 7 days from the initiation of mechanical ventilation.Exclusion criteriaThe exclusion criteria are defined as follows: subject age < 18 years; time interval more than 7 days since the initiation of mechanical ventilation; more than 48 h since the onset of ARDS; patient, surrogate, or physician not committed to full intensive care support; positive pregnancy test at the time of screening; and contraindications against iloprost.", [["ARDS", "DISEASE", 41, 45], ["ARDS", "DISEASE", 325, 329], ["iloprost", "CHEMICAL", 490, 498], ["iloprost", "CHEMICAL", 490, 498], ["Patients", "ORGANISM", 0, 8], ["patient", "ORGANISM", 331, 338], ["iloprost", "SIMPLE_CHEMICAL", 490, 498], ["Patients", "SPECIES", 0, 8], ["patient", "SPECIES", 331, 338], ["ARDS onset", "PROBLEM", 41, 51], ["mechanical ventilation", "TREATMENT", 100, 122], ["mechanical ventilation", "TREATMENT", 267, 289], ["ARDS", "PROBLEM", 325, 329], ["positive pregnancy test", "PROBLEM", 410, 433], ["screening", "TEST", 449, 458], ["iloprost", "TREATMENT", 490, 498], ["mechanical ventilation", "OBSERVATION", 100, 122], ["mechanical ventilation", "OBSERVATION", 267, 289], ["ARDS", "OBSERVATION", 325, 329]]], ["These are defined as conditions in which the effects of iloprost on platelets might increase the risk of hemorrhage (e.g., active peptic ulcers, trauma, intracranial hemorrhage), severe coronary heart disease, myocardial infarction (within the last 6 months), decompensated heart failure, severe arrhythmias, unstable angina pectoris, pulmonary arterial hypertension caused by the occlusion of pulmonary veins, cerebrovascular events (e.g., transient ischemic attack, stroke) within the last 3 months, and congenital or acquired valvular defects with clinically relevant myocardial function disorders not related to pulmonary hypertension.", [["platelets", "ANATOMY", 68, 77], ["peptic", "ANATOMY", 130, 136], ["intracranial", "ANATOMY", 153, 165], ["coronary", "ANATOMY", 186, 194], ["heart", "ANATOMY", 195, 200], ["myocardial", "ANATOMY", 210, 220], ["heart", "ANATOMY", 274, 279], ["pulmonary arterial", "ANATOMY", 335, 353], ["pulmonary veins", "ANATOMY", 394, 409], ["cerebrovascular", "ANATOMY", 411, 426], ["valvular", "ANATOMY", 529, 537], ["myocardial", "ANATOMY", 571, 581], ["pulmonary", "ANATOMY", 616, 625], ["iloprost", "CHEMICAL", 56, 64], ["hemorrhage", "DISEASE", 105, 115], ["ulcers", "DISEASE", 137, 143], ["trauma", "DISEASE", 145, 151], ["intracranial hemorrhage", "DISEASE", 153, 176], ["coronary heart disease", "DISEASE", 186, 208], ["myocardial infarction", "DISEASE", 210, 231], ["decompensated heart failure", "DISEASE", 260, 287], ["arrhythmias", "DISEASE", 296, 307], ["angina pectoris", "DISEASE", 318, 333], ["pulmonary arterial hypertension", "DISEASE", 335, 366], ["cerebrovascular events", "DISEASE", 411, 433], ["transient ischemic attack", "DISEASE", 441, 466], ["stroke", "DISEASE", 468, 474], ["valvular defects", "DISEASE", 529, 545], ["myocardial function disorders", "DISEASE", 571, 600], ["pulmonary hypertension", "DISEASE", 616, 638], ["iloprost", "CHEMICAL", 56, 64], ["iloprost", "SIMPLE_CHEMICAL", 56, 64], ["platelets", "CELL", 68, 77], ["heart", "ORGAN", 195, 200], ["myocardial", "MULTI-TISSUE_STRUCTURE", 210, 220], ["heart", "ORGAN", 274, 279], ["pulmonary arterial", "MULTI-TISSUE_STRUCTURE", 335, 353], ["pulmonary veins", "MULTI-TISSUE_STRUCTURE", 394, 409], ["cerebrovascular", "MULTI-TISSUE_STRUCTURE", 411, 426], ["valvular", "ORGAN", 529, 537], ["myocardial", "MULTI-TISSUE_STRUCTURE", 571, 581], ["pulmonary", "ORGAN", 616, 625], ["platelets", "CELL_TYPE", 68, 77], ["iloprost on platelets", "TREATMENT", 56, 77], ["hemorrhage", "PROBLEM", 105, 115], ["active peptic ulcers", "PROBLEM", 123, 143], ["trauma", "PROBLEM", 145, 151], ["intracranial hemorrhage", "PROBLEM", 153, 176], ["severe coronary heart disease", "PROBLEM", 179, 208], ["myocardial infarction", "PROBLEM", 210, 231], ["decompensated heart failure", "PROBLEM", 260, 287], ["severe arrhythmias", "PROBLEM", 289, 307], ["unstable angina pectoris", "PROBLEM", 309, 333], ["pulmonary arterial hypertension", "PROBLEM", 335, 366], ["the occlusion of pulmonary veins", "PROBLEM", 377, 409], ["cerebrovascular events", "PROBLEM", 411, 433], ["transient ischemic attack", "PROBLEM", 441, 466], ["stroke", "PROBLEM", 468, 474], ["congenital or acquired valvular defects", "PROBLEM", 506, 545], ["clinically relevant myocardial function disorders", "PROBLEM", 551, 600], ["pulmonary hypertension", "PROBLEM", 616, 638], ["hemorrhage", "OBSERVATION", 105, 115], ["active", "OBSERVATION_MODIFIER", 123, 129], ["peptic ulcers", "OBSERVATION", 130, 143], ["intracranial", "ANATOMY", 153, 165], ["hemorrhage", "OBSERVATION", 166, 176], ["severe", "OBSERVATION_MODIFIER", 179, 185], ["coronary heart", "ANATOMY", 186, 200], ["disease", "OBSERVATION", 201, 208], ["myocardial", "ANATOMY", 210, 220], ["infarction", "OBSERVATION", 221, 231], ["decompensated", "OBSERVATION_MODIFIER", 260, 273], ["heart", "ANATOMY", 274, 279], ["failure", "OBSERVATION", 280, 287], ["severe", "OBSERVATION_MODIFIER", 289, 295], ["arrhythmias", "OBSERVATION", 296, 307], ["unstable", "OBSERVATION_MODIFIER", 309, 317], ["angina pectoris", "OBSERVATION", 318, 333], ["pulmonary arterial", "ANATOMY", 335, 353], ["hypertension", "OBSERVATION", 354, 366], ["occlusion", "OBSERVATION", 381, 390], ["pulmonary veins", "ANATOMY", 394, 409], ["cerebrovascular", "ANATOMY", 411, 426], ["transient", "OBSERVATION_MODIFIER", 441, 450], ["ischemic", "OBSERVATION_MODIFIER", 451, 459], ["stroke", "OBSERVATION", 468, 474], ["congenital", "OBSERVATION", 506, 516], ["valvular", "ANATOMY", 529, 537], ["defects", "OBSERVATION", 538, 545], ["pulmonary", "ANATOMY", 616, 625], ["hypertension", "OBSERVATION", 626, 638]]], ["Patients who received iloprost treatment for any indication within 48 h prior to enrollment in the clinical trial or patients who were on thrombin inhibitors or nitric oxide (NO) within the previous 24 h before study randomization were also excluded.", [["iloprost", "CHEMICAL", 22, 30], ["nitric oxide", "CHEMICAL", 161, 173], ["NO", "CHEMICAL", 175, 177], ["iloprost", "CHEMICAL", 22, 30], ["nitric oxide", "CHEMICAL", 161, 173], ["NO", "CHEMICAL", 175, 177], ["Patients", "ORGANISM", 0, 8], ["iloprost", "SIMPLE_CHEMICAL", 22, 30], ["patients", "ORGANISM", 117, 125], ["thrombin", "GENE_OR_GENE_PRODUCT", 138, 146], ["nitric oxide", "SIMPLE_CHEMICAL", 161, 173], ["NO", "SIMPLE_CHEMICAL", 175, 177], ["thrombin", "PROTEIN", 138, 146], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 117, 125], ["iloprost treatment", "TREATMENT", 22, 40], ["thrombin inhibitors", "TREATMENT", 138, 157], ["nitric oxide", "TREATMENT", 161, 173], ["study randomization", "TEST", 211, 230]]], ["Additionally, patients dependent on the sponsor, investigator, or their employees were not included in the study.Study drugThe IMP is iloprost (Ventavis\u00ae; Drug code SUB14185MIG; ATC code B01AC11), manufactured by Berlimed S.A., Madrid, Spain (for Bayer Pharma AG, Germany).", [["IMP", "CHEMICAL", 127, 130], ["iloprost", "CHEMICAL", 134, 142], ["Ventavis\u00ae", "CHEMICAL", 144, 153], ["IMP", "CHEMICAL", 127, 130], ["iloprost", "CHEMICAL", 134, 142], ["Ventavis\u00ae", "CHEMICAL", 144, 153], ["patients", "ORGANISM", 14, 22], ["IMP", "SIMPLE_CHEMICAL", 127, 130], ["iloprost", "SIMPLE_CHEMICAL", 134, 142], ["patients", "SPECIES", 14, 22], ["the study", "TEST", 103, 112], ["iloprost (Ventavis\u00ae", "TREATMENT", 134, 153], ["Drug code SUB", "TREATMENT", 155, 168], ["ATC code B01AC11)", "TREATMENT", 178, 195], ["dependent", "OBSERVATION_MODIFIER", 23, 32]]], ["It will be used as a concentrate for use in nebulizers and will be administered by inhalation three times a day (20 \u03bcg per administration).", [["nebulizers", "TREATMENT", 44, 54]]], ["The administration of the drug will occur at the same time each day \u00b1 1 h.", [["the drug", "TREATMENT", 22, 30]]], ["In cases of severe adverse effects, the dosage will be reduced to 20 \u03bcg once a day (morning).", [["severe adverse effects", "PROBLEM", 12, 34], ["the dosage", "TREATMENT", 36, 46], ["severe", "OBSERVATION_MODIFIER", 12, 18]]], ["Other dose modifications or temporary cessation of the study drug will not be allowed.Study drugIloprost is usually dissolved in 0.9% sodium chloride (NaCl), which is used to keep the ventilator circuit moist as standard of care.", [["drugIloprost", "CHEMICAL", 92, 104], ["sodium chloride", "CHEMICAL", 134, 149], ["NaCl", "CHEMICAL", 151, 155], ["drugIloprost", "CHEMICAL", 92, 104], ["sodium chloride", "CHEMICAL", 134, 149], ["NaCl", "CHEMICAL", 151, 155], ["drugIloprost", "SIMPLE_CHEMICAL", 92, 104], ["sodium chloride", "SIMPLE_CHEMICAL", 134, 149], ["NaCl", "SIMPLE_CHEMICAL", 151, 155], ["Other dose modifications", "TREATMENT", 0, 24], ["temporary cessation", "TREATMENT", 28, 47], ["the study drug", "TREATMENT", 51, 65], ["Study drugIloprost", "TREATMENT", 86, 104], ["sodium chloride (NaCl)", "TREATMENT", 134, 156], ["the ventilator circuit", "TREATMENT", 180, 202], ["ventilator circuit", "OBSERVATION", 184, 202]]], ["Therefore, in the control group, NaCl 0.9% will be used to keep the airway circuit moist, which is the standard of care for the treatment of patients with pulmonary insufficiency [7] .", [["airway", "ANATOMY", 68, 74], ["pulmonary", "ANATOMY", 155, 164], ["NaCl", "CHEMICAL", 33, 37], ["pulmonary insufficiency", "DISEASE", 155, 178], ["NaCl", "CHEMICAL", 33, 37], ["airway", "MULTI-TISSUE_STRUCTURE", 68, 74], ["patients", "ORGANISM", 141, 149], ["pulmonary", "ORGAN", 155, 164], ["patients", "SPECIES", 141, 149], ["NaCl", "TREATMENT", 33, 37], ["the airway circuit", "TREATMENT", 64, 82], ["the treatment", "TREATMENT", 124, 137], ["pulmonary insufficiency", "PROBLEM", 155, 178], ["airway", "ANATOMY", 68, 74], ["pulmonary", "ANATOMY", 155, 164], ["insufficiency", "OBSERVATION", 165, 178]]], ["Considering the pharmacokinetic and dynamic profile of iloprost, we have suggested an approach of an application of three times per day, with a dose of 20 \u03bcg, which seems to be an average dose in the trials reported up to now.", [["iloprost", "CHEMICAL", 55, 63], ["iloprost", "CHEMICAL", 55, 63], ["iloprost", "SIMPLE_CHEMICAL", 55, 63], ["iloprost", "TREATMENT", 55, 63]]], ["The rationale behind this was that iloprost also exerts an anti- inflammatory effect that may last up to 6 h [29] [30] [31] [32] [33] .", [["iloprost", "CHEMICAL", 35, 43], ["iloprost", "CHEMICAL", 35, 43], ["iloprost", "SIMPLE_CHEMICAL", 35, 43], ["[29] [30] [31] [32] [33]", "SIMPLE_CHEMICAL", 109, 133], ["iloprost", "TREATMENT", 35, 43], ["an anti- inflammatory effect", "PROBLEM", 56, 84], ["inflammatory", "OBSERVATION", 65, 77]]], ["Therefore, an administration of iloprost three times a day would allow a significant time frame per day to be covered by anti-inflammation due to this drug.", [["iloprost", "CHEMICAL", 32, 40], ["iloprost", "CHEMICAL", 32, 40], ["iloprost", "SIMPLE_CHEMICAL", 32, 40], ["iloprost", "TREATMENT", 32, 40]]], ["The duration of 5 days was included in the trial because the pathophysiology of ARDS develops within the first few days and is progressive during that period.RandomizationRandomization lists will be generated at the biostatistical center.", [["ARDS", "DISEASE", 80, 84], ["ARDS", "PROBLEM", 80, 84], ["RandomizationRandomization", "TREATMENT", 158, 184], ["ARDS", "OBSERVATION", 80, 84], ["progressive", "OBSERVATION_MODIFIER", 127, 138]]], ["Based on these lists, numbered envelopes will be provided and used for randomization.Concomitant medication and treatmentsRelevant additional medications and treatments such as vasopressors, inotropes, anti-infective agents, inhalative therapy or sedation, steroids, and immunosuppressive therapy administered to the subjects on entry to the trial or at any time during the trial are regarded as concomitant medications and treatments and must be documented on the appropriate pages of the case report form (CRF); these data will be grouped according to class of medication.", [["steroids", "CHEMICAL", 257, 265], ["CRF", "DISEASE", 508, 511], ["steroids", "CHEMICAL", 257, 265], ["randomization", "TREATMENT", 71, 84], ["Concomitant medication", "TREATMENT", 85, 107], ["treatments", "TREATMENT", 112, 122], ["Relevant additional medications", "TREATMENT", 122, 153], ["treatments", "TREATMENT", 158, 168], ["vasopressors", "TREATMENT", 177, 189], ["inotropes", "TREATMENT", 191, 200], ["anti-infective agents", "TREATMENT", 202, 223], ["inhalative therapy", "TREATMENT", 225, 243], ["sedation", "TREATMENT", 247, 255], ["steroids", "TREATMENT", 257, 265], ["immunosuppressive therapy", "TREATMENT", 271, 296], ["concomitant medications", "TREATMENT", 396, 419], ["treatments", "TREATMENT", 424, 434], ["medication", "TREATMENT", 563, 573]]], ["Depending on the substance, the documentation varies in details (e.g., dosing).Intervention planThis study will consist of the following consecutive phases: study entry, treatment, and follow-up.", [["This study", "TEST", 96, 106], ["treatment", "TREATMENT", 170, 179]]], ["The time points and trial procedures are listed in Table 2 .", [["trial procedures", "TREATMENT", 20, 36]]], ["All patients included in this trial will receive standard care for ARDS according to the ARDS network, with special consideration of lung-protective ventilation strategies.Study entryIn this trial, patients with ARDS present an emergency situation, such as the diagnosis of ARDS requiring intensive care unit (ICU) admission and ventilation therapy, which does not allow for any delay of diagnostic workup or therapy.", [["lung", "ANATOMY", 133, 137], ["ARDS", "DISEASE", 67, 71], ["ARDS", "DISEASE", 89, 93], ["ARDS", "DISEASE", 212, 216], ["ARDS", "DISEASE", 274, 278], ["patients", "ORGANISM", 4, 12], ["lung", "ORGAN", 133, 137], ["patients", "ORGANISM", 198, 206], ["patients", "SPECIES", 4, 12], ["patients", "SPECIES", 198, 206], ["standard care", "TREATMENT", 49, 62], ["ARDS", "PROBLEM", 67, 71], ["lung-protective ventilation strategies", "TREATMENT", 133, 171], ["ARDS", "PROBLEM", 212, 216], ["ARDS", "PROBLEM", 274, 278], ["ventilation therapy", "TREATMENT", 329, 348], ["diagnostic workup", "TEST", 388, 405], ["therapy", "TREATMENT", 409, 416], ["lung", "ANATOMY", 133, 137], ["ARDS", "OBSERVATION", 274, 278]]], ["Additionally, due to severe symptoms, the vast majority of patients who meet the eligibility criteria for the trial are assumed to be unable to give consent in the acute admission phase, and legally authorized representatives (LARs) might not be available in most cases.", [["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67], ["severe symptoms", "PROBLEM", 21, 36], ["severe", "OBSERVATION_MODIFIER", 21, 27], ["symptoms", "OBSERVATION", 28, 36]]], ["This is also in line with local regulations: e.g., \u00a741 of the German Drug Law allows the start of a treatment in an emergency situation without prior consent if the immediate treatment is necessary to save the patient's life, recover the patient's health, or ease the patient's suffering.Study entryIn this situation the consent of an independent physician not directly involved in the study conduct will be sought before the beginning of any study-related activity.", [["patient", "ORGANISM", 210, 217], ["patient", "ORGANISM", 238, 245], ["patient", "ORGANISM", 268, 275], ["patient", "SPECIES", 210, 217], ["patient", "SPECIES", 238, 245], ["patient", "SPECIES", 268, 275], ["a treatment", "TREATMENT", 98, 109], ["the immediate treatment", "TREATMENT", 161, 184], ["Study entry", "TEST", 288, 299], ["any study", "TEST", 439, 448]]], ["The consent has to be obtained as soon as the patient is able to give consent or a LAR is available.", [["patient", "ORGANISM", 46, 53], ["LAR", "GENE_OR_GENE_PRODUCT", 83, 86], ["patient", "SPECIES", 46, 53]]], ["Independently, personal consent will be obtained from each patient after recovering consciousness and competence for decisionmaking or by a legal representative in cases recovering is not achieved during the study duration (i.e., day 27).", [["patient", "ORGANISM", 59, 66], ["patient", "SPECIES", 59, 66], ["consciousness", "PROBLEM", 84, 97]]], ["When possible, however, the patient or his legal representative is to be informed both in writing and verbally by the investigator before any study-specific procedure is Iloprost or NaCl 0.9% (control) X X X X X Clinical assessment including outcome X X X X X X X X X Laboratory testing X X X X X X X X Adverse/serious adverse event monitoring X X X X X X X Plasma biomarkers X X X X X X Barthel Index X X X X SOFA score X X X X X X X X Health-related questionnaire X VES X performed.", [["Iloprost", "CHEMICAL", 170, 178], ["NaCl", "CHEMICAL", 182, 186], ["Iloprost", "CHEMICAL", 170, 178], ["NaCl", "CHEMICAL", 182, 186], ["patient", "ORGANISM", 28, 35], ["Iloprost", "SIMPLE_CHEMICAL", 170, 178], ["X X", "DNA", 264, 267], ["X X X X X X X X", "DNA", 287, 302], ["X X X X X X X", "DNA", 344, 357], ["X X X X X X", "DNA", 376, 387], ["X VES X", "DNA", 466, 473], ["patient", "SPECIES", 28, 35], ["any study", "TEST", 138, 147], ["specific procedure", "TREATMENT", 148, 166], ["Iloprost or NaCl", "TREATMENT", 170, 186], ["Clinical assessment", "TEST", 212, 231], ["Laboratory testing", "TEST", 268, 286], ["Adverse/serious adverse event", "PROBLEM", 303, 332], ["monitoring X X X X X X X Plasma biomarkers", "TREATMENT", 333, 375], ["Barthel Index", "TEST", 388, 401], ["SOFA score", "TEST", 410, 420], ["Health", "TEST", 437, 443], ["monitoring X X X X", "OBSERVATION_MODIFIER", 333, 351]]], ["Each patient or his legal representative will be informed about the modalities of the clinical study in accordance with the provided patient information.", [["patient", "ORGANISM", 5, 12], ["patient", "ORGANISM", 133, 140], ["patient", "SPECIES", 5, 12], ["patient", "SPECIES", 133, 140], ["the clinical study", "TEST", 82, 100]]], ["Informed consent from the patient will be obtained using a form approved by the ethics committee (EC) of the Universit\u00e4tsklinikum T\u00fcbingen or the local EC if the patient is treated in a collaborating institution.Treatment phaseThe treatment group will receive 20 \u03bcg of nebulized iloprost three times per day for 5 days in addition to standard care.", [["EC", "ANATOMY", 152, 154], ["iloprost", "CHEMICAL", 279, 287], ["iloprost", "CHEMICAL", 279, 287], ["patient", "ORGANISM", 26, 33], ["EC", "CELL", 98, 100], ["EC", "CELL", 152, 154], ["patient", "ORGANISM", 162, 169], ["iloprost", "SIMPLE_CHEMICAL", 279, 287], ["EC", "CELL_TYPE", 152, 154], ["patient", "SPECIES", 26, 33], ["patient", "SPECIES", 162, 169], ["Treatment phase", "TEST", 212, 227], ["nebulized iloprost", "TREATMENT", 269, 287]]], ["Iloprost will be measured in blood samples to determine the serum levels within this setting.Treatment phaseThe control group will receive nebulized 0.9% NaCl with an equal volume three times per day for 5 days.", [["blood samples", "ANATOMY", 29, 42], ["serum", "ANATOMY", 60, 65], ["Iloprost", "CHEMICAL", 0, 8], ["NaCl", "CHEMICAL", 154, 158], ["Iloprost", "CHEMICAL", 0, 8], ["NaCl", "CHEMICAL", 154, 158], ["Iloprost", "SIMPLE_CHEMICAL", 0, 8], ["blood samples", "ORGANISM_SUBSTANCE", 29, 42], ["serum", "ORGANISM_SUBSTANCE", 60, 65], ["Iloprost", "TREATMENT", 0, 8], ["blood samples", "TEST", 29, 42], ["the serum levels", "TEST", 56, 72], ["Treatment phase", "TEST", 93, 108], ["nebulized 0.9% NaCl", "TREATMENT", 139, 158], ["an equal volume", "TREATMENT", 164, 179]]], ["After 5 days, the trial treatment will be complete (Fig. 1) .", [["the trial treatment", "TREATMENT", 14, 33]]], ["Blood samples will be drawn at defined time points for a variety of biomarkers to better assess the associations among coagulation, inflammation, and iloprost treatment.", [["Blood samples", "ANATOMY", 0, 13], ["inflammation", "DISEASE", 132, 144], ["iloprost", "CHEMICAL", 150, 158], ["iloprost", "CHEMICAL", 150, 158], ["Blood samples", "ORGANISM_SUBSTANCE", 0, 13], ["iloprost", "SIMPLE_CHEMICAL", 150, 158], ["Blood samples", "TEST", 0, 13], ["a variety of biomarkers", "TEST", 55, 78], ["inflammation", "PROBLEM", 132, 144], ["iloprost treatment", "TREATMENT", 150, 168], ["inflammation", "OBSERVATION", 132, 144], ["iloprost treatment", "OBSERVATION", 150, 168]]], ["Key cointerventions (infection control, aspiration precautions, fluids, and transfusion) will be standardized across all patients.", [["infection", "DISEASE", 21, 30], ["patients", "ORGANISM", 121, 129], ["patients", "SPECIES", 121, 129], ["Key cointerventions (infection control", "TREATMENT", 0, 38], ["aspiration precautions", "TREATMENT", 40, 62], ["fluids", "TREATMENT", 64, 70], ["transfusion", "TREATMENT", 76, 87]]], ["Mechanical ventilation will be standardized (see Additional file 1).Follow-upHospital survivors will undergo a brief follow-up phone survey to assess functional status (Barthel Index), a health-related questionnaire, and the Vulnerable Elders Survey (VES) to assess frailty 6 months after enrollment.", [["Mechanical ventilation", "TREATMENT", 0, 22]]], ["The patients will be visited daily until day 28 or until discharge from the ICU, which could be beyond day 28.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12]]], ["If discharged, the next visit will be on day 90; if patients are still in the ICU, there will still be daily visits until this time point.", [["patients", "ORGANISM", 52, 60], ["patients", "SPECIES", 52, 60]]], ["Data will be collected according to the study procedure until then.", [["the study procedure", "TEST", 36, 55]]], ["Each visit will consist of a clinical examination, a blood sample, assessment of the functional capacity through the Barthel Index, and assessment of the severity of illness through the Sequential Organ Failure Assessment (SOFA) score.", [["blood sample", "ANATOMY", 53, 65], ["Organ", "ANATOMY", 197, 202], ["illness", "DISEASE", 166, 173], ["blood", "ORGANISM_SUBSTANCE", 53, 58], ["a clinical examination", "TEST", 27, 49], ["a blood sample", "TEST", 51, 65], ["assessment", "TEST", 67, 77], ["the Barthel Index", "TEST", 113, 130], ["assessment", "TEST", 136, 146], ["illness", "PROBLEM", 166, 173], ["the Sequential Organ Failure Assessment", "TEST", 182, 221]]], ["Blood samples will be drawn at defined visits for a variety of biomarkers to better assess the associations among coagulation, inflammation, and iloprost treatment (Table 3) .Outcome measurements Study objectivesThe primary objective and endpoint is to assess the effect of iloprost on the improvement of oxygenation (PaO 2 /FiO 2 ratio) in patients with ARDS.Outcome measurements Study objectivesAs secondary objectives, the absolute incidence of the following parameters will be determined: Fig. 1 Trial protocol and intervention scheme.", [["Blood samples", "ANATOMY", 0, 13], ["inflammation", "DISEASE", 127, 139], ["iloprost", "CHEMICAL", 145, 153], ["iloprost", "CHEMICAL", 274, 282], ["ARDS", "DISEASE", 355, 359], ["iloprost", "CHEMICAL", 145, 153], ["iloprost", "CHEMICAL", 274, 282], ["Blood samples", "ORGANISM_SUBSTANCE", 0, 13], ["iloprost", "SIMPLE_CHEMICAL", 145, 153], ["iloprost", "SIMPLE_CHEMICAL", 274, 282], ["FiO 2", "GENE_OR_GENE_PRODUCT", 325, 330], ["patients", "ORGANISM", 341, 349], ["patients", "SPECIES", 341, 349], ["Blood samples", "TEST", 0, 13], ["inflammation", "PROBLEM", 127, 139], ["iloprost treatment", "TREATMENT", 145, 163], ["Outcome measurements", "TEST", 175, 195], ["iloprost", "TREATMENT", 274, 282], ["oxygenation", "TEST", 305, 316], ["PaO", "TEST", 318, 321], ["FiO", "TEST", 325, 328], ["ARDS", "PROBLEM", 355, 359], ["Outcome measurements", "TEST", 360, 380], ["intervention scheme", "TREATMENT", 519, 538], ["ARDS", "OBSERVATION", 355, 359]]], ["After screening and determination of eligibility, patients will be included after a maximum of 48 h after the onset of ARDS.", [["ARDS", "DISEASE", 119, 123], ["patients", "ORGANISM", 50, 58], ["patients", "SPECIES", 50, 58], ["screening", "TEST", 6, 15], ["ARDS", "PROBLEM", 119, 123], ["ARDS", "OBSERVATION", 119, 123]]], ["Within this time period, screening, consent, and randomization will be initialized.", [["screening", "TEST", 25, 34], ["randomization", "TREATMENT", 49, 62]]], ["In addition, lung-protective ventilation will be instituted.", [["lung", "ANATOMY", 13, 17], ["lung", "ORGAN", 13, 17], ["lung-protective ventilation", "TREATMENT", 13, 40], ["lung", "ANATOMY", 13, 17], ["protective ventilation", "OBSERVATION", 18, 40]]], ["After randomization, iloprost 3 \u00d7 20 \u03bcg (intervention) or NaCl 0.9% (control) will be administered for 5 days through a standard ultrasound nebulizer.", [["iloprost", "CHEMICAL", 21, 29], ["NaCl", "CHEMICAL", 58, 62], ["iloprost", "CHEMICAL", 21, 29], ["NaCl", "CHEMICAL", 58, 62], ["iloprost", "SIMPLE_CHEMICAL", 21, 29], ["randomization", "TREATMENT", 6, 19], ["iloprost", "TREATMENT", 21, 29], ["NaCl", "TREATMENT", 58, 62], ["a standard ultrasound nebulizer", "TREATMENT", 118, 149]]], ["Daily recordings will be made with respect to the development of the PaO 2 /FiO 2 ratio and the severity of ARDS, organ failure, lung injury, and potential adverse events.", [["organ", "ANATOMY", 114, 119], ["lung", "ANATOMY", 129, 133], ["ARDS", "DISEASE", 108, 112], ["organ failure", "DISEASE", 114, 127], ["lung injury", "DISEASE", 129, 140], ["PaO 2", "CHEMICAL", 69, 74], ["FiO 2", "CHEMICAL", 76, 81], ["PaO 2", "GENE_OR_GENE_PRODUCT", 69, 74], ["FiO 2", "GENE_OR_GENE_PRODUCT", 76, 81], ["organ", "ORGAN", 114, 119], ["lung", "ORGAN", 129, 133], ["the PaO", "TEST", 65, 72], ["FiO", "TEST", 76, 79], ["ARDS", "PROBLEM", 108, 112], ["organ failure", "PROBLEM", 114, 127], ["lung injury", "PROBLEM", 129, 140], ["potential adverse events", "PROBLEM", 146, 170], ["ARDS", "OBSERVATION", 108, 112], ["organ", "ANATOMY", 114, 119], ["failure", "OBSERVATION", 120, 127], ["lung", "ANATOMY", 129, 133], ["injury", "OBSERVATION", 134, 140]]], ["The treatment with iloprost or NaCl (0.9%) will be stopped after 5 days.", [["iloprost", "CHEMICAL", 19, 27], ["NaCl", "CHEMICAL", 31, 35], ["iloprost", "CHEMICAL", 19, 27], ["NaCl", "CHEMICAL", 31, 35], ["iloprost", "SIMPLE_CHEMICAL", 19, 27], ["NaCl", "SIMPLE_CHEMICAL", 31, 35], ["iloprost or NaCl", "TREATMENT", 19, 35]]], ["The follow-up period will then continue up to 90 days and 6 months to determine the outcome, quality of life, and pulmonary/secondary organ function Overall survival in the 90-day follow-up period (90day all-cause mortality) Duration of mechanical ventilation support ICU length of stay Ventilator-associated pneumonia Pulmonary hemorrhage Gastrointestinal hemorrhage Pulmonary embolism Hospital discharge or d90Outcome measurements Study objectivesLaboratory testingOutcome measurements Study objectivesBlood count X a X a X a X a X a X a X b X c X X Procalcitonin X a X a X a X a X a X a X b X c X X IL-6 X a X a X a X a X a X a X b X c X X PaO 2 /FiO 2 X a X a X a X a X a X a X b X c Hemoglobin X a X a X a X a X a X a X b X c X X Hemostasis parameters X a X a X a X a X a X a X b X c X XOutcome measurements Study objectivesRenal parameters X a X a X a X a X a X a X b X c X XClinical parametersVentilation support including ventilation parameters X a X a X a X a X a X a X a Prone positioning X a X a X a X a X a X a X a ECMO X a X a X a X a X a X a X a Relaxation X a X a X a X a X a X a X a High-frequency ventilation X a X a X a X a X a X a X a Tracheotomy Hemodynamic parameters X a X a X a X a X a X a X b X X XClinical parametersVasopressor therapy X a X a X a X a X a X a X a Inotrope therapy X a X a X a X a X a X a X a Fluid balance X a X a X a X a X a X a X a Transfusion of red blood cells X X X X X X X b X X X Transfusion of thrombocytes X X X X X X X b X X X Anticoagulation Infection X X X X X X X b X X X Anti-infective therapy X X X X X X X b X X X The exploratory objectives are 6-month survival, quality of life (QOL) assessed with a short-form survey (SF12), functional status (Barthel Index), and frailty (VES) assessed by phone follow-up interview.Efficacy parametersThe following parameters will be used to determine the treatment efficacy: Improvement of oxygenation (PaO 2 /FiO 2 ) on a daily basis in relationship to baseline Overall survival in the 90-day follow-up period Decrease in duration and severity of ARDS SOFA scores: to be calculated based on data in hospital records Duration of mechanical ventilation support: documentation in hospital records ICU length of stay: documentation in hospital recordsEfficacy parametersVentilator-associated pneumonia: documentation of microbiological findings in hospital records Incidence of barotrauma: documentation of ventilator parameters in hospital records Reduced morbidity assessed through SOFA score, also according to the incidence of complications and increased functionality assessed through the Barthel Index Delirium: documentation (e.g., confusion assessment method for the ICU [CAM-ICU]) in hospital records ICU-acquired weakness: documentation in hospital records Discharge location: documentation in hospital records, phone call.Efficacy parametersThe demographic parameters at enrollment include age, sex, race, ICU admission diagnosis, and comorbidities (such as diabetes, existing malignancy, any kind of pre-existing pulmonary disease, and hypertension).Efficacy parametersThe main clinical data obtained during the ICU daily assessment are as follows:Efficacy parametersLaboratory data: Blood count, procalcitonin, interleukin (IL)-6, creatinine, urea, partial thromboplastin time (PTT), D-dimers, international normalized ratio (INR), aspartate aminotransferase (AST), alanine aminotransferase (ALT), albumin, cholinesterase (CHE), brain natriuretic peptide (BNP) Weekly assessments of the ICU will include the following:Efficacy parametersDifferential blood count Creatinine clearance ECMO post-oxygenator PaO 2 SOFA score Assessment at discharge Chronic renal failure at discharge Hepatic failure at discharge Length of stay in the ICU Length of stay in the hospital Discharge from hospital to a nursing home Discharge from hospital to home Discharge from hospital to a rehabilitation unit Residence in nursing home at 6 monthsEfficacy parametersThe final assessment will consist of the following:Efficacy parametersDays of ECMO support Ventilator days Tracheotomy Need for mechanical ventilation at home Incidence of pulmonary hemorrhage defined by an indication for blood transfusion, radiological finding, or a decrease in oxygenation Incidence of barotrauma Incidence of pleural drainage Incidence of pulmonary embolism defined by the following parameters:Efficacy parametersNew hypotension Sign of right ventricular failure on echocardiography Biomarkers Computed tomography (CT) scan (optional) Incidence of gastrointestinal bleeding defined by the following parameters: upper gastrointestinal bleeding, blood vomiting, lower gastrointestinal bleeding, melena, indication for blood transfusion, endoscopic diagnosis/intervention Incidence of cerebral hemorrhage defined by the following parameters: impairment as measured by the Glasgow Coma Scale, CT scan Infections: incidence of positive blood culture, pneumonia, wound infection, peritonitis, surgical intervention due to infection, bacterial infection, fungal infection, viral infection, or multidrugresistant Gram-negative bacteria (MRGN) infection Anti-infective therapy: generic, duration, incidence of changing anti-infective therapy due to inadequate treatment Incidence of surgical intervention.Data collection and management Case report formThe trial case report form (CRF) is the primary data collection instrument for the trial.", [["pulmonary", "ANATOMY", 114, 123], ["organ", "ANATOMY", 134, 139], ["Pulmonary", "ANATOMY", 319, 328], ["Blood", "ANATOMY", 504, 509], ["Renal", "ANATOMY", 829, 834], ["red blood cells", "ANATOMY", 1391, 1406], ["pulmonary", "ANATOMY", 3017, 3026], ["Blood", "ANATOMY", 3188, 3193], ["blood", "ANATOMY", 3555, 3560], ["renal", "ANATOMY", 3658, 3663], ["Hepatic", "ANATOMY", 3685, 3692], ["pulmonary", "ANATOMY", 4122, 4131], ["blood", "ANATOMY", 4172, 4177], ["pleural", "ANATOMY", 4279, 4286], ["pulmonary", "ANATOMY", 4309, 4318], ["right ventricular", "ANATOMY", 4407, 4424], ["gastrointestinal", "ANATOMY", 4518, 4534], ["gastrointestinal", "ANATOMY", 4587, 4603], ["blood", "ANATOMY", 4614, 4619], ["lower gastrointestinal", "ANATOMY", 4630, 4652], ["blood", "ANATOMY", 4686, 4691], ["cerebral", "ANATOMY", 4752, 4760], ["blood", "ANATOMY", 4901, 4906], ["wound", "ANATOMY", 4927, 4932], ["pneumonia", "DISEASE", 309, 318], ["Pulmonary hemorrhage", "DISEASE", 319, 339], ["Gastrointestinal hemorrhage", "DISEASE", 340, 367], ["Pulmonary embolism", "DISEASE", 368, 386], ["ARDS", "DISEASE", 2043, 2047], ["pneumonia", "DISEASE", 2284, 2293], ["barotrauma", "DISEASE", 2370, 2380], ["Delirium", "DISEASE", 2600, 2608], ["confusion", "DISEASE", 2631, 2640], ["diabetes", "DISEASE", 2961, 2969], ["malignancy", "DISEASE", 2980, 2990], ["pre-existing pulmonary disease", "DISEASE", 3004, 3034], ["hypertension", "DISEASE", 3040, 3052], ["creatinine", "CHEMICAL", 3236, 3246], ["urea", "CHEMICAL", 3248, 3252], ["aspartate", "CHEMICAL", 3337, 3346], ["alanine", "CHEMICAL", 3371, 3378], ["Chronic renal failure", "DISEASE", 3650, 3671], ["Hepatic failure", "DISEASE", 3685, 3700], ["pulmonary hemorrhage", "DISEASE", 4122, 4142], ["barotrauma", "DISEASE", 4255, 4265], ["pleural drainage", "DISEASE", 4279, 4295], ["pulmonary embolism", "DISEASE", 4309, 4327], ["hypotension", "DISEASE", 4387, 4398], ["ventricular failure", "DISEASE", 4413, 4432], ["gastrointestinal bleeding", "DISEASE", 4518, 4543], ["gastrointestinal bleeding", "DISEASE", 4587, 4612], ["blood vomiting", "DISEASE", 4614, 4628], ["lower gastrointestinal bleeding", "DISEASE", 4630, 4661], ["melena", "DISEASE", 4663, 4669], ["cerebral hemorrhage", "DISEASE", 4752, 4771], ["Coma", "DISEASE", 4847, 4851], ["Infections", "DISEASE", 4867, 4877], ["pneumonia", "DISEASE", 4916, 4925], ["wound infection", "DISEASE", 4927, 4942], ["peritonitis", "DISEASE", 4944, 4955], ["infection", "DISEASE", 4986, 4995], ["bacterial infection", "DISEASE", 4997, 5016], ["fungal infection", "DISEASE", 5018, 5034], ["viral infection", "DISEASE", 5036, 5051], ["MRGN", "DISEASE", 5099, 5103], ["infection", "DISEASE", 5105, 5114], ["CRF", "DISEASE", 5341, 5344], ["creatinine", "CHEMICAL", 3236, 3246], ["urea", "CHEMICAL", 3248, 3252], ["aspartate", "CHEMICAL", 3337, 3346], ["alanine", "CHEMICAL", 3371, 3378], ["Creatinine", "CHEMICAL", 3567, 3577], ["pulmonary", "ORGAN", 114, 123], ["organ", "ORGAN", 134, 139], ["Blood", "ORGANISM_SUBSTANCE", 504, 509], ["Renal", "ORGAN", 829, 834], ["pulmonary", "ORGAN", 3017, 3026], ["Blood", "ORGANISM_SUBSTANCE", 3188, 3193], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 3201, 3214], ["interleukin (IL)-6", "GENE_OR_GENE_PRODUCT", 3216, 3234], ["creatinine", "SIMPLE_CHEMICAL", 3236, 3246], ["urea", "SIMPLE_CHEMICAL", 3248, 3252], ["thromboplastin", "GENE_OR_GENE_PRODUCT", 3262, 3276], ["D-dimers", "SIMPLE_CHEMICAL", 3289, 3297], ["aspartate aminotransferase", "SIMPLE_CHEMICAL", 3337, 3363], ["AST", "SIMPLE_CHEMICAL", 3365, 3368], ["alanine aminotransferase", "GENE_OR_GENE_PRODUCT", 3371, 3395], ["ALT", "SIMPLE_CHEMICAL", 3397, 3400], ["albumin", "GENE_OR_GENE_PRODUCT", 3403, 3410], ["cholinesterase", "SIMPLE_CHEMICAL", 3412, 3426], ["CHE", "SIMPLE_CHEMICAL", 3428, 3431], ["brain natriuretic peptide", "GENE_OR_GENE_PRODUCT", 3434, 3459], ["BNP", "GENE_OR_GENE_PRODUCT", 3461, 3464], ["blood", "ORGANISM_SUBSTANCE", 3555, 3560], ["Creatinine", "SIMPLE_CHEMICAL", 3567, 3577], ["renal", "ORGAN", 3658, 3663], ["Hepatic", "ORGAN", 3685, 3692], ["pulmonary", "ORGAN", 4122, 4131], ["blood", "ORGANISM_SUBSTANCE", 4172, 4177], ["pleural", "ORGAN", 4279, 4286], ["pulmonary", "ORGAN", 4309, 4318], ["ventricular", "MULTI-TISSUE_STRUCTURE", 4413, 4424], ["gastrointestinal", "ORGANISM_SUBDIVISION", 4518, 4534], ["upper gastrointestinal", "ORGANISM_SUBDIVISION", 4581, 4603], ["blood", "ORGANISM_SUBSTANCE", 4614, 4619], ["lower gastrointestinal", "ORGANISM_SUBDIVISION", 4630, 4652], ["blood", "ORGANISM_SUBSTANCE", 4686, 4691], ["cerebral", "ORGAN", 4752, 4760], ["blood", "ORGANISM_SUBSTANCE", 4901, 4906], ["wound", "PATHOLOGICAL_FORMATION", 4927, 4932], ["Gram-negative bacteria", "GENE_OR_GENE_PRODUCT", 5075, 5097], ["X a X a X a X a X", "DNA", 520, 537], ["X b X c X X", "DNA", 540, 551], ["Procalcitonin X", "DNA", 552, 567], ["X", "DNA", 570, 571], ["X", "DNA", 574, 575], ["X", "DNA", 578, 579], ["X", "DNA", 582, 583], ["X", "DNA", 586, 587], ["X b X c X X IL", "DNA", 590, 604], ["6 X", "DNA", 605, 608], ["X", "DNA", 611, 612], ["X", "DNA", 615, 616], ["X", "DNA", 619, 620], ["X", "DNA", 623, 624], ["X", "DNA", 627, 628], ["X b X c X X PaO 2", "DNA", 631, 648], ["FiO 2 X", "DNA", 650, 657], ["X", "DNA", 660, 661], ["X", "DNA", 664, 665], ["X", "DNA", 668, 669], ["X", "DNA", 672, 673], ["X", "DNA", 676, 677], ["X b X c Hemoglobin X", "DNA", 680, 700], ["X", "DNA", 703, 704], ["X", "DNA", 707, 708], ["X", "DNA", 711, 712], ["X", "DNA", 715, 716], ["X", "DNA", 719, 720], ["X b X c X X", "DNA", 723, 734], ["X", "DNA", 757, 758], ["X a X a X a X a X", "DNA", 761, 778], ["X a X a X a X a X a X a Prone positioning X a X a X a X a X a X a X", "DNA", 957, 1024], ["ECMO X", "DNA", 1027, 1033], ["X a X a X a X a X a X", "DNA", 1036, 1057], ["Relaxation X", "DNA", 1060, 1072], ["X a X a X a X a X a X a High-frequency ventilation X", "DNA", 1075, 1127], ["X a X a X a X a X a X a Tracheotomy Hemodynamic parameters X", "DNA", 1130, 1190], ["X a X a X a X a X a X b X X", "DNA", 1193, 1220], ["X a X a X a X a X a X a Inotrope therapy X", "DNA", 1265, 1307], ["X a X a X a X a X a X", "DNA", 1310, 1331], ["X a X a X a X a X a X", "DNA", 1352, 1373], ["red blood cells", "CELL_TYPE", 1391, 1406], ["X X X X X X X", "DNA", 1407, 1420], ["X X X", "DNA", 1423, 1428], ["thrombocytes X X X X X X X b X X X", "DNA", 1444, 1478], ["X X X X X X X b X X X", "DNA", 1505, 1526], ["X X X X X X X b X X X", "DNA", 1550, 1571], ["procalcitonin", "PROTEIN", 3201, 3214], ["interleukin (IL)-6", "PROTEIN", 3216, 3234], ["INR", "PROTEIN", 3331, 3334], ["aspartate aminotransferase", "PROTEIN", 3337, 3363], ["AST", "PROTEIN", 3365, 3368], ["alanine aminotransferase", "PROTEIN", 3371, 3395], ["ALT", "PROTEIN", 3397, 3400], ["albumin", "PROTEIN", 3403, 3410], ["cholinesterase", "PROTEIN", 3412, 3426], ["mechanical ventilation support", "TREATMENT", 237, 267], ["Ventilator", "TREATMENT", 287, 297], ["pneumonia", "PROBLEM", 309, 318], ["Pulmonary hemorrhage", "PROBLEM", 319, 339], ["Gastrointestinal hemorrhage", "PROBLEM", 340, 367], ["Pulmonary embolism", "PROBLEM", 368, 386], ["Outcome measurements", "TEST", 467, 487], ["Study objectives", "TEST", 488, 504], ["Blood count", "TEST", 504, 515], ["PaO", "TEST", 643, 646], ["a X b X c X X Hemostasis parameters", "TREATMENT", 721, 756], ["Study objectives", "TEST", 813, 829], ["Ventilation support", "TREATMENT", 900, 919], ["ventilation parameters", "TREATMENT", 930, 952], ["a High-frequency ventilation", "TREATMENT", 1097, 1125], ["a Tracheotomy Hemodynamic parameters", "TREATMENT", 1152, 1188], ["Vasopressor therapy", "TREATMENT", 1241, 1260], ["a X a Inotrope therapy", "TREATMENT", 1283, 1305], ["a X a Fluid balance", "TREATMENT", 1328, 1347], ["a Transfusion of red blood cells", "TREATMENT", 1374, 1406], ["Transfusion of thrombocytes", "TREATMENT", 1429, 1456], ["Anticoagulation Infection", "PROBLEM", 1479, 1504], ["Anti-infective therapy", "TREATMENT", 1527, 1549], ["The exploratory objectives", "TEST", 1572, 1598], ["Efficacy parameters", "TEST", 1776, 1795], ["oxygenation (PaO", "TREATMENT", 1885, 1901], ["ARDS", "PROBLEM", 2043, 2047], ["SOFA scores", "TEST", 2048, 2059], ["mechanical ventilation support", "TREATMENT", 2124, 2154], ["Efficacy parameters", "TEST", 2243, 2262], ["pneumonia", "PROBLEM", 2284, 2293], ["barotrauma", "PROBLEM", 2370, 2380], ["Reduced morbidity", "PROBLEM", 2441, 2458], ["SOFA score", "TEST", 2476, 2486], ["complications", "PROBLEM", 2523, 2536], ["increased functionality", "PROBLEM", 2541, 2564], ["acquired weakness", "PROBLEM", 2706, 2723], ["Efficacy parameters", "TEST", 2825, 2844], ["comorbidities", "PROBLEM", 2938, 2951], ["diabetes", "PROBLEM", 2961, 2969], ["existing malignancy", "PROBLEM", 2971, 2990], ["pre-existing pulmonary disease", "PROBLEM", 3004, 3034], ["hypertension", "PROBLEM", 3040, 3052], ["Efficacy parameters", "TEST", 3054, 3073], ["the ICU daily assessment", "TEST", 3112, 3136], ["Efficacy parameters", "TEST", 3152, 3171], ["Laboratory data", "TEST", 3171, 3186], ["Blood count", "TEST", 3188, 3199], ["procalcitonin", "TEST", 3201, 3214], ["interleukin (IL)", "TEST", 3216, 3232], ["creatinine", "TEST", 3236, 3246], ["urea", "TEST", 3248, 3252], ["partial thromboplastin time", "TEST", 3254, 3281], ["PTT", "TEST", 3283, 3286], ["D-dimers", "TEST", 3289, 3297], ["international normalized ratio", "TEST", 3299, 3329], ["INR", "TEST", 3331, 3334], ["aspartate aminotransferase", "TEST", 3337, 3363], ["AST", "TEST", 3365, 3368], ["alanine aminotransferase", "TEST", 3371, 3395], ["ALT", "TEST", 3397, 3400], ["albumin", "TEST", 3403, 3410], ["cholinesterase", "TEST", 3412, 3426], ["brain natriuretic peptide", "TEST", 3434, 3459], ["BNP", "TEST", 3461, 3464], ["Efficacy parameters", "TEST", 3523, 3542], ["Differential blood count", "TEST", 3542, 3566], ["Creatinine", "TEST", 3567, 3577], ["clearance", "TEST", 3578, 3587], ["ECMO", "TEST", 3588, 3592], ["PaO", "TEST", 3609, 3612], ["SOFA score", "TEST", 3615, 3625], ["Assessment", "TEST", 3626, 3636], ["Chronic renal failure", "PROBLEM", 3650, 3671], ["Hepatic failure", "PROBLEM", 3685, 3700], ["Efficacy parameters", "TEST", 3931, 3950], ["The final assessment", "TEST", 3950, 3970], ["Efficacy parameters", "TEST", 4001, 4020], ["ECMO support Ventilator", "TREATMENT", 4028, 4051], ["Tracheotomy", "TREATMENT", 4057, 4068], ["mechanical ventilation", "TREATMENT", 4078, 4100], ["pulmonary hemorrhage", "PROBLEM", 4122, 4142], ["blood transfusion", "TREATMENT", 4172, 4189], ["radiological finding", "TEST", 4191, 4211], ["barotrauma", "PROBLEM", 4255, 4265], ["pleural drainage", "TREATMENT", 4279, 4295], ["pulmonary embolism", "PROBLEM", 4309, 4327], ["Efficacy parameters", "TEST", 4364, 4383], ["New hypotension", "PROBLEM", 4383, 4398], ["right ventricular failure", "PROBLEM", 4407, 4432], ["echocardiography Biomarkers", "TEST", 4436, 4463], ["Computed tomography", "TEST", 4464, 4483], ["CT) scan", "TEST", 4485, 4493], ["gastrointestinal bleeding", "PROBLEM", 4518, 4543], ["upper gastrointestinal bleeding", "PROBLEM", 4581, 4612], ["blood vomiting", "PROBLEM", 4614, 4628], ["lower gastrointestinal bleeding", "PROBLEM", 4630, 4661], ["melena", "PROBLEM", 4663, 4669], ["blood transfusion", "TREATMENT", 4686, 4703], ["endoscopic diagnosis", "TEST", 4705, 4725], ["intervention", "TREATMENT", 4726, 4738], ["cerebral hemorrhage", "PROBLEM", 4752, 4771], ["impairment", "PROBLEM", 4809, 4819], ["the Glasgow Coma Scale", "TEST", 4835, 4857], ["CT scan", "TEST", 4859, 4866], ["positive blood culture", "PROBLEM", 4892, 4914], ["pneumonia", "PROBLEM", 4916, 4925], ["wound infection", "PROBLEM", 4927, 4942], ["peritonitis", "PROBLEM", 4944, 4955], ["surgical intervention", "TREATMENT", 4957, 4978], ["infection", "PROBLEM", 4986, 4995], ["bacterial infection", "PROBLEM", 4997, 5016], ["fungal infection", "PROBLEM", 5018, 5034], ["viral infection", "PROBLEM", 5036, 5051], ["multidrugresistant Gram-negative bacteria (MRGN) infection", "PROBLEM", 5056, 5114], ["Anti-infective therapy", "TREATMENT", 5115, 5137], ["changing anti-infective therapy", "TREATMENT", 5171, 5202], ["surgical intervention", "TREATMENT", 5244, 5265], ["pulmonary", "ANATOMY", 114, 123], ["mechanical ventilation", "OBSERVATION", 237, 259], ["pneumonia", "OBSERVATION", 309, 318], ["Pulmonary", "ANATOMY", 319, 328], ["hemorrhage", "OBSERVATION", 329, 339], ["Gastrointestinal", "ANATOMY", 340, 356], ["hemorrhage", "OBSERVATION", 357, 367], ["Pulmonary", "ANATOMY", 368, 377], ["embolism", "OBSERVATION", 378, 386], ["thrombocytes X X X", "OBSERVATION_MODIFIER", 1444, 1462], ["pneumonia", "OBSERVATION", 2284, 2293], ["barotrauma", "OBSERVATION", 2370, 2380], ["malignancy", "OBSERVATION", 2980, 2990], ["pulmonary", "ANATOMY", 3017, 3026], ["disease", "OBSERVATION", 3027, 3034], ["hypertension", "OBSERVATION", 3040, 3052], ["renal", "ANATOMY", 3658, 3663], ["failure", "OBSERVATION", 3664, 3671], ["Hepatic", "ANATOMY", 3685, 3692], ["failure", "OBSERVATION", 3693, 3700], ["pulmonary", "ANATOMY", 4122, 4131], ["hemorrhage", "OBSERVATION", 4132, 4142], ["decrease", "OBSERVATION_MODIFIER", 4218, 4226], ["oxygenation", "OBSERVATION_MODIFIER", 4230, 4241], ["barotrauma", "OBSERVATION", 4255, 4265], ["pleural", "ANATOMY", 4279, 4286], ["drainage", "OBSERVATION", 4287, 4295], ["pulmonary", "ANATOMY", 4309, 4318], ["embolism", "OBSERVATION", 4319, 4327], ["hypotension", "OBSERVATION", 4387, 4398], ["right ventricular", "ANATOMY", 4407, 4424], ["failure", "OBSERVATION", 4425, 4432], ["gastrointestinal", "ANATOMY", 4518, 4534], ["bleeding", "OBSERVATION", 4535, 4543], ["upper", "ANATOMY_MODIFIER", 4581, 4586], ["gastrointestinal", "ANATOMY", 4587, 4603], ["bleeding", "OBSERVATION", 4604, 4612], ["gastrointestinal", "ANATOMY", 4636, 4652], ["bleeding", "OBSERVATION", 4653, 4661], ["melena", "OBSERVATION", 4663, 4669], ["cerebral", "ANATOMY", 4752, 4760], ["hemorrhage", "OBSERVATION", 4761, 4771], ["pneumonia", "OBSERVATION", 4916, 4925], ["wound", "ANATOMY", 4927, 4932], ["infection", "OBSERVATION", 4933, 4942], ["peritonitis", "OBSERVATION", 4944, 4955], ["infection", "OBSERVATION", 4986, 4995], ["bacterial", "OBSERVATION_MODIFIER", 4997, 5006], ["infection", "OBSERVATION", 5007, 5016], ["fungal", "OBSERVATION_MODIFIER", 5018, 5024], ["infection", "OBSERVATION", 5025, 5034], ["viral", "OBSERVATION_MODIFIER", 5036, 5041], ["infection", "OBSERVATION", 5042, 5051], ["negative bacteria", "OBSERVATION_MODIFIER", 5080, 5097]]], ["For this project, electronic CRFs (eCRFs) will be used.", [["electronic CRFs (eCRFs)", "TREATMENT", 18, 41]]], ["Entered data will be subjected to plausibility checks directly implemented in the CRF, monitoring, and medical review.", [["CRF", "DISEASE", 82, 85], ["plausibility checks", "TEST", 34, 53]]], ["The trial master file, the CRFs, and other material supplied for the conduct of the study will be retained by the sponsor/ clinical research organization (CRO) according to applicable regulations and laws.", [["the study", "TEST", 80, 89]]], ["The investigator(s) will archive all trial data (source data and investigator site file [ISF], including the subject identification list and relevant correspondence) according to the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) consolidated guideline on good clinical practice (GCP) and local laws or regulations.Statistical analyses Study population definitionThe study population will consist of the following: those to be assessed for eligibility (n = 300); those to be assigned to the trial (n = 150); those to be analyzed (n = 150 in the intention-to-treat [ITT] analysis, other endpoints n = 120).", [["ICH", "DISEASE", 302, 305], ["Human", "ORGANISM", 291, 296], ["Human", "SPECIES", 291, 296], ["Registration of Pharmaceuticals", "TREATMENT", 255, 286], ["Human Use (ICH)", "TREATMENT", 291, 306], ["Statistical analyses", "TEST", 392, 412], ["The study population", "TEST", 440, 460], ["ITT] analysis", "TEST", 642, 655]]], ["The sample size and power consideration refers to 120 evaluable patients, and it is assumed that the power will not be decreased in the analysis of the ITT population using multiple imputation.", [["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 64, 72], ["The sample size", "TEST", 0, 15], ["the ITT population", "TREATMENT", 148, 166], ["multiple imputation", "TREATMENT", 173, 192], ["size", "OBSERVATION_MODIFIER", 11, 15], ["decreased", "OBSERVATION", 119, 128]]], ["Furthermore, baseline adjustment will not be taken into account, which leads to a conservative sample size estimation.Statistical analyses Study population definitionIn a previous study on iloprost with 20 patients, an increase from 177 \u00b1 60 to 213 \u00b1 67 was observed for the PaO 2 /FiO 2 , which was significant at the 0.01 level [27] .", [["iloprost", "CHEMICAL", 189, 197], ["iloprost", "CHEMICAL", 189, 197], ["iloprost", "SIMPLE_CHEMICAL", 189, 197], ["patients", "ORGANISM", 206, 214], ["patients", "SPECIES", 206, 214], ["a conservative sample size estimation", "TEST", 80, 117], ["a previous study", "TEST", 169, 185], ["iloprost", "TREATMENT", 189, 197], ["the PaO", "TEST", 271, 278], ["FiO", "TEST", 282, 285], ["size", "OBSERVATION_MODIFIER", 102, 106]]], ["Recalculation shows that the intraindividual standard deviation must have been considerably smaller, as a p value of 0.01 corresponds to an effect size of 0.93 (intraindividually) and thus to an intraindividual standard deviation of approximately 40 in this study.Statistical analyses Study population definitionIn our study, we can show effect sizes of 0.525 assuming 116 error degrees of freedom, taking into account 1 day for baseline adjustment and 3 days for the study center (inquiry, power 80%, level of significance 0.05, twosided t test).", [["Recalculation", "TEST", 0, 13], ["the intraindividual standard deviation", "PROBLEM", 25, 63], ["a p value", "TEST", 104, 113], ["an effect size", "TEST", 137, 151], ["an intraindividual standard deviation", "TEST", 192, 229], ["this study", "TEST", 253, 263], ["Statistical analyses", "TEST", 264, 284], ["our study", "TEST", 315, 324], ["the study", "TEST", 464, 473], ["intraindividual", "OBSERVATION_MODIFIER", 29, 44], ["standard deviation", "OBSERVATION", 45, 63], ["considerably", "OBSERVATION_MODIFIER", 79, 91], ["smaller", "OBSERVATION_MODIFIER", 92, 99], ["effect", "OBSERVATION_MODIFIER", 140, 146], ["size", "OBSERVATION_MODIFIER", 147, 151], ["intraindividual", "OBSERVATION_MODIFIER", 195, 210], ["standard deviation", "OBSERVATION", 211, 229], ["sizes", "OBSERVATION_MODIFIER", 345, 350]]], ["If we assume the recalculated standard deviation from the previous study in our study (which is still conservative due to the linear baseline adjustment used in our study), an (interindividual) effect size of 0.525 corresponds to a difference of approximately 21 in the PaO 2 /FiO 2 ratio in the treatment arm compared to the control arm.", [["FiO 2", "CHEMICAL", 277, 282], ["FiO 2", "GENE_OR_GENE_PRODUCT", 277, 282], ["the previous study", "TEST", 54, 72], ["our study", "TEST", 76, 85], ["our study", "TEST", 161, 170], ["the PaO", "TEST", 266, 273], ["FiO", "TEST", 277, 280], ["the treatment arm", "TREATMENT", 292, 309], ["size", "OBSERVATION_MODIFIER", 201, 205], ["arm", "ANATOMY", 334, 337]]], ["This seems to be a reasonable and relevant effect.Analysis of primary variablesThe primary endpoint of PaO 2 /FiO 2 at day 6 after the baseline will be analyzed daily using a baseline adjusted analysis of covariance model with the last measurement of the PaO 2 /FiO 2 ratio before treatment as the baseline, with the study arm as a second-level factor.", [["PaO 2", "CHEMICAL", 103, 108], ["FiO 2", "GENE_OR_GENE_PRODUCT", 262, 267], ["primary variables", "PROBLEM", 62, 79], ["PaO 2 /FiO", "TREATMENT", 103, 113], ["covariance model", "TEST", 205, 221], ["the PaO", "TREATMENT", 251, 258], ["treatment", "TREATMENT", 281, 290], ["the study arm", "TEST", 313, 326]]], ["The study center will be included in the analysis as a nuisance factor.", [["The study", "TEST", 0, 9], ["the analysis", "TEST", 37, 49]]], ["Additionally, an interaction term between baseline and treatment will be included in the model if this term is significant.", [["treatment", "TREATMENT", 55, 64]]], ["In the case of interaction, the main effect will be retrieved for the arithmetic mean of the baseline values using the centered variable for PaO 2 /FiO 2 .", [["PaO 2", "CHEMICAL", 141, 146], ["FiO 2", "CHEMICAL", 148, 153], ["FiO 2", "PROTEIN", 148, 153], ["PaO", "TREATMENT", 141, 144]]], ["Multiple imputation will be applied in the ITT population of patients receiving at least one dose of treatment or the control.Analysis of secondary variablesStatistical analysis of the prespecified secondary endpoints will be performed with descriptive and exploratory statistical methods according to the scale and observed distribution (absolute and percentage frequencies, chi-square tests, logistic regression models for categorical variables; means and standard deviations, medians, and quartiles, or ranges with t tests or Mann-Whitney tests and linear regression models for continuous variables; Kaplan-Meier curves, log-rank tests, and Cox proportional hazard models for censored data).", [["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69], ["Multiple imputation", "TREATMENT", 0, 19], ["treatment", "TREATMENT", 101, 110], ["the control", "TREATMENT", 114, 125], ["secondary variables", "PROBLEM", 138, 157], ["Statistical analysis", "TEST", 157, 177], ["exploratory statistical methods", "TEST", 257, 288], ["the scale", "TEST", 302, 311], ["percentage frequencies", "TEST", 352, 374], ["chi-square tests", "TEST", 376, 392], ["logistic regression models", "TEST", 394, 420], ["categorical variables", "TEST", 425, 446], ["t tests", "TEST", 518, 525], ["Whitney tests", "TEST", 534, 547], ["Meier curves", "TEST", 610, 622], ["log-rank tests", "TEST", 624, 638], ["censored data", "TEST", 679, 692]]], ["The p values will be reported but should not be considered part of the confirmatory analysis.Subgroup analysisPlanned subgroup analyses will be performed according to the following:Subgroup analysisSex and race (only for subgroups larger than 40 subjects) Patients with increased pulmonary arterial pressure Direct vs. indirect lung injury Age stratified by decades.Stopping rulesFor safety reasons, after the enrollment of 20 patients (day 28 after last dose IMP Patient 20), an interim analysis of the following will be performed:Stopping rules1.", [["pulmonary arterial", "ANATOMY", 280, 298], ["lung", "ANATOMY", 328, 332], ["lung injury", "DISEASE", 328, 339], ["Patients", "ORGANISM", 256, 264], ["pulmonary arterial", "MULTI-TISSUE_STRUCTURE", 280, 298], ["lung", "ORGAN", 328, 332], ["patients", "ORGANISM", 427, 435], ["Patients", "SPECIES", 256, 264], ["patients", "SPECIES", 427, 435], ["Patient", "SPECIES", 464, 471], ["The p values", "TEST", 0, 12], ["the confirmatory analysis", "TEST", 67, 92], ["Subgroup analysis", "TEST", 93, 110], ["subgroup analyses", "TEST", 118, 135], ["increased pulmonary arterial pressure Direct", "PROBLEM", 270, 314], ["indirect lung injury", "PROBLEM", 319, 339], ["an interim analysis", "TEST", 477, 496], ["increased", "OBSERVATION_MODIFIER", 270, 279], ["pulmonary arterial", "ANATOMY", 280, 298], ["pressure", "OBSERVATION_MODIFIER", 299, 307], ["lung", "ANATOMY", 328, 332], ["injury", "OBSERVATION", 333, 339]]], ["An increased risk of pulmonary hemorrhage \u2265 grade III according to CTCAE Version 5.0 in the treatment (iloprost) arm 2.", [["pulmonary", "ANATOMY", 21, 30], ["pulmonary hemorrhage", "DISEASE", 21, 41], ["iloprost", "CHEMICAL", 103, 111], ["iloprost", "CHEMICAL", 103, 111], ["pulmonary", "ORGAN", 21, 30], ["pulmonary hemorrhage", "PROBLEM", 21, 41], ["grade III", "PROBLEM", 44, 53], ["CTCAE Version", "TEST", 67, 80], ["the treatment (iloprost) arm", "TREATMENT", 88, 116], ["increased", "OBSERVATION_MODIFIER", 3, 12], ["pulmonary", "ANATOMY", 21, 30], ["hemorrhage", "OBSERVATION", 31, 41], ["grade III", "OBSERVATION_MODIFIER", 44, 53], ["arm", "ANATOMY", 113, 116]]], ["Levels of IMP in the serum.Stopping rulesThe results will be discussed with the DSMB.", [["serum", "ANATOMY", 21, 26], ["IMP", "CHEMICAL", 10, 13], ["IMP", "CHEMICAL", 10, 13], ["IMP", "SIMPLE_CHEMICAL", 10, 13], ["serum", "ORGANISM_SUBSTANCE", 21, 26], ["IMP", "PROTEIN", 10, 13], ["Levels", "TEST", 0, 6], ["IMP in the serum", "TEST", 10, 26]]], ["The DSMB has to assess whether the results allow continuation of the study as planned.Stopping rulesMoreover, after treatment of a total of 100 patients (day 28 after the last dose IMP Patient 100), an interim analysis of an increased risk of pulmonary hemorrhage \u2265 grade III according to CTCAE Version 5.0 in the treatment (iloprost) arm will be performed, and the results will again be discussed with the DSMB.", [["pulmonary", "ANATOMY", 243, 252], ["pulmonary hemorrhage", "DISEASE", 243, 263], ["iloprost", "CHEMICAL", 325, 333], ["patients", "ORGANISM", 144, 152], ["pulmonary", "ORGAN", 243, 252], ["iloprost", "SIMPLE_CHEMICAL", 325, 333], ["patients", "SPECIES", 144, 152], ["the study", "TEST", 65, 74], ["treatment", "TREATMENT", 116, 125], ["an interim analysis", "TEST", 199, 218], ["pulmonary hemorrhage", "PROBLEM", 243, 263], ["grade III", "PROBLEM", 266, 275], ["CTCAE Version", "TEST", 289, 302], ["the treatment (iloprost) arm", "TREATMENT", 310, 338], ["increased", "OBSERVATION_MODIFIER", 225, 234], ["pulmonary", "ANATOMY", 243, 252], ["hemorrhage", "OBSERVATION", 253, 263], ["arm", "ANATOMY", 335, 338]]], ["The DSMB must assess whether the results allow continuation of the study as planned.Stopping rulesMoreover, in the following situations, a premature termination of the trial must be considered:Stopping rules3.", [["the study", "TEST", 63, 72], ["a premature termination", "TREATMENT", 137, 160]]], ["Insufficient recruitment rate.Biometric reportThe biometric report will be delivered according to the SOP BI07 of the statistical center (IKEaB).", [["recruitment rate", "OBSERVATION", 13, 29]]], ["In summary, the report will contain sections on the statistical methodology, preprocessing of data, and the descriptive, exploratory, and confirmatory analyses.", [["sections", "ANATOMY", 36, 44], ["confirmatory analyses", "TEST", 138, 159]]], ["It will be reviewed by the principal investigator (PI) before presenting the final version.DiscussionTo date, there is no pharmacologic intervention to treat or prevent the development of lung injury or ARDS.", [["lung", "ANATOMY", 188, 192], ["lung injury", "DISEASE", 188, 199], ["ARDS", "DISEASE", 203, 207], ["lung", "ORGAN", 188, 192], ["pharmacologic intervention", "TREATMENT", 122, 148], ["lung injury", "PROBLEM", 188, 199], ["ARDS", "PROBLEM", 203, 207], ["no", "UNCERTAINTY", 119, 121], ["lung", "ANATOMY", 188, 192], ["injury", "OBSERVATION", 193, 199], ["ARDS", "OBSERVATION", 203, 207]]], ["Iloprost-containing medications are well recognized epidemiologically as an effective therapeutic agent for the treatment of moderate to severe pulmonary hypertension.", [["pulmonary", "ANATOMY", 144, 153], ["Iloprost", "CHEMICAL", 0, 8], ["pulmonary hypertension", "DISEASE", 144, 166], ["Iloprost", "CHEMICAL", 0, 8], ["Iloprost", "SIMPLE_CHEMICAL", 0, 8], ["pulmonary", "ORGAN", 144, 153], ["Iloprost-containing medications", "TREATMENT", 0, 31], ["an effective therapeutic agent", "TREATMENT", 73, 103], ["the treatment", "TREATMENT", 108, 121], ["moderate to severe pulmonary hypertension", "PROBLEM", 125, 166], ["moderate", "OBSERVATION_MODIFIER", 125, 133], ["severe", "OBSERVATION_MODIFIER", 137, 143], ["pulmonary", "ANATOMY", 144, 153], ["hypertension", "OBSERVATION", 154, 166]]], ["Iloprost has been shown to exert antiplatelet and anti-inflammatory actions in small clinical observation studies and several preclinical laboratory examinations.", [["Iloprost", "CHEMICAL", 0, 8], ["Iloprost", "CHEMICAL", 0, 8], ["Iloprost", "SIMPLE_CHEMICAL", 0, 8], ["Iloprost", "TREATMENT", 0, 8], ["antiplatelet", "TREATMENT", 33, 45], ["anti-inflammatory actions", "TREATMENT", 50, 75], ["small clinical observation studies", "TEST", 79, 113], ["several preclinical laboratory examinations", "TEST", 118, 161]]], ["However, the use of iloprost for the treatment of ARDS is not novel; it has been used in small studies before.", [["iloprost", "CHEMICAL", 20, 28], ["ARDS", "DISEASE", 50, 54], ["iloprost", "CHEMICAL", 20, 28], ["iloprost", "SIMPLE_CHEMICAL", 20, 28], ["iloprost", "TREATMENT", 20, 28], ["ARDS", "PROBLEM", 50, 54], ["small studies", "TEST", 89, 102], ["ARDS", "OBSERVATION", 50, 54], ["small", "OBSERVATION_MODIFIER", 89, 94]]], ["Indeed, we propose in this study to systemically evaluate the application of iloprost in a randomized controlled trial (RCT) to identify the potential use and benefit of iloprost in ARDS.", [["iloprost", "CHEMICAL", 77, 85], ["iloprost", "CHEMICAL", 170, 178], ["ARDS", "DISEASE", 182, 186], ["iloprost", "CHEMICAL", 77, 85], ["iloprost", "CHEMICAL", 170, 178], ["iloprost", "SIMPLE_CHEMICAL", 77, 85], ["iloprost", "SIMPLE_CHEMICAL", 170, 178], ["this study", "TEST", 22, 32], ["iloprost", "TREATMENT", 77, 85], ["a randomized controlled trial (RCT)", "TREATMENT", 89, 124], ["iloprost", "TREATMENT", 170, 178], ["ARDS", "PROBLEM", 182, 186], ["iloprost", "OBSERVATION", 170, 178], ["ARDS", "OBSERVATION", 182, 186]]], ["The composite endpoint was chosen, as it is likely to be more sensitive than just 28-day mortality to detect an effect signal.", [["an effect signal", "PROBLEM", 109, 125]]], ["Although it is not a double-blinded strategy, the recorded objectives will help support or refute our hypothesis that iloprost reduces lung inflammation during early ARDS.DiscussionThis study includes some possible pitfalls, like the single-blinded design.", [["lung", "ANATOMY", 135, 139], ["iloprost", "CHEMICAL", 118, 126], ["lung inflammation", "DISEASE", 135, 152], ["ARDS", "DISEASE", 166, 170], ["iloprost", "CHEMICAL", 118, 126], ["iloprost", "SIMPLE_CHEMICAL", 118, 126], ["lung", "ORGAN", 135, 139], ["a double-blinded strategy", "TREATMENT", 19, 44], ["iloprost reduces lung inflammation", "PROBLEM", 118, 152], ["early ARDS", "PROBLEM", 160, 170], ["This study", "TEST", 181, 191], ["lung", "ANATOMY", 135, 139], ["inflammation", "OBSERVATION", 140, 152], ["early", "OBSERVATION_MODIFIER", 160, 165], ["ARDS", "OBSERVATION", 166, 170]]], ["However, due to randomization and based on the close data acquisition, we will be able to minimize bias.DiscussionHowever, in addition to the effect of iloprost on lung inflammation, this study will also be a resource for information about clotting issues in terms of the systemic and local anticoagulation effects of iloprost in lung tissue, and also in other compartments besides the lung.", [["lung", "ANATOMY", 164, 168], ["lung tissue", "ANATOMY", 330, 341], ["compartments", "ANATOMY", 361, 373], ["lung", "ANATOMY", 386, 390], ["iloprost", "CHEMICAL", 152, 160], ["lung inflammation", "DISEASE", 164, 181], ["iloprost", "CHEMICAL", 318, 326], ["iloprost", "CHEMICAL", 152, 160], ["iloprost", "CHEMICAL", 318, 326], ["iloprost", "SIMPLE_CHEMICAL", 152, 160], ["lung", "ORGAN", 164, 168], ["iloprost", "SIMPLE_CHEMICAL", 318, 326], ["lung tissue", "TISSUE", 330, 341], ["lung", "ORGAN", 386, 390], ["randomization", "TREATMENT", 16, 29], ["the close data acquisition", "TEST", 43, 69], ["iloprost", "TREATMENT", 152, 160], ["lung inflammation", "PROBLEM", 164, 181], ["this study", "TEST", 183, 193], ["clotting issues", "PROBLEM", 240, 255], ["local anticoagulation effects", "TREATMENT", 285, 314], ["iloprost in lung tissue", "TREATMENT", 318, 341], ["iloprost", "OBSERVATION", 152, 160], ["lung", "ANATOMY", 164, 168], ["inflammation", "OBSERVATION", 169, 181], ["local", "OBSERVATION_MODIFIER", 285, 290], ["anticoagulation", "OBSERVATION", 291, 306], ["iloprost", "OBSERVATION", 318, 326], ["lung", "ANATOMY", 330, 334], ["tissue", "OBSERVATION", 335, 341], ["lung", "ANATOMY", 386, 390]]], ["Although iloprost is used frequently in pulmonary hypertension, there are currently no data about iloprost concentration in the blood after inhalative treatment.", [["pulmonary", "ANATOMY", 40, 49], ["blood", "ANATOMY", 128, 133], ["iloprost", "CHEMICAL", 9, 17], ["pulmonary hypertension", "DISEASE", 40, 62], ["iloprost", "CHEMICAL", 98, 106], ["iloprost", "CHEMICAL", 9, 17], ["iloprost", "CHEMICAL", 98, 106], ["iloprost", "SIMPLE_CHEMICAL", 9, 17], ["pulmonary", "ORGAN", 40, 49], ["iloprost", "SIMPLE_CHEMICAL", 98, 106], ["blood", "ORGANISM_SUBSTANCE", 128, 133], ["iloprost", "TREATMENT", 9, 17], ["pulmonary hypertension", "PROBLEM", 40, 62], ["iloprost concentration", "TREATMENT", 98, 120], ["inhalative treatment", "TREATMENT", 140, 160], ["iloprost", "OBSERVATION", 9, 17], ["pulmonary", "ANATOMY", 40, 49], ["hypertension", "OBSERVATION", 50, 62]]], ["In addition, iloprost may have a positive effect on lung compliance during acute ARDS as well as during resolution, since it has been shown to have a lasting positive effect on fibrosis in the lung and other tissues in animal models [34, 35] .", [["lung", "ANATOMY", 52, 56], ["lung", "ANATOMY", 193, 197], ["tissues", "ANATOMY", 208, 215], ["iloprost", "CHEMICAL", 13, 21], ["ARDS", "DISEASE", 81, 85], ["fibrosis", "DISEASE", 177, 185], ["iloprost", "CHEMICAL", 13, 21], ["iloprost", "SIMPLE_CHEMICAL", 13, 21], ["lung", "ORGAN", 52, 56], ["lung", "ORGAN", 193, 197], ["tissues", "TISSUE", 208, 215], ["iloprost", "TREATMENT", 13, 21], ["lung compliance", "TREATMENT", 52, 67], ["acute ARDS", "PROBLEM", 75, 85], ["fibrosis in the lung", "PROBLEM", 177, 197], ["positive", "OBSERVATION_MODIFIER", 33, 41], ["effect", "OBSERVATION_MODIFIER", 42, 48], ["lung", "ANATOMY", 52, 56], ["compliance", "OBSERVATION", 57, 67], ["acute", "OBSERVATION_MODIFIER", 75, 80], ["ARDS", "OBSERVATION", 81, 85], ["lasting", "OBSERVATION_MODIFIER", 150, 157], ["positive effect", "OBSERVATION_MODIFIER", 158, 173], ["fibrosis", "OBSERVATION", 177, 185], ["lung", "ANATOMY", 193, 197]]], ["In one-lung ventilation, iloprost seems to reduce intrapulmonary shunts, resulting in better oxygenation [36, 37] .", [["lung", "ANATOMY", 7, 11], ["intrapulmonary", "ANATOMY", 50, 64], ["iloprost", "CHEMICAL", 25, 33], ["iloprost", "CHEMICAL", 25, 33], ["lung", "ORGAN", 7, 11], ["iloprost", "SIMPLE_CHEMICAL", 25, 33], ["intrapulmonary", "MULTI-TISSUE_STRUCTURE", 50, 64], ["iloprost", "TREATMENT", 25, 33], ["intrapulmonary shunts", "TREATMENT", 50, 71], ["lung", "ANATOMY", 7, 11], ["ventilation", "OBSERVATION", 12, 23], ["iloprost", "OBSERVATION", 25, 33], ["intrapulmonary", "ANATOMY", 50, 64], ["shunts", "OBSERVATION", 65, 71]]], ["In this context, the analysis of ventilator-free days or time on ECMO may reveal important information.", [["ECMO", "TREATMENT", 65, 69]]], ["Further on, intravenous application of iloprost may improve microcirculation, resulting in better kidney recovery in patients with sepsis [37, 38] .", [["intravenous", "ANATOMY", 12, 23], ["kidney", "ANATOMY", 98, 104], ["iloprost", "CHEMICAL", 39, 47], ["sepsis", "DISEASE", 131, 137], ["iloprost", "CHEMICAL", 39, 47], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 12, 23], ["iloprost", "SIMPLE_CHEMICAL", 39, 47], ["kidney", "ORGAN", 98, 104], ["patients", "ORGANISM", 117, 125], ["patients", "SPECIES", 117, 125], ["intravenous application of iloprost", "TREATMENT", 12, 47], ["sepsis", "PROBLEM", 131, 137], ["kidney", "ANATOMY", 98, 104], ["sepsis", "OBSERVATION", 131, 137]]], ["Patients with ARDS frequently show multiorgan failure.", [["multiorgan", "ANATOMY", 35, 45], ["ARDS", "DISEASE", 14, 18], ["multiorgan failure", "DISEASE", 35, 53], ["Patients", "ORGANISM", 0, 8], ["multiorgan", "ORGAN", 35, 45], ["Patients", "SPECIES", 0, 8], ["ARDS", "PROBLEM", 14, 18], ["multiorgan failure", "PROBLEM", 35, 53], ["ARDS", "OBSERVATION", 14, 18], ["multiorgan failure", "OBSERVATION", 35, 53]]], ["Therefore, the comparison of incidence and time frame for extracorporeal therapy may give insights on the effect of inhaled iloprost on microcirculation in other organs.", [["extracorporeal", "ANATOMY", 58, 72], ["organs", "ANATOMY", 162, 168], ["iloprost", "CHEMICAL", 124, 132], ["iloprost", "CHEMICAL", 124, 132], ["iloprost", "SIMPLE_CHEMICAL", 124, 132], ["organs", "ORGAN", 162, 168], ["extracorporeal therapy", "TREATMENT", 58, 80], ["inhaled iloprost", "TREATMENT", 116, 132], ["organs", "ANATOMY", 162, 168]]], ["Therefore, iloprost may positively influence the outcome of ARDS patients by at least one of the effects described above.", [["iloprost", "CHEMICAL", 11, 19], ["ARDS", "DISEASE", 60, 64], ["iloprost", "CHEMICAL", 11, 19], ["iloprost", "SIMPLE_CHEMICAL", 11, 19], ["patients", "ORGANISM", 65, 73], ["patients", "SPECIES", 65, 73], ["iloprost", "TREATMENT", 11, 19], ["ARDS", "PROBLEM", 60, 64]]], ["This study will be the first to describe the effects of iloprost on inflammation, fibrosis, bleeding events, and oxygenation organ failure and anticoagulation during a continuous time frame of at least 5 days in critically ill patients.", [["organ", "ANATOMY", 125, 130], ["iloprost", "CHEMICAL", 56, 64], ["inflammation", "DISEASE", 68, 80], ["fibrosis", "DISEASE", 82, 90], ["bleeding", "DISEASE", 92, 100], ["oxygenation organ failure", "DISEASE", 113, 138], ["critically ill", "DISEASE", 212, 226], ["iloprost", "CHEMICAL", 56, 64], ["iloprost", "SIMPLE_CHEMICAL", 56, 64], ["organ", "ORGAN", 125, 130], ["patients", "ORGANISM", 227, 235], ["patients", "SPECIES", 227, 235], ["This study", "TEST", 0, 10], ["iloprost", "TREATMENT", 56, 64], ["inflammation", "PROBLEM", 68, 80], ["fibrosis", "PROBLEM", 82, 90], ["bleeding events", "PROBLEM", 92, 107], ["oxygenation organ failure", "PROBLEM", 113, 138], ["anticoagulation", "TREATMENT", 143, 158], ["iloprost", "OBSERVATION", 56, 64], ["inflammation", "OBSERVATION", 68, 80], ["fibrosis", "OBSERVATION", 82, 90], ["bleeding", "OBSERVATION", 92, 100], ["oxygenation organ failure", "OBSERVATION", 113, 138]]]], "b9d587239806b4c15ec6412ce1f03015c47d5e58": [["IntroductionThe recent devastating outbreaks of Zaire ebolavirus (EBOV) in western Africa have shown the inadequacies of the world's healthcare system.", [["Zaire ebolavirus", "ORGANISM", 48, 64], ["EBOV", "ORGANISM", 66, 70], ["Zaire ebolavirus", "SPECIES", 48, 64], ["Zaire ebolavirus", "SPECIES", 48, 64], ["EBOV", "SPECIES", 66, 70], ["Zaire ebolavirus", "PROBLEM", 48, 64], ["devastating", "OBSERVATION_MODIFIER", 23, 34], ["Zaire ebolavirus", "OBSERVATION", 48, 64]]], ["Even though the first recorded EBOV outbreak was in 1976, much of the pathogenesis of the virion remains unclear [1] .", [["EBOV", "DISEASE", 31, 35], ["EBOV", "ORGANISM", 31, 35], ["EBOV", "SPECIES", 31, 35], ["the virion", "PROBLEM", 86, 96]]], ["While much effort has focused on the action of viral proteins produced within infected immune (macrophages and dendritic cells) and tissue cells, much is left to be discovered with regard to interactions of soluble Ebola virus proteins and infiltrating non-infected immune cells such as macrophages.IntroductionWithin the order Mononegavirales, family Filoviridae, and genus Ebolavirus, there are currently five species of virus.", [["immune", "ANATOMY", 87, 93], ["macrophages", "ANATOMY", 95, 106], ["dendritic cells", "ANATOMY", 111, 126], ["tissue cells", "ANATOMY", 132, 144], ["immune cells", "ANATOMY", 266, 278], ["macrophages", "ANATOMY", 287, 298], ["immune", "CELL", 87, 93], ["macrophages", "CELL", 95, 106], ["dendritic cells", "CELL", 111, 126], ["tissue cells", "CELL", 132, 144], ["Ebola virus", "ORGANISM", 215, 226], ["immune cells", "CELL", 266, 278], ["macrophages", "CELL", 287, 298], ["viral proteins", "PROTEIN", 47, 61], ["macrophages", "CELL_TYPE", 95, 106], ["dendritic cells", "CELL_TYPE", 111, 126], ["tissue cells", "CELL_TYPE", 132, 144], ["soluble Ebola virus proteins", "PROTEIN", 207, 235], ["infiltrating non-infected immune cells", "CELL_TYPE", 240, 278], ["macrophages", "CELL_TYPE", 287, 298], ["Ebola virus", "SPECIES", 215, 226], ["Ebola virus", "SPECIES", 215, 226], ["viral proteins", "PROBLEM", 47, 61], ["dendritic cells", "PROBLEM", 111, 126], ["tissue cells", "PROBLEM", 132, 144], ["soluble Ebola virus proteins", "TREATMENT", 207, 235], ["infiltrating non-infected immune cells", "PROBLEM", 240, 278], ["macrophages", "PROBLEM", 287, 298], ["Filoviridae", "TREATMENT", 352, 363], ["genus Ebolavirus", "PROBLEM", 369, 385], ["virus", "PROBLEM", 423, 428], ["dendritic cells", "OBSERVATION", 111, 126], ["tissue cells", "OBSERVATION", 132, 144], ["infiltrating", "OBSERVATION_MODIFIER", 240, 252], ["non-infected immune cells", "OBSERVATION", 253, 278], ["macrophages", "OBSERVATION", 287, 298], ["genus Ebolavirus", "OBSERVATION", 369, 385]]], ["The species include Zaire, Sudan, Reston, Bundibugyo, and Ta\u03ca Forest.", [["Bundibugyo", "TREATMENT", 42, 52]]], ["All species can infect and cause disease in humans, with the exception of the Reston virus.", [["humans", "ORGANISM", 44, 50], ["Reston virus", "ORGANISM", 78, 90], ["humans", "SPECIES", 44, 50], ["humans", "SPECIES", 44, 50], ["Reston virus", "SPECIES", 78, 90], ["All species", "PROBLEM", 0, 11], ["disease in humans", "PROBLEM", 33, 50], ["the Reston virus", "PROBLEM", 74, 90], ["Reston virus", "OBSERVATION", 78, 90]]], ["The Zaire strain is the most common during known outbreaks, and one of the most studied in laboratory settings [2, 3] .IntroductionThe Ebolavirus virion is an enveloped virion with negative, singlestranded, RNA genome.", [["Ebolavirus virion", "ORGANISM", 135, 152], ["negative, singlestranded, RNA genome", "DNA", 181, 217], ["The Zaire strain", "PROBLEM", 0, 16], ["The Ebolavirus virion", "TREATMENT", 131, 152], ["Zaire strain", "OBSERVATION", 4, 16], ["most common", "OBSERVATION_MODIFIER", 24, 35], ["outbreaks", "OBSERVATION", 49, 58], ["Ebolavirus virion", "OBSERVATION", 135, 152], ["RNA genome", "OBSERVATION", 207, 217]]], ["The genome encodes for eight different proteins, including the envelope spike glycoprotein (GP).", [["envelope spike glycoprotein", "GENE_OR_GENE_PRODUCT", 63, 90], ["envelope spike glycoprotein", "PROTEIN", 63, 90], ["GP", "PROTEIN", 92, 94], ["eight different proteins", "PROBLEM", 23, 47]]], ["The glycoprotein consists of two subunits: G 1 and G 2 [4] .", [["G 1", "GENE_OR_GENE_PRODUCT", 43, 46], ["G 2", "GENE_OR_GENE_PRODUCT", 51, 54], ["glycoprotein", "PROTEIN", 4, 16], ["G 1", "PROTEIN", 43, 46]]], ["The G 1 subunit has a mucin-like domain, which is highly glycosylated and is usually implicated in attachment to host cells [5] .IntroductionThe glycoprotein has a transmembrane portion on the C-terminal end, which can be cleaved by tumor necrosis factor-alpha converting enzyme (TACE) [6] .", [["cells", "ANATOMY", 118, 123], ["transmembrane", "ANATOMY", 164, 177], ["tumor", "DISEASE", 233, 238], ["C", "CHEMICAL", 193, 194], ["G 1", "GENE_OR_GENE_PRODUCT", 4, 7], ["mucin", "GENE_OR_GENE_PRODUCT", 22, 27], ["host cells", "CELL", 113, 123], ["tumor necrosis factor-alpha converting enzyme", "GENE_OR_GENE_PRODUCT", 233, 278], ["G 1 subunit", "PROTEIN", 4, 15], ["mucin-like domain", "PROTEIN", 22, 39], ["host cells", "CELL_TYPE", 113, 123], ["glycoprotein", "PROTEIN", 145, 157], ["transmembrane portion", "PROTEIN", 164, 185], ["C-terminal end", "PROTEIN", 193, 207], ["tumor necrosis factor-alpha converting enzyme", "PROTEIN", 233, 278], ["TACE", "PROTEIN", 280, 284], ["a mucin-like domain", "PROBLEM", 20, 39], ["tumor necrosis factor", "PROBLEM", 233, 254], ["alpha converting enzyme (TACE)", "TREATMENT", 255, 285], ["mucin-like domain", "OBSERVATION_MODIFIER", 22, 39], ["highly", "OBSERVATION_MODIFIER", 50, 56], ["glycosylated", "OBSERVATION", 57, 69], ["terminal", "ANATOMY_MODIFIER", 195, 203], ["tumor", "OBSERVATION_MODIFIER", 233, 238], ["necrosis", "OBSERVATION", 239, 247]]], ["This cleavage creates the shed glycoprotein and the delta peptide portion.", [["shed glycoprotein", "PROTEIN", 26, 43], ["delta peptide portion", "PROTEIN", 52, 73], ["This cleavage", "PROBLEM", 0, 13], ["the delta peptide portion", "TREATMENT", 48, 73], ["delta", "OBSERVATION_MODIFIER", 52, 57]]], ["The shed glycoprotein has been the subject of several studies; however, the biological function of the shed glycoprotein has not been completely defined [6] [7] [8] [9] .", [["[6] [7] [8] [9]", "SIMPLE_CHEMICAL", 153, 168], ["shed glycoprotein", "PROTEIN", 4, 21], ["shed glycoprotein", "PROTEIN", 103, 120], ["The shed glycoprotein", "TREATMENT", 0, 21], ["several studies", "TEST", 46, 61]]], ["There is some suggestion that it sequesters antibodies against the spike glycoprotein, and helps with virion immune evasion [6] , or that it could cause the production of pro-inflammatory cytokines [7] .IntroductionThe glycoprotein can also be cleaved at the TACE cleavage site while it remains intracellular, and because this protein lacks a transmembrane domain and the delta peptide, it is secreted through the normal secretory pathway [10] [11] [12] [13] .", [["intracellular", "ANATOMY", 295, 308], ["transmembrane", "ANATOMY", 343, 356], ["antibodies against the spike glycoprotein", "GENE_OR_GENE_PRODUCT", 44, 85], ["TACE", "GENE_OR_GENE_PRODUCT", 259, 263], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 295, 308], ["transmembrane", "CELLULAR_COMPONENT", 343, 356], ["antibodies", "PROTEIN", 44, 54], ["spike glycoprotein", "PROTEIN", 67, 85], ["pro-inflammatory cytokines", "PROTEIN", 171, 197], ["glycoprotein", "PROTEIN", 219, 231], ["TACE cleavage site", "PROTEIN", 259, 277], ["transmembrane domain", "PROTEIN", 343, 363], ["the spike glycoprotein", "PROBLEM", 63, 85], ["virion immune evasion", "TREATMENT", 102, 123], ["pro-inflammatory cytokines", "PROBLEM", 171, 197], ["The glycoprotein", "TREATMENT", 215, 231], ["the TACE cleavage site", "TREATMENT", 255, 277], ["the delta peptide", "TREATMENT", 368, 385]]], ["This protein is known as the secreted glycoprotein (sGP) [4, 9, 14, 15] .", [["sGP", "GENE_OR_GENE_PRODUCT", 52, 55], ["secreted glycoprotein", "PROTEIN", 29, 50], ["sGP", "PROTEIN", 52, 55], ["This protein", "TEST", 0, 12]]], ["The soluble forms of GP (both shed and secreted) have been measured at very high levels within patient blood serum [6, 7, 9] .IntroductionMacrophages are critically important sentinel cells that detect and respond to threats within the body.", [["blood serum", "ANATOMY", 103, 114], ["Macrophages", "ANATOMY", 138, 149], ["cells", "ANATOMY", 184, 189], ["body", "ANATOMY", 236, 240], ["GP", "GENE_OR_GENE_PRODUCT", 21, 23], ["patient", "ORGANISM", 95, 102], ["blood", "ORGANISM_SUBSTANCE", 103, 108], ["serum", "ORGANISM_SUBSTANCE", 109, 114], ["Macrophages", "CELL", 138, 149], ["cells", "CELL", 184, 189], ["body", "ORGANISM_SUBDIVISION", 236, 240], ["GP", "PROTEIN", 21, 23], ["Macrophages", "CELL_TYPE", 138, 149], ["sentinel cells", "CELL_TYPE", 175, 189], ["patient", "SPECIES", 95, 102], ["patient blood serum", "TEST", 95, 114], ["sentinel cells", "OBSERVATION", 175, 189], ["body", "ANATOMY", 236, 240]]], ["Depending upon the type of challenge, they can acquire relative phenotypes that better equip them to more efficiently respond to threats.", [["relative phenotypes", "PROBLEM", 55, 74]]], ["Macrophages that are facing a bacterial or viral infection can assume the classical or M1-like phenotype, associated with high pro-inflammatory (IL-6, TNF\u03b1, IL-12, etc.) cytokine production, and high phagocytic capabilities.", [["Macrophages", "ANATOMY", 0, 11], ["infection", "DISEASE", 49, 58], ["Macrophages", "CELL", 0, 11], ["IL-6", "GENE_OR_GENE_PRODUCT", 145, 149], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 151, 155], ["IL-12", "GENE_OR_GENE_PRODUCT", 157, 162], ["Macrophages", "CELL_TYPE", 0, 11], ["cytokine", "PROTEIN", 170, 178], ["Macrophages", "PROBLEM", 0, 11], ["a bacterial or viral infection", "PROBLEM", 28, 58], ["the classical or M1-like phenotype", "PROBLEM", 70, 104], ["IL", "TEST", 145, 147], ["TNF", "TEST", 151, 154], ["IL", "TEST", 157, 159], ["cytokine production", "PROBLEM", 170, 189], ["high phagocytic capabilities", "PROBLEM", 195, 223], ["bacterial", "OBSERVATION_MODIFIER", 30, 39], ["viral", "OBSERVATION_MODIFIER", 43, 48], ["infection", "OBSERVATION", 49, 58], ["high phagocytic capabilities", "OBSERVATION", 195, 223]]], ["Macrophages fighting a helminth infection can assume the M2-like phenotype, which is associated with higher production of anti-inflammatory cytokines (IL-4, IL-10, etc.), effector molecules (Arg1, FIZZ1, YM1, etc.), and cell markers (CD206, Egr2, etc.).", [["Macrophages", "ANATOMY", 0, 11], ["cell", "ANATOMY", 220, 224], ["helminth infection", "DISEASE", 23, 41], ["Macrophages", "CELL", 0, 11], ["IL-4", "GENE_OR_GENE_PRODUCT", 151, 155], ["IL-10", "GENE_OR_GENE_PRODUCT", 157, 162], ["etc.", "GENE_OR_GENE_PRODUCT", 164, 168], ["Arg1", "GENE_OR_GENE_PRODUCT", 191, 195], ["FIZZ1", "GENE_OR_GENE_PRODUCT", 197, 202], ["YM1", "GENE_OR_GENE_PRODUCT", 204, 207], ["cell", "CELL", 220, 224], ["CD206", "GENE_OR_GENE_PRODUCT", 234, 239], ["Egr2", "GENE_OR_GENE_PRODUCT", 241, 245], ["Macrophages", "CELL_TYPE", 0, 11], ["anti-inflammatory cytokines", "PROTEIN", 122, 149], ["IL-4", "PROTEIN", 151, 155], ["IL", "PROTEIN", 157, 159], ["effector molecules", "PROTEIN", 171, 189], ["Arg1", "PROTEIN", 191, 195], ["FIZZ1", "PROTEIN", 197, 202], ["YM1", "PROTEIN", 204, 207], ["cell markers", "PROTEIN", 220, 232], ["CD206", "PROTEIN", 234, 239], ["Egr2", "PROTEIN", 241, 245], ["Macrophages", "PROBLEM", 0, 11], ["a helminth infection", "PROBLEM", 21, 41], ["the M2-like phenotype", "PROBLEM", 53, 74], ["anti-inflammatory cytokines", "TREATMENT", 122, 149], ["IL", "TEST", 151, 153], ["IL", "TEST", 157, 159], ["effector molecules", "PROBLEM", 171, 189], ["cell markers", "TEST", 220, 232], ["helminth", "OBSERVATION_MODIFIER", 23, 31], ["infection", "OBSERVATION", 32, 41], ["anti-inflammatory cytokines", "OBSERVATION", 122, 149]]], ["Macrophages and dendritic cells (DCs) are early targets in EBOV pathogenesis.", [["Macrophages", "ANATOMY", 0, 11], ["dendritic cells", "ANATOMY", 16, 31], ["DCs", "ANATOMY", 33, 36], ["Macrophages", "CELL", 0, 11], ["dendritic cells", "CELL", 16, 31], ["DCs", "CELL", 33, 36], ["EBOV", "ORGANISM", 59, 63], ["Macrophages", "CELL_TYPE", 0, 11], ["dendritic cells", "CELL_TYPE", 16, 31], ["DCs", "CELL_TYPE", 33, 36], ["EBOV", "SPECIES", 59, 63], ["Macrophages", "PROBLEM", 0, 11], ["dendritic cells", "PROBLEM", 16, 31], ["EBOV pathogenesis", "PROBLEM", 59, 76], ["dendritic cells", "OBSERVATION", 16, 31], ["EBOV", "OBSERVATION_MODIFIER", 59, 63]]], ["Once infected, these cells gain access to the blood and disseminate the virus systemically into tissues and blood vasculature [10] [11] [12] 16] .", [["cells", "ANATOMY", 21, 26], ["blood", "ANATOMY", 46, 51], ["tissues", "ANATOMY", 96, 103], ["blood vasculature", "ANATOMY", 108, 125], ["cells", "CELL", 21, 26], ["blood", "ORGANISM_SUBSTANCE", 46, 51], ["tissues", "TISSUE", 96, 103], ["blood vasculature", "MULTI-TISSUE_STRUCTURE", 108, 125], ["the blood", "TEST", 42, 51], ["blood vasculature", "TEST", 108, 125], ["virus", "OBSERVATION", 72, 77]]], ["Viral invasion of endothelia and production of pro-inflammatory cytokines by the circulating infected macrophages and DCs lead to the development of viral hemorrhagic fever that is characteristic of EBOV infection [13] .IntroductionHere we report that macrophages, and not monocytes, have reduced pro-inflammatory cytokine production when incubated with EBOV sGP.", [["endothelia", "ANATOMY", 18, 28], ["macrophages", "ANATOMY", 102, 113], ["DCs", "ANATOMY", 118, 121], ["macrophages", "ANATOMY", 252, 263], ["monocytes", "ANATOMY", 273, 282], ["viral hemorrhagic fever", "DISEASE", 149, 172], ["EBOV infection", "DISEASE", 199, 213], ["endothelia", "TISSUE", 18, 28], ["macrophages", "CELL", 102, 113], ["DCs", "CELL", 118, 121], ["EBOV", "ORGANISM", 199, 203], ["macrophages", "CELL", 252, 263], ["monocytes", "CELL", 273, 282], ["EBOV", "ORGANISM", 354, 358], ["sGP", "GENE_OR_GENE_PRODUCT", 359, 362], ["pro-inflammatory cytokines", "PROTEIN", 47, 73], ["circulating infected macrophages", "CELL_TYPE", 81, 113], ["DCs", "CELL_TYPE", 118, 121], ["macrophages", "CELL_TYPE", 252, 263], ["monocytes", "CELL_TYPE", 273, 282], ["pro-inflammatory cytokine", "PROTEIN", 297, 322], ["EBOV sGP", "PROTEIN", 354, 362], ["EBOV", "SPECIES", 199, 203], ["EBOV", "SPECIES", 354, 358], ["Viral invasion of endothelia", "PROBLEM", 0, 28], ["pro-inflammatory cytokines", "PROBLEM", 47, 73], ["the circulating infected macrophages", "PROBLEM", 77, 113], ["DCs", "PROBLEM", 118, 121], ["viral hemorrhagic fever", "PROBLEM", 149, 172], ["EBOV infection", "PROBLEM", 199, 213], ["macrophages", "PROBLEM", 252, 263], ["monocytes", "PROBLEM", 273, 282], ["reduced pro-inflammatory cytokine production", "PROBLEM", 289, 333], ["EBOV sGP", "PROBLEM", 354, 362], ["invasion", "OBSERVATION", 6, 14], ["endothelia", "ANATOMY", 18, 28], ["pro-inflammatory cytokines", "OBSERVATION", 47, 73], ["infected", "OBSERVATION_MODIFIER", 93, 101], ["macrophages", "OBSERVATION", 102, 113], ["viral", "OBSERVATION_MODIFIER", 149, 154], ["hemorrhagic", "OBSERVATION_MODIFIER", 155, 166], ["fever", "OBSERVATION", 167, 172], ["characteristic of", "UNCERTAINTY", 181, 198], ["EBOV", "OBSERVATION_MODIFIER", 199, 203], ["infection", "OBSERVATION", 204, 213], ["macrophages", "OBSERVATION", 252, 263], ["reduced", "OBSERVATION_MODIFIER", 289, 296], ["pro-inflammatory cytokine", "OBSERVATION", 297, 322]]], ["The inhibitory effects of sGP are insufficient to counter concomitant stimulation with lipopolysaccharide (LPS).", [["sGP", "CHEMICAL", 26, 29], ["lipopolysaccharide", "CHEMICAL", 87, 105], ["LPS", "CHEMICAL", 107, 110], ["sGP", "SIMPLE_CHEMICAL", 26, 29], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 87, 105], ["LPS", "SIMPLE_CHEMICAL", 107, 110], ["sGP", "PROTEIN", 26, 29], ["concomitant stimulation", "TREATMENT", 58, 81], ["lipopolysaccharide (LPS", "TREATMENT", 87, 110]]], ["Furthermore, sGP has no effect upon the capacity of activated macrophages to phagocytose antigen.", [["macrophages", "ANATOMY", 62, 73], ["sGP", "CHEMICAL", 13, 16], ["sGP", "SIMPLE_CHEMICAL", 13, 16], ["macrophages", "CELL", 62, 73], ["sGP", "PROTEIN", 13, 16], ["activated macrophages", "CELL_TYPE", 52, 73], ["phagocytose antigen", "PROTEIN", 77, 96], ["phagocytose antigen", "TEST", 77, 96], ["no", "UNCERTAINTY", 21, 23], ["effect", "OBSERVATION_MODIFIER", 24, 30]]], ["However, chemotaxis of activated macrophages is significantly diminished by sGP and likely is associated with reduced levels of CD11b integrin.", [["macrophages", "ANATOMY", 33, 44], ["macrophages", "CELL", 33, 44], ["sGP", "GENE_OR_GENE_PRODUCT", 76, 79], ["CD11b integrin", "GENE_OR_GENE_PRODUCT", 128, 142], ["activated macrophages", "CELL_TYPE", 23, 44], ["sGP", "PROTEIN", 76, 79], ["CD11b integrin", "PROTEIN", 128, 142], ["activated macrophages", "PROBLEM", 23, 44], ["CD11b integrin", "TREATMENT", 128, 142], ["macrophages", "OBSERVATION", 33, 44], ["significantly", "OBSERVATION_MODIFIER", 48, 61], ["diminished", "OBSERVATION_MODIFIER", 62, 72], ["CD11b integrin", "OBSERVATION", 128, 142]]], ["Overall, EBOV sGP may have a major role in the pathogenesis of EBOV through impairment of activated macrophages.Cell cultureHuman THP-1 monocyte cells (ATCC) were cultured in complete media containing RPMI 1640 (GE Healthcare) supplemented with 10% FBS that had been heat-inactivated for 30 min at 57\u00b0C, 0.05 mM 2mercaptoethanol and gentamycin.", [["macrophages", "ANATOMY", 100, 111], ["Cell cultureHuman THP-1 monocyte cells", "ANATOMY", 112, 150], ["ATCC", "ANATOMY", 152, 156], ["FBS", "ANATOMY", 249, 252], ["EBOV", "DISEASE", 63, 67], ["RPMI 1640", "CHEMICAL", 201, 210], ["2mercaptoethanol", "CHEMICAL", 312, 328], ["gentamycin", "CHEMICAL", 333, 343], ["2mercaptoethanol", "CHEMICAL", 312, 328], ["gentamycin", "CHEMICAL", 333, 343], ["EBOV", "ORGANISM", 9, 13], ["sGP", "GENE_OR_GENE_PRODUCT", 14, 17], ["EBOV", "ORGANISM", 63, 67], ["macrophages", "CELL", 100, 111], ["Cell", "CELL", 112, 116], ["THP-1 monocyte cells", "CELL", 130, 150], ["ATCC", "CELL", 152, 156], ["FBS", "ORGANISM_SUBSTANCE", 249, 252], ["2mercaptoethanol", "SIMPLE_CHEMICAL", 312, 328], ["gentamycin", "SIMPLE_CHEMICAL", 333, 343], ["EBOV sGP", "PROTEIN", 9, 17], ["activated macrophages", "CELL_TYPE", 90, 111], ["Cell cultureHuman THP-1 monocyte cells", "CELL_LINE", 112, 150], ["ATCC", "CELL_LINE", 152, 156], ["EBOV", "SPECIES", 9, 13], ["EBOV", "SPECIES", 63, 67], ["ATCC", "SPECIES", 152, 156], ["EBOV", "PROBLEM", 63, 67], ["activated macrophages", "PROBLEM", 90, 111], ["Cell cultureHuman THP", "TEST", 112, 133], ["monocyte cells", "TEST", 136, 150], ["ATCC", "TEST", 152, 156], ["10% FBS", "TREATMENT", 245, 252], ["0.05 mM 2mercaptoethanol", "TREATMENT", 304, 328], ["gentamycin", "TREATMENT", 333, 343], ["EBOV", "OBSERVATION", 9, 13], ["EBOV", "OBSERVATION", 63, 67], ["activated macrophages", "OBSERVATION", 90, 111], ["1 monocyte cells", "OBSERVATION_MODIFIER", 134, 150]]], ["Cells were maintained in an incubator at 37\u00b0C in 5% CO 2 -humidified atmosphere.Macrophage differentiation and polarizationTHP-1 monocyte cells were differentiated into M 0 macrophages over a 3-day incubation with 200 nM phorbol 12-myristate 13-acetate (PMA) stimulation followed by a 5-day rest [17] .", [["Cells", "ANATOMY", 0, 5], ["Macrophage", "ANATOMY", 80, 90], ["THP-1 monocyte cells", "ANATOMY", 123, 143], ["M 0 macrophages", "ANATOMY", 169, 184], ["phorbol 12-myristate 13-acetate", "CHEMICAL", 221, 252], ["PMA", "CHEMICAL", 254, 257], ["CO", "CHEMICAL", 52, 54], ["phorbol 12-myristate 13-acetate", "CHEMICAL", 221, 252], ["PMA", "CHEMICAL", 254, 257], ["Cells", "CELL", 0, 5], ["Macrophage", "CELL", 80, 90], ["THP-1", "GENE_OR_GENE_PRODUCT", 123, 128], ["M 0 macrophages", "CELL", 169, 184], ["phorbol 12-myristate 13-acetate", "SIMPLE_CHEMICAL", 221, 252], ["PMA", "SIMPLE_CHEMICAL", 254, 257], ["THP-1 monocyte cells", "CELL_LINE", 123, 143], ["M 0 macrophages", "CELL_LINE", 169, 184], ["Macrophage differentiation", "TEST", 80, 106], ["polarizationTHP", "TEST", 111, 126], ["monocyte cells", "TEST", 129, 143], ["200 nM phorbol", "TREATMENT", 214, 228], ["myristate 13-acetate (PMA) stimulation", "TREATMENT", 232, 270], ["polarization", "OBSERVATION_MODIFIER", 111, 123]]], ["The M0 macrophages were polarized into the M1 phenotype with 20 ng/mL IFN\u03b3 for 24 h, or the M2 phenotype with 20 ng/mL of IL-4 and 20 ng/mL of IL-13 for 24 h [18] .", [["M0 macrophages", "ANATOMY", 4, 18], ["M0 macrophages", "CELL", 4, 18], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 70, 74], ["IL-4", "GENE_OR_GENE_PRODUCT", 122, 126], ["IL-13", "GENE_OR_GENE_PRODUCT", 143, 148], ["M0 macrophages", "CELL_LINE", 4, 18], ["IFN\u03b3", "PROTEIN", 70, 74], ["IL", "PROTEIN", 122, 124], ["IL", "PROTEIN", 143, 145], ["IL", "TEST", 122, 124], ["IL", "TEST", 143, 145], ["M1", "ANATOMY", 43, 45]]], ["M1 and M2 phenotypes were confirmed using flow cytometry assessment of characteristic cellular markers (data not shown).THP-1 cell activation and incubation with EBOV sGPTHP-1 monocytes or M0, M1, or M2 macrophages were treated with 1 \u03bcg/ml LPS (Sigma) or PBS for 24 h, washed and followed by incubation with low (4 \u03bcg/ml) or high (8 \u03bcg/ml) concentrations of sGP, recombinant EBOV sGP lacking the transmembrane domain (IBT Bioservices) [19] , or PBS over 24 h.", [["cellular", "ANATOMY", 86, 94], ["THP-1 cell", "ANATOMY", 120, 130], ["sGPTHP-1 monocytes", "ANATOMY", 167, 185], ["M0", "ANATOMY", 189, 191], ["M1", "ANATOMY", 193, 195], ["M2 macrophages", "ANATOMY", 200, 214], ["transmembrane", "ANATOMY", 397, 410], ["LPS", "CHEMICAL", 241, 244], ["sGP", "CHEMICAL", 359, 362], ["M1", "CELL", 0, 2], ["M2", "GENE_OR_GENE_PRODUCT", 7, 9], ["cellular", "CELL", 86, 94], ["THP-1 cell", "CELL", 120, 130], ["EBOV", "ORGANISM", 162, 166], ["sGPTHP-1 monocytes", "CELL", 167, 185], ["M0", "CELL", 189, 191], ["M1", "CELL", 193, 195], ["M2 macrophages", "CELL", 200, 214], ["LPS", "SIMPLE_CHEMICAL", 241, 244], ["Sigma", "SIMPLE_CHEMICAL", 246, 251], ["sGP", "SIMPLE_CHEMICAL", 359, 362], ["EBOV", "ORGANISM", 376, 380], ["cellular markers", "PROTEIN", 86, 102], ["monocytes", "CELL_TYPE", 176, 185], ["M0", "CELL_LINE", 189, 191], ["M1", "CELL_LINE", 193, 195], ["M2 macrophages", "CELL_LINE", 200, 214], ["sGP", "PROTEIN", 359, 362], ["recombinant EBOV sGP", "PROTEIN", 364, 384], ["transmembrane domain", "PROTEIN", 397, 417], ["EBOV", "SPECIES", 376, 380], ["flow cytometry assessment", "TEST", 42, 67], ["THP-1 cell activation", "TEST", 120, 141], ["incubation", "TEST", 146, 156], ["EBOV sGPTHP", "TEST", 162, 173], ["monocytes", "TEST", 176, 185], ["PBS", "TREATMENT", 256, 259], ["sGP", "TREATMENT", 359, 362], ["recombinant EBOV sGP", "TREATMENT", 364, 384], ["the transmembrane domain (IBT Bioservices)", "TREATMENT", 393, 435], ["PBS", "TREATMENT", 446, 449], ["M2", "ANATOMY", 7, 9], ["cellular markers", "OBSERVATION", 86, 102], ["1 cell", "OBSERVATION_MODIFIER", 124, 130], ["M1", "ANATOMY", 193, 195], ["M2", "ANATOMY", 200, 202]]], ["EBOV sGP used in this study is created in mammalian cells, is fully glycosylated, and has no inhibition on the formation of dimers or trimers that could occur.THP-1 cell activation and incubation with EBOV sGPAlternatively, to test sGP impact prior to stimulation of M1 and M2 macrophages, sGP (4 \u03bcg/ml) was added with cytokines during polarization over 24 h, cultures were washed, and then activated for an additional 24 h with LPS (1 \u03bcg/ml).", [["cells", "ANATOMY", 52, 57], ["THP-1 cell", "ANATOMY", 159, 169], ["M1", "ANATOMY", 267, 269], ["M2 macrophages", "ANATOMY", 274, 288], ["sGP", "CHEMICAL", 5, 8], ["LPS", "CHEMICAL", 429, 432], ["EBOV", "ORGANISM", 0, 4], ["mammalian cells", "CELL", 42, 57], ["THP-1 cell", "CELL", 159, 169], ["EBOV", "ORGANISM", 201, 205], ["sGP", "GENE_OR_GENE_PRODUCT", 232, 235], ["M1", "CELL", 267, 269], ["M2 macrophages", "CELL", 274, 288], ["sGP", "SIMPLE_CHEMICAL", 290, 293], ["LPS", "SIMPLE_CHEMICAL", 429, 432], ["EBOV sGP", "PROTEIN", 0, 8], ["mammalian cells", "CELL_TYPE", 42, 57], ["sGP", "PROTEIN", 232, 235], ["M1 and M2 macrophages", "CELL_LINE", 267, 288], ["cytokines", "PROTEIN", 319, 328], ["EBOV", "SPECIES", 0, 4], ["EBOV", "SPECIES", 201, 205], ["EBOV sGP", "TEST", 0, 8], ["this study", "TEST", 17, 27], ["EBOV sGPAlternatively", "TREATMENT", 201, 222], ["stimulation of M1", "TREATMENT", 252, 269], ["sGP", "TEST", 290, 293], ["cultures", "TEST", 360, 368], ["LPS", "TREATMENT", 429, 432], ["mammalian cells", "OBSERVATION", 42, 57], ["1 cell", "OBSERVATION_MODIFIER", 163, 169]]], ["Assessment of the effect of sGP upon M1 and M2 macrophages at the time of activation involved stimulation of both populations with LPS (1 \u03bcg/ml), sGP (4 \u03bcg/ml), LPS + sGP or PBS for 24 h.", [["M1", "ANATOMY", 37, 39], ["M2 macrophages", "ANATOMY", 44, 58], ["LPS", "CHEMICAL", 131, 134], ["sGP", "CHEMICAL", 146, 149], ["LPS", "CHEMICAL", 161, 164], ["sGP", "CHEMICAL", 167, 170], ["sGP", "GENE_OR_GENE_PRODUCT", 28, 31], ["M1", "CELL", 37, 39], ["M2 macrophages", "CELL", 44, 58], ["LPS", "SIMPLE_CHEMICAL", 131, 134], ["sGP", "SIMPLE_CHEMICAL", 146, 149], ["LPS + sGP", "SIMPLE_CHEMICAL", 161, 170], ["PBS", "SIMPLE_CHEMICAL", 174, 177], ["sGP", "PROTEIN", 28, 31], ["M1 and M2 macrophages", "CELL_LINE", 37, 58], ["LPS", "TEST", 131, 134], ["sGP", "TEST", 146, 149], ["LPS", "TEST", 161, 164]]], ["At the completion of the assay (48 h), cell supernatants were harvested and tested by ELISA.Assessment of cytokine productionThe ELISA assays were performed utilizing the Ready-Set-Go ELISA kits (ThermoFisher Scientific) for IL-6, TNF\u03b1 and IL-10 following the manufacturer's instructions.", [["cell supernatants", "ANATOMY", 39, 56], ["cell", "CELL", 39, 43], ["IL-6", "GENE_OR_GENE_PRODUCT", 225, 229], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 231, 235], ["IL-10", "GENE_OR_GENE_PRODUCT", 240, 245], ["cytokine", "PROTEIN", 106, 114], ["IL-6", "PROTEIN", 225, 229], ["TNF\u03b1", "PROTEIN", 231, 235], ["IL", "PROTEIN", 240, 242], ["the assay", "TEST", 21, 30], ["cell supernatants", "TREATMENT", 39, 56], ["cytokine production", "TEST", 106, 125], ["The ELISA assays", "TEST", 125, 141], ["IL", "TEST", 225, 227]]], ["All ELISA procedures were read on a BioTek Eon microplate spectrophotometer (BioTek Instruments Inc.) and analyzed using Gen 5 software version 2.01.14.Flow cytometryFollowing incubation of polarized macrophages with LPS, sGP, PBS or combinations of these as indicated, adherent cells were collected from culture plates via trypsinization with 0.25% trypsin-EDTA.", [["macrophages", "ANATOMY", 200, 211], ["cells", "ANATOMY", 279, 284], ["LPS", "CHEMICAL", 217, 220], ["trypsin-EDTA", "CHEMICAL", 350, 362], ["macrophages", "CELL", 200, 211], ["LPS", "SIMPLE_CHEMICAL", 217, 220], ["sGP", "SIMPLE_CHEMICAL", 222, 225], ["PBS", "SIMPLE_CHEMICAL", 227, 230], ["cells", "CELL", 279, 284], ["trypsin-EDTA", "SIMPLE_CHEMICAL", 350, 362], ["polarized macrophages", "CELL_TYPE", 190, 211], ["adherent cells", "CELL_TYPE", 270, 284], ["All ELISA procedures", "TREATMENT", 0, 20], ["a BioTek Eon microplate spectrophotometer (BioTek Instruments", "TREATMENT", 34, 95], ["Flow cytometry", "TEST", 152, 166], ["polarized macrophages", "TREATMENT", 190, 211], ["LPS", "TREATMENT", 217, 220], ["sGP", "TEST", 222, 225], ["PBS", "TREATMENT", 227, 230], ["adherent cells", "PROBLEM", 270, 284], ["culture plates", "TEST", 305, 319], ["trypsinization", "TEST", 324, 338], ["polarized macrophages", "OBSERVATION", 190, 211]]], ["Staining was performed using standard procedures and fixed with 10% formalin.", [["formalin", "CHEMICAL", 68, 76], ["formalin", "CHEMICAL", 68, 76], ["formalin", "SIMPLE_CHEMICAL", 68, 76], ["Staining", "TEST", 0, 8], ["standard procedures", "TREATMENT", 29, 48], ["10% formalin", "TREATMENT", 64, 76]]], ["Human-specific CD11b-APC (eBioscience) was utilized.", [["Human", "ORGANISM", 0, 5], ["CD11b", "GENE_OR_GENE_PRODUCT", 15, 20], ["APC", "GENE_OR_GENE_PRODUCT", 21, 24], ["CD11b", "PROTEIN", 15, 20], ["APC", "PROTEIN", 21, 24], ["eBioscience", "PROTEIN", 26, 37], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human-specific CD11b-APC (eBioscience)", "TREATMENT", 0, 38]]], ["Flow cytometry was performed using a Millipore Guava Cytometer (Millipore) and analyzed with GuavaSoft 2.6 software.Phagocytosis assayThe ability to phagocytose foreign particles was measured utilizing a FITC labeled-chicken ovalbumin peptide (OVA-FITC, Fisher) [20] .", [["FITC", "CHEMICAL", 204, 208], ["FITC", "CHEMICAL", 248, 252], ["FITC", "SIMPLE_CHEMICAL", 204, 208], ["chicken", "ORGANISM", 217, 224], ["ovalbumin peptide", "SIMPLE_CHEMICAL", 225, 242], ["OVA-FITC", "SIMPLE_CHEMICAL", 244, 252], ["chicken", "SPECIES", 217, 224], ["chicken", "SPECIES", 217, 224], ["Flow cytometry", "TEST", 0, 14], ["a Millipore Guava Cytometer (Millipore", "TREATMENT", 35, 73], ["GuavaSoft", "TREATMENT", 93, 102], ["Phagocytosis assay", "TEST", 116, 134], ["phagocytose foreign particles", "TREATMENT", 149, 178], ["a FITC labeled-chicken ovalbumin peptide", "TREATMENT", 202, 242]]], ["Polarized macrophages were treated with LPS (1 \u00b5g/mL) or PBS for 24 h, washed, then treated with sGP (4 \u00b5g/mL) or PBS for an additional 24 h.", [["macrophages", "ANATOMY", 10, 21], ["LPS", "CHEMICAL", 40, 43], ["sGP", "CHEMICAL", 97, 100], ["sGP", "CHEMICAL", 97, 100], ["macrophages", "CELL", 10, 21], ["LPS", "SIMPLE_CHEMICAL", 40, 43], ["sGP", "SIMPLE_CHEMICAL", 97, 100], ["Polarized macrophages", "CELL_TYPE", 0, 21], ["Polarized macrophages", "PROBLEM", 0, 21], ["LPS", "TREATMENT", 40, 43], ["PBS", "TREATMENT", 57, 60], ["sGP", "TREATMENT", 97, 100], ["PBS", "TREATMENT", 114, 117], ["macrophages", "OBSERVATION", 10, 21]]], ["The cells were washed, and OVA-FITC (0.25 mg/mL), complete unconjugated ovalbumin protein (1 mg/mL, Invivogen), or PBS was added.", [["cells", "ANATOMY", 4, 9], ["OVA-FITC", "CHEMICAL", 27, 35], ["FITC", "CHEMICAL", 31, 35], ["cells", "CELL", 4, 9], ["OVA-FITC", "SIMPLE_CHEMICAL", 27, 35], ["Invivogen", "SIMPLE_CHEMICAL", 100, 109], ["PBS", "SIMPLE_CHEMICAL", 115, 118], ["unconjugated ovalbumin protein", "PROTEIN", 59, 89], ["The cells", "TREATMENT", 0, 9], ["OVA-FITC", "TREATMENT", 27, 35], ["complete unconjugated ovalbumin protein", "TREATMENT", 50, 89], ["Invivogen", "TREATMENT", 100, 109], ["PBS", "TREATMENT", 115, 118]]], ["At 30 min, 1 h, and 3 h incubation time, the adherent cells were collected by treatment with 0.25% trypsin/EDTA.", [["cells", "ANATOMY", 54, 59], ["EDTA", "CHEMICAL", 107, 111], ["cells", "CELL", 54, 59], ["trypsin", "GENE_OR_GENE_PRODUCT", 99, 106], ["EDTA", "SIMPLE_CHEMICAL", 107, 111], ["adherent cells", "CELL_TYPE", 45, 59], ["trypsin", "PROTEIN", 99, 106], ["the adherent cells", "TREATMENT", 41, 59], ["EDTA", "TREATMENT", 107, 111]]], ["The cells were washed three times in cold PBS to remove any bound, but not phagocytosed molecules.", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["phagocytosed molecules", "PROTEIN", 75, 97], ["cold PBS", "TREATMENT", 37, 45], ["any bound", "PROBLEM", 56, 65], ["phagocytosed molecules", "PROBLEM", 75, 97]]], ["Cells were fixed with 10% formalin and analyzed by flow cytometry.", [["Cells", "ANATOMY", 0, 5], ["formalin", "CHEMICAL", 26, 34], ["formalin", "CHEMICAL", 26, 34], ["Cells", "CELL", 0, 5], ["formalin", "SIMPLE_CHEMICAL", 26, 34], ["Cells", "TEST", 0, 5], ["10% formalin", "TREATMENT", 22, 34], ["flow cytometry", "TEST", 51, 65]]], ["The cells were gated to exclude debris.Chemotaxis assayChemotaxis was assayed as previously described [21] .", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["debris", "PROBLEM", 32, 38], ["Chemotaxis assayChemotaxis", "TEST", 39, 65], ["debris", "OBSERVATION", 32, 38]]], ["In brief, Corning Transwell Plates (Sigma) with 8 \u03bcm pore size were used.", [["pore", "ANATOMY", 53, 57], ["8 \u03bcm pore size", "TREATMENT", 48, 62]]], ["M1 macrophages were treated with LPS, sGP, or PBS as indicated, trypsinized, and counted.", [["M1 macrophages", "ANATOMY", 0, 14], ["LPS", "CHEMICAL", 33, 36], ["M1 macrophages", "CELL", 0, 14], ["LPS", "SIMPLE_CHEMICAL", 33, 36], ["sGP", "SIMPLE_CHEMICAL", 38, 41], ["M1 macrophages", "CELL_LINE", 0, 14], ["LPS", "TREATMENT", 33, 36], ["sGP", "TEST", 38, 41], ["PBS", "TREATMENT", 46, 49]]], ["M1 macrophages (3 \u00d7 10 5 ) were placed into the apical chamber in complete media.", [["M1 macrophages", "ANATOMY", 0, 14], ["apical chamber", "ANATOMY", 48, 62], ["M1 macrophages", "CELL", 0, 14], ["M1 macrophages", "CELL_TYPE", 0, 14], ["apical", "ANATOMY_MODIFIER", 48, 54], ["chamber", "ANATOMY_MODIFIER", 55, 62], ["complete media", "OBSERVATION", 66, 80]]], ["MCP-1, or CCL-2, (10 ng/mL, Peprotech) was added into the basal chamber of some wells, and PBS to the others.", [["MCP-1", "GENE_OR_GENE_PRODUCT", 0, 5], ["CCL-2", "GENE_OR_GENE_PRODUCT", 10, 15], ["MCP", "PROTEIN", 0, 3], ["Peprotech", "PROTEIN", 28, 37], ["MCP", "TEST", 0, 3], ["CCL", "TEST", 10, 13], ["basal", "ANATOMY_MODIFIER", 58, 63], ["chamber", "ANATOMY_MODIFIER", 64, 71]]], ["The cells were incubated for 24 h.", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9]]], ["Remaining macrophages in the wells were trypsinized, and counted using a hemocytometer (Becton, Dickinson, and Company), and measured via flow cytometry.", [["macrophages", "ANATOMY", 10, 21], ["macrophages", "CELL", 10, 21], ["wells", "CELL", 29, 34], ["macrophages", "CELL_TYPE", 10, 21], ["flow cytometry", "TEST", 138, 152], ["macrophages", "OBSERVATION", 10, 21]]], ["The cells were gated to exclude debris, and cells that migrated across the membrane as events per 30 s.", [["cells", "ANATOMY", 4, 9], ["debris", "ANATOMY", 32, 38], ["cells", "ANATOMY", 44, 49], ["membrane", "ANATOMY", 75, 83], ["cells", "CELL", 4, 9], ["cells", "CELL", 44, 49], ["membrane", "CELLULAR_COMPONENT", 75, 83], ["debris", "PROBLEM", 32, 38], ["cells", "PROBLEM", 44, 49], ["debris", "OBSERVATION", 32, 38]]], ["The flow data was represented as percent increase in chemotaxis and calculated as: 100% -[(number of cells that migrated to the basal chamber without chemokine/number of cells that migrated to the basal chamber in the presence of chemokine) \u00d7 100%].Statistical analysisMeans and standard deviations were expressed in the data and assessed for statistical significance using the unpaired Student's t-test.", [["cells", "ANATOMY", 101, 106], ["cells", "ANATOMY", 170, 175], ["cells", "CELL", 101, 106], ["cells", "CELL", 170, 175], ["chemokine", "PROTEIN", 150, 159], ["chemokine", "PROTEIN", 230, 239], ["The flow data", "TEST", 0, 13], ["chemotaxis", "TEST", 53, 63], ["chemokine/number of cells", "TREATMENT", 150, 175], ["Statistical analysisMeans", "TEST", 249, 274], ["standard deviations", "PROBLEM", 279, 298], ["the data", "TEST", 317, 325], ["increase", "OBSERVATION_MODIFIER", 41, 49], ["basal", "ANATOMY_MODIFIER", 128, 133], ["chamber", "ANATOMY_MODIFIER", 134, 141]]], ["When comparing two groups, a p-value of \u2264.05 was considered significant, unless otherwise noted.", [["a p-value", "TEST", 27, 36]]], ["Experiments were performed in duplicates and were performed a minimum of three times to observe consistent trends.EBOV sGP differentially inhibits production of IL-6 by macrophages but not monocytesCertainly EBOV initiates infection by invading tissue macrophages and dendritic cells, ultimately resulting in systemic dissemination from the entry point.", [["macrophages", "ANATOMY", 169, 180], ["monocytes", "ANATOMY", 189, 198], ["tissue macrophages", "ANATOMY", 245, 263], ["dendritic cells", "ANATOMY", 268, 283], ["sGP", "CHEMICAL", 119, 122], ["infection", "DISEASE", 223, 232], ["EBOV", "ORGANISM", 114, 118], ["IL-6", "GENE_OR_GENE_PRODUCT", 161, 165], ["macrophages", "CELL", 169, 180], ["monocytes", "CELL", 189, 198], ["EBOV", "ORGANISM", 208, 212], ["tissue macrophages", "CELL", 245, 263], ["dendritic cells", "CELL", 268, 283], ["EBOV sGP", "PROTEIN", 114, 122], ["IL-6", "PROTEIN", 161, 165], ["macrophages", "CELL_TYPE", 169, 180], ["monocytes", "CELL_TYPE", 189, 198], ["invading tissue macrophages", "CELL_TYPE", 236, 263], ["dendritic cells", "CELL_TYPE", 268, 283], ["EBOV", "SPECIES", 114, 118], ["EBOV", "SPECIES", 208, 212], ["EBOV sGP", "TEST", 114, 122], ["IL", "TEST", 161, 163], ["monocytes", "TEST", 189, 198], ["EBOV", "PROBLEM", 208, 212], ["infection", "PROBLEM", 223, 232], ["invading tissue macrophages", "PROBLEM", 236, 263], ["dendritic cells", "PROBLEM", 268, 283], ["systemic dissemination", "PROBLEM", 309, 331], ["not", "UNCERTAINTY", 185, 188], ["monocytes", "OBSERVATION", 189, 198], ["EBOV", "OBSERVATION", 208, 212], ["infection", "OBSERVATION", 223, 232], ["invading tissue macrophages", "OBSERVATION", 236, 263], ["dendritic cells", "OBSERVATION", 268, 283], ["systemic", "OBSERVATION_MODIFIER", 309, 317], ["dissemination", "OBSERVATION", 318, 331], ["entry point", "OBSERVATION", 341, 352]]], ["Interestingly, the virus directs the synthesis and secretion of the modified glycoprotein (sGP) from these infected cells into the surrounding tissues and blood.", [["cells", "ANATOMY", 116, 121], ["tissues", "ANATOMY", 143, 150], ["blood", "ANATOMY", 155, 160], ["glycoprotein", "GENE_OR_GENE_PRODUCT", 77, 89], ["cells", "CELL", 116, 121], ["tissues", "TISSUE", 143, 150], ["blood", "ORGANISM_SUBSTANCE", 155, 160], ["modified glycoprotein", "PROTEIN", 68, 89], ["GP", "PROTEIN", 92, 94], ["infected cells", "CELL_TYPE", 107, 121], ["the virus", "PROBLEM", 15, 24], ["virus", "OBSERVATION", 19, 24], ["infected cells", "OBSERVATION", 107, 121], ["surrounding tissues", "ANATOMY", 131, 150], ["blood", "OBSERVATION_MODIFIER", 155, 160]]], ["The purpose of this maneuver may be to deter immune reactivity which could slow the replication and dissemination process rather than simply act as an anti-EBOV antibody sink.", [["anti-EBOV antibody", "PROTEIN", 151, 169], ["this maneuver", "TREATMENT", 15, 28], ["immune reactivity", "PROBLEM", 45, 62]]], ["This is more likely the case during the early phases of disease prior to antibody synthesis.", [["disease", "PROBLEM", 56, 63], ["antibody synthesis", "TREATMENT", 73, 91], ["more likely", "UNCERTAINTY", 8, 19]]], ["Given the importance of monocytes and macrophages in the early innate response to viral invaders, first we sought to examine the effect of EBOV sGP upon the activation of non-infected monocytes and macrophages.", [["monocytes", "ANATOMY", 24, 33], ["macrophages", "ANATOMY", 38, 49], ["monocytes", "ANATOMY", 184, 193], ["macrophages", "ANATOMY", 198, 209], ["monocytes", "CELL", 24, 33], ["macrophages", "CELL", 38, 49], ["EBOV", "ORGANISM", 139, 143], ["sGP", "GENE_OR_GENE_PRODUCT", 144, 147], ["monocytes", "CELL", 184, 193], ["macrophages", "CELL", 198, 209], ["monocytes", "CELL_TYPE", 24, 33], ["macrophages", "CELL_TYPE", 38, 49], ["EBOV sGP", "PROTEIN", 139, 147], ["non-infected monocytes", "CELL_TYPE", 171, 193], ["macrophages", "CELL_TYPE", 198, 209], ["EBOV", "SPECIES", 139, 143], ["monocytes", "PROBLEM", 24, 33], ["macrophages", "PROBLEM", 38, 49], ["viral invaders", "PROBLEM", 82, 96], ["EBOV sGP", "PROBLEM", 139, 147], ["monocytes", "ANATOMY", 24, 33], ["viral invaders", "OBSERVATION", 82, 96], ["EBOV", "OBSERVATION", 139, 143], ["non-infected monocytes", "OBSERVATION", 171, 193]]], ["In order to test this in vitro, the human monocytic cell line, THP-1, which can be differentiated into macrophages by treatment with 200 nM PMA for three days, followed by a five-day rest, was used as a source of cells [17] .", [["monocytic cell line", "ANATOMY", 42, 61], ["THP-1", "ANATOMY", 63, 68], ["macrophages", "ANATOMY", 103, 114], ["cells", "ANATOMY", 213, 218], ["PMA", "CHEMICAL", 140, 143], ["PMA", "CHEMICAL", 140, 143], ["human", "ORGANISM", 36, 41], ["monocytic cell line", "CELL", 42, 61], ["THP-1", "CELL", 63, 68], ["macrophages", "CELL", 103, 114], ["PMA", "SIMPLE_CHEMICAL", 140, 143], ["cells", "CELL", 213, 218], ["human monocytic cell line", "CELL_LINE", 36, 61], ["THP-1", "CELL_LINE", 63, 68], ["macrophages", "CELL_TYPE", 103, 114], ["human", "SPECIES", 36, 41], ["human", "SPECIES", 36, 41], ["the human monocytic cell line", "TREATMENT", 32, 61], ["THP", "TEST", 63, 66], ["monocytic cell line", "OBSERVATION", 42, 61], ["macrophages", "OBSERVATION", 103, 114]]], ["The THP-1 monocytes and macrophages were challenged with LPS for 24 h as a way to activate the cells and trigger cytokine production.", [["THP-1 monocytes", "ANATOMY", 4, 19], ["macrophages", "ANATOMY", 24, 35], ["cells", "ANATOMY", 95, 100], ["LPS", "CHEMICAL", 57, 60], ["THP-1 monocytes", "CELL", 4, 19], ["macrophages", "CELL", 24, 35], ["LPS", "SIMPLE_CHEMICAL", 57, 60], ["cells", "CELL", 95, 100], ["THP-1 monocytes", "CELL_LINE", 4, 19], ["macrophages", "CELL_TYPE", 24, 35], ["cytokine", "PROTEIN", 113, 121], ["LPS", "TREATMENT", 57, 60], ["cytokine production", "PROBLEM", 113, 132], ["monocytes", "ANATOMY", 10, 19], ["macrophages", "ANATOMY", 24, 35]]], ["Subsequently, the cells were washed with PBS and treated with either a low (4 \u03bcg/ml) or high (8 \u03bcg/ml) dose of sGP for 24 h.", [["cells", "ANATOMY", 18, 23], ["sGP", "CHEMICAL", 111, 114], ["cells", "CELL", 18, 23], ["sGP", "SIMPLE_CHEMICAL", 111, 114], ["the cells", "TREATMENT", 14, 23], ["PBS", "TREATMENT", 41, 44], ["sGP", "TREATMENT", 111, 114]]], ["IL-6 production by monocytes was not statistically affected by either dosage of sGP (Fig. 1A) .", [["monocytes", "ANATOMY", 19, 28], ["IL-6", "GENE_OR_GENE_PRODUCT", 0, 4], ["monocytes", "CELL", 19, 28], ["sGP", "SIMPLE_CHEMICAL", 80, 83], ["IL-6", "PROTEIN", 0, 4], ["monocytes", "CELL_TYPE", 19, 28], ["sGP", "PROTEIN", 80, 83], ["IL", "TREATMENT", 0, 2]]], ["However, the production of IL-6 by macrophages was significantly inhibited in the presence of sGP (Fig. 1B) .", [["macrophages", "ANATOMY", 35, 46], ["IL-6", "GENE_OR_GENE_PRODUCT", 27, 31], ["macrophages", "CELL", 35, 46], ["sGP", "SIMPLE_CHEMICAL", 94, 97], ["IL-6", "PROTEIN", 27, 31], ["macrophages", "CELL_TYPE", 35, 46], ["sGP", "PROTEIN", 94, 97]]], ["The low and high doses of sGP seemed to affect the activated macrophages equally; therefore, we chose to use the low dose throughout the remainder of the study.", [["macrophages", "ANATOMY", 61, 72], ["sGP", "CHEMICAL", 26, 29], ["sGP", "SIMPLE_CHEMICAL", 26, 29], ["macrophages", "CELL", 61, 72], ["sGP", "PROTEIN", 26, 29], ["activated macrophages", "CELL_TYPE", 51, 72], ["the study", "TEST", 150, 159], ["low", "OBSERVATION_MODIFIER", 4, 7], ["high doses", "OBSERVATION_MODIFIER", 12, 22], ["macrophages", "OBSERVATION", 61, 72]]], ["The results suggest that sGP may have a direct inhibitory effect on non-infected macrophages.Polarization of macrophages is unaltered by EBOV sGPTHP-1 differentiated macrophages (M0) can be polarized into the M1 phenotype with the treatment of IFN\u03b3.", [["macrophages", "ANATOMY", 81, 92], ["macrophages", "ANATOMY", 109, 120], ["macrophages", "ANATOMY", 166, 177], ["M0", "ANATOMY", 179, 181], ["sGP", "CHEMICAL", 25, 28], ["sGP", "SIMPLE_CHEMICAL", 25, 28], ["macrophages", "CELL", 81, 92], ["macrophages", "CELL", 109, 120], ["EBOV", "ORGANISM", 137, 141], ["sGPTHP-1", "GENE_OR_GENE_PRODUCT", 142, 150], ["macrophages", "CELL", 166, 177], ["M0", "CELL", 179, 181], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 244, 248], ["sGP", "PROTEIN", 25, 28], ["non-infected macrophages", "CELL_TYPE", 68, 92], ["macrophages", "CELL_TYPE", 109, 120], ["EBOV sGPTHP-1 differentiated macrophages", "CELL_LINE", 137, 177], ["M0", "CELL_LINE", 179, 181], ["IFN\u03b3", "PROTEIN", 244, 248], ["EBOV", "SPECIES", 137, 141], ["a direct inhibitory effect on non-infected macrophages", "PROBLEM", 38, 92], ["EBOV sGPTHP", "TEST", 137, 148], ["IFN\u03b3", "TREATMENT", 244, 248], ["non-infected macrophages", "OBSERVATION", 68, 92], ["macrophages", "OBSERVATION", 109, 120], ["M1", "ANATOMY", 209, 211]]], ["To test whether sGP will inhibit the polarization of M1 macrophages, M0 macrophages were incubated with sGP and IFN\u03b3 simultaneously for 24 h and then washed, and stimulated with LPS to induce cytokine production.", [["M1 macrophages", "ANATOMY", 53, 67], ["M0 macrophages", "ANATOMY", 69, 83], ["LPS", "CHEMICAL", 178, 181], ["sGP", "SIMPLE_CHEMICAL", 16, 19], ["M1 macrophages", "CELL", 53, 67], ["M0 macrophages", "CELL", 69, 83], ["sGP", "SIMPLE_CHEMICAL", 104, 107], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 112, 116], ["LPS", "SIMPLE_CHEMICAL", 178, 181], ["sGP", "PROTEIN", 16, 19], ["M1 macrophages", "CELL_TYPE", 53, 67], ["M0 macrophages", "CELL_LINE", 69, 83], ["sGP", "PROTEIN", 104, 107], ["IFN\u03b3", "PROTEIN", 112, 116], ["cytokine", "PROTEIN", 192, 200], ["sGP", "TEST", 104, 107], ["IFN", "TREATMENT", 112, 115], ["LPS", "TREATMENT", 178, 181], ["cytokine production", "PROBLEM", 192, 211]]], ["When EBOV sGP was present during the polarization of M1 macrophages, there was no significant effect on the cytokine profile that is characteristic for M1 macrophages ( Fig. 2A) .", [["M1 macrophages", "ANATOMY", 53, 67], ["M1 macrophages", "ANATOMY", 152, 166], ["EBOV", "ORGANISM", 5, 9], ["sGP", "GENE_OR_GENE_PRODUCT", 10, 13], ["M1 macrophages", "CELL", 53, 67], ["M1 macrophages", "CELL", 152, 166], ["EBOV sGP", "PROTEIN", 5, 13], ["M1 macrophages", "CELL_TYPE", 53, 67], ["cytokine", "PROTEIN", 108, 116], ["M1 macrophages", "CELL_TYPE", 152, 166], ["EBOV", "SPECIES", 5, 9], ["EBOV sGP", "TEST", 5, 13], ["significant effect on the cytokine profile", "PROBLEM", 82, 124], ["M1 macrophages", "PROBLEM", 152, 166], ["no", "UNCERTAINTY", 79, 81], ["significant", "OBSERVATION_MODIFIER", 82, 93], ["effect", "OBSERVATION", 94, 100], ["characteristic for", "UNCERTAINTY", 133, 151], ["M1 macrophages", "OBSERVATION", 152, 166]]], ["The production of the pro-inflammatory cytokines, TNF\u03b1 and IL-6, should be high for M1 macrophages as compared to resting M0 or M2 macrophages, and there was no significant change in these cytokine levels when macrophages were polarized with IFN\u03b3 in the presence of sGP.", [["M1 macrophages", "ANATOMY", 84, 98], ["M0", "ANATOMY", 122, 124], ["M2 macrophages", "ANATOMY", 128, 142], ["macrophages", "ANATOMY", 210, 221], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 50, 54], ["IL-6", "GENE_OR_GENE_PRODUCT", 59, 63], ["M1 macrophages", "CELL", 84, 98], ["M0", "CELL", 122, 124], ["M2 macrophages", "CELL", 128, 142], ["macrophages", "CELL", 210, 221], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 242, 246], ["sGP", "GENE_OR_GENE_PRODUCT", 266, 269], ["pro-inflammatory cytokines", "PROTEIN", 22, 48], ["TNF\u03b1", "PROTEIN", 50, 54], ["IL-6", "PROTEIN", 59, 63], ["M1 macrophages", "CELL_TYPE", 84, 98], ["M2 macrophages", "CELL_TYPE", 128, 142], ["cytokine", "PROTEIN", 189, 197], ["macrophages", "CELL_TYPE", 210, 221], ["IFN\u03b3", "PROTEIN", 242, 246], ["sGP", "PROTEIN", 266, 269], ["the pro-inflammatory cytokines", "TEST", 18, 48], ["TNF", "TEST", 50, 53], ["IL", "TEST", 59, 61], ["M1 macrophages", "PROBLEM", 84, 98], ["significant change in these cytokine levels", "PROBLEM", 161, 204], ["macrophages", "PROBLEM", 210, 221], ["IFN", "TREATMENT", 242, 245], ["sGP", "PROBLEM", 266, 269], ["pro-inflammatory cytokines", "OBSERVATION", 22, 48], ["no", "UNCERTAINTY", 158, 160], ["significant", "OBSERVATION_MODIFIER", 161, 172], ["change", "OBSERVATION", 173, 179], ["sGP", "OBSERVATION", 266, 269]]], ["Typically, M1 macrophages produce low levels of the anti-inflammatory cytokine, IL-10, upon stimulation with LPS and the level of the cytokine was not affected by the presence of sGP during M1 polarization ( Fig. 2A) .", [["M1 macrophages", "ANATOMY", 11, 25], ["LPS", "CHEMICAL", 109, 112], ["M1 macrophages", "CELL", 11, 25], ["IL-10", "GENE_OR_GENE_PRODUCT", 80, 85], ["LPS", "SIMPLE_CHEMICAL", 109, 112], ["sGP", "GENE_OR_GENE_PRODUCT", 179, 182], ["M1 macrophages", "CELL_LINE", 11, 25], ["anti-inflammatory cytokine", "PROTEIN", 52, 78], ["IL-10", "PROTEIN", 80, 85], ["cytokine", "PROTEIN", 134, 142], ["sGP", "PROTEIN", 179, 182], ["the anti-inflammatory cytokine", "TREATMENT", 48, 78], ["LPS", "TREATMENT", 109, 112], ["low levels", "OBSERVATION_MODIFIER", 34, 44], ["anti-inflammatory cytokine", "OBSERVATION", 52, 78]]], ["Interestingly, the basal level of IL-10 production by the M1 macrophages was significantly greater than that of LPS-stimulated cells.", [["M1 macrophages", "ANATOMY", 58, 72], ["cells", "ANATOMY", 127, 132], ["LPS", "CHEMICAL", 112, 115], ["IL-10", "GENE_OR_GENE_PRODUCT", 34, 39], ["M1 macrophages", "CELL", 58, 72], ["LPS", "SIMPLE_CHEMICAL", 112, 115], ["cells", "CELL", 127, 132], ["IL-10", "PROTEIN", 34, 39], ["M1 macrophages", "CELL_LINE", 58, 72], ["LPS-stimulated cells", "CELL_LINE", 112, 132], ["basal", "ANATOMY_MODIFIER", 19, 24], ["M1", "ANATOMY", 58, 60], ["significantly", "OBSERVATION_MODIFIER", 77, 90], ["greater", "OBSERVATION_MODIFIER", 91, 98]]], ["This is likely due to the ability of LPS to promote M1 macrophage functions thereby resulting in a lower IL-10 production by these stimulated cells [22] .", [["M1 macrophage", "ANATOMY", 52, 65], ["cells", "ANATOMY", 142, 147], ["LPS", "CHEMICAL", 37, 40], ["LPS", "SIMPLE_CHEMICAL", 37, 40], ["M1 macrophage", "CELL", 52, 65], ["IL-10", "GENE_OR_GENE_PRODUCT", 105, 110], ["cells", "CELL", 142, 147], ["stimulated cells", "CELL_TYPE", 131, 147], ["LPS", "TREATMENT", 37, 40], ["a lower IL", "TREATMENT", 97, 107], ["these stimulated cells", "TEST", 125, 147], ["likely due to", "UNCERTAINTY", 8, 21]]], ["Of note, basal production of IL-10 by sGP-cultured M1 macrophages was decreased relative to LPS-stimulated cells.", [["M1 macrophages", "ANATOMY", 51, 65], ["cells", "ANATOMY", 107, 112], ["LPS", "CHEMICAL", 92, 95], ["IL-10", "GENE_OR_GENE_PRODUCT", 29, 34], ["sGP", "GENE_OR_GENE_PRODUCT", 38, 41], ["M1 macrophages", "CELL", 51, 65], ["LPS", "SIMPLE_CHEMICAL", 92, 95], ["cells", "CELL", 107, 112], ["IL-10", "PROTEIN", 29, 34], ["sGP-cultured M1 macrophages", "CELL_LINE", 38, 65], ["LPS-stimulated cells", "CELL_LINE", 92, 112], ["IL", "TEST", 29, 31], ["sGP", "TEST", 38, 41], ["LPS", "TEST", 92, 95], ["basal", "ANATOMY_MODIFIER", 9, 14]]], ["Possibly sGP ligation to an unknown receptor on the macrophages resulted in activation of an adaptor protein which operated to reduce basal release of IL-10.", [["macrophages", "ANATOMY", 52, 63], ["sGP", "GENE_OR_GENE_PRODUCT", 9, 12], ["macrophages", "CELL", 52, 63], ["IL-10", "GENE_OR_GENE_PRODUCT", 151, 156], ["sGP", "PROTEIN", 9, 12], ["macrophages", "CELL_TYPE", 52, 63], ["adaptor protein", "PROTEIN", 93, 108], ["IL", "PROTEIN", 151, 153], ["sGP ligation", "TREATMENT", 9, 21], ["an adaptor protein", "TREATMENT", 90, 108], ["basal release of IL", "TREATMENT", 134, 153], ["sGP", "OBSERVATION_MODIFIER", 9, 12], ["ligation", "OBSERVATION", 13, 21], ["macrophages", "OBSERVATION", 52, 63]]], ["However, activation of sGP-treated M1 macrophages resulted in restoration of IL-10 levels to that of LPS-stimulated cells.Polarization of macrophages is unaltered by EBOV sGPTo test whether sGP had any effect upon the polarization of M2 macrophages, THP-1 macrophages were treated with IL-4, IL-13, and sGP for 24 h, washed, and subsequently activated by LPS an additional 24 h.", [["M1 macrophages", "ANATOMY", 35, 49], ["cells", "ANATOMY", 116, 121], ["macrophages", "ANATOMY", 138, 149], ["M2 macrophages", "ANATOMY", 234, 248], ["THP-1 macrophages", "ANATOMY", 250, 267], ["LPS", "CHEMICAL", 101, 104], ["LPS", "CHEMICAL", 355, 358], ["sGP", "GENE_OR_GENE_PRODUCT", 23, 26], ["M1 macrophages", "CELL", 35, 49], ["IL-10", "GENE_OR_GENE_PRODUCT", 77, 82], ["LPS", "SIMPLE_CHEMICAL", 101, 104], ["cells", "CELL", 116, 121], ["macrophages", "CELL", 138, 149], ["EBOV", "ORGANISM", 166, 170], ["sGPTo", "GENE_OR_GENE_PRODUCT", 171, 176], ["sGP", "SIMPLE_CHEMICAL", 190, 193], ["M2 macrophages", "CELL", 234, 248], ["THP-1 macrophages", "CELL", 250, 267], ["IL-4", "GENE_OR_GENE_PRODUCT", 286, 290], ["IL-13", "GENE_OR_GENE_PRODUCT", 292, 297], ["sGP", "SIMPLE_CHEMICAL", 303, 306], ["LPS", "SIMPLE_CHEMICAL", 355, 358], ["sGP", "PROTEIN", 23, 26], ["M1 macrophages", "CELL_LINE", 35, 49], ["IL", "PROTEIN", 77, 79], ["LPS-stimulated cells", "CELL_LINE", 101, 121], ["macrophages", "CELL_TYPE", 138, 149], ["EBOV sGPTo", "PROTEIN", 166, 176], ["sGP", "PROTEIN", 190, 193], ["M2 macrophages", "CELL_TYPE", 234, 248], ["THP-1 macrophages", "CELL_LINE", 250, 267], ["IL", "PROTEIN", 286, 288], ["IL", "PROTEIN", 292, 294], ["sGP", "PROTEIN", 303, 306], ["EBOV", "SPECIES", 166, 170], ["sGP", "TEST", 23, 26], ["restoration of IL", "TREATMENT", 62, 79], ["EBOV sGPTo test", "TEST", 166, 181], ["THP", "TEST", 250, 253], ["IL", "TREATMENT", 286, 288], ["IL", "TREATMENT", 292, 294], ["macrophages", "OBSERVATION", 138, 149], ["macrophages", "ANATOMY", 256, 267]]], ["M2 macrophages produce low levels of pro-inflammatory cytokines, and high levels of IL-10 as compared to M1 macrophages (Fig. 2B) .", [["M2 macrophages", "ANATOMY", 0, 14], ["M1 macrophages", "ANATOMY", 105, 119], ["M2 macrophages", "CELL", 0, 14], ["IL-10", "GENE_OR_GENE_PRODUCT", 84, 89], ["M1 macrophages", "CELL", 105, 119], ["Fig. 2B", "CELL", 121, 128], ["M2 macrophages", "CELL_LINE", 0, 14], ["pro-inflammatory cytokines", "PROTEIN", 37, 63], ["IL-10", "PROTEIN", 84, 89], ["M1 macrophages", "CELL_TYPE", 105, 119], ["M2 macrophages", "PROBLEM", 0, 14], ["low levels of pro-inflammatory cytokines", "PROBLEM", 23, 63], ["high levels of IL", "PROBLEM", 69, 86], ["low levels", "OBSERVATION_MODIFIER", 23, 33], ["pro-inflammatory cytokines", "OBSERVATION", 37, 63], ["high", "OBSERVATION_MODIFIER", 69, 73]]], ["When sGP was given at the same time as the polarizing cytokines, the production of TNF\u03b1, IL-6, and IL-10 by M2 macrophages was unchanged (Fig. 2B ).", [["M2 macrophages", "ANATOMY", 108, 122], ["sGP", "CHEMICAL", 5, 8], ["sGP", "SIMPLE_CHEMICAL", 5, 8], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 83, 87], ["IL-6", "GENE_OR_GENE_PRODUCT", 89, 93], ["IL-10", "GENE_OR_GENE_PRODUCT", 99, 104], ["M2 macrophages", "CELL", 108, 122], ["sGP", "PROTEIN", 5, 8], ["cytokines", "PROTEIN", 54, 63], ["TNF\u03b1", "PROTEIN", 83, 87], ["IL-10", "PROTEIN", 99, 104], ["M2 macrophages", "CELL_TYPE", 108, 122], ["the polarizing cytokines", "TEST", 39, 63], ["TNF\u03b1", "TEST", 83, 87], ["IL", "TEST", 89, 91], ["IL", "TEST", 99, 101], ["unchanged", "OBSERVATION_MODIFIER", 127, 136]]], ["In addition, the significant inhibition of basal IL-10 noted in sGP-treated M1 macrophages was not evident of M2 macrophages when given with M2-polarizing cytokines.", [["M1 macrophages", "ANATOMY", 76, 90], ["M2 macrophages", "ANATOMY", 110, 124], ["IL-10", "GENE_OR_GENE_PRODUCT", 49, 54], ["sGP", "SIMPLE_CHEMICAL", 64, 67], ["M1 macrophages", "CELL", 76, 90], ["M2 macrophages", "CELL", 110, 124], ["basal IL-10", "PROTEIN", 43, 54], ["sGP-treated M1 macrophages", "CELL_LINE", 64, 90], ["M2 macrophages", "CELL_TYPE", 110, 124], ["M2", "PROTEIN", 141, 143], ["cytokines", "PROTEIN", 155, 164], ["basal IL", "TEST", 43, 51], ["sGP", "TEST", 64, 67], ["M2 macrophages", "PROBLEM", 110, 124], ["M2-polarizing cytokines", "TREATMENT", 141, 164], ["significant", "OBSERVATION_MODIFIER", 17, 28], ["basal", "ANATOMY_MODIFIER", 43, 48], ["not evident", "UNCERTAINTY", 95, 106], ["M2 macrophages", "OBSERVATION", 110, 124]]], ["Overall, the findings indicate sGP does not disturb the process of macrophage polarization but may have a role in the function of polarized macrophages.Pro-inflammatory cytokine production by activated macrophages is selectively inhibited by EBOV sGPWhen considering whether sGP can impact non-infected macrophage function, sGP, a soluble viral protein, would likely encounter macrophages within the body that were either previously activated or undergoing activation.", [["macrophage", "ANATOMY", 67, 77], ["macrophages", "ANATOMY", 140, 151], ["macrophages", "ANATOMY", 202, 213], ["macrophage", "ANATOMY", 303, 313], ["macrophages", "ANATOMY", 377, 388], ["body", "ANATOMY", 400, 404], ["sGP", "SIMPLE_CHEMICAL", 31, 34], ["macrophage", "CELL", 67, 77], ["macrophages", "CELL", 140, 151], ["macrophages", "CELL", 202, 213], ["EBOV sGPWhen", "ORGANISM", 242, 254], ["sGP", "GENE_OR_GENE_PRODUCT", 275, 278], ["macrophage", "CELL", 303, 313], ["sGP", "GENE_OR_GENE_PRODUCT", 324, 327], ["macrophages", "CELL", 377, 388], ["body", "ORGANISM_SUBDIVISION", 400, 404], ["sGP", "PROTEIN", 31, 34], ["polarized macrophages", "CELL_TYPE", 130, 151], ["Pro-inflammatory cytokine", "PROTEIN", 152, 177], ["activated macrophages", "CELL_TYPE", 192, 213], ["EBOV sGPWhen", "PROTEIN", 242, 254], ["sGP", "PROTEIN", 275, 278], ["sGP", "PROTEIN", 324, 327], ["soluble viral protein", "PROTEIN", 331, 352], ["macrophages", "CELL_TYPE", 377, 388], ["EBOV", "SPECIES", 242, 246], ["macrophage polarization", "PROBLEM", 67, 90], ["Pro-inflammatory cytokine production", "PROBLEM", 152, 188], ["activated macrophages", "PROBLEM", 192, 213], ["a soluble viral protein", "PROBLEM", 329, 352], ["macrophage polarization", "OBSERVATION", 67, 90], ["polarized macrophages", "OBSERVATION", 130, 151], ["macrophage function", "OBSERVATION", 303, 322], ["macrophages", "OBSERVATION", 377, 388], ["body", "ANATOMY", 400, 404]]], ["To test the hypothesis that sGP inhibits functions of polarized non-infected macrophages that were previously activated by microbial stimuli (LPS), THP-1 macrophages were cultured with IFN\u03b3 for 24 h followed by LPS or PBS for 24 h.", [["macrophages", "ANATOMY", 77, 88], ["THP-1 macrophages", "ANATOMY", 148, 165], ["sGP", "CHEMICAL", 28, 31], ["LPS", "CHEMICAL", 142, 145], ["LPS", "CHEMICAL", 211, 214], ["sGP", "SIMPLE_CHEMICAL", 28, 31], ["macrophages", "CELL", 77, 88], ["LPS", "SIMPLE_CHEMICAL", 142, 145], ["THP-1 macrophages", "CELL", 148, 165], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 185, 189], ["LPS", "SIMPLE_CHEMICAL", 211, 214], ["sGP", "PROTEIN", 28, 31], ["polarized non-infected macrophages", "CELL_TYPE", 54, 88], ["THP-1 macrophages", "CELL_LINE", 148, 165], ["IFN\u03b3", "PROTEIN", 185, 189], ["polarized non-infected macrophages", "PROBLEM", 54, 88], ["microbial stimuli", "TEST", 123, 140], ["LPS", "TEST", 142, 145], ["THP", "TEST", 148, 151], ["IFN", "TEST", 185, 188], ["PBS", "TREATMENT", 218, 221], ["polarized", "OBSERVATION_MODIFIER", 54, 63], ["non-infected macrophages", "OBSERVATION", 64, 88]]], ["Subsequently, the cells were washed with PBS and treated with sGP or PBS for an additional 24 h.", [["cells", "ANATOMY", 18, 23], ["sGP", "CHEMICAL", 62, 65], ["sGP", "CHEMICAL", 62, 65], ["cells", "CELL", 18, 23], ["sGP", "SIMPLE_CHEMICAL", 62, 65], ["the cells", "TREATMENT", 14, 23], ["PBS", "TREATMENT", 41, 44], ["sGP", "TREATMENT", 62, 65], ["PBS", "TREATMENT", 69, 72]]], ["Therefore, total incubation time from polarization to activation and supernatant harvest is 72 h.", [["supernatant", "ANATOMY", 69, 80], ["supernatant harvest", "TREATMENT", 69, 88]]], ["Strikingly, sGP was able to inhibit the production of the pro-inflammatory cytokines, TNF\u03b1 and IL-6, while not affecting the levels of the anti-inflammatory cytokine, IL-10 in both M1 and M2 macrophages (Fig. 3) .", [["M1", "ANATOMY", 181, 183], ["M2 macrophages", "ANATOMY", 188, 202], ["sGP", "SIMPLE_CHEMICAL", 12, 15], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 86, 90], ["IL-6", "GENE_OR_GENE_PRODUCT", 95, 99], ["IL-10", "GENE_OR_GENE_PRODUCT", 167, 172], ["M1", "CELL", 181, 183], ["M2 macrophages", "CELL", 188, 202], ["sGP", "PROTEIN", 12, 15], ["pro-inflammatory cytokines", "PROTEIN", 58, 84], ["TNF\u03b1", "PROTEIN", 86, 90], ["IL-6", "PROTEIN", 95, 99], ["anti-inflammatory cytokine", "PROTEIN", 139, 165], ["IL-10", "PROTEIN", 167, 172], ["M1 and M2 macrophages", "CELL_LINE", 181, 202], ["the pro-inflammatory cytokines", "TEST", 54, 84], ["TNF", "TEST", 86, 89], ["IL", "TEST", 95, 97], ["the anti-inflammatory cytokine", "TEST", 135, 165], ["IL", "TEST", 167, 169], ["anti-inflammatory cytokine", "ANATOMY", 139, 165], ["M1", "ANATOMY", 181, 183], ["M2 macrophages", "ANATOMY", 188, 202]]], ["While sGP alone did not provoke cytokine production by the macrophages, perhaps the treatment of polarized macrophages with LPS and then sGP is reducing cellular viability.", [["macrophages", "ANATOMY", 59, 70], ["macrophages", "ANATOMY", 107, 118], ["cellular", "ANATOMY", 153, 161], ["sGP", "CHEMICAL", 6, 9], ["LPS", "CHEMICAL", 124, 127], ["sGP", "CHEMICAL", 137, 140], ["sGP", "CHEMICAL", 6, 9], ["sGP", "SIMPLE_CHEMICAL", 6, 9], ["macrophages", "CELL", 59, 70], ["macrophages", "CELL", 107, 118], ["LPS", "SIMPLE_CHEMICAL", 124, 127], ["sGP", "SIMPLE_CHEMICAL", 137, 140], ["cellular", "CELL", 153, 161], ["sGP", "PROTEIN", 6, 9], ["cytokine", "PROTEIN", 32, 40], ["macrophages", "CELL_TYPE", 59, 70], ["polarized macrophages", "CELL_TYPE", 97, 118], ["sGP", "PROTEIN", 137, 140], ["cytokine production", "PROBLEM", 32, 51], ["polarized macrophages", "PROBLEM", 97, 118], ["LPS", "PROBLEM", 124, 127], ["polarized macrophages", "OBSERVATION", 97, 118], ["reducing", "OBSERVATION_MODIFIER", 144, 152], ["cellular viability", "OBSERVATION", 153, 171]]], ["In order to determine if the experimental approach is promoting cell death of the cells, M1 macrophages were cultured as above and then assessed for expression of 7-AAD (7-amino-actinomycin D), a cell viability stain, by flow cytometry.", [["cell", "ANATOMY", 64, 68], ["cells", "ANATOMY", 82, 87], ["M1 macrophages", "ANATOMY", 89, 103], ["cell", "ANATOMY", 196, 200], ["death", "DISEASE", 69, 74], ["7-amino-actinomycin D", "CHEMICAL", 170, 191], ["7-AAD", "CHEMICAL", 163, 168], ["7-amino-actinomycin D", "CHEMICAL", 170, 191], ["cell", "CELL", 64, 68], ["cells", "CELL", 82, 87], ["M1 macrophages", "CELL", 89, 103], ["7-AAD", "SIMPLE_CHEMICAL", 163, 168], ["7-amino-actinomycin D", "SIMPLE_CHEMICAL", 170, 191], ["cell", "CELL", 196, 200], ["M1 macrophages", "CELL_LINE", 89, 103], ["cell death of the cells", "PROBLEM", 64, 87], ["expression", "TEST", 149, 159], ["AAD", "TEST", 165, 168], ["a cell viability stain", "TEST", 194, 216], ["flow cytometry", "TEST", 221, 235], ["cell death", "OBSERVATION", 64, 74], ["flow cytometry", "OBSERVATION", 221, 235]]], ["Viability greater than 90% was observed in all the groups (LPS, sGP and LPS \u2192 sGP) tested ( Supplementary Fig. 1 ).Pro-inflammatory cytokine production by activated macrophages is selectively inhibited by EBOV sGPTherefore, sGP is able to inhibit the production of pro-inflammatory cytokines by previously activated polarized macrophages.", [["macrophages", "ANATOMY", 165, 176], ["macrophages", "ANATOMY", 326, 337], ["LPS", "CHEMICAL", 59, 62], ["LPS", "CHEMICAL", 72, 75], ["LPS", "SIMPLE_CHEMICAL", 59, 62], ["sGP", "SIMPLE_CHEMICAL", 64, 67], ["LPS", "SIMPLE_CHEMICAL", 72, 75], ["macrophages", "CELL", 165, 176], ["EBOV sGPTherefore", "ORGANISM", 205, 222], ["sGP", "GENE_OR_GENE_PRODUCT", 224, 227], ["macrophages", "CELL", 326, 337], ["Pro-inflammatory cytokine", "PROTEIN", 115, 140], ["activated macrophages", "CELL_TYPE", 155, 176], ["pro-inflammatory cytokines", "PROTEIN", 265, 291], ["activated polarized macrophages", "CELL_TYPE", 306, 337], ["EBOV", "SPECIES", 205, 209], ["Viability", "TEST", 0, 9], ["LPS", "TEST", 59, 62], ["sGP", "TEST", 64, 67], ["LPS", "TEST", 72, 75], ["Pro-inflammatory cytokine production", "PROBLEM", 115, 151], ["activated macrophages", "PROBLEM", 155, 176], ["pro-inflammatory cytokines", "PROBLEM", 265, 291], ["greater", "OBSERVATION_MODIFIER", 10, 17], ["pro-inflammatory cytokines", "OBSERVATION", 265, 291], ["polarized macrophages", "OBSERVATION", 316, 337]]], ["Can sGP restrain polarized macrophages from producing cytokines when given simultaneously with the LPS stimuli?", [["macrophages", "ANATOMY", 27, 38], ["sGP", "GENE_OR_GENE_PRODUCT", 4, 7], ["macrophages", "CELL", 27, 38], ["LPS", "SIMPLE_CHEMICAL", 99, 102], ["sGP", "PROTEIN", 4, 7], ["polarized macrophages", "CELL_TYPE", 17, 38], ["cytokines", "PROTEIN", 54, 63], ["the LPS stimuli", "TEST", 95, 110], ["polarized macrophages", "OBSERVATION", 17, 38]]], ["To test this possibility, M1 and M2 macrophages were cultured with both LPS and sGP for 24 h.", [["M1", "ANATOMY", 26, 28], ["M2 macrophages", "ANATOMY", 33, 47], ["LPS", "CHEMICAL", 72, 75], ["sGP", "CHEMICAL", 80, 83], ["M1", "CELL", 26, 28], ["M2 macrophages", "CELL", 33, 47], ["LPS", "SIMPLE_CHEMICAL", 72, 75], ["sGP", "SIMPLE_CHEMICAL", 80, 83], ["M1 and M2 macrophages", "CELL_LINE", 26, 47], ["sGP", "TEST", 80, 83]]], ["Interestingly, there was no significant difference between the LPS + sGP and LPS only treated M1 or M2 macrophages in terms of IL-6 and IL-10 production ( Fig. 3C and D) .Pro-inflammatory cytokine production by activated macrophages is selectively inhibited by EBOV sGPThese results suggest that EBOV sGP selectively inhibits the production of pro-inflammatory cytokines, but not anti-inflammatory cytokines from activated M1 and M2 macrophages.", [["M1", "ANATOMY", 94, 96], ["M2 macrophages", "ANATOMY", 100, 114], ["macrophages", "ANATOMY", 221, 232], ["M1", "ANATOMY", 423, 425], ["M2 macrophages", "ANATOMY", 430, 444], ["LPS", "CHEMICAL", 63, 66], ["sGP", "CHEMICAL", 69, 72], ["LPS", "CHEMICAL", 77, 80], ["LPS + sGP", "SIMPLE_CHEMICAL", 63, 72], ["LPS", "SIMPLE_CHEMICAL", 77, 80], ["M1", "CELL", 94, 96], ["M2 macrophages", "CELL", 100, 114], ["IL-6", "GENE_OR_GENE_PRODUCT", 127, 131], ["IL-10", "GENE_OR_GENE_PRODUCT", 136, 141], ["D", "SIMPLE_CHEMICAL", 167, 168], ["macrophages", "CELL", 221, 232], ["EBOV", "ORGANISM", 261, 265], ["sGPThese", "GENE_OR_GENE_PRODUCT", 266, 274], ["EBOV sGP", "ORGANISM", 296, 304], ["M1", "CELL", 423, 425], ["M2 macrophages", "CELL", 430, 444], ["M1", "CELL_LINE", 94, 96], ["M2 macrophages", "CELL_LINE", 100, 114], ["Pro-inflammatory cytokine", "PROTEIN", 171, 196], ["activated macrophages", "CELL_TYPE", 211, 232], ["EBOV sGP", "PROTEIN", 296, 304], ["pro-inflammatory cytokines", "PROTEIN", 344, 370], ["anti-inflammatory cytokines", "PROTEIN", 380, 407], ["M1 and M2 macrophages", "CELL_LINE", 423, 444], ["EBOV", "SPECIES", 261, 265], ["EBOV", "SPECIES", 296, 300], ["the LPS", "TEST", 59, 66], ["sGP", "TEST", 69, 72], ["LPS", "TEST", 77, 80], ["IL", "TEST", 127, 129], ["IL", "TEST", 136, 138], ["Pro-inflammatory cytokine production", "PROBLEM", 171, 207], ["activated macrophages", "PROBLEM", 211, 232], ["EBOV sGP", "PROBLEM", 296, 304], ["pro-inflammatory cytokines", "PROBLEM", 344, 370], ["anti-inflammatory cytokines", "TEST", 380, 407], ["no", "UNCERTAINTY", 25, 27], ["significant", "OBSERVATION_MODIFIER", 28, 39], ["difference", "OBSERVATION", 40, 50], ["pro-inflammatory cytokines", "OBSERVATION", 344, 370]]], ["Furthermore, this inhibitory effect could be superseded by the stimulatory effect of LPS.Phagocytosis is unaffected by the presence of EBOV sGPOne of the most important effector functions of macrophages is the capacity to phagocytose microbial pathogens [23] .", [["macrophages", "ANATOMY", 191, 202], ["LPS", "CHEMICAL", 85, 88], ["LPS", "SIMPLE_CHEMICAL", 85, 88], ["EBOV", "ORGANISM", 135, 139], ["sGPOne", "GENE_OR_GENE_PRODUCT", 140, 146], ["macrophages", "CELL", 191, 202], ["macrophages", "CELL_TYPE", 191, 202], ["EBOV", "SPECIES", 135, 139], ["LPS", "PROBLEM", 85, 88], ["Phagocytosis", "PROBLEM", 89, 101], ["EBOV", "OBSERVATION", 135, 139]]], ["Macrophages can recognize self-and non-self-particles and phagocytose them for destruction or antigen presentation.", [["Macrophages", "ANATOMY", 0, 11], ["Macrophages", "CELL", 0, 11], ["Macrophages", "CELL_TYPE", 0, 11], ["destruction", "PROBLEM", 79, 90], ["antigen presentation", "PROBLEM", 94, 114]]], ["Given that EBOV sGP was able to interfere with pro-inflammatory cytokine production by previously activated macrophages (Fig. 3A and B) ; it may be acting to suppress the early immune response in general.", [["macrophages", "ANATOMY", 108, 119], ["EBOV", "ORGANISM", 11, 15], ["sGP", "GENE_OR_GENE_PRODUCT", 16, 19], ["macrophages", "CELL", 108, 119], ["Fig. 3A", "CELL", 121, 128], ["B", "GENE_OR_GENE_PRODUCT", 133, 134], ["EBOV sGP", "PROTEIN", 11, 19], ["pro-inflammatory cytokine", "PROTEIN", 47, 72], ["activated macrophages", "CELL_TYPE", 98, 119], ["EBOV", "SPECIES", 11, 15], ["EBOV sGP", "PROBLEM", 11, 19], ["pro-inflammatory cytokine production", "TREATMENT", 47, 83]]], ["As professional phagocytes, macrophages aid in the early response to control or clear the body of microbial invaders.", [["phagocytes", "ANATOMY", 16, 26], ["macrophages", "ANATOMY", 28, 39], ["body", "ANATOMY", 90, 94], ["phagocytes", "CELL", 16, 26], ["macrophages", "CELL", 28, 39], ["body", "ORGANISM_SUBDIVISION", 90, 94], ["professional phagocytes", "CELL_TYPE", 3, 26], ["macrophages", "CELL_TYPE", 28, 39], ["macrophages", "PROBLEM", 28, 39], ["microbial invaders", "OBSERVATION", 98, 116]]], ["Prior to assessment of sGP for the ability to impair phagocytic activity, M1 macrophages were treated with PBS, unconjugated, complete OVA protein (1 mg/mL), and OVA-FITC (0.25 mg/mL), and incubated for 30 min, 1 h, or 3 h to determine an optimum incubation time for the assay.", [["M1 macrophages", "ANATOMY", 74, 88], ["FITC", "CHEMICAL", 166, 170], ["sGP", "GENE_OR_GENE_PRODUCT", 23, 26], ["M1 macrophages", "CELL", 74, 88], ["PBS", "SIMPLE_CHEMICAL", 107, 110], ["unconjugated", "SIMPLE_CHEMICAL", 112, 124], ["OVA-FITC", "SIMPLE_CHEMICAL", 162, 170], ["sGP", "PROTEIN", 23, 26], ["M1 macrophages", "CELL_TYPE", 74, 88], ["OVA protein", "PROTEIN", 135, 146], ["assessment", "TEST", 9, 19], ["sGP", "TEST", 23, 26], ["PBS", "TREATMENT", 107, 110], ["complete OVA protein", "TREATMENT", 126, 146], ["OVA-FITC", "TREATMENT", 162, 170], ["the assay", "TEST", 267, 276], ["phagocytic activity", "OBSERVATION", 53, 72]]], ["After trypsinization, the cells were washed 3 times with cold PBS to stop antigen uptake and remove particles that only bound to the cellular surface, and assessed for antigen accumulation within the cells.", [["cells", "ANATOMY", 26, 31], ["cellular surface", "ANATOMY", 133, 149], ["cells", "ANATOMY", 200, 205], ["cells", "CELL", 26, 31], ["cellular surface", "CELLULAR_COMPONENT", 133, 149], ["antigen", "GENE_OR_GENE_PRODUCT", 168, 175], ["cells", "CELL", 200, 205], ["trypsinization", "TREATMENT", 6, 20], ["the cells", "TREATMENT", 22, 31], ["cold PBS", "TREATMENT", 57, 65], ["antigen uptake", "PROBLEM", 74, 88], ["antigen accumulation within the cells", "PROBLEM", 168, 205], ["cellular", "OBSERVATION_MODIFIER", 133, 141], ["surface", "OBSERVATION_MODIFIER", 142, 149]]], ["As shown in Fig. 4A , over a 3-h period, the intensity of OVA accumulation increased and the 3-h culture time was determined as the optimal incubation time.Phagocytosis is unaffected by the presence of EBOV sGPTo test the capacity EBOV sGP to modulate the phagocytic capabilities of M1 macrophages, the cells were activated with either LPS or PBS for 24 h, washed, then treated with either sGP or PBS for an additional 24 h (Fig. 4B) .", [["M1 macrophages", "ANATOMY", 283, 297], ["cells", "ANATOMY", 303, 308], ["LPS", "CHEMICAL", 336, 339], ["sGP", "CHEMICAL", 390, 393], ["OVA", "SIMPLE_CHEMICAL", 58, 61], ["EBOV", "ORGANISM", 202, 206], ["sGPTo", "GENE_OR_GENE_PRODUCT", 207, 212], ["EBOV", "ORGANISM", 231, 235], ["sGP", "GENE_OR_GENE_PRODUCT", 236, 239], ["M1 macrophages", "CELL", 283, 297], ["cells", "CELL", 303, 308], ["LPS", "SIMPLE_CHEMICAL", 336, 339], ["PBS", "SIMPLE_CHEMICAL", 343, 346], ["sGP", "SIMPLE_CHEMICAL", 390, 393], ["EBOV sGPTo", "PROTEIN", 202, 212], ["EBOV sGP", "PROTEIN", 231, 239], ["M1 macrophages", "CELL_TYPE", 283, 297], ["EBOV", "SPECIES", 202, 206], ["EBOV", "SPECIES", 231, 235], ["OVA accumulation", "PROBLEM", 58, 74], ["the 3-h culture time", "TEST", 89, 109], ["Phagocytosis", "PROBLEM", 156, 168], ["EBOV sGPTo test", "TEST", 202, 217], ["LPS", "TREATMENT", 336, 339], ["PBS", "TREATMENT", 343, 346], ["PBS", "TREATMENT", 397, 400], ["Fig", "OBSERVATION", 12, 15], ["OVA accumulation", "OBSERVATION", 58, 74], ["increased", "OBSERVATION_MODIFIER", 75, 84], ["phagocytic capabilities", "OBSERVATION", 256, 279], ["M1 macrophages", "OBSERVATION", 283, 297]]], ["The percentage of cells that phagocytosed the OVA-FITC particle were statistically unremarkable between the LPS only group and the group activated with LPS and treated with sGP (Fig. 4C) , suggesting that the phagocytic ability of M1 macrophages, which is pivotal to macrophage functioning, is not significantly affected by the presence of EBOV sGP.Chemotaxis to MCP-1 is inhibited by EBOV sGPInterestingly, if phagocytic activity of macrophages is not altered by EBOV sGP but pro-inflammatory cytokine production is inhibited, the viral protein may be operating to promote EBOV survival and dissemination through the impairment of inflammation-related events associated with the migration and cytokine production by non-infected macrophages.", [["cells", "ANATOMY", 18, 23], ["M1 macrophages", "ANATOMY", 231, 245], ["macrophage", "ANATOMY", 267, 277], ["macrophages", "ANATOMY", 434, 445], ["macrophages", "ANATOMY", 730, 741], ["LPS", "CHEMICAL", 108, 111], ["LPS", "CHEMICAL", 152, 155], ["inflammation", "DISEASE", 632, 644], ["FITC", "CHEMICAL", 50, 54], ["cells", "CELL", 18, 23], ["FITC", "GENE_OR_GENE_PRODUCT", 50, 54], ["LPS", "SIMPLE_CHEMICAL", 108, 111], ["LPS", "SIMPLE_CHEMICAL", 152, 155], ["sGP", "SIMPLE_CHEMICAL", 173, 176], ["M1 macrophages", "CELL", 231, 245], ["macrophage", "CELL", 267, 277], ["EBOV", "ORGANISM", 340, 344], ["sGP", "GENE_OR_GENE_PRODUCT", 345, 348], ["MCP-1", "GENE_OR_GENE_PRODUCT", 363, 368], ["EBOV", "ORGANISM", 385, 389], ["macrophages", "CELL", 434, 445], ["EBOV", "ORGANISM", 464, 468], ["sGP", "GENE_OR_GENE_PRODUCT", 469, 472], ["EBOV", "ORGANISM", 574, 578], ["macrophages", "CELL", 730, 741], ["M1 macrophages", "CELL_TYPE", 231, 245], ["EBOV sGP", "PROTEIN", 340, 348], ["MCP", "PROTEIN", 363, 366], ["macrophages", "CELL_TYPE", 434, 445], ["EBOV sGP", "PROTEIN", 464, 472], ["cytokine", "PROTEIN", 494, 502], ["viral protein", "PROTEIN", 532, 545], ["cytokine", "PROTEIN", 694, 702], ["non-infected macrophages", "CELL_TYPE", 717, 741], ["EBOV", "SPECIES", 340, 344], ["EBOV", "SPECIES", 385, 389], ["EBOV", "SPECIES", 464, 468], ["EBOV", "SPECIES", 574, 578], ["the LPS", "TEST", 104, 111], ["LPS", "TREATMENT", 152, 155], ["sGP (Fig. 4C", "TREATMENT", 173, 185], ["the phagocytic ability of M1 macrophages", "PROBLEM", 205, 245], ["EBOV sGP", "PROBLEM", 340, 348], ["MCP", "TEST", 363, 366], ["phagocytic activity of macrophages", "PROBLEM", 411, 445], ["EBOV sGP", "PROBLEM", 464, 472], ["pro-inflammatory cytokine production", "PROBLEM", 477, 513], ["the viral protein", "PROBLEM", 528, 545], ["EBOV survival", "TREATMENT", 574, 587], ["inflammation", "PROBLEM", 632, 644], ["related events", "PROBLEM", 645, 659], ["the migration", "PROBLEM", 676, 689], ["FITC particle", "OBSERVATION", 50, 63], ["significantly affected", "OBSERVATION_MODIFIER", 298, 320], ["EBOV sGP", "OBSERVATION", 340, 348], ["macrophages", "OBSERVATION", 434, 445], ["EBOV survival", "OBSERVATION", 574, 587], ["inflammation", "OBSERVATION", 632, 644], ["non-infected macrophages", "OBSERVATION", 717, 741]]], ["Therefore, we tested the chemotactic ability of activated M1 macrophages after treatment with sGP.", [["M1 macrophages", "ANATOMY", 58, 72], ["M1 macrophages", "CELL", 58, 72], ["sGP", "SIMPLE_CHEMICAL", 94, 97], ["activated M1 macrophages", "CELL_TYPE", 48, 72], ["sGP", "PROTEIN", 94, 97], ["activated M1 macrophages", "TREATMENT", 48, 72], ["sGP", "PROBLEM", 94, 97]]], ["Previously activated M1 macrophages were incubated with sGP for 24 h, washed, and then placed in the apical chamber of a chemotaxis assay.", [["M1 macrophages", "ANATOMY", 21, 35], ["M1 macrophages", "CELL", 21, 35], ["sGP", "SIMPLE_CHEMICAL", 56, 59], ["M1 macrophages", "CELL_TYPE", 21, 35], ["sGP", "PROTEIN", 56, 59], ["sGP", "TEST", 56, 59], ["a chemotaxis assay", "TEST", 119, 137], ["M1 macrophages", "OBSERVATION", 21, 35], ["apical", "ANATOMY_MODIFIER", 101, 107], ["chamber", "ANATOMY_MODIFIER", 108, 115], ["chemotaxis assay", "OBSERVATION", 121, 137]]], ["The chemokine, monocyte chemoattractant protein-1 (MCP-1), or PBS was added to the basal chamber in complete media.", [["monocyte chemoattractant protein-1", "GENE_OR_GENE_PRODUCT", 15, 49], ["MCP-1", "GENE_OR_GENE_PRODUCT", 51, 56], ["PBS", "SIMPLE_CHEMICAL", 62, 65], ["chemokine", "PROTEIN", 4, 13], ["monocyte chemoattractant protein-1", "PROTEIN", 15, 49], ["MCP", "PROTEIN", 51, 54], ["The chemokine, monocyte chemoattractant protein", "TEST", 0, 47], ["MCP", "TEST", 51, 54], ["PBS", "TREATMENT", 62, 65]]], ["The macrophages were allowed to migrate to the basal chamber for 24 h.", [["macrophages", "ANATOMY", 4, 15], ["macrophages", "CELL", 4, 15], ["macrophages", "CELL_TYPE", 4, 15], ["macrophages", "OBSERVATION", 4, 15]]], ["Upon harvest, live cells from the basal chamber were counted by 30 s assessment of live cells from each well by flow cytometry.", [["cells", "ANATOMY", 19, 24], ["cells", "ANATOMY", 88, 93], ["cells", "CELL", 19, 24], ["cells", "CELL", 88, 93], ["live cells", "CELL_TYPE", 14, 24], ["live cells", "CELL_TYPE", 83, 93], ["harvest", "TREATMENT", 5, 12], ["live cells", "PROBLEM", 14, 24], ["flow cytometry", "TEST", 112, 126], ["harvest", "OBSERVATION", 5, 12], ["basal", "ANATOMY_MODIFIER", 34, 39], ["chamber", "ANATOMY_MODIFIER", 40, 47]]], ["In Fig. 5 , the activated M1 macrophages (LPS \u2192 PBS and LPS \u2192 sGP) showed a significant increase in the percent of chemotaxis compared to inactivated M1 macrophages (PBS \u2192 PBS and PBS \u2192 sGP).", [["M1 macrophages", "ANATOMY", 26, 40], ["M1 macrophages", "ANATOMY", 150, 164], ["M1 macrophages", "CELL", 26, 40], ["LPS", "SIMPLE_CHEMICAL", 42, 45], ["LPS", "SIMPLE_CHEMICAL", 56, 59], ["M1 macrophages", "CELL", 150, 164], ["activated M1 macrophages", "CELL_TYPE", 16, 40], ["M1 macrophages", "CELL_TYPE", 150, 164], ["the activated M1 macrophages", "TEST", 12, 40], ["LPS", "TEST", 42, 45], ["PBS", "TEST", 48, 51], ["LPS \u2192 sGP", "TEST", 56, 65], ["chemotaxis", "PROBLEM", 115, 125], ["PBS", "TEST", 166, 169], ["PBS", "TEST", 172, 175], ["PBS", "TEST", 180, 183], ["significant", "OBSERVATION_MODIFIER", 76, 87], ["increase", "OBSERVATION_MODIFIER", 88, 96]]], ["The percent of chemotaxis of the activated macrophages treated with sGP was decreased compared to activated M1 macrophages incubated with PBS.", [["macrophages", "ANATOMY", 43, 54], ["M1 macrophages", "ANATOMY", 108, 122], ["sGP", "CHEMICAL", 68, 71], ["macrophages", "CELL", 43, 54], ["sGP", "SIMPLE_CHEMICAL", 68, 71], ["M1 macrophages", "CELL", 108, 122], ["activated macrophages", "CELL_TYPE", 33, 54], ["sGP", "PROTEIN", 68, 71], ["M1 macrophages", "CELL_LINE", 108, 122], ["the activated macrophages", "PROBLEM", 29, 54], ["sGP", "TREATMENT", 68, 71], ["PBS", "TREATMENT", 138, 141], ["percent", "OBSERVATION_MODIFIER", 4, 11], ["chemotaxis", "OBSERVATION_MODIFIER", 15, 25], ["macrophages", "OBSERVATION", 43, 54]]], ["The results suggest that LPS provokes migratory functions of macrophages and sGP can operate to impair migration of the activated macrophages towards MCP-1.EBOV sGP downregulates expression of macrophage integrin CD11bMacrophage migration towards MCP-1 was compromised in the presence of EBOV sGP.", [["macrophages", "ANATOMY", 61, 72], ["macrophages", "ANATOMY", 130, 141], ["macrophage", "ANATOMY", 193, 203], ["LPS", "CHEMICAL", 25, 28], ["LPS", "SIMPLE_CHEMICAL", 25, 28], ["macrophages", "CELL", 61, 72], ["sGP", "GENE_OR_GENE_PRODUCT", 77, 80], ["macrophages", "CELL", 130, 141], ["MCP-1", "GENE_OR_GENE_PRODUCT", 150, 155], ["EBOV", "ORGANISM", 156, 160], ["sGP", "GENE_OR_GENE_PRODUCT", 161, 164], ["macrophage", "CELL", 193, 203], ["integrin", "GENE_OR_GENE_PRODUCT", 204, 212], ["MCP-1", "GENE_OR_GENE_PRODUCT", 247, 252], ["EBOV", "ORGANISM", 288, 292], ["macrophages", "CELL_TYPE", 61, 72], ["sGP", "PROTEIN", 77, 80], ["activated macrophages", "CELL_TYPE", 120, 141], ["MCP", "PROTEIN", 150, 153], ["EBOV sGP", "PROTEIN", 156, 164], ["macrophage integrin", "PROTEIN", 193, 212], ["CD11", "PROTEIN", 213, 217], ["MCP", "PROTEIN", 247, 250], ["EBOV sGP", "PROTEIN", 288, 296], ["EBOV", "SPECIES", 156, 160], ["EBOV", "SPECIES", 288, 292], ["LPS", "PROBLEM", 25, 28], ["macrophages", "PROBLEM", 61, 72], ["MCP", "TEST", 150, 153], ["macrophage integrin", "TREATMENT", 193, 212], ["bMacrophage migration", "PROBLEM", 217, 238], ["MCP", "TEST", 247, 250], ["EBOV sGP", "PROBLEM", 288, 296], ["macrophage", "OBSERVATION_MODIFIER", 193, 203], ["EBOV sGP", "OBSERVATION", 288, 296]]], ["Interestingly, the integrin, CD11b, has been shown to be critical for the migration of macrophages and not dendritic cells towards chemokines [24, 25] .", [["macrophages", "ANATOMY", 87, 98], ["dendritic cells", "ANATOMY", 107, 122], ["integrin", "GENE_OR_GENE_PRODUCT", 19, 27], ["CD11b", "GENE_OR_GENE_PRODUCT", 29, 34], ["macrophages", "CELL", 87, 98], ["dendritic cells", "CELL", 107, 122], ["integrin", "PROTEIN", 19, 27], ["CD11b", "PROTEIN", 29, 34], ["macrophages", "CELL_TYPE", 87, 98], ["dendritic cells", "CELL_TYPE", 107, 122], ["chemokines", "PROTEIN", 131, 141], ["the migration of macrophages", "PROBLEM", 70, 98], ["chemokines", "TEST", 131, 141], ["macrophages", "OBSERVATION", 87, 98], ["not", "UNCERTAINTY", 103, 106], ["dendritic cells", "OBSERVATION", 107, 122]]], ["Therefore, EBOV sGP may be altering the expression of CD11b to impact the migratory capacity of activated macrophages.", [["macrophages", "ANATOMY", 106, 117], ["EBOV", "ORGANISM", 11, 15], ["sGP", "GENE_OR_GENE_PRODUCT", 16, 19], ["CD11b", "GENE_OR_GENE_PRODUCT", 54, 59], ["macrophages", "CELL", 106, 117], ["EBOV sGP", "PROTEIN", 11, 19], ["CD11b", "PROTEIN", 54, 59], ["activated macrophages", "CELL_TYPE", 96, 117], ["EBOV", "SPECIES", 11, 15], ["EBOV sGP", "TEST", 11, 19], ["CD11b", "PROBLEM", 54, 59], ["migratory", "OBSERVATION_MODIFIER", 74, 83], ["activated macrophages", "OBSERVATION", 96, 117]]], ["To test this possibility, activated M1 macrophages were cultured with sGP for 24 h and CD11b expression was assessed by flow cytometry.", [["M1 macrophages", "ANATOMY", 36, 50], ["M1 macrophages", "CELL", 36, 50], ["sGP", "SIMPLE_CHEMICAL", 70, 73], ["CD11b", "GENE_OR_GENE_PRODUCT", 87, 92], ["M1 macrophages", "CELL_LINE", 36, 50], ["sGP", "PROTEIN", 70, 73], ["CD11b", "PROTEIN", 87, 92], ["sGP", "TEST", 70, 73], ["CD11b expression", "TEST", 87, 103], ["flow cytometry", "TEST", 120, 134]]], ["Indeed, levels of surface CD11b were decreased only in the activated macrophages incubated with sGP (1 \u03bcg/mL) or sGP (4 \u03bcg/mL) for an additional 24 h.", [["surface", "ANATOMY", 18, 25], ["macrophages", "ANATOMY", 69, 80], ["sGP", "CHEMICAL", 96, 99], ["sGP", "CHEMICAL", 113, 116], ["sGP", "CHEMICAL", 96, 99], ["sGP", "CHEMICAL", 113, 116], ["CD11b", "GENE_OR_GENE_PRODUCT", 26, 31], ["macrophages", "CELL", 69, 80], ["sGP", "SIMPLE_CHEMICAL", 96, 99], ["sGP", "SIMPLE_CHEMICAL", 113, 116], ["surface CD11b", "PROTEIN", 18, 31], ["activated macrophages", "CELL_TYPE", 59, 80], ["surface CD11b", "TEST", 18, 31], ["sGP", "TEST", 96, 99], ["sGP", "TEST", 113, 116]]], ["In the sGP \u2192 LPS group, IFN\u03b3 (20 ng/mL) or IL-4 (20 ng/mL) and IL-13 (20 ng/mL), and sGP (4 \u03bcg/mL) were given for 24 h, then the cells were washed and LPS (1 \u03bcg/mL) was added for 24 h.", [["cells", "ANATOMY", 129, 134], ["LPS", "CHEMICAL", 13, 16], ["LPS", "CHEMICAL", 151, 154], ["sGP", "SIMPLE_CHEMICAL", 7, 10], ["LPS", "SIMPLE_CHEMICAL", 13, 16], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 24, 28], ["IL-4", "GENE_OR_GENE_PRODUCT", 43, 47], ["IL-13", "GENE_OR_GENE_PRODUCT", 63, 68], ["sGP", "SIMPLE_CHEMICAL", 85, 88], ["cells", "CELL", 129, 134], ["LPS", "SIMPLE_CHEMICAL", 151, 154], ["IFN\u03b3", "PROTEIN", 24, 28], ["IFN", "TEST", 24, 27], ["IL", "TEST", 43, 45], ["IL", "TEST", 63, 65], ["sGP", "TEST", 85, 88], ["LPS", "TEST", 151, 154]]], ["Supernatants from the cultures were harvested after a total of 48 incubation hours and the production of TNF\u03b1, IL-6, and IL-10 was measured via ELISA. (n = 3, P < .05, ns indicates not significant).", [["Supernatants", "ANATOMY", 0, 12], ["cultures", "ANATOMY", 22, 30], ["Supernatants", "CELL", 0, 12], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 105, 109], ["IL-6", "GENE_OR_GENE_PRODUCT", 111, 115], ["IL-10", "GENE_OR_GENE_PRODUCT", 121, 126], ["TNF\u03b1", "PROTEIN", 105, 109], ["IL", "PROTEIN", 121, 123], ["the cultures", "TEST", 18, 30], ["TNF\u03b1", "TEST", 105, 109], ["IL", "TEST", 111, 113], ["IL", "TEST", 121, 123], ["P", "TEST", 159, 160], ["ns", "TEST", 168, 170]]], ["This suggests that EBOV sGP is decreasing the chemotactic ability of activated M1 macrophages by reducing CD11b expression.DiscussionCurrently, a major role of sGP in the EBOV pathogenesis has yet to be clearly demonstrated.", [["M1 macrophages", "ANATOMY", 79, 93], ["EBOV", "DISEASE", 171, 175], ["EBOV", "ORGANISM", 19, 23], ["sGP", "GENE_OR_GENE_PRODUCT", 24, 27], ["M1 macrophages", "CELL", 79, 93], ["CD11b", "GENE_OR_GENE_PRODUCT", 106, 111], ["sGP", "GENE_OR_GENE_PRODUCT", 160, 163], ["EBOV", "ORGANISM", 171, 175], ["EBOV sGP", "PROTEIN", 19, 27], ["activated M1 macrophages", "CELL_TYPE", 69, 93], ["CD11b", "PROTEIN", 106, 111], ["sGP", "PROTEIN", 160, 163], ["EBOV", "SPECIES", 19, 23], ["EBOV", "SPECIES", 171, 175], ["EBOV sGP", "PROBLEM", 19, 27], ["the EBOV pathogenesis", "PROBLEM", 167, 188], ["EBOV", "OBSERVATION", 19, 23], ["decreasing", "OBSERVATION_MODIFIER", 31, 41], ["chemotactic", "OBSERVATION_MODIFIER", 46, 57], ["M1 macrophages", "OBSERVATION", 79, 93], ["CD11b expression", "OBSERVATION", 106, 122], ["sGP", "OBSERVATION", 160, 163], ["EBOV", "OBSERVATION", 171, 175]]], ["Previously, it was thought that the primary role sGP served in pathogenesis was acting as a decoy molecule for antibody production [6] .", [["sGP", "GENE_OR_GENE_PRODUCT", 49, 52], ["sGP", "PROTEIN", 49, 52], ["decoy molecule", "PROTEIN", 92, 106], ["the primary role sGP", "PROBLEM", 32, 52], ["antibody production", "PROBLEM", 111, 130]]], ["In this study, we show for the first time that sGP has profound inhibitory effects upon activated macrophages that may condition the cells for susceptibility to infection by progeny virion.", [["macrophages", "ANATOMY", 98, 109], ["cells", "ANATOMY", 133, 138], ["sGP", "CHEMICAL", 47, 50], ["infection", "DISEASE", 161, 170], ["sGP", "GENE_OR_GENE_PRODUCT", 47, 50], ["macrophages", "CELL", 98, 109], ["cells", "CELL", 133, 138], ["sGP", "PROTEIN", 47, 50], ["activated macrophages", "CELL_TYPE", 88, 109], ["this study", "TEST", 3, 13], ["profound inhibitory effects", "PROBLEM", 55, 82], ["activated macrophages", "PROBLEM", 88, 109], ["susceptibility to infection", "PROBLEM", 143, 170], ["profound", "OBSERVATION_MODIFIER", 55, 63], ["inhibitory effects", "OBSERVATION", 64, 82]]], ["EBOV sGP inhibited the production of pro-inflammatory cytokines, impaired chemotaxis, and downregulated integrin expression.", [["EBOV", "ORGANISM", 0, 4], ["integrin", "GENE_OR_GENE_PRODUCT", 104, 112], ["pro-inflammatory cytokines", "PROTEIN", 37, 63], ["integrin", "PROTEIN", 104, 112], ["EBOV", "SPECIES", 0, 4], ["EBOV sGP", "PROBLEM", 0, 8], ["pro-inflammatory cytokines", "PROBLEM", 37, 63], ["impaired chemotaxis", "PROBLEM", 65, 84], ["pro-inflammatory cytokines", "OBSERVATION", 37, 63], ["impaired", "OBSERVATION_MODIFIER", 65, 73], ["chemotaxis", "OBSERVATION_MODIFIER", 74, 84], ["integrin expression", "OBSERVATION", 104, 123]]], ["Phagocytosis of the activated macrophages was unaffected which is consistent with recent data supporting the notion that EBOV utilizes \"apoptotic mimicry\" and the phagocytosis mechanisms to invade the macrophages [16] .", [["macrophages", "ANATOMY", 30, 41], ["macrophages", "ANATOMY", 201, 212], ["macrophages", "CELL", 30, 41], ["EBOV", "ORGANISM", 121, 125], ["macrophages", "CELL", 201, 212], ["activated macrophages", "CELL_TYPE", 20, 41], ["macrophages", "CELL_TYPE", 201, 212], ["EBOV", "SPECIES", 121, 125], ["the activated macrophages", "PROBLEM", 16, 41], ["EBOV", "PROBLEM", 121, 125], ["the phagocytosis mechanisms", "PROBLEM", 159, 186], ["macrophages", "OBSERVATION", 30, 41], ["consistent with", "UNCERTAINTY", 66, 81]]], ["Thus, our findings suggest that sGP is produced to halt activated macrophage anti-viral activities and potentially preserving the entry site for the virion.", [["macrophage", "ANATOMY", 66, 76], ["virion", "ANATOMY", 149, 155], ["sGP", "CHEMICAL", 32, 35], ["sGP", "GENE_OR_GENE_PRODUCT", 32, 35], ["macrophage", "CELL", 66, 76], ["virion", "CELLULAR_COMPONENT", 149, 155], ["sGP", "PROTEIN", 32, 35], ["activated macrophage anti-viral activities", "TREATMENT", 56, 98], ["macrophage anti-viral", "OBSERVATION", 66, 87]]], ["In addition, once the activated macrophages are infected, EBOV glycoprotein and viral protein-40 may operate to override sGP-mediated inhibition to restore migration and cytokine production resulting in systemic dissemination of the virus and viral hemorrhagic fever.DiscussionEBOV titers have been shown to peak and plateau by day 6 postinfection at levels 10-fold greater than the titer levels of influenza virus infection [26] .", [["macrophages", "ANATOMY", 32, 43], ["viral hemorrhagic fever", "DISEASE", 243, 266], ["influenza virus infection", "DISEASE", 399, 424], ["macrophages", "CELL", 32, 43], ["EBOV", "ORGANISM", 58, 62], ["viral protein-40", "GENE_OR_GENE_PRODUCT", 80, 96], ["sGP", "GENE_OR_GENE_PRODUCT", 121, 124], ["influenza virus", "ORGANISM", 399, 414], ["activated macrophages", "CELL_TYPE", 22, 43], ["EBOV glycoprotein", "PROTEIN", 58, 75], ["viral protein-40", "PROTEIN", 80, 96], ["sGP", "PROTEIN", 121, 124], ["cytokine", "PROTEIN", 170, 178], ["influenza virus", "SPECIES", 399, 414], ["EBOV", "SPECIES", 58, 62], ["influenza virus", "SPECIES", 399, 414], ["infected", "PROBLEM", 48, 56], ["EBOV glycoprotein", "TREATMENT", 58, 75], ["viral protein", "TEST", 80, 93], ["sGP-mediated inhibition", "TREATMENT", 121, 144], ["restore migration", "PROBLEM", 148, 165], ["cytokine production", "PROBLEM", 170, 189], ["systemic dissemination", "PROBLEM", 203, 225], ["the virus", "PROBLEM", 229, 238], ["viral hemorrhagic fever", "PROBLEM", 243, 266], ["DiscussionEBOV titers", "TEST", 267, 288], ["influenza virus infection", "PROBLEM", 399, 424], ["viral", "OBSERVATION_MODIFIER", 243, 248], ["hemorrhagic", "OBSERVATION_MODIFIER", 249, 260], ["fever", "OBSERVATION", 261, 266], ["influenza virus", "OBSERVATION", 399, 414]]], ["This suggests an unusually high rate of viral replication that likely is accompanied by large amounts of pathogen-associated molecular patterns including the viral nucleic acids.", [["nucleic acids", "CHEMICAL", 164, 177], ["viral replication", "PROBLEM", 40, 57], ["large amounts of pathogen", "PROBLEM", 88, 113], ["the viral nucleic acids", "PROBLEM", 154, 177], ["unusually", "OBSERVATION_MODIFIER", 17, 26], ["high", "OBSERVATION_MODIFIER", 27, 31], ["viral replication", "OBSERVATION", 40, 57], ["large", "OBSERVATION_MODIFIER", 88, 93], ["amounts", "OBSERVATION_MODIFIER", 94, 101], ["pathogen", "OBSERVATION", 105, 113], ["molecular patterns", "OBSERVATION", 125, 143], ["viral nucleic acids", "OBSERVATION", 158, 177]]], ["M1 and M2 macrophage pro-inflammatory cytokine production is inhibited by EBOV sGP if given after activation, but not during activation.", [["macrophage", "ANATOMY", 10, 20], ["M1", "CELL", 0, 2], ["M2 macrophage", "CELL", 7, 20], ["EBOV", "ORGANISM", 74, 78], ["sGP", "GENE_OR_GENE_PRODUCT", 79, 82], ["cytokine", "PROTEIN", 38, 46], ["EBOV sGP", "PROTEIN", 74, 82], ["EBOV", "SPECIES", 74, 78], ["M2", "ANATOMY", 7, 9], ["pro-inflammatory cytokine production", "OBSERVATION", 21, 57]]], ["THP-1 monocytes were differentiated into macrophages.", [["THP-1 monocytes", "ANATOMY", 0, 15], ["macrophages", "ANATOMY", 41, 52], ["THP-1 monocytes", "CELL", 0, 15], ["macrophages", "CELL", 41, 52], ["THP-1 monocytes", "CELL_LINE", 0, 15], ["macrophages", "CELL_TYPE", 41, 52], ["THP-1 monocytes", "TEST", 0, 15], ["macrophages", "OBSERVATION", 41, 52]]], ["For the PBS, LPS, and sGP groups, macrophages were treated for 24 h with (A, C) IFN\u03b3 (20 ng/mL) or (B, D) IL-4 (20 ng/mL) and IL-13 (20 ng/mL).", [["macrophages", "ANATOMY", 34, 45], ["LPS", "CHEMICAL", 13, 16], ["LPS", "SIMPLE_CHEMICAL", 13, 16], ["sGP", "SIMPLE_CHEMICAL", 22, 25], ["macrophages", "CELL", 34, 45], ["A, C) IFN\u03b3", "SIMPLE_CHEMICAL", 74, 84], ["IL-4", "GENE_OR_GENE_PRODUCT", 106, 110], ["IL-13", "GENE_OR_GENE_PRODUCT", 126, 131], ["macrophages", "CELL_TYPE", 34, 45], ["IFN", "PROTEIN", 80, 83], ["the PBS", "TEST", 4, 11], ["LPS", "TEST", 13, 16], ["IFN", "TEST", 80, 83], ["B, D) IL", "TREATMENT", 100, 108], ["IL", "TEST", 126, 128]]], ["Subsequently, the macrophages were then stimulated with PBS, LPS (1 \u03bcg/mL) or sGP (4 \u03bcg/mL) for an additional 24 h.", [["macrophages", "ANATOMY", 18, 29], ["LPS", "CHEMICAL", 61, 64], ["sGP", "CHEMICAL", 78, 81], ["macrophages", "CELL", 18, 29], ["PBS", "SIMPLE_CHEMICAL", 56, 59], ["LPS", "SIMPLE_CHEMICAL", 61, 64], ["sGP", "SIMPLE_CHEMICAL", 78, 81], ["macrophages", "CELL_TYPE", 18, 29], ["the macrophages", "TREATMENT", 14, 29], ["LPS", "TEST", 61, 64], ["sGP", "TEST", 78, 81], ["macrophages", "ANATOMY", 18, 29]]], ["In the LPS \u2192 sGP group, (A) IFN\u03b3 (20 ng/mL) or (B) IL-4 (20 ng/mL) and IL-13 (20 ng/mL) were given for 24 h.", [["LPS", "CHEMICAL", 7, 10], ["LPS", "SIMPLE_CHEMICAL", 7, 10], ["sGP", "SIMPLE_CHEMICAL", 13, 16], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 28, 32], ["IL-4", "GENE_OR_GENE_PRODUCT", 51, 55], ["IL-13", "GENE_OR_GENE_PRODUCT", 71, 76], ["IFN\u03b3", "PROTEIN", 28, 32], ["IFN", "TEST", 28, 31], ["IL", "TEST", 51, 53], ["IL", "TEST", 71, 73]]], ["Then the cells were washed and LPS (1 \u03bcg/mL) was given for 24 h.", [["cells", "ANATOMY", 9, 14], ["LPS", "CHEMICAL", 31, 34], ["cells", "CELL", 9, 14], ["LPS", "SIMPLE_CHEMICAL", 31, 34], ["the cells", "TREATMENT", 5, 14], ["LPS", "TEST", 31, 34]]], ["The cells were washed again and sGP (4 \u03bcg/mL) was added for 24 h.", [["cells", "ANATOMY", 4, 9], ["sGP", "CHEMICAL", 32, 35], ["cells", "CELL", 4, 9], ["sGP", "SIMPLE_CHEMICAL", 32, 35], ["The cells", "TREATMENT", 0, 9], ["sGP", "TREATMENT", 32, 35]]], ["(C-D) In the LPS + sGP group, LPS (1 \u03bcg/mL) and sGP (4 \u03bcg/mL) were given simultaneously for 24 h after the polarization steps.", [["LPS", "CHEMICAL", 13, 16], ["sGP", "CHEMICAL", 19, 22], ["LPS", "CHEMICAL", 30, 33], ["sGP", "CHEMICAL", 48, 51], ["C-D", "SIMPLE_CHEMICAL", 1, 4], ["LPS + sGP", "SIMPLE_CHEMICAL", 13, 22], ["LPS", "SIMPLE_CHEMICAL", 30, 33], ["sGP", "SIMPLE_CHEMICAL", 48, 51], ["(C-D) In the LPS", "TEST", 0, 16], ["LPS", "TEST", 30, 33], ["sGP", "TEST", 48, 51]]], ["Supernatants from the cultures were harvested and the production of TNF\u03b1, IL-6, and IL-10 was measured via ELISA. (n = 3, P < .05, ns indicates not significant). monocytes have been shown to emigrate from the bone marrow and into the bloodstream during the first 72 h of microbial infection [27] .", [["Supernatants", "ANATOMY", 0, 12], ["cultures", "ANATOMY", 22, 30], ["monocytes", "ANATOMY", 162, 171], ["bone marrow", "ANATOMY", 209, 220], ["bloodstream", "ANATOMY", 234, 245], ["infection", "DISEASE", 281, 290], ["Supernatants", "CELL", 0, 12], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 68, 72], ["IL-6", "GENE_OR_GENE_PRODUCT", 74, 78], ["IL-10", "GENE_OR_GENE_PRODUCT", 84, 89], ["monocytes", "CELL", 162, 171], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 209, 220], ["TNF\u03b1", "PROTEIN", 68, 72], ["IL", "PROTEIN", 84, 86], ["monocytes", "CELL_TYPE", 162, 171], ["the cultures", "TEST", 18, 30], ["TNF\u03b1", "TEST", 68, 72], ["IL", "TEST", 74, 76], ["IL", "TEST", 84, 86], ["P", "TEST", 122, 123], ["ns", "TEST", 131, 133], ["monocytes", "TEST", 162, 171], ["microbial infection", "PROBLEM", 271, 290], ["bone marrow", "ANATOMY", 209, 220], ["bloodstream", "ANATOMY", 234, 245], ["infection", "OBSERVATION", 281, 290]]], ["However, systemic spread of the virus and high mortality suggests that despite the rapid mobilization of the innate response, EBOV is able to overwhelm the early host response in order to infect \"carrier\" cells (i.e. macrophages and DCs) for the purpose of disseminating the virus from the site of initial infection.", [["carrier\" cells", "ANATOMY", 196, 210], ["macrophages", "ANATOMY", 217, 228], ["DCs", "ANATOMY", 233, 236], ["infection", "DISEASE", 306, 315], ["EBOV", "ORGANISM", 126, 130], ["cells", "CELL", 205, 210], ["macrophages", "CELL", 217, 228], ["DCs", "CELL", 233, 236], ["carrier\" cells", "CELL_TYPE", 196, 210], ["macrophages", "CELL_TYPE", 217, 228], ["DCs", "CELL_TYPE", 233, 236], ["EBOV", "SPECIES", 126, 130], ["the virus", "PROBLEM", 28, 37], ["EBOV", "PROBLEM", 126, 130], ["disseminating the virus", "PROBLEM", 257, 280], ["initial infection", "PROBLEM", 298, 315], ["systemic", "OBSERVATION_MODIFIER", 9, 17], ["spread", "OBSERVATION_MODIFIER", 18, 24], ["virus", "OBSERVATION", 32, 37], ["virus", "OBSERVATION", 275, 280], ["initial", "OBSERVATION_MODIFIER", 298, 305], ["infection", "OBSERVATION", 306, 315]]], ["The hypothesis put forward in this work was that EBOV sGP operates to inhibit effector activities of these immune cells prior to their infection.", [["immune cells", "ANATOMY", 107, 119], ["sGP", "CHEMICAL", 54, 57], ["infection", "DISEASE", 135, 144], ["EBOV", "ORGANISM", 49, 53], ["sGP", "GENE_OR_GENE_PRODUCT", 54, 57], ["immune cells", "CELL", 107, 119], ["EBOV sGP", "PROTEIN", 49, 57], ["immune cells", "CELL_TYPE", 107, 119], ["EBOV", "SPECIES", 49, 53], ["EBOV sGP", "PROBLEM", 49, 57], ["these immune cells", "PROBLEM", 101, 119], ["their infection", "PROBLEM", 129, 144], ["infection", "OBSERVATION", 135, 144]]], ["Efforts to assess the modulation of DCs by sGP are underway (unpublished data).", [["DCs", "ANATOMY", 36, 39], ["DCs", "CELL", 36, 39], ["sGP", "GENE_OR_GENE_PRODUCT", 43, 46], ["DCs", "CELL_TYPE", 36, 39], ["sGP", "PROTEIN", 43, 46]]], ["Here, the focus was on monocytes and macrophages (resting and activated).", [["monocytes", "ANATOMY", 23, 32], ["macrophages", "ANATOMY", 37, 48], ["monocytes", "CELL", 23, 32], ["macrophages", "CELL", 37, 48], ["monocytes", "CELL_TYPE", 23, 32], ["macrophages", "CELL_TYPE", 37, 48], ["monocytes", "TEST", 23, 32]]], ["Monocytes have little impact upon viral replication given their limited phagocytic ability and cytokine production and likely are not a target of EBOV sGP.", [["Monocytes", "ANATOMY", 0, 9], ["Monocytes", "CELL", 0, 9], ["EBOV", "ORGANISM", 146, 150], ["sGP", "GENE_OR_GENE_PRODUCT", 151, 154], ["Monocytes", "CELL_TYPE", 0, 9], ["cytokine", "PROTEIN", 95, 103], ["EBOV sGP", "PROTEIN", 146, 154], ["EBOV", "SPECIES", 146, 150], ["Monocytes", "PROBLEM", 0, 9], ["viral replication", "TREATMENT", 34, 51], ["cytokine production", "PROBLEM", 95, 114], ["EBOV sGP", "PROBLEM", 146, 154], ["viral replication", "OBSERVATION", 34, 51], ["EBOV sGP", "OBSERVATION", 146, 154]]], ["This notion was supported by the inability of sGP to alter IL-6 production by THP-1 monocytes (Fig. 1A) .", [["THP-1 monocytes", "ANATOMY", 78, 93], ["sGP", "SIMPLE_CHEMICAL", 46, 49], ["IL-6", "GENE_OR_GENE_PRODUCT", 59, 63], ["THP-1 monocytes", "CELL", 78, 93], ["Fig. 1A", "CELL", 95, 102], ["sGP", "PROTEIN", 46, 49], ["IL-6", "PROTEIN", 59, 63], ["THP-1 monocytes", "CELL_LINE", 78, 93], ["alter IL", "TEST", 53, 61], ["THP", "TEST", 78, 81]]], ["By contrast, upon differentiation of monocytes into macrophages using PMA, and activation by LPS, THP-1 macrophages produced significantly less IL-6 ( Fig. 1B) .", [["monocytes", "ANATOMY", 37, 46], ["macrophages", "ANATOMY", 52, 63], ["THP-1 macrophages", "ANATOMY", 98, 115], ["PMA", "CHEMICAL", 70, 73], ["LPS", "CHEMICAL", 93, 96], ["PMA", "CHEMICAL", 70, 73], ["monocytes", "CELL", 37, 46], ["macrophages", "CELL", 52, 63], ["PMA", "SIMPLE_CHEMICAL", 70, 73], ["LPS", "SIMPLE_CHEMICAL", 93, 96], ["THP-1 macrophages", "CELL", 98, 115], ["IL-6", "GENE_OR_GENE_PRODUCT", 144, 148], ["Fig. 1B", "GENE_OR_GENE_PRODUCT", 151, 158], ["monocytes", "CELL_TYPE", 37, 46], ["macrophages", "CELL_TYPE", 52, 63], ["THP-1 macrophages", "CELL_LINE", 98, 115], ["IL-6", "PROTEIN", 144, 148], ["PMA", "TEST", 70, 73], ["LPS", "TEST", 93, 96], ["THP", "TEST", 98, 101]]], ["Therefore, sGP impacts macrophages only after differentiation from monocytes.", [["macrophages", "ANATOMY", 23, 34], ["monocytes", "ANATOMY", 67, 76], ["sGP", "SIMPLE_CHEMICAL", 11, 14], ["macrophages", "CELL", 23, 34], ["monocytes", "CELL", 67, 76], ["sGP", "PROTEIN", 11, 14], ["macrophages", "CELL_TYPE", 23, 34], ["monocytes", "CELL_TYPE", 67, 76], ["sGP impacts macrophages", "PROBLEM", 11, 34], ["monocytes", "TEST", 67, 76], ["impacts", "OBSERVATION_MODIFIER", 15, 22], ["macrophages", "OBSERVATION", 23, 34]]], ["This could suggest that the receptor on which sGP is binding is only expressed on differentiated macrophages and not monocytes.", [["macrophages", "ANATOMY", 97, 108], ["monocytes", "ANATOMY", 117, 126], ["sGP", "GENE_OR_GENE_PRODUCT", 46, 49], ["macrophages", "CELL", 97, 108], ["monocytes", "CELL", 117, 126], ["sGP", "PROTEIN", 46, 49], ["differentiated macrophages", "CELL_TYPE", 82, 108], ["monocytes", "CELL_TYPE", 117, 126], ["monocytes", "PROBLEM", 117, 126], ["differentiated", "OBSERVATION_MODIFIER", 82, 96], ["macrophages", "OBSERVATION", 97, 108], ["not", "UNCERTAINTY", 113, 116], ["monocytes", "OBSERVATION", 117, 126]]], ["Work is proceeding to identify the sGP receptor as well as the signaling that may be initiated in macrophages upon incubation with sGP.DiscussionDifferentiated macrophages undergo polarization into M1-like and M2-like effector cells in order to support microbial elimination; each genetic program configured for particular groups of pathogens, bacteria/viruses and helminths, respectively.", [["macrophages", "ANATOMY", 98, 109], ["macrophages", "ANATOMY", 160, 171], ["M1-like", "ANATOMY", 198, 205], ["M2-like effector cells", "ANATOMY", 210, 232], ["helminths", "DISEASE", 365, 374], ["sGP receptor", "GENE_OR_GENE_PRODUCT", 35, 47], ["macrophages", "CELL", 98, 109], ["sGP", "GENE_OR_GENE_PRODUCT", 131, 134], ["Differentiated macrophages", "CELL", 145, 171], ["M1-like", "CELL", 198, 205], ["M2-like effector cells", "CELL", 210, 232], ["sGP receptor", "PROTEIN", 35, 47], ["macrophages", "CELL_TYPE", 98, 109], ["sGP", "PROTEIN", 131, 134], ["Differentiated macrophages", "CELL_TYPE", 145, 171], ["M1-like and M2-like effector cells", "CELL_LINE", 198, 232], ["microbial elimination", "PROBLEM", 253, 274], ["pathogens", "PROBLEM", 333, 342], ["bacteria", "PROBLEM", 344, 352], ["viruses", "PROBLEM", 353, 360], ["macrophages", "OBSERVATION", 160, 171], ["polarization", "OBSERVATION_MODIFIER", 180, 192], ["effector cells", "OBSERVATION", 218, 232]]], ["Viruses such as severe acute respiratory syndrome coronavirus, human immunodeficiency virus and human cytomegalovirus have all been associated with promoting M2 polarization to support successful viral replication [28] .", [["acute respiratory syndrome coronavirus", "DISEASE", 23, 61], ["human immunodeficiency virus", "DISEASE", 63, 91], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 16, 61], ["human immunodeficiency virus", "ORGANISM", 63, 91], ["human", "ORGANISM", 96, 101], ["cytomegalovirus", "ORGANISM", 102, 117], ["human", "SPECIES", 63, 68], ["immunodeficiency virus", "SPECIES", 69, 91], ["human", "SPECIES", 96, 101], ["cytomegalovirus", "SPECIES", 102, 117], ["severe acute respiratory syndrome coronavirus", "SPECIES", 16, 61], ["human immunodeficiency virus", "SPECIES", 63, 91], ["human cytomegalovirus", "SPECIES", 96, 117], ["Viruses", "PROBLEM", 0, 7], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 16, 61], ["human immunodeficiency virus", "PROBLEM", 63, 91], ["human cytomegalovirus", "PROBLEM", 96, 117], ["successful viral replication", "TREATMENT", 185, 213], ["severe", "OBSERVATION_MODIFIER", 16, 22], ["acute", "OBSERVATION_MODIFIER", 23, 28], ["respiratory syndrome coronavirus", "OBSERVATION", 29, 61], ["immunodeficiency virus", "OBSERVATION", 69, 91], ["cytomegalovirus", "OBSERVATION", 102, 117]]], ["Thus, it was thought that EBOV may similarly promote M2 polarization through the secretion of a viral protein to modulate this process.", [["EBOV", "ORGANISM", 26, 30], ["M2", "GENE_OR_GENE_PRODUCT", 53, 55], ["viral protein", "PROTEIN", 96, 109], ["EBOV", "SPECIES", 26, 30], ["EBOV", "PROBLEM", 26, 30], ["a viral protein", "PROBLEM", 94, 109], ["M2 polarization", "OBSERVATION", 53, 68]]], ["Using the in vitro THP-1 model, EBOV sGP did not demonstrate the ability to affect the polarization of macrophages into M1 or M2 phenotypes (Fig. 2) .", [["macrophages", "ANATOMY", 103, 114], ["M1", "ANATOMY", 120, 122], ["THP-1", "GENE_OR_GENE_PRODUCT", 19, 24], ["EBOV", "ORGANISM", 32, 36], ["macrophages", "CELL", 103, 114], ["M1", "CELL", 120, 122], ["M2", "GENE_OR_GENE_PRODUCT", 126, 128], ["EBOV sGP", "PROTEIN", 32, 40], ["macrophages", "CELL_TYPE", 103, 114], ["EBOV", "SPECIES", 32, 36], ["EBOV sGP", "TEST", 32, 40], ["M1", "ANATOMY", 120, 122], ["M2", "ANATOMY", 126, 128]]], ["This would seem to suggest that the spread of EBOV can benefit from correctly polarized macrophages.", [["macrophages", "ANATOMY", 88, 99], ["EBOV", "DISEASE", 46, 50], ["EBOV", "ORGANISM", 46, 50], ["macrophages", "CELL", 88, 99], ["polarized macrophages", "CELL_TYPE", 78, 99], ["EBOV", "SPECIES", 46, 50], ["EBOV", "PROBLEM", 46, 50], ["polarized macrophages", "OBSERVATION", 78, 99]]], ["Again, because the macrophages were cultured with sGP prior to activation with LPS, it strongly suggests that the receptor for the viral protein is expressed or upregulated after the cells are stimulated.DiscussionIndeed, the production of IL-10 is not affected when sGP is given after macrophage activation, or during activation.", [["macrophages", "ANATOMY", 19, 30], ["cells", "ANATOMY", 183, 188], ["macrophage", "ANATOMY", 286, 296], ["LPS", "CHEMICAL", 79, 82], ["macrophages", "CELL", 19, 30], ["sGP", "GENE_OR_GENE_PRODUCT", 50, 53], ["LPS", "SIMPLE_CHEMICAL", 79, 82], ["cells", "CELL", 183, 188], ["IL-10", "GENE_OR_GENE_PRODUCT", 240, 245], ["sGP", "SIMPLE_CHEMICAL", 267, 270], ["macrophage", "CELL", 286, 296], ["macrophages", "CELL_TYPE", 19, 30], ["sGP", "PROTEIN", 50, 53], ["viral protein", "PROTEIN", 131, 144], ["IL", "PROTEIN", 240, 242], ["sGP", "PROTEIN", 267, 270], ["LPS", "TREATMENT", 79, 82], ["the viral protein", "PROBLEM", 127, 144], ["macrophage activation", "TREATMENT", 286, 307], ["macrophages", "OBSERVATION", 19, 30]]], ["The production is also not affected if sGP is given during the polarization of M2 macrophages as noted above.", [["M2 macrophages", "ANATOMY", 79, 93], ["sGP", "CHEMICAL", 39, 42], ["sGP", "CHEMICAL", 39, 42], ["sGP", "SIMPLE_CHEMICAL", 39, 42], ["M2 macrophages", "CELL", 79, 93], ["sGP", "PROTEIN", 39, 42], ["M2 macrophages", "CELL_TYPE", 79, 93], ["sGP", "TEST", 39, 42]]], ["However, if sGP is given during the polarization of M1 macrophages then the production of IL-10 is significantly decreased.", [["M1 macrophages", "ANATOMY", 52, 66], ["sGP", "CHEMICAL", 12, 15], ["sGP", "GENE_OR_GENE_PRODUCT", 12, 15], ["M1 macrophages", "CELL", 52, 66], ["IL-10", "GENE_OR_GENE_PRODUCT", 90, 95], ["sGP", "PROTEIN", 12, 15], ["M1 macrophages", "CELL_TYPE", 52, 66], ["IL", "PROTEIN", 90, 92], ["sGP", "TEST", 12, 15], ["significantly", "OBSERVATION_MODIFIER", 99, 112], ["decreased", "OBSERVATION_MODIFIER", 113, 122]]], ["This could possibly be due to the activity of some sGP-mediated activation of a regulatory adaptor protein such as interferon regulatory factor-4 (IRF4), which has a profound inhibitory effect on proinflammatory cytokine production [29] , but a milder inhibitory effect on IL-10 production [30, 31] .", [["sGP", "GENE_OR_GENE_PRODUCT", 51, 54], ["interferon regulatory factor-4", "GENE_OR_GENE_PRODUCT", 115, 145], ["IRF4", "GENE_OR_GENE_PRODUCT", 147, 151], ["IL-10", "GENE_OR_GENE_PRODUCT", 273, 278], ["sGP", "PROTEIN", 51, 54], ["regulatory adaptor protein", "PROTEIN", 80, 106], ["interferon regulatory factor-4", "PROTEIN", 115, 145], ["IRF4", "PROTEIN", 147, 151], ["proinflammatory cytokine", "PROTEIN", 196, 220], ["IL", "PROTEIN", 273, 275], ["a regulatory adaptor protein", "TREATMENT", 78, 106], ["interferon regulatory factor", "TREATMENT", 115, 143], ["a profound inhibitory effect", "PROBLEM", 164, 192], ["proinflammatory cytokine production", "PROBLEM", 196, 231], ["a milder inhibitory effect", "PROBLEM", 243, 269], ["could possibly be due to", "UNCERTAINTY", 5, 29]]], ["The fact that sGP only interferes with the IL-10 production if given during the polarization step could be due to a role of a regulatory protein such as IRF-4 in the differentiation process of hematopoietic stem cells [31] .", [["hematopoietic stem cells", "ANATOMY", 193, 217], ["sGP", "SIMPLE_CHEMICAL", 14, 17], ["IL-10", "GENE_OR_GENE_PRODUCT", 43, 48], ["IRF-4", "GENE_OR_GENE_PRODUCT", 153, 158], ["hematopoietic stem cells", "CELL", 193, 217], ["sGP", "PROTEIN", 14, 17], ["IL", "PROTEIN", 43, 45], ["regulatory protein", "PROTEIN", 126, 144], ["IRF-4", "PROTEIN", 153, 158], ["hematopoietic stem cells", "CELL_TYPE", 193, 217], ["the IL", "TREATMENT", 39, 45], ["a regulatory protein", "PROBLEM", 124, 144], ["IRF", "TEST", 153, 156], ["hematopoietic stem cells", "PROBLEM", 193, 217], ["hematopoietic stem cells", "OBSERVATION", 193, 217]]], ["IRF-4 has been previously shown to be a target of viral processes to suppress the immune response and promote viral pathogenesis [32, 33] .", [["IRF-4", "GENE_OR_GENE_PRODUCT", 0, 5], ["IRF-4", "PROTEIN", 0, 5], ["IRF", "TEST", 0, 3], ["viral processes", "PROBLEM", 50, 65]]], ["Therefore, it is possible that the presence of sGP promotes IRF-4 activity and suppresses pro-inflammatory cytokines, and only impacts the IL-10 production of M1 macrophages.", [["M1 macrophages", "ANATOMY", 159, 173], ["sGP", "GENE_OR_GENE_PRODUCT", 47, 50], ["IRF-4", "GENE_OR_GENE_PRODUCT", 60, 65], ["IL-10", "GENE_OR_GENE_PRODUCT", 139, 144], ["M1 macrophages", "CELL", 159, 173], ["sGP", "PROTEIN", 47, 50], ["IRF-4", "PROTEIN", 60, 65], ["pro-inflammatory cytokines", "PROTEIN", 90, 116], ["M1 macrophages", "CELL_TYPE", 159, 173], ["sGP promotes IRF", "PROBLEM", 47, 63], ["pro-inflammatory cytokines", "TEST", 90, 116], ["the IL", "TREATMENT", 135, 141]]], ["This is a possibility that will be pursued in future work.DiscussionPrevious studies have reported that shed EBOV glycoprotein can mitigate production of pro-inflammatory cytokines by innate immune cells, but the authors state that the secreted version was unable to stimulate the macrophages [7] .", [["immune cells", "ANATOMY", 191, 203], ["macrophages", "ANATOMY", 281, 292], ["EBOV", "ORGANISM", 109, 113], ["innate immune cells", "CELL", 184, 203], ["macrophages", "CELL", 281, 292], ["EBOV glycoprotein", "PROTEIN", 109, 126], ["pro-inflammatory cytokines", "PROTEIN", 154, 180], ["innate immune cells", "CELL_TYPE", 184, 203], ["macrophages", "CELL_TYPE", 281, 292], ["EBOV", "SPECIES", 109, 113], ["DiscussionPrevious studies", "TEST", 58, 84], ["EBOV glycoprotein", "TREATMENT", 109, 126], ["pro-inflammatory cytokines", "PROBLEM", 154, 180], ["innate immune cells", "TREATMENT", 184, 203], ["the secreted version", "PROBLEM", 232, 252]]], ["Other studies also show that soluble EBOV glycoprotein (shed, secreted, and spike) has no effect on macrophages [34] .", [["macrophages", "ANATOMY", 100, 111], ["EBOV glycoprotein", "GENE_OR_GENE_PRODUCT", 37, 54], ["shed", "GENE_OR_GENE_PRODUCT", 56, 60], ["macrophages", "CELL", 100, 111], ["EBOV glycoprotein", "PROTEIN", 37, 54], ["shed", "PROTEIN", 56, 60], ["macrophages", "CELL_TYPE", 100, 111], ["EBOV", "SPECIES", 37, 41], ["Other studies", "TEST", 0, 13], ["soluble EBOV glycoprotein", "PROBLEM", 29, 54], ["effect on macrophages", "PROBLEM", 90, 111], ["no", "UNCERTAINTY", 87, 89]]], ["Both of these studies were asking whether non-activated macrophages are stimulated to produce cytokines when treated with EBOV secreted glycoprotein; essentially asking whether sGP stimulates macrophage cytokine production.", [["macrophages", "ANATOMY", 56, 67], ["macrophage", "ANATOMY", 192, 202], ["macrophages", "CELL", 56, 67], ["EBOV", "ORGANISM", 122, 126], ["sGP", "GENE_OR_GENE_PRODUCT", 177, 180], ["macrophage", "CELL", 192, 202], ["non-activated macrophages", "CELL_TYPE", 42, 67], ["cytokines", "PROTEIN", 94, 103], ["EBOV secreted glycoprotein", "PROTEIN", 122, 148], ["sGP", "PROTEIN", 177, 180], ["cytokine", "PROTEIN", 203, 211], ["EBOV", "SPECIES", 122, 126], ["these studies", "TEST", 8, 21], ["non-activated macrophages", "PROBLEM", 42, 67], ["EBOV secreted glycoprotein", "TREATMENT", 122, 148], ["sGP stimulates macrophage cytokine production", "PROBLEM", 177, 222]]], ["Thus, the finding that sGP can inhibit the production of pro-inflammatory cytokines by previously activated macrophages is novel (Fig. 3) .", [["macrophages", "ANATOMY", 108, 119], ["sGP", "CHEMICAL", 23, 26], ["sGP", "SIMPLE_CHEMICAL", 23, 26], ["macrophages", "CELL", 108, 119], ["sGP", "PROTEIN", 23, 26], ["pro-inflammatory cytokines", "PROTEIN", 57, 83], ["activated macrophages", "CELL_TYPE", 98, 119], ["pro-inflammatory cytokines", "PROBLEM", 57, 83], ["previously activated macrophages", "PROBLEM", 87, 119], ["pro-inflammatory cytokines", "OBSERVATION", 57, 83]]], ["The inhibitory effect of sGP upon IL-6 and TNF\u03b1 production may occur at either the genetic or protein secretion level.", [["sGP", "CHEMICAL", 25, 28], ["sGP", "SIMPLE_CHEMICAL", 25, 28], ["IL-6", "GENE_OR_GENE_PRODUCT", 34, 38], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 43, 47], ["sGP", "PROTEIN", 25, 28], ["IL-6", "PROTEIN", 34, 38], ["TNF\u03b1", "PROTEIN", 43, 47], ["IL", "TEST", 34, 36], ["TNF\u03b1 production", "PROBLEM", 43, 58], ["sGP", "OBSERVATION_MODIFIER", 25, 28]]], ["When administered to mice, the half-life of LPS is 12 h and is likely much shorter in vitro [35] .", [["LPS", "CHEMICAL", 44, 47], ["mice", "ORGANISM", 21, 25], ["LPS", "SIMPLE_CHEMICAL", 44, 47], ["mice", "SPECIES", 21, 25], ["mice", "SPECIES", 21, 25]]], ["Given that the macrophages are activated with LPS for 24 h and then washed to remove excess LPS before sGP is added, this suggests that sGP does not compete with LPS for TLR4 binding as is thought for shed GP [7] .", [["macrophages", "ANATOMY", 15, 26], ["LPS", "CHEMICAL", 46, 49], ["LPS", "CHEMICAL", 92, 95], ["sGP", "CHEMICAL", 103, 106], ["LPS", "CHEMICAL", 162, 165], ["macrophages", "CELL", 15, 26], ["LPS", "SIMPLE_CHEMICAL", 46, 49], ["LPS", "SIMPLE_CHEMICAL", 92, 95], ["sGP", "SIMPLE_CHEMICAL", 103, 106], ["sGP", "SIMPLE_CHEMICAL", 136, 139], ["LPS", "SIMPLE_CHEMICAL", 162, 165], ["TLR4", "GENE_OR_GENE_PRODUCT", 170, 174], ["macrophages", "CELL_TYPE", 15, 26], ["sGP", "PROTEIN", 103, 106], ["sGP", "PROTEIN", 136, 139], ["TLR4", "PROTEIN", 170, 174], ["LPS", "TREATMENT", 46, 49], ["excess LPS", "PROBLEM", 85, 95], ["TLR4 binding", "PROBLEM", 170, 182]]], ["So, EBOV sGP must affect LPS-induced signaling downstream, perhaps intervening to inhibit the activation of NF-\u03baB by reinstating the action of I\u03baB kinase (IKK) [36] .", [["LPS", "CHEMICAL", 25, 28], ["EBOV", "ORGANISM", 4, 8], ["sGP", "GENE_OR_GENE_PRODUCT", 9, 12], ["LPS", "SIMPLE_CHEMICAL", 25, 28], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 108, 113], ["I\u03baB kinase", "GENE_OR_GENE_PRODUCT", 143, 153], ["IKK", "GENE_OR_GENE_PRODUCT", 155, 158], ["EBOV sGP", "PROTEIN", 4, 12], ["NF-\u03baB", "PROTEIN", 108, 113], ["I\u03baB kinase", "PROTEIN", 143, 153], ["IKK", "PROTEIN", 155, 158], ["EBOV", "SPECIES", 4, 8], ["EBOV sGP", "TEST", 4, 12], ["LPS", "TEST", 25, 28], ["signaling downstream", "PROBLEM", 37, 57]]], ["Another LPS-induced pathway that may be influenced by sGP are the mitogen-activated protein kinases, MAPK.", [["LPS", "CHEMICAL", 8, 11], ["LPS", "SIMPLE_CHEMICAL", 8, 11], ["sGP", "GENE_OR_GENE_PRODUCT", 54, 57], ["mitogen-activated protein kinases", "GENE_OR_GENE_PRODUCT", 66, 99], ["MAPK", "GENE_OR_GENE_PRODUCT", 101, 105], ["sGP", "PROTEIN", 54, 57], ["mitogen-activated protein kinases", "PROTEIN", 66, 99], ["MAPK", "PROTEIN", 101, 105], ["Another LPS", "TEST", 0, 11], ["sGP", "TEST", 54, 57], ["the mitogen", "TEST", 62, 73], ["activated protein kinases", "TEST", 74, 99], ["MAPK", "TEST", 101, 105], ["may be", "UNCERTAINTY", 33, 39]]], ["LPS binding to Toll-like receptor 4 induces MyD88 signaling through recruitment and phosphorylation of IL-1 receptor-associated kinase (IRAK-4); which, in turn, activates IRAK-1.", [["LPS", "CHEMICAL", 0, 3], ["LPS", "SIMPLE_CHEMICAL", 0, 3], ["Toll-like receptor 4", "GENE_OR_GENE_PRODUCT", 15, 35], ["MyD88", "GENE_OR_GENE_PRODUCT", 44, 49], ["IL-1 receptor-associated kinase", "GENE_OR_GENE_PRODUCT", 103, 134], ["IRAK-4", "GENE_OR_GENE_PRODUCT", 136, 142], ["IRAK-1", "GENE_OR_GENE_PRODUCT", 171, 177], ["Toll-like receptor 4", "PROTEIN", 15, 35], ["MyD88", "PROTEIN", 44, 49], ["IL-1 receptor-associated kinase (IRAK-4", "PROTEIN", 103, 142], ["IRAK-1", "PROTEIN", 171, 177], ["LPS binding", "PROBLEM", 0, 11], ["phosphorylation of IL", "TEST", 84, 105], ["kinase", "TEST", 128, 134], ["IRAK", "TEST", 136, 140], ["IRAK", "TEST", 171, 175]]], ["MAPK (and NF-\u03baB) are subsequently activated leading to cytokine production [37] .", [["MAPK", "GENE_OR_GENE_PRODUCT", 0, 4], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 10, 15], ["MAPK", "PROTEIN", 0, 4], ["NF-\u03baB", "PROTEIN", 10, 15], ["cytokine", "PROTEIN", 55, 63], ["MAPK", "TEST", 0, 4], ["NF", "TEST", 10, 12], ["cytokine production", "PROBLEM", 55, 74]]], ["Two proteins that block IRAK-4 may be triggered by sGP, Tollip and IRAK-M.", [["IRAK-4", "GENE_OR_GENE_PRODUCT", 24, 30], ["sGP", "GENE_OR_GENE_PRODUCT", 51, 54], ["Tollip", "GENE_OR_GENE_PRODUCT", 56, 62], ["IRAK-M.", "GENE_OR_GENE_PRODUCT", 67, 74], ["IRAK-4", "PROTEIN", 24, 30], ["sGP", "PROTEIN", 51, 54], ["Tollip", "PROTEIN", 56, 62], ["IRAK", "PROTEIN", 67, 71], ["block IRAK", "OBSERVATION", 18, 28]]], ["Another protein, suppressor of cytokine signaling-1 (SOCS-1), could also be induced by sGP to interfere with cytokine production.", [["suppressor of cytokine signaling-1", "GENE_OR_GENE_PRODUCT", 17, 51], ["SOCS-1", "GENE_OR_GENE_PRODUCT", 53, 59], ["sGP", "SIMPLE_CHEMICAL", 87, 90], ["suppressor of cytokine signaling-1 (SOCS-1", "PROTEIN", 17, 59], ["sGP", "PROTEIN", 87, 90], ["cytokine", "PROTEIN", 109, 117], ["Another protein", "TEST", 0, 15], ["cytokine signaling", "TEST", 31, 49], ["cytokine production", "PROBLEM", 109, 128]]], ["Additionally, since IL-10 production by M2 macrophages was unchanged in the presence of sGP, it is highly unlikely that sGP impedes pro-inflammatory cytokine production by blocking protein secretory pathways.", [["M2 macrophages", "ANATOMY", 40, 54], ["IL-10", "GENE_OR_GENE_PRODUCT", 20, 25], ["M2 macrophages", "CELL", 40, 54], ["sGP", "GENE_OR_GENE_PRODUCT", 88, 91], ["sGP", "SIMPLE_CHEMICAL", 120, 123], ["IL-10", "PROTEIN", 20, 25], ["M2 macrophages", "CELL_TYPE", 40, 54], ["sGP", "PROTEIN", 88, 91], ["sGP", "PROTEIN", 120, 123], ["pro-inflammatory cytokine", "PROTEIN", 132, 157], ["IL", "TEST", 20, 22], ["sGP", "PROBLEM", 88, 91], ["sGP impedes pro-inflammatory cytokine production", "PROBLEM", 120, 168], ["blocking protein secretory pathways", "PROBLEM", 172, 207], ["unchanged", "OBSERVATION_MODIFIER", 59, 68], ["sGP", "OBSERVATION", 88, 91], ["highly unlikely", "UNCERTAINTY", 99, 114], ["pro-inflammatory cytokine", "OBSERVATION", 132, 157]]], ["An understanding of how sGP affects NF-\u03baB as well as the MAPK signaling pathways leading to cytokine production are underway.DiscussionWhile sGP appeared to have the capacity to interfere with LPSmediated signals following activation, sGP was incapable of altering LPS signals when given at the same time as the stimulant ( Fig. 3C and D) .", [["LPS", "CHEMICAL", 265, 268], ["sGP", "GENE_OR_GENE_PRODUCT", 24, 27], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 36, 41], ["MAPK", "GENE_OR_GENE_PRODUCT", 57, 61], ["sGP", "GENE_OR_GENE_PRODUCT", 141, 144], ["sGP", "SIMPLE_CHEMICAL", 235, 238], ["LPS", "SIMPLE_CHEMICAL", 265, 268], ["sGP", "PROTEIN", 24, 27], ["NF-\u03baB", "PROTEIN", 36, 41], ["MAPK", "PROTEIN", 57, 61], ["cytokine", "PROTEIN", 92, 100], ["sGP", "PROTEIN", 141, 144], ["sGP", "PROTEIN", 235, 238], ["the MAPK signaling pathways", "PROBLEM", 53, 80], ["cytokine production", "PROBLEM", 92, 111], ["the capacity", "PROBLEM", 162, 174], ["altering LPS signals", "PROBLEM", 256, 276]]], ["Possibly, sGP has a much shorter half-life than LPS; and thus, cytokines could be reduced for a short term and then restored by the time cytokine concentrations are determined at the 24-h endpoint of the experiment.", [["sGP", "CHEMICAL", 10, 13], ["LPS", "CHEMICAL", 48, 51], ["sGP", "SIMPLE_CHEMICAL", 10, 13], ["LPS", "SIMPLE_CHEMICAL", 48, 51], ["sGP", "PROTEIN", 10, 13], ["cytokines", "PROTEIN", 63, 72], ["cytokine", "PROTEIN", 137, 145], ["cytokines", "TREATMENT", 63, 72]]], ["An examination of the cytokine production at 12, 16, 20 and 24 h will address this issue.", [["cytokine", "PROTEIN", 22, 30], ["An examination", "TEST", 0, 14], ["the cytokine production", "TEST", 18, 41]]], ["This rapid turnover may account for the projected high levels of sGP in the tissues and blood of infected animals [7] .", [["tissues", "ANATOMY", 76, 83], ["blood", "ANATOMY", 88, 93], ["sGP", "GENE_OR_GENE_PRODUCT", 65, 68], ["tissues", "TISSUE", 76, 83], ["blood", "ORGANISM_SUBSTANCE", 88, 93], ["sGP", "PROTEIN", 65, 68], ["This rapid turnover", "PROBLEM", 0, 19], ["the projected high levels of sGP in the tissues", "PROBLEM", 36, 83], ["infected animals", "PROBLEM", 97, 113], ["may account for", "UNCERTAINTY", 20, 35], ["tissues", "ANATOMY", 76, 83], ["infected", "OBSERVATION_MODIFIER", 97, 105]]], ["EBOV GP and LPS have also been suggested to compete for the same receptor, TLR4; a possible attachment factor for the virus [7, 13, 38] , which is expressed on macrophages.", [["macrophages", "ANATOMY", 160, 171], ["LPS", "CHEMICAL", 12, 15], ["EBOV GP", "ORGANISM", 0, 7], ["LPS", "SIMPLE_CHEMICAL", 12, 15], ["TLR4", "GENE_OR_GENE_PRODUCT", 75, 79], ["macrophages", "CELL", 160, 171], ["TLR4", "PROTEIN", 75, 79], ["attachment factor", "PROTEIN", 92, 109], ["macrophages", "CELL_TYPE", 160, 171], ["EBOV", "SPECIES", 0, 4], ["attachment factor", "PROBLEM", 92, 109], ["the virus", "PROBLEM", 114, 123], ["macrophages", "OBSERVATION", 160, 171]]], ["Whether the secreted, truncated version of GP may also bind to TLR4 is unknown.", [["GP", "GENE_OR_GENE_PRODUCT", 43, 45], ["TLR4", "GENE_OR_GENE_PRODUCT", 63, 67], ["GP", "PROTEIN", 43, 45], ["TLR4", "PROTEIN", 63, 67]]], ["From these studies, sGP appeared not to have an impact upon cellular functions until the cells were activated suggesting that the receptor may not be constitutively expressed.", [["cellular", "ANATOMY", 60, 68], ["cells", "ANATOMY", 89, 94], ["sGP", "SIMPLE_CHEMICAL", 20, 23], ["cellular", "CELL", 60, 68], ["cells", "CELL", 89, 94], ["sGP", "PROTEIN", 20, 23], ["these studies", "TEST", 5, 18]]], ["Interestingly, related studies with natural killer (NK) cells lacking TLR4 and treatment with sGP have shown inhibition of NK effector functions indicating that sGP may at least have an alternate receptor which exists both on activated macrophages and NK cells (unpublished data).DiscussionMacrophages are widely known for their ability to phagocytose particles and clean up cellular debris in the tissues.", [["natural killer (NK) cells", "ANATOMY", 36, 61], ["NK", "ANATOMY", 123, 125], ["macrophages", "ANATOMY", 236, 247], ["NK cells", "ANATOMY", 252, 260], ["Macrophages", "ANATOMY", 290, 301], ["cellular debris", "ANATOMY", 375, 390], ["tissues", "ANATOMY", 398, 405], ["natural killer (NK) cells", "CELL", 36, 61], ["TLR4", "GENE_OR_GENE_PRODUCT", 70, 74], ["sGP", "GENE_OR_GENE_PRODUCT", 94, 97], ["NK", "CELL", 123, 125], ["sGP", "GENE_OR_GENE_PRODUCT", 161, 164], ["macrophages", "CELL", 236, 247], ["NK cells", "CELL", 252, 260], ["Macrophages", "CELL", 290, 301], ["cellular", "CELL", 375, 383], ["tissues", "TISSUE", 398, 405], ["natural killer (NK) cells", "CELL_TYPE", 36, 61], ["TLR4", "PROTEIN", 70, 74], ["sGP", "PROTEIN", 94, 97], ["sGP", "PROTEIN", 161, 164], ["activated macrophages", "CELL_TYPE", 226, 247], ["NK cells", "CELL_TYPE", 252, 260], ["Macrophages", "CELL_TYPE", 290, 301], ["natural killer (NK) cells", "TREATMENT", 36, 61], ["TLR4 and treatment", "TREATMENT", 70, 88], ["sGP", "TREATMENT", 94, 97], ["NK effector functions", "PROBLEM", 123, 144], ["an alternate receptor", "PROBLEM", 183, 204], ["phagocytose particles", "PROBLEM", 340, 361], ["clean up cellular debris in the tissues", "PROBLEM", 366, 405], ["NK cells", "OBSERVATION", 252, 260], ["clean", "OBSERVATION_MODIFIER", 366, 371], ["up cellular", "OBSERVATION_MODIFIER", 372, 383], ["debris", "OBSERVATION", 384, 390], ["tissues", "ANATOMY", 398, 405]]], ["Phagocytic action is increased when the macrophages assume the M1 phenotype, and is relatively lower for the M2 phenotype.", [["macrophages", "ANATOMY", 40, 51], ["macrophages", "CELL", 40, 51], ["M2", "GENE_OR_GENE_PRODUCT", 109, 111], ["macrophages", "CELL_TYPE", 40, 51], ["Phagocytic action", "TEST", 0, 17], ["the M2 phenotype", "PROBLEM", 105, 121], ["increased", "OBSERVATION_MODIFIER", 21, 30], ["macrophages", "OBSERVATION", 40, 51], ["M1 phenotype", "OBSERVATION", 63, 75], ["M2 phenotype", "OBSERVATION", 109, 121]]], ["The soluble antigen, ovalbumin, has been shown to be phagocytosed by DCs via the C-type lectin, mannose receptor [39] .", [["DCs", "ANATOMY", 69, 72], ["mannose", "CHEMICAL", 96, 103], ["ovalbumin", "GENE_OR_GENE_PRODUCT", 21, 30], ["DCs", "CELL", 69, 72], ["C-type lectin", "GENE_OR_GENE_PRODUCT", 81, 94], ["mannose receptor", "GENE_OR_GENE_PRODUCT", 96, 112], ["soluble antigen", "PROTEIN", 4, 19], ["ovalbumin", "PROTEIN", 21, 30], ["DCs", "CELL_TYPE", 69, 72], ["C-type lectin", "PROTEIN", 81, 94], ["mannose receptor", "PROTEIN", 96, 112], ["The soluble antigen", "TREATMENT", 0, 19], ["ovalbumin", "TREATMENT", 21, 30]]], ["C-type lectins have also been implicated as the possible attachment factor for EBOV entry into the host cells [11, 40] .", [["cells", "ANATOMY", 104, 109], ["C-type lectins", "GENE_OR_GENE_PRODUCT", 0, 14], ["EBOV", "ORGANISM", 79, 83], ["cells", "CELL", 104, 109], ["C-type lectins", "PROTEIN", 0, 14], ["attachment factor", "PROTEIN", 57, 74], ["host cells", "CELL_TYPE", 99, 109], ["EBOV", "SPECIES", 79, 83], ["C-type lectins", "PROBLEM", 0, 14], ["attachment factor", "PROBLEM", 57, 74]]], ["Interestingly, phagocytosis of ovalbumin by activated THP-1 M1 macrophages was not affected by treatment of sGP (Fig. 4) .", [["THP-1 M1 macrophages", "ANATOMY", 54, 74], ["ovalbumin", "GENE_OR_GENE_PRODUCT", 31, 40], ["THP-1 M1 macrophages", "CELL", 54, 74], ["sGP", "SIMPLE_CHEMICAL", 108, 111], ["activated THP-1 M1 macrophages", "CELL_LINE", 44, 74], ["sGP", "PROTEIN", 108, 111], ["ovalbumin", "TREATMENT", 31, 40], ["sGP", "TEST", 108, 111]]], ["If the proposed hypothesis were correct, sGP would not interfere with the ability of the macrophages to uptake the virus through C-type lectins.", [["macrophages", "ANATOMY", 89, 100], ["sGP", "SIMPLE_CHEMICAL", 41, 44], ["macrophages", "CELL", 89, 100], ["C-type lectins", "GENE_OR_GENE_PRODUCT", 129, 143], ["sGP", "PROTEIN", 41, 44], ["macrophages", "CELL_TYPE", 89, 100], ["C-type lectins", "PROTEIN", 129, 143]]], ["Thus, C-type lectins may be important EBOV ligands for cell entry [16] .DiscussionThe migratory ability of macrophages is essential to their function as antigen-presenting cells.", [["cell", "ANATOMY", 55, 59], ["macrophages", "ANATOMY", 107, 118], ["cells", "ANATOMY", 172, 177], ["C-type lectins", "GENE_OR_GENE_PRODUCT", 6, 20], ["EBOV", "ORGANISM", 38, 42], ["cell", "CELL", 55, 59], ["macrophages", "CELL", 107, 118], ["cells", "CELL", 172, 177], ["C-type lectins", "PROTEIN", 6, 20], ["macrophages", "CELL_TYPE", 107, 118], ["antigen-presenting cells", "CELL_TYPE", 153, 177], ["C-type lectins", "TREATMENT", 6, 20], ["cell entry", "TEST", 55, 65]]], ["EBOV sGP exhibited the ability to diminish the capacity of THP-1 M1 macrophages to migrate in response to MCP-1 (Fig. 5A) .", [["THP-1 M1 macrophages", "ANATOMY", 59, 79], ["EBOV", "ORGANISM", 0, 4], ["THP-1 M1 macrophages", "CELL", 59, 79], ["MCP-1", "GENE_OR_GENE_PRODUCT", 106, 111], ["EBOV sGP", "PROTEIN", 0, 8], ["THP-1 M1 macrophages", "CELL_LINE", 59, 79], ["MCP", "PROTEIN", 106, 109], ["EBOV", "SPECIES", 0, 4], ["EBOV sGP", "TEST", 0, 8], ["MCP", "TEST", 106, 109]]], ["Interestingly, the integrin CD11b is widely accepted as a marker of macrophage phenotypes; it has also been shown to be necessary for chemotactic ability of activated macrophages [41, 42] .", [["macrophage", "ANATOMY", 68, 78], ["macrophages", "ANATOMY", 167, 178], ["integrin CD11b", "GENE_OR_GENE_PRODUCT", 19, 33], ["macrophage", "CELL", 68, 78], ["macrophages", "CELL", 167, 178], ["integrin CD11b", "PROTEIN", 19, 33], ["activated macrophages", "CELL_TYPE", 157, 178], ["the integrin CD11b", "TEST", 15, 33], ["macrophage phenotypes", "PROBLEM", 68, 89], ["activated macrophages", "PROBLEM", 157, 178], ["integrin CD11b", "OBSERVATION", 19, 33], ["widely", "OBSERVATION_MODIFIER", 37, 43], ["macrophage phenotypes", "OBSERVATION", 68, 89]]], ["The assessment of CD11b in activated macrophages incubated with sGP demonstrated reduced expression of the cellular marker as compared to controls (Fig. 5B ).ConclusionIn conclusion, our results suggest a novel mechanism whereby EBOV sGP shuts down anti-viral immunity mediated by activated macrophages to create a pool of susceptible cells primed for infection.", [["macrophages", "ANATOMY", 37, 48], ["cellular", "ANATOMY", 107, 115], ["macrophages", "ANATOMY", 291, 302], ["cells", "ANATOMY", 335, 340], ["infection", "DISEASE", 352, 361], ["CD11b", "GENE_OR_GENE_PRODUCT", 18, 23], ["macrophages", "CELL", 37, 48], ["sGP", "GENE_OR_GENE_PRODUCT", 64, 67], ["cellular", "CELL", 107, 115], ["EBOV", "ORGANISM", 229, 233], ["sGP", "GENE_OR_GENE_PRODUCT", 234, 237], ["macrophages", "CELL", 291, 302], ["cells", "CELL", 335, 340], ["CD11b", "PROTEIN", 18, 23], ["activated macrophages", "CELL_TYPE", 27, 48], ["sGP", "PROTEIN", 64, 67], ["EBOV sGP", "PROTEIN", 229, 237], ["activated macrophages", "CELL_TYPE", 281, 302], ["susceptible cells", "CELL_TYPE", 323, 340], ["EBOV", "SPECIES", 229, 233], ["The assessment", "TEST", 0, 14], ["the cellular marker", "TEST", 103, 122], ["a novel mechanism", "PROBLEM", 203, 220], ["EBOV sGP", "PROBLEM", 229, 237], ["anti-viral immunity", "TREATMENT", 249, 268], ["susceptible cells", "PROBLEM", 323, 340], ["infection", "PROBLEM", 352, 361], ["reduced", "OBSERVATION_MODIFIER", 81, 88], ["cellular marker", "OBSERVATION", 107, 122], ["infection", "OBSERVATION", 352, 361]]], ["Indeed, EBOV sGP inhibited pro-inflammatory cytokine production and chemotaxis while preserving the cellular ability to take up antigens.", [["cellular", "ANATOMY", 100, 108], ["sGP", "CHEMICAL", 13, 16], ["EBOV", "ORGANISM", 8, 12], ["sGP", "GENE_OR_GENE_PRODUCT", 13, 16], ["cellular", "CELL", 100, 108], ["EBOV sGP", "PROTEIN", 8, 16], ["pro-inflammatory cytokine", "PROTEIN", 27, 52], ["EBOV", "SPECIES", 8, 12], ["EBOV sGP", "PROBLEM", 8, 16], ["pro-inflammatory cytokine production", "PROBLEM", 27, 63], ["chemotaxis", "PROBLEM", 68, 78], ["pro-inflammatory cytokine production", "OBSERVATION", 27, 63]]], ["Therefore, sGP may play a major role in EBOV pathogenesis in two ways.", [["sGP", "CHEMICAL", 11, 14], ["sGP", "GENE_OR_GENE_PRODUCT", 11, 14], ["EBOV", "ORGANISM", 40, 44], ["sGP", "PROTEIN", 11, 14], ["EBOV", "SPECIES", 40, 44], ["EBOV", "OBSERVATION", 40, 44]]], ["First, by impairing activated macrophages, the virus can rapidly produce progeny virion and spread to other parts of the body.", [["macrophages", "ANATOMY", 30, 41], ["body", "ANATOMY", 121, 125], ["macrophages", "CELL", 30, 41], ["body", "ORGANISM_SUBDIVISION", 121, 125], ["activated macrophages", "CELL_TYPE", 20, 41], ["impairing activated macrophages", "PROBLEM", 10, 41], ["the virus", "PROBLEM", 43, 52], ["progeny virion", "PROBLEM", 73, 87], ["activated macrophages", "OBSERVATION", 20, 41], ["progeny virion", "OBSERVATION", 73, 87], ["body", "ANATOMY", 121, 125]]], ["Second, the paralyzed macrophages serve as a pool of susceptible host cells for infection.", [["macrophages", "ANATOMY", 22, 33], ["cells", "ANATOMY", 70, 75], ["infection", "DISEASE", 80, 89], ["macrophages", "CELL", 22, 33], ["host cells", "CELL", 65, 75], ["paralyzed macrophages", "CELL_TYPE", 12, 33], ["susceptible host cells", "CELL_TYPE", 53, 75], ["the paralyzed macrophages", "TREATMENT", 8, 33], ["susceptible host cells", "PROBLEM", 53, 75], ["infection", "PROBLEM", 80, 89], ["paralyzed", "ANATOMY", 12, 21], ["macrophages", "OBSERVATION", 22, 33], ["host cells", "OBSERVATION", 65, 75], ["infection", "OBSERVATION", 80, 89]]], ["This information may be an important consideration when devising therapies given the unusually high replication rate of the virus and copious production of soluble viral proteins such as sGP, which may diminish efficacy of host immunity.", [["sGP", "GENE_OR_GENE_PRODUCT", 187, 190], ["soluble viral proteins", "PROTEIN", 156, 178], ["sGP", "PROTEIN", 187, 190], ["devising therapies", "TREATMENT", 56, 74], ["the virus", "PROBLEM", 120, 129], ["copious production of soluble viral proteins", "PROBLEM", 134, 178], ["sGP", "PROBLEM", 187, 190]]]], "60bb4454a34fb7642d6805ff6261abc91809a135": [["BackgroundSanitation is defined by the World Health Organization (WHO) as: \"Sanitation generally refers to the provision of facilities and services for the safe disposal of human urine and faeces.", [["urine", "ANATOMY", 179, 184], ["faeces", "ANATOMY", 189, 195], ["human", "ORGANISM", 173, 178], ["urine", "ORGANISM_SUBSTANCE", 179, 184], ["faeces", "ORGANISM_SUBSTANCE", 189, 195], ["human", "SPECIES", 173, 178], ["human", "SPECIES", 173, 178]]], ["Inadequate sanitation is a major cause of disease world-wide and improving sanitation is known to have a significant beneficial impact on health both in households and across communities.", [["disease", "PROBLEM", 42, 49], ["disease", "OBSERVATION", 42, 49], ["wide", "OBSERVATION_MODIFIER", 56, 60]]], ["Sanitation is in general inadequate in rural areas and in developing countries [1, 2] while regarded as safe in the developed countries in the community as well as in healthcare.", [["Sanitation", "TREATMENT", 0, 10]]], ["However, it is not sufficient to have access to water and modern drainage systems unless adequate sanitation is maintained.", [["modern drainage systems", "TREATMENT", 58, 81], ["drainage", "OBSERVATION", 65, 73]]], ["Quality assurance maintenance work is implemented in pharmaceutical and food industry in order to reduce the risk of exposure to the hazards (e.g. pathogens causing clinical manifestations) in the disposals.", [["the hazards", "PROBLEM", 129, 140], ["clinical manifestations", "PROBLEM", 165, 188]]], ["However, in the community or in healthcare, sanitation is not prioritized and often forgotten [3] , despite that wastewater disposal contains increased level of human microbes and that there are several reports implicating drains as a source of infection (Table 1) .", [["infection", "DISEASE", 245, 254], ["human", "ORGANISM", 161, 166], ["human", "SPECIES", 161, 166], ["human", "SPECIES", 161, 166], ["wastewater disposal", "TREATMENT", 113, 132], ["drains", "TREATMENT", 223, 229], ["infection", "PROBLEM", 245, 254], ["increased", "OBSERVATION_MODIFIER", 142, 151], ["drains", "OBSERVATION", 223, 229], ["infection", "OBSERVATION", 245, 254]]], ["For instance, in the community the severe acute respiratory syndrome (SARS) outbreak in 2003 at Amoy Garden was reported by WHO to likely have been caused by faulty plumbing due to lack of maintenance causing dry out traps [4] and in healthcare, Starlander and Melhus reported in 2012 of a minor outbreak of extended spectrum \u03b2-lactamase (ESBL) producing Klebsiella pneumoniae due to contaminated sink drains [5] .", [["acute respiratory syndrome", "DISEASE", 42, 68], ["SARS", "DISEASE", 70, 74], ["ESBL", "CHEMICAL", 339, 343], ["Klebsiella pneumoniae", "DISEASE", 355, 376], ["extended spectrum \u03b2-lactamase", "GENE_OR_GENE_PRODUCT", 308, 337], ["Klebsiella pneumoniae", "ORGANISM", 355, 376], ["Klebsiella pneumoniae", "SPECIES", 355, 376], ["Klebsiella pneumoniae", "SPECIES", 355, 376], ["the severe acute respiratory syndrome", "PROBLEM", 31, 68], ["faulty plumbing", "PROBLEM", 158, 173], ["dry out traps", "PROBLEM", 209, 222], ["ESBL", "PROBLEM", 339, 343], ["Klebsiella pneumoniae", "PROBLEM", 355, 376], ["contaminated sink drains", "TREATMENT", 384, 408], ["severe", "OBSERVATION_MODIFIER", 35, 41], ["acute", "OBSERVATION_MODIFIER", 42, 47], ["respiratory syndrome", "OBSERVATION", 48, 68], ["Klebsiella pneumoniae", "OBSERVATION", 355, 376]]], ["Indeed, drains are implicated as being a source of microbes causing infection both in community and healthcare [6, 7] .", [["infection", "DISEASE", 68, 77], ["drains", "TREATMENT", 8, 14], ["infection", "PROBLEM", 68, 77], ["drains", "OBSERVATION", 8, 14], ["infection", "OBSERVATION", 68, 77]]], ["Breathnach et al. further pointed out that proper design and maintenance of the wastewater system are essential to prevent infections at intensive care units (ICU) [7] .", [["infections", "DISEASE", 123, 133], ["the wastewater system", "TREATMENT", 76, 97], ["infections", "PROBLEM", 123, 133]]], ["However, its impact on infection rates has not yet been fully elucidated.BackgroundIn the current paper, different aspects supporting the role of drainage systems and sanitation to cause infections and emergence of resistance are delineated.", [["infection", "DISEASE", 23, 32], ["infections", "DISEASE", 187, 197], ["infection rates", "PROBLEM", 23, 38], ["drainage systems", "TREATMENT", 146, 162], ["sanitation", "TREATMENT", 167, 177], ["infections", "PROBLEM", 187, 197], ["infection", "OBSERVATION", 23, 32], ["infections", "OBSERVATION", 187, 197]]], ["Aspects considered are from past and recent outbreaks, from developing and developed countries, and also, the ways to prevent spread of bacteria in the working environment, at wastewater treatment plants, and food industry.", [["bacteria", "PROBLEM", 136, 144], ["outbreaks", "OBSERVATION", 44, 53], ["bacteria", "OBSERVATION", 136, 144]]], ["Presented data will hopefully contribute to a better understanding of the importance of proper sanitation and its maintenance to prevent infections.MethodsPapers were found in PubMed and Google Scholar starting 1907 using key words such as sanitation, infection, transmission, drains, sinks, outbreaks, drainage systems, sewage, wastewater treatment plants, bacteria, virus, resistance, antibiotics, biofilm, infection prevention, and health care associated infections.", [["infections", "DISEASE", 137, 147], ["infection", "DISEASE", 252, 261], ["infection", "DISEASE", 409, 418], ["infections", "DISEASE", 458, 468], ["proper sanitation", "TREATMENT", 88, 105], ["infections", "PROBLEM", 137, 147], ["infection", "PROBLEM", 252, 261], ["drains", "TREATMENT", 277, 283], ["drainage systems", "TREATMENT", 303, 319], ["sewage", "TREATMENT", 321, 327], ["wastewater treatment plants", "TREATMENT", 329, 356], ["bacteria", "PROBLEM", 358, 366], ["virus", "PROBLEM", 368, 373], ["antibiotics", "TREATMENT", 387, 398], ["biofilm", "TREATMENT", 400, 407], ["infection prevention", "TREATMENT", 409, 429], ["health care associated infections", "PROBLEM", 435, 468], ["infections", "OBSERVATION", 137, 147], ["infection", "OBSERVATION", 252, 261], ["drains", "OBSERVATION", 277, 283], ["infection", "OBSERVATION", 409, 418], ["infections", "OBSERVATION", 458, 468]]], ["The fact that contamination on surfaces, transmission of pathogens, and infections must be prevented not only in health care but also in industry and in the community led to that experiences from these disciplines were explored if useful also to health care.", [["infections", "DISEASE", 72, 82], ["contamination on surfaces", "PROBLEM", 14, 39], ["pathogens", "PROBLEM", 57, 66], ["infections", "PROBLEM", 72, 82], ["contamination", "OBSERVATION", 14, 27]]], ["Guidance documents were found at the databases of e.g. World Health Organization, Health and Safety Executive (UK), Centers for Disease Control and Prevention (CDC), Atlanta, GA and quality management systems were found by searching God Manufacturing Practice and hazard analysis critical control points (HACCP).", [["Disease Control", "TREATMENT", 128, 143]]], ["The search outcome, 71 references, is summarized in this review and describes aspects that support the finding that drainage systems if not properly installed or designed and maintained shall be considered as hazardous that may cause infections and emergence of pathogens armed with additional resistance and virulence as well as other diseases e.g. allergies against mold.Results and discussionWastewater as a source of infection Developing countriesResults and discussionIn particular developing countries and to some extent also developed countries, rural areas predominantly, sanitation is inadequate resulting in diseases such as infections [2] .", [["infections", "DISEASE", 234, 244], ["allergies", "DISEASE", 350, 359], ["infection", "DISEASE", 421, 430], ["infections", "DISEASE", 635, 645], ["drainage systems", "TREATMENT", 116, 132], ["infections", "PROBLEM", 234, 244], ["pathogens", "PROBLEM", 262, 271], ["virulence", "PROBLEM", 309, 318], ["other diseases e.g. allergies", "PROBLEM", 330, 359], ["mold", "PROBLEM", 368, 372], ["infection", "PROBLEM", 421, 430], ["diseases", "PROBLEM", 618, 626], ["infections", "PROBLEM", 635, 645], ["may cause", "UNCERTAINTY", 224, 233], ["infections", "OBSERVATION", 234, 244]]], ["It is estimated that there are over 4 billion diarrheal cases per year resulting in 2.2 million deaths [2] .", [["diarrheal", "DISEASE", 46, 55], ["deaths", "DISEASE", 96, 102]]], ["The major cause is exposure to excreta and wastewater where Vibrio cholerae and Salmonella typhi are notable causes of diarrheal diseases [25, 26] .", [["diarrheal diseases", "DISEASE", 119, 137], ["excreta", "ORGANISM_SUBSTANCE", 31, 38], ["Vibrio cholerae", "ORGANISM", 60, 75], ["Salmonella typhi", "ORGANISM", 80, 96], ["Vibrio cholerae", "SPECIES", 60, 75], ["Salmonella typhi", "SPECIES", 80, 96], ["Vibrio cholerae", "SPECIES", 60, 75], ["Salmonella typhi", "SPECIES", 80, 96], ["Vibrio cholerae", "PROBLEM", 60, 75], ["Salmonella typhi", "PROBLEM", 80, 96], ["diarrheal diseases", "PROBLEM", 119, 137], ["diarrheal diseases", "OBSERVATION", 119, 137]]], ["Interventions focusing on sanitation has shown to reduce the percentage in diarrheal morbidity with 36% [27] .", [["diarrheal", "DISEASE", 75, 84], ["Interventions", "TREATMENT", 0, 13], ["sanitation", "TREATMENT", 26, 36], ["diarrheal morbidity", "PROBLEM", 75, 94]]], ["In numbers, the return of investment is huge.", [["huge", "OBSERVATION_MODIFIER", 40, 44]]], ["Every US$1 invested on sanitation brings a $5.50 return by keeping people healthy and productive.", [["people", "ORGANISM", 67, 73], ["people", "SPECIES", 67, 73]]], ["In comparison, poor sanitation, costs countries between 0.5 and 7.2% of their gross domestic product (GDP) [28] .", [["GDP", "SIMPLE_CHEMICAL", 102, 105], ["costs countries", "TEST", 32, 47]]], ["The potential savings and need for better quality in life has resulted in e.g. the UN-Water wastewater task force involving different stakeholders working to improve sanitation [29] .Working environment at wastewater treatment plantsIn excreta disposal there is a high load of microorganisms such as viruses, bacteria, fungi, and protozoa that could cause infections [30, 31] .", [["infections", "DISEASE", 356, 366], ["The potential savings", "TREATMENT", 0, 21], ["treatment plants", "TREATMENT", 217, 233], ["a high load of microorganisms", "PROBLEM", 262, 291], ["viruses", "PROBLEM", 300, 307], ["bacteria", "PROBLEM", 309, 317], ["fungi", "PROBLEM", 319, 324], ["protozoa", "PROBLEM", 330, 338], ["infections", "PROBLEM", 356, 366], ["excreta disposal", "OBSERVATION", 236, 252], ["high load", "OBSERVATION_MODIFIER", 264, 273]]], ["Based on the study of Korzeniewska and Harnisz, the load of enteric bacteria is probably underestimated due to insufficient detection methods [32] .", [["the study", "TEST", 9, 18], ["Korzeniewska", "TREATMENT", 22, 34], ["Harnisz", "TREATMENT", 39, 46], ["enteric bacteria", "PROBLEM", 60, 76], ["enteric bacteria", "OBSERVATION", 60, 76]]], ["Furthermore, it has been shown that both air and water are contaminated by bacteria in the sewage at Wastewater Treatment Plants (WWTP) jeopardizing the health of both plant workers and surrounding population [32] .", [["bacteria", "PROBLEM", 75, 83], ["both", "OBSERVATION_MODIFIER", 36, 40], ["air", "OBSERVATION", 41, 44], ["bacteria", "OBSERVATION_MODIFIER", 75, 83]]], ["Clearly human excreta must be managed in a safe way to minimize the risk of exposure to microbes of clinical significance.", [["human", "ORGANISM", 8, 13], ["excreta", "ORGANISM_SUBSTANCE", 14, 21], ["human", "SPECIES", 8, 13], ["human", "SPECIES", 8, 13]]], ["This condition is further realized in regulations and guidance documents by e.g. the Centers for Disease Control and Prevention (CDC), Health Safety Executive (HSE) in UK, and Environmental Protection Agencies (EPA) to assure safe working environment for workers exposed to excreta disposal [33] [34] [35] .", [["Disease Control", "TREATMENT", 97, 112]]], ["Sadly, despite abolition of manual scavenging in India, about 1.2 million scavengers work as sanitary workers and face numerous health hazards among them infections [36] .Food IndustryIn food industry, food safety is essential and regulated.Food IndustryRegulations have been spawn from risk impact assessments (RIA) and cost-benefit analysis [37] .", [["infections", "DISEASE", 154, 164], ["impact assessments", "TEST", 292, 310], ["RIA", "TEST", 312, 315], ["cost-benefit analysis", "TEST", 321, 342]]], ["The production is run applying two different systems, hazard analysis critical control points (HACCP) and Good Manufacturing Practice (GMP) intended to assure the safety of food.", [["GMP", "CHEMICAL", 135, 138], ["hazard analysis", "TEST", 54, 69]]], ["A major focus is on the reduction of microbes.", [["major", "OBSERVATION_MODIFIER", 2, 7], ["focus", "OBSERVATION", 8, 13], ["reduction", "OBSERVATION_MODIFIER", 24, 33], ["microbes", "OBSERVATION", 37, 45]]], ["Noteworthy, is the architectural demands of GMP.", [["GMP", "CHEMICAL", 44, 47], ["GMP", "CHEMICAL", 44, 47], ["GMP", "SIMPLE_CHEMICAL", 44, 47]]], ["GMP focus on e.g. that the facilities must be built and the work must be done so that the risk of contamination is minimized and the quality of the product can be assured.", [["GMP", "CHEMICAL", 0, 3], ["GMP", "CHEMICAL", 0, 3], ["contamination", "PROBLEM", 98, 111], ["contamination", "OBSERVATION", 98, 111]]], ["In practice, sinks must be placed strategically to ease the drainage of water during cleaning, and in clean rooms or sterile rooms with the highest clean air requirements, sinks or floor drains are not allowed.", [["the drainage of water during cleaning", "TREATMENT", 56, 93], ["sterile rooms", "TREATMENT", 117, 130], ["floor drains", "TREATMENT", 181, 193], ["air", "OBSERVATION", 154, 157]]], ["Pipes must be made of certain materials and their dimensions must differ from those drainage design requirements in ordinary buildings.", [["Pipes", "TREATMENT", 0, 5], ["those drainage", "TREATMENT", 78, 92]]], ["Floor drains should be kept to a minimum and must be free from debris, giving off no offensive odors.", [["Floor drains", "TREATMENT", 0, 12], ["debris", "PROBLEM", 63, 69], ["offensive odors", "PROBLEM", 85, 100], ["drains", "OBSERVATION", 6, 12], ["debris", "OBSERVATION", 63, 69]]], ["In addition, all building drains must be cleaned and sanitized on a regular basis.", [["all building drains", "TREATMENT", 13, 32], ["drains", "OBSERVATION", 26, 32]]], ["Their design must prevent the possibility of backflow.", [["must prevent the possibility", "UNCERTAINTY", 13, 41], ["backflow", "OBSERVATION", 45, 53]]], ["Open channels should be easy to clean and disinfect.", [["Open channels", "TREATMENT", 0, 13]]], ["These drains must always be filled with water as a physical barrier and their covers must remain intact.", [["These drains", "TREATMENT", 0, 12], ["a physical barrier", "TREATMENT", 49, 67], ["drains", "OBSERVATION", 6, 12], ["filled", "OBSERVATION", 28, 34], ["intact", "OBSERVATION", 97, 103]]], ["Furthermore, it is essential and mandatory to continuously monitor and include environmental sampling.", [["environmental sampling", "TEST", 79, 101]]], ["If this principle holds, then the risk of cross-contamination from the building's drainage systems to other surfaces and/or individuals at hospitals is indeed high.", [["cross-contamination", "PROBLEM", 42, 61], ["the building's drainage systems", "TREATMENT", 67, 98]]], ["However, GMP systems are not applied in healthcare.", [["GMP", "CHEMICAL", 9, 12], ["GMP", "CHEMICAL", 9, 12], ["GMP", "SIMPLE_CHEMICAL", 9, 12], ["GMP systems", "TREATMENT", 9, 20]]], ["Although, HACCP has been evaluated for its applicability to reduce infections but only a handful studies have been found [38] .", [["infections", "DISEASE", 67, 77], ["infections", "PROBLEM", 67, 77], ["a handful studies", "TEST", 87, 104], ["infections", "OBSERVATION", 67, 77]]], ["Thus, practices or maintenance programs considering the sanitation are pretty much up to each hospital.Wastewater as a source of emerging novel pathogensSewage sludge can end up on landfills but this is problematic since the leakages from the landfill may reach the groundwater [39] .", [["maintenance programs", "TREATMENT", 19, 39], ["emerging novel pathogens", "PROBLEM", 129, 153], ["Sewage sludge", "PROBLEM", 153, 166], ["landfills", "TREATMENT", 181, 190], ["the leakages", "PROBLEM", 221, 233], ["the landfill", "TREATMENT", 239, 251], ["sludge", "OBSERVATION", 160, 166], ["leakages", "OBSERVATION", 225, 233]]], ["WWTP then offer better management of the sewage since it has to go through different stabilization treatments in order to produce safe sewage sludge [40] .", [["WWTP", "TREATMENT", 0, 4], ["different stabilization treatments", "TREATMENT", 75, 109], ["safe sewage sludge", "PROBLEM", 130, 148], ["sludge", "OBSERVATION", 142, 148]]], ["However, WWTPs are focusing mainly on stabilizing organic residues and heavy metals while microbes are neglected.", [["stabilizing organic residues", "PROBLEM", 38, 66], ["WWTPs", "OBSERVATION", 9, 14], ["organic residues", "OBSERVATION", 50, 66], ["heavy", "OBSERVATION_MODIFIER", 71, 76], ["metals", "OBSERVATION_MODIFIER", 77, 83]]], ["Sewage sludge commonly contains high load of microbes that are able to infect both humans and animals but currently ways of accurate detection and treatment are lacking [32, 41] .", [["humans", "ORGANISM", 83, 89], ["humans", "SPECIES", 83, 89], ["humans", "SPECIES", 83, 89], ["Sewage sludge", "PROBLEM", 0, 13], ["high load of microbes", "PROBLEM", 32, 53], ["treatment", "TREATMENT", 147, 156], ["sludge", "OBSERVATION", 7, 13], ["high load", "OBSERVATION", 32, 41], ["microbes", "OBSERVATION", 45, 53]]], ["Detection with conventional plate count technique is most likely not working since bacteria can exist in viable but non-culturable stage and hence the load will be underestimated [42] .", [["conventional plate count technique", "TEST", 15, 49], ["bacteria", "PROBLEM", 83, 91], ["most likely not", "UNCERTAINTY", 53, 68]]], ["These reservoirs of microbes could then go undetected and be spread to the environment and infect crops, animals, and humans [43] .", [["humans", "ORGANISM", 118, 124], ["humans", "SPECIES", 118, 124], ["humans", "SPECIES", 118, 124]]], ["This mode of genetic transfer is most likely to have occurred in the case of the rise of the German isolate of Escherichia coli (E. coli) that was found to have two different mechanisms of virulence [47] .", [["Escherichia coli", "ORGANISM", 111, 127], ["E. coli", "ORGANISM", 129, 136], ["Escherichia coli", "SPECIES", 111, 127], ["E. coli", "SPECIES", 129, 136], ["Escherichia coli", "SPECIES", 111, 127], ["E. coli", "SPECIES", 129, 136], ["Escherichia coli", "PROBLEM", 111, 127], ["E. coli", "PROBLEM", 129, 136], ["most likely", "UNCERTAINTY", 33, 44], ["Escherichia coli", "OBSERVATION", 111, 127]]], ["This isolate belonged to enteroaggregative E. coli (EAEC) carrying virulence factors on a plasmid (a mobile genetic material) and it obtained the shiga toxin gene carried on a phage (a mobile genetic element) from a shiga toxin producing E. coli (STEC).", [["plasmid", "ANATOMY", 90, 97], ["enteroaggregative E. coli", "ORGANISM", 25, 50], ["EAEC", "CELL", 52, 56], ["shiga toxin", "GENE_OR_GENE_PRODUCT", 146, 157], ["shiga toxin producing", "ORGANISM", 216, 237], ["E. coli", "ORGANISM", 238, 245], ["STEC", "CELL", 247, 251], ["virulence factors", "PROTEIN", 67, 84], ["plasmid", "DNA", 90, 97], ["shiga toxin gene", "DNA", 146, 162], ["mobile genetic element", "DNA", 185, 207], ["E. coli", "SPECIES", 43, 50], ["E. coli", "SPECIES", 238, 245], ["E. coli", "SPECIES", 43, 50], ["E. coli", "SPECIES", 238, 245], ["STEC", "SPECIES", 247, 251], ["This isolate", "TREATMENT", 0, 12], ["enteroaggregative E. coli", "PROBLEM", 25, 50], ["EAEC", "PROBLEM", 52, 56], ["virulence factors", "PROBLEM", 67, 84], ["a plasmid", "TREATMENT", 88, 97], ["the shiga toxin gene", "PROBLEM", 142, 162], ["a phage", "TREATMENT", 174, 181], ["a shiga toxin", "TEST", 214, 227], ["E. coli", "PROBLEM", 238, 245], ["E. coli", "OBSERVATION_MODIFIER", 43, 50]]], ["It caused unpredictable novel clinical manifestations in a severe outbreak in Germany 2011 with nearly 7,000 reported cases and 18 deaths due to gastroenteritis and 35 deaths due to hemolytic uremic syndrome [47] .", [["deaths", "DISEASE", 131, 137], ["gastroenteritis", "DISEASE", 145, 160], ["deaths", "DISEASE", 168, 174], ["hemolytic uremic syndrome", "DISEASE", 182, 207], ["unpredictable novel clinical manifestations", "PROBLEM", 10, 53], ["gastroenteritis", "PROBLEM", 145, 160], ["hemolytic uremic syndrome", "PROBLEM", 182, 207], ["unpredictable", "OBSERVATION_MODIFIER", 10, 23], ["severe", "OBSERVATION_MODIFIER", 59, 65], ["outbreak", "OBSERVATION_MODIFIER", 66, 74], ["gastroenteritis", "OBSERVATION", 145, 160], ["hemolytic", "OBSERVATION_MODIFIER", 182, 191]]], ["The ease by that bacteria can share genetic information on mobile elements and the knowledge that genes coding for resistance is coded by mobile genetic elements probably will present further unwanted surprises [48] .", [["mobile elements", "DNA", 59, 74]]], ["The fear of creation of multi-resistant bacteria is enforced by the fact that antibiotics are discharged from manufacturers and hospitals and will stress the bacteria in the sewage or environment to develop and disseminate resistance [46, 49, 50] .", [["multi-resistant bacteria", "PROBLEM", 24, 48], ["antibiotics", "TREATMENT", 78, 89], ["stress the bacteria", "PROBLEM", 147, 166], ["multi-resistant", "OBSERVATION_MODIFIER", 24, 39], ["bacteria", "OBSERVATION", 40, 48]]], ["Evidence was presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy that hospital sewage is breeding ground for genetic exchange of resistance between bacteria in the environment and clinical isolates [51] .", [["Antimicrobial Agents", "TREATMENT", 62, 82], ["Chemotherapy", "TREATMENT", 87, 99], ["hospital sewage", "TREATMENT", 105, 120], ["resistance between bacteria", "PROBLEM", 164, 191]]], ["Furthermore, it was recently proven that resistance cassettes against five classes of antibiotics (\u03b2-lactams, aminoglycosides, amphenicols, sulfonamides, and tetracyclines) had a perfect genetic match in a clinical relevant bacteria and an environmental bacteria [52] .", [["\u03b2-lactams", "CHEMICAL", 99, 108], ["aminoglycosides", "CHEMICAL", 110, 125], ["amphenicols", "CHEMICAL", 127, 138], ["sulfonamides", "CHEMICAL", 140, 152], ["tetracyclines", "CHEMICAL", 158, 171], ["\u03b2-lactams", "CHEMICAL", 99, 108], ["aminoglycosides", "CHEMICAL", 110, 125], ["amphenicols", "CHEMICAL", 127, 138], ["sulfonamides", "CHEMICAL", 140, 152], ["tetracyclines", "CHEMICAL", 158, 171], ["\u03b2-lactams", "SIMPLE_CHEMICAL", 99, 108], ["aminoglycosides", "SIMPLE_CHEMICAL", 110, 125], ["amphenicols", "SIMPLE_CHEMICAL", 127, 138], ["sulfonamides", "SIMPLE_CHEMICAL", 140, 152], ["tetracyclines", "SIMPLE_CHEMICAL", 158, 171], ["resistance cassettes", "TREATMENT", 41, 61], ["antibiotics", "TREATMENT", 86, 97], ["\u03b2-lactams", "TREATMENT", 99, 108], ["aminoglycosides", "TREATMENT", 110, 125], ["amphenicols", "TREATMENT", 127, 138], ["sulfonamides", "TREATMENT", 140, 152], ["tetracyclines", "TREATMENT", 158, 171], ["a clinical relevant bacteria", "PROBLEM", 204, 232], ["an environmental bacteria", "PROBLEM", 237, 262]]], ["This study explained the mechanism of lateral spread but also how antibiotic resistance disseminate and can have clinical implications.", [["This study", "TEST", 0, 10], ["lateral spread", "PROBLEM", 38, 52]]], ["In the era of increased antibiotic resistance and less available effective therapies, it is increasingly difficult to treat infections.", [["infections", "DISEASE", 124, 134], ["increased antibiotic resistance", "TREATMENT", 14, 45], ["effective therapies", "TREATMENT", 65, 84], ["infections", "PROBLEM", 124, 134], ["increased", "OBSERVATION_MODIFIER", 14, 23], ["antibiotic resistance", "OBSERVATION", 24, 45]]], ["Still with effective antibiotics, infections remain a primary cause of morbidity and mortality in the developed world [53] .", [["infections", "DISEASE", 34, 44], ["effective antibiotics", "TREATMENT", 11, 32], ["infections", "PROBLEM", 34, 44], ["morbidity", "PROBLEM", 71, 80], ["effective", "OBSERVATION_MODIFIER", 11, 20], ["antibiotics", "OBSERVATION", 21, 32], ["morbidity", "OBSERVATION", 71, 80]]], ["In relation to this dark prediction, the WHO has stated that: \"Antibiotic resistance is one of the greatest threats to global health security extending far beyond the human health sector\".", [["human", "ORGANISM", 167, 172], ["human", "SPECIES", 167, 172], ["human", "SPECIES", 167, 172], ["Antibiotic resistance", "TREATMENT", 63, 84]]], ["The future looks dark also in respect to the possibility of finding the substance that will kill and not provoke resistance [54] .", [["dark", "PROBLEM", 17, 21]]], ["Therefore the return of investment to develop novel antibiotics is judged not worth the effort, hence few drugs are in the pipeline [54, 55] .", [["novel antibiotics", "TREATMENT", 46, 63]]], ["Instead, focus has been directed to preventive measurements.", [["preventive measurements", "TEST", 36, 59]]], ["Infection prevention programs have been enforced by the World Health Organization (WHO), European Commission and the US, and national governments [56] [57] [58] [59] .Drains as source of infectionThe clinical impact of drains as reservoirs of microorganisms has not yet been fully explored although it is widely established that human excretions such as faeces, urine, oral-nasal aerosols, and skin flakes will carry microbial burden consisting of bacteria and/or virus.", [["faeces", "ANATOMY", 354, 360], ["urine", "ANATOMY", 362, 367], ["oral", "ANATOMY", 369, 373], ["nasal", "ANATOMY", 374, 379], ["skin flakes", "ANATOMY", 394, 405], ["infection", "DISEASE", 187, 196], ["human", "ORGANISM", 329, 334], ["faeces", "ORGANISM_SUBSTANCE", 354, 360], ["urine", "ORGANISM_SUBSTANCE", 362, 367], ["oral", "ORGANISM_SUBDIVISION", 369, 373], ["skin", "ORGAN", 394, 398], ["human", "SPECIES", 329, 334], ["human", "SPECIES", 329, 334], ["Infection prevention programs", "TREATMENT", 0, 29], ["Drains", "TREATMENT", 167, 173], ["infection", "PROBLEM", 187, 196], ["drains", "TREATMENT", 219, 225], ["microorganisms", "PROBLEM", 243, 257], ["human excretions", "TEST", 329, 345], ["faeces, urine", "TEST", 354, 367], ["oral-nasal aerosols", "TREATMENT", 369, 388], ["skin flakes", "PROBLEM", 394, 405], ["microbial burden", "PROBLEM", 417, 433], ["bacteria", "PROBLEM", 448, 456], ["virus", "PROBLEM", 464, 469], ["infection", "OBSERVATION", 187, 196], ["drains", "OBSERVATION", 219, 225], ["nasal", "ANATOMY", 374, 379], ["skin", "ANATOMY", 394, 398], ["bacteria", "OBSERVATION", 448, 456]]], ["For instance, there are 120 different viruses in human faeces [43] .", [["human", "ORGANISM", 49, 54], ["human", "SPECIES", 49, 54], ["human", "SPECIES", 49, 54], ["120 different", "OBSERVATION_MODIFIER", 24, 37], ["viruses", "OBSERVATION", 38, 45]]], ["It is also reported that patient flora can be detected in sinks and building drains [10, 12, 60] .", [["patient", "ORGANISM", 25, 32], ["patient", "SPECIES", 25, 32], ["building drains", "TREATMENT", 68, 83]]], ["In a new longstay hospital, it was discovered that identical strains were found in the sinks as well as in the admitted patients [60] .", [["patients", "ORGANISM", 120, 128], ["patients", "SPECIES", 120, 128], ["identical strains", "PROBLEM", 51, 68], ["new", "OBSERVATION_MODIFIER", 5, 8]]], ["The major correlating strains were pathogens such as the Escherichia coli, Klebsiella, Pseudomonas and Acinetobacter species, all being gram-negative bacteria, with higher correlation to strains isolated from the throats and intestines of patients.", [["throats", "ANATOMY", 213, 220], ["intestines", "ANATOMY", 225, 235], ["Escherichia coli", "ORGANISM", 57, 73], ["Klebsiella, Pseudomonas", "ORGANISM", 75, 98], ["Acinetobacter species", "ORGANISM", 103, 124], ["throats", "ORGANISM_SUBDIVISION", 213, 220], ["intestines", "ORGAN", 225, 235], ["patients", "ORGANISM", 239, 247], ["Escherichia coli", "SPECIES", 57, 73], ["patients", "SPECIES", 239, 247], ["Escherichia coli", "SPECIES", 57, 73], ["pathogens", "PROBLEM", 35, 44], ["the Escherichia coli", "TEST", 53, 73], ["Klebsiella", "PROBLEM", 75, 85], ["Pseudomonas", "PROBLEM", 87, 98], ["Acinetobacter species", "PROBLEM", 103, 124], ["gram", "TEST", 136, 140], ["bacteria", "PROBLEM", 150, 158], ["strains", "PROBLEM", 187, 194], ["Escherichia coli", "OBSERVATION", 57, 73], ["Klebsiella", "OBSERVATION_MODIFIER", 75, 85], ["Pseudomonas", "OBSERVATION_MODIFIER", 87, 98], ["Acinetobacter species", "OBSERVATION", 103, 124], ["throats", "ANATOMY", 213, 220], ["intestines", "ANATOMY", 225, 235]]], ["Actually, the major reservoir of multi-drug resistant Gram-negative bacilli is the gut of man and animals.", [["gut", "ANATOMY", 83, 86], ["Gram", "GENE_OR_GENE_PRODUCT", 54, 58], ["gut", "ORGANISM_SUBDIVISION", 83, 86], ["man", "ORGANISM", 90, 93], ["man", "SPECIES", 90, 93], ["major", "OBSERVATION_MODIFIER", 14, 19], ["reservoir", "OBSERVATION_MODIFIER", 20, 29], ["negative bacilli", "OBSERVATION", 59, 75]]], ["At hospitals, discharge of antibiotics are also high [49] .", [["antibiotics", "TREATMENT", 27, 38]]], ["Clearly, drains are reservoirs for microbes and antibiotic residues.", [["drains", "TREATMENT", 9, 15], ["reservoirs", "TREATMENT", 20, 30], ["antibiotic residues", "TREATMENT", 48, 67], ["drains", "OBSERVATION", 9, 15]]], ["It is also clear that microbes in drains and pipes adheres to the surfaces of drains and draining pipes as microbial biofilms, creating a complex ecosystem of different microbes that are fed by organic and inorganic matters [61] .", [["biofilms", "ANATOMY", 117, 125], ["microbes in drains", "TREATMENT", 22, 40], ["pipes", "TREATMENT", 45, 50], ["the surfaces of drains", "TREATMENT", 62, 84], ["draining pipes", "TREATMENT", 89, 103], ["microbial biofilms", "TREATMENT", 107, 125], ["clear", "OBSERVATION_MODIFIER", 11, 16], ["microbes", "OBSERVATION", 22, 30], ["drains", "OBSERVATION", 34, 40], ["surfaces", "OBSERVATION_MODIFIER", 66, 74], ["drains", "OBSERVATION", 78, 84], ["draining pipes", "OBSERVATION", 89, 103], ["complex", "OBSERVATION_MODIFIER", 138, 145], ["ecosystem", "OBSERVATION_MODIFIER", 146, 155]]], ["Hota et al. elegantly showed the presence of Pseudomonas aeruginosa (P. aeruginosa) biofilm in drainage systems and their role in the propagation of an outbreak [61] .", [["biofilm", "ANATOMY", 84, 91], ["Pseudomonas aeruginosa", "ORGANISM", 45, 67], ["P. aeruginosa", "ORGANISM", 69, 82], ["Pseudomonas aeruginosa", "SPECIES", 45, 67], ["P. aeruginosa", "SPECIES", 69, 82], ["Pseudomonas aeruginosa", "SPECIES", 45, 67], ["P. aeruginosa", "SPECIES", 69, 82], ["Pseudomonas aeruginosa", "PROBLEM", 45, 67], ["P. aeruginosa", "PROBLEM", 69, 82], ["biofilm", "PROBLEM", 84, 91], ["drainage systems", "TREATMENT", 95, 111], ["Pseudomonas", "OBSERVATION", 45, 56]]], ["It is also known that bacteria such as S. aureus promote the transfer of antibiotic resistance to other bacteria when present in biofilm [62] .", [["S. aureus", "ORGANISM", 39, 48], ["S. aureus", "SPECIES", 39, 48], ["S. aureus", "SPECIES", 39, 48], ["bacteria", "PROBLEM", 22, 30], ["S. aureus", "PROBLEM", 39, 48], ["antibiotic resistance", "TREATMENT", 73, 94], ["other bacteria", "PROBLEM", 98, 112], ["bacteria", "OBSERVATION", 22, 30], ["aureus", "OBSERVATION", 42, 48]]], ["Certainly, drains seem to act as cradles to the emergence of bacteria armed with abilities to resist multiple antibiotics.", [["drains", "TREATMENT", 11, 17], ["bacteria", "PROBLEM", 61, 69], ["multiple antibiotics", "TREATMENT", 101, 121], ["drains", "OBSERVATION", 11, 17]]], ["The development of resistance is probably enhanced at hospitals due to that more bacteria and more antibiotics are flushed down the drains due to the very nature of hospitals constantly caring for numerous different patients that are ill and treated with antibiotics.", [["patients", "ORGANISM", 216, 224], ["patients", "SPECIES", 216, 224], ["resistance", "PROBLEM", 19, 29], ["more bacteria", "PROBLEM", 76, 89], ["antibiotics", "TREATMENT", 99, 110], ["the drains", "TREATMENT", 128, 138], ["antibiotics", "TREATMENT", 255, 266], ["resistance", "OBSERVATION", 19, 29], ["probably", "UNCERTAINTY", 33, 41], ["enhanced", "OBSERVATION_MODIFIER", 42, 50], ["bacteria", "OBSERVATION", 81, 89], ["drains", "OBSERVATION", 132, 138]]], ["Thus, biofilm in building drains, not properly maintained, have the potential of spreading even more resistant bacteria.", [["biofilm", "ANATOMY", 6, 13], ["biofilm in building drains", "TREATMENT", 6, 32], ["spreading even more resistant bacteria", "PROBLEM", 81, 119], ["biofilm", "OBSERVATION_MODIFIER", 6, 13], ["drains", "OBSERVATION", 26, 32]]], ["This was indicated in the extended non-frequent outbreak of Carbapenem resistant Klebsiella pneumonia (KPC) at an ICU [16] .", [["Carbapenem", "CHEMICAL", 60, 70], ["Klebsiella pneumonia", "DISEASE", 81, 101], ["Klebsiella pneumonia", "SPECIES", 81, 101], ["Carbapenem resistant Klebsiella pneumonia", "PROBLEM", 60, 101], ["Klebsiella", "OBSERVATION_MODIFIER", 81, 91], ["pneumonia", "OBSERVATION", 92, 101]]], ["The source of transmission was found to be drains that was detected by molecular profiling to be the only source to harbor KPC, persistently.", [["KPC", "GENE_OR_GENE_PRODUCT", 123, 126], ["drains", "TREATMENT", 43, 49], ["drains", "OBSERVATION", 43, 49]]], ["Outbreak with P. aeruginosa, revealed that patients were not colonized on admittance, but acquired a multi-resistant P. aeruginosa during hospitalization [17] .", [["P. aeruginosa", "DISEASE", 117, 130], ["P. aeruginosa", "ORGANISM", 14, 27], ["patients", "ORGANISM", 43, 51], ["P. aeruginosa", "ORGANISM", 117, 130], ["P. aeruginosa", "SPECIES", 14, 27], ["patients", "SPECIES", 43, 51], ["P. aeruginosa", "SPECIES", 117, 130], ["P. aeruginosa", "SPECIES", 14, 27], ["P. aeruginosa", "SPECIES", 117, 130], ["P. aeruginosa", "PROBLEM", 14, 27], ["a multi-resistant P. aeruginosa", "PROBLEM", 99, 130]]], ["By running antibiogram and molecular profiling, drains were found to be the only source.", [["running antibiogram", "TEST", 3, 22], ["molecular profiling", "TEST", 27, 46], ["drains", "TREATMENT", 48, 54], ["drains", "OBSERVATION", 48, 54]]], ["Therefore these reservoirs are crucial to control.", [["these reservoirs", "TREATMENT", 10, 26], ["reservoirs", "OBSERVATION", 16, 26]]], ["Maintenance of proper sanitation must then be guarded where seepage and backflow never should occur.", [["proper sanitation", "TREATMENT", 15, 32]]], ["The difficulty of eradicating antibiotic resistant bacteria from sink drains at an intensive care unit (ICU) was recently reported [9] .", [["eradicating antibiotic resistant bacteria", "PROBLEM", 18, 59], ["sink drains", "TREATMENT", 65, 76], ["sink drains", "OBSERVATION", 65, 76]]], ["Several different cleaning methods were tried including hypochlorite, mechanical, and pressurized steam at a temperature of 170\u00b0C. However, none of these methods worked.", [["hypochlorite", "CHEMICAL", 56, 68], ["hypochlorite", "CHEMICAL", 56, 68], ["hypochlorite", "SIMPLE_CHEMICAL", 56, 68], ["Several different cleaning methods", "TREATMENT", 0, 34], ["hypochlorite", "TREATMENT", 56, 68], ["mechanical", "TREATMENT", 70, 80], ["pressurized steam", "TREATMENT", 86, 103], ["different", "OBSERVATION_MODIFIER", 8, 17], ["cleaning", "OBSERVATION", 18, 26]]], ["This highlights the need for physical barriers such as water seals for drains that prevent the exposure to microbes in the drains and a way to control the integrity of the barrier.The impact of malfunctioning plumbingThe malfunctioning plumbing was recognized as a problem already during the cholera outbreak in London by J. Snow in the 19 th century [63] .", [["cholera", "DISEASE", 292, 299], ["barrier", "TISSUE", 172, 179], ["physical barriers", "TREATMENT", 29, 46], ["water seals", "TREATMENT", 55, 66], ["drains", "TREATMENT", 71, 77], ["the drains", "TREATMENT", 119, 129], ["malfunctioning plumbing", "TREATMENT", 194, 217], ["The malfunctioning plumbing", "PROBLEM", 217, 244], ["drains", "OBSERVATION", 123, 129], ["malfunctioning plumbing", "OBSERVATION", 194, 217], ["malfunctioning", "OBSERVATION_MODIFIER", 221, 235], ["plumbing", "OBSERVATION", 236, 244]]], ["Later in 1907, it was shown in a sham study that malfunctioning plumbing created aerosols with microorganisms that could be transmitted to humans both indirectly through environmental surfaces and directly through aerosols and cause disease [64] .", [["humans", "ORGANISM", 139, 145], ["humans", "SPECIES", 139, 145], ["humans", "SPECIES", 139, 145], ["a sham study", "TEST", 31, 43], ["malfunctioning plumbing created aerosols", "PROBLEM", 49, 89], ["microorganisms", "PROBLEM", 95, 109], ["disease", "PROBLEM", 233, 240]]], ["Sham studies, also in present time support earlier findings and stress the importance of a physical barrier by a water seal between the drainage systems and surroundings [65] .", [["Sham studies", "TEST", 0, 12], ["a physical barrier", "TREATMENT", 89, 107], ["a water seal", "TREATMENT", 111, 123], ["the drainage systems", "TREATMENT", 132, 152]]], ["The creation of aerosols has been shown to occur when the plumbing is not correctly designed or if there are leakages, stops or by dried U-traps.", [["The creation of aerosols", "TREATMENT", 0, 24], ["leakages", "PROBLEM", 109, 117], ["aerosols", "OBSERVATION", 16, 24], ["leakages", "OBSERVATION", 109, 117]]], ["Also, aerosols can be created upon flushing the toilet or in situations when water is poured from taps to sinks and drains [66, 67] .", [["aerosols", "TREATMENT", 6, 14], ["flushing the toilet", "TREATMENT", 35, 54], ["drains", "TREATMENT", 116, 122]]], ["As shown in the SARS outbreak at Amoy Gardens, aerosols can enter the ventilation system and be spread to all the other connected rooms igniting a fearsome spread [67] .", [["SARS", "DISEASE", 16, 20]]], ["The outbreak at Amoy Gardens highlights the need for good maintenance practices and water safety programs with recommended actions [68] .", [["water safety programs", "TREATMENT", 84, 105]]], ["In the event of backflow or flooding from the drainage systems of wastewater into the building, prompt actions must be taken to protect health and property [31] .", [["backflow", "PROBLEM", 16, 24], ["flooding", "PROBLEM", 28, 36], ["the drainage systems", "TREATMENT", 42, 62], ["backflow", "OBSERVATION", 16, 24], ["flooding", "OBSERVATION", 28, 36]]], ["Among public health professionals, it is well known that if wastewater leaks to structures and furnishing harmful substances such as gases and pathogenic microorganisms can enter as well as increased humidity that can promote environmental microorganisms to multiply and cause diseases and mold-associated allergies [31] .", [["allergies", "DISEASE", 306, 315], ["wastewater leaks to structures", "PROBLEM", 60, 90], ["harmful substances", "TREATMENT", 106, 124], ["pathogenic microorganisms", "PROBLEM", 143, 168], ["increased humidity", "PROBLEM", 190, 208], ["diseases", "PROBLEM", 277, 285], ["mold-associated allergies", "PROBLEM", 290, 315]]], ["In recommended guidelines by EPA in the US, these highlight the increased safety risks due to the high threat of infection, in the event of sewage backflow into buildings [31] .", [["infection", "DISEASE", 113, 122], ["EPA", "SIMPLE_CHEMICAL", 29, 32], ["the increased safety risks", "PROBLEM", 60, 86], ["the high threat of infection", "PROBLEM", 94, 122], ["increased", "OBSERVATION_MODIFIER", 64, 73], ["infection", "OBSERVATION", 113, 122]]], ["Consequences of malfunctioning plumbing can indeed cause outbreaks [7] .", [["malfunctioning plumbing", "PROBLEM", 16, 39]]], ["In one outbreak in London, 85 patients became infected during 2005 and 2011, with overall mortality at 40%, but for patients with sepsis, mortality was 78%.", [["sepsis", "DISEASE", 130, 136], ["patients", "ORGANISM", 30, 38], ["patients", "ORGANISM", 116, 124], ["patients", "SPECIES", 30, 38], ["patients", "SPECIES", 116, 124], ["sepsis", "PROBLEM", 130, 136], ["mortality", "TEST", 138, 147], ["one", "OBSERVATION_MODIFIER", 3, 6], ["outbreak", "OBSERVATION_MODIFIER", 7, 15], ["infected", "OBSERVATION", 46, 54], ["sepsis", "OBSERVATION", 130, 136]]], ["Yet another outbreak occurred in Southern England with four cases and no deaths.", [["deaths", "DISEASE", 73, 79], ["deaths", "PROBLEM", 73, 79], ["outbreak", "OBSERVATION_MODIFIER", 12, 20]]], ["Both outbreaks were caused by multidrug-resistant P. aeruginosa.", [["multidrug-resistant P. aeruginosa", "DISEASE", 30, 63], ["multidrug-resistant", "ORGANISM", 30, 49], ["P. aeruginosa", "ORGANISM", 50, 63], ["P. aeruginosa", "SPECIES", 50, 63], ["P. aeruginosa", "SPECIES", 50, 63], ["multidrug-resistant P. aeruginosa", "PROBLEM", 30, 63]]], ["There had been 391 notifications of blockages in the wastewater system at the hospitals each year.", [["blockages in the wastewater system", "PROBLEM", 36, 70], ["blockages", "OBSERVATION", 36, 45]]], ["Blockages had been due to patient wipes and paper towels causing backflow to toilets and showers, leakages, etc. near clinical areas [7] .", [["patient", "ORGANISM", 26, 33], ["patient", "SPECIES", 26, 33], ["Blockages", "PROBLEM", 0, 9], ["paper towels", "TREATMENT", 44, 56], ["backflow to toilets", "PROBLEM", 65, 84], ["leakages", "PROBLEM", 98, 106], ["leakages", "OBSERVATION", 98, 106]]], ["It was first after re-plumbing, replacing toilet bowls, and etc., the infection rates were notably reduced.", [["infection", "DISEASE", 70, 79], ["toilet bowls", "TREATMENT", 42, 54], ["the infection rates", "TEST", 66, 85], ["infection", "OBSERVATION", 70, 79], ["reduced", "OBSERVATION_MODIFIER", 99, 106]]], ["The authors stressed the importance of hospital design and engineering in controlling and preventing infection, a factor that highlights the need for engagement from the clinical staff, engineers, and janitors.", [["infection", "DISEASE", 101, 110], ["infection", "PROBLEM", 101, 110], ["infection", "OBSERVATION", 101, 110]]], ["Also, to consider, these outbreaks were identified due to the unusual antibiogram of organisms and could thus be linked to the hospital wastewater systems.", [["these outbreaks", "PROBLEM", 19, 34], ["the unusual antibiogram of organisms", "PROBLEM", 58, 94]]], ["Clearly, hospital wastewater system could be a source of many cases of infection with different bacteria.", [["infection", "DISEASE", 71, 80], ["infection", "PROBLEM", 71, 80], ["different bacteria", "PROBLEM", 86, 104], ["infection", "OBSERVATION", 71, 80]]], ["Breathnach et al. concluded: \"However, unless the organisms are distinctive in some way, such as being multiply resistant, or several cases with the same species linked in time or place, it is likely that the source of many such infections will remain unrecognized\" [7] .Maintenance of sanitation is essentialFacts point at that sanitation is essential to maintain, to reduce the risk of infection [1] .", [["infections", "DISEASE", 229, 239], ["infection", "DISEASE", 388, 397], ["the organisms", "PROBLEM", 46, 59], ["many such infections", "PROBLEM", 219, 239], ["sanitation", "TREATMENT", 286, 296], ["infection", "PROBLEM", 388, 397], ["infection", "OBSERVATION", 388, 397]]], ["In a press release from WHO it stated that in \"absence of proper maintenance and without consistent monitoring, reviewing, enforcing and updating of building standards and practices, inadequate plumbing and sewage systems could continue to enhance the potential of SARS and some other diseases to spread [4] \".", [["SARS", "DISEASE", 265, 269], ["inadequate plumbing and sewage systems", "PROBLEM", 183, 221], ["SARS", "PROBLEM", 265, 269], ["some other diseases", "PROBLEM", 274, 293]]], ["Numerous cases from both developing and developed countries describe outbreaks caused by faulty sanitation [2] ( Table 1 ).", [["Numerous cases", "PROBLEM", 0, 14]]], ["Furthermore, it is easily forgotten since the drainage systems is out of sight.", [["the drainage systems", "TREATMENT", 42, 62], ["forgotten", "OBSERVATION", 26, 35], ["drainage", "OBSERVATION", 46, 54]]], ["Thus drainage systems are neglected as potential reservoirs of transmission of microorganisms.", [["drainage systems", "TREATMENT", 5, 21], ["transmission of microorganisms", "PROBLEM", 63, 93], ["drainage", "OBSERVATION", 5, 13]]], ["It is when they cease to function adequately because of e.g. leakages or blockages that the threats to health becomes a reality and inspections followed by reparations or even total exchange of drainage systems are required [31, 69] .", [["e.g. leakages", "PROBLEM", 56, 69], ["blockages", "PROBLEM", 73, 82], ["drainage systems", "TREATMENT", 194, 210], ["leakages", "OBSERVATION", 61, 69]]], ["The awareness about the impact of inadequate sanitation seems poor.", [["inadequate sanitation", "TREATMENT", 34, 55]]], ["The illnesses are many and affect the health and economy of individuals, society, and nations [31] .Research needInterdisciplinary work is needed in order to establish guidelines for healthy sanitation in buildings focusing on the clinical need for infection control supported by architectural design and maintenance practices.", [["infection", "DISEASE", 249, 258], ["The illnesses", "PROBLEM", 0, 13], ["healthy sanitation", "TREATMENT", 183, 201], ["infection control", "TREATMENT", 249, 266], ["maintenance practices", "TREATMENT", 305, 326], ["illnesses", "OBSERVATION", 4, 13]]], ["To accomplish the task, three aspects important for infection reduction must be evaluated.", [["infection", "DISEASE", 52, 61], ["infection reduction", "TREATMENT", 52, 71], ["infection", "OBSERVATION", 52, 61]]], ["1) Detection of pathogen containing aerosols and surface contaminants should be done and further analyzed by molecular profiling and antibiograms in order to trace outbreak related pathogens.Research need2) Current architectural designs should be evaluated if constructed from an infection reduction perspective.", [["surface", "ANATOMY", 49, 56], ["infection", "DISEASE", 280, 289], ["pathogen containing aerosols and surface contaminants", "PROBLEM", 16, 69], ["molecular profiling", "TEST", 109, 128], ["antibiograms", "TEST", 133, 145], ["trace outbreak related pathogens", "PROBLEM", 158, 190], ["Current architectural designs", "TREATMENT", 207, 236], ["an infection reduction perspective", "TREATMENT", 277, 311], ["aerosols", "OBSERVATION_MODIFIER", 36, 44], ["infection", "OBSERVATION", 280, 289]]], ["Possibly, the GMP guideline in food industry and their demands from an infection reduction perspective could be a good start to learn from.", [["GMP", "CHEMICAL", 14, 17], ["infection", "DISEASE", 71, 80], ["GMP", "CHEMICAL", 14, 17], ["GMP", "SIMPLE_CHEMICAL", 14, 17], ["the GMP guideline", "TREATMENT", 10, 27], ["an infection reduction perspective", "TREATMENT", 68, 102], ["infection", "OBSERVATION", 71, 80]]], ["Also, the building and facility sectors should be involved to develop what actions are required to maintain a safe sanitation system and with what detection methods maintenance can be surveyed.", [["a safe sanitation system", "TREATMENT", 108, 132]]], ["One detection method that could meet the demands for accurate monitoring of the status in the drainage systems is a technique based on sonar technology, developed by Gormley et al. [70] .", [["the drainage systems", "TREATMENT", 90, 110], ["drainage", "OBSERVATION", 94, 102]]], ["The need for guidance is especially urgent within healthcare owing to that at hospitals the majority are patients that are sick with less fit immune system and therefore more receptive to infections and thus in need of antibiotics that are effective.", [["infections", "DISEASE", 188, 198], ["patients", "ORGANISM", 105, 113], ["patients", "SPECIES", 105, 113], ["infections", "PROBLEM", 188, 198], ["antibiotics", "TREATMENT", 219, 230], ["infections", "OBSERVATION", 188, 198]]], ["Further research is needed to explore how aerosols produced with or without faulty drainage systems can be disseminated by existing ventilation system and cause disease.", [["faulty drainage systems", "TREATMENT", 76, 99], ["existing ventilation system", "TREATMENT", 123, 150], ["disease", "PROBLEM", 161, 168], ["ventilation system", "OBSERVATION", 132, 150]]], ["In the case with the SARS outbreak, it was clearly shown that the spread of the virus containing aerosols created from the drains was facilitated by the ventilation system.", [["SARS", "DISEASE", 21, 25], ["the SARS outbreak", "PROBLEM", 17, 34], ["the virus", "PROBLEM", 76, 85], ["the drains", "TREATMENT", 119, 129], ["drains", "OBSERVATION", 123, 129], ["ventilation system", "OBSERVATION", 153, 171]]], ["It was further proven in a sham study that aerosols were created and spread by the airflow upon flushing a toilet [67] .", [["a sham study", "TEST", 25, 37]]], ["Spread of pathogens from wastewater via the drainage systems and out where no physical barrier exist has also been proven in yet other sham studies [71] evoking further issues such as what are the consequences of letting out gases and aerosols through the roof, possibly next to a ventilation inlet, or if there is a leakage along the drainage systems within the building [71] ?", [["pathogens", "PROBLEM", 10, 19], ["the drainage systems", "TREATMENT", 40, 60], ["physical barrier", "TREATMENT", 78, 94], ["other sham studies", "TEST", 129, 147], ["a ventilation inlet", "TREATMENT", 279, 298], ["a leakage along the drainage systems", "PROBLEM", 315, 351], ["pathogens", "OBSERVATION_MODIFIER", 10, 19], ["drainage", "OBSERVATION", 44, 52], ["leakage", "OBSERVATION", 317, 324]]], ["Leakage or seepage shall be considered and its consequences analyzed.", [["Leakage", "PROBLEM", 0, 7], ["seepage", "OBSERVATION", 11, 18]]], ["One possible effect could be that humidity is increased thus promoting microbial growth of for e.g. fungi risking mold in the building and allergies to the inhabitants.", [["allergies", "DISEASE", 139, 148], ["fungi risking mold", "PROBLEM", 100, 118], ["possible", "UNCERTAINTY", 4, 12], ["increased", "OBSERVATION_MODIFIER", 46, 55], ["microbial", "OBSERVATION_MODIFIER", 71, 80], ["growth", "OBSERVATION_MODIFIER", 81, 87]]], ["The impact of microscopic sized leakage is also of interest to study if these would allow microorganisms being microscopically small; virus being 0.1 \u03bcm, bacteria around 1 to 10 \u03bcm, and fungi around 10 \u03bcm big, to leak.", [["microscopic sized leakage", "PROBLEM", 14, 39], ["microorganisms", "PROBLEM", 90, 104], ["microscopically small; virus", "PROBLEM", 111, 139], ["bacteria", "PROBLEM", 154, 162], ["fungi", "PROBLEM", 186, 191], ["leak", "PROBLEM", 213, 217], ["microscopic sized", "OBSERVATION_MODIFIER", 14, 31], ["leakage", "OBSERVATION", 32, 39], ["leak", "OBSERVATION", 213, 217]]], ["Results may show that it is essential that drainage systems must be completely tight and intact where openings have physical barriers.ConclusionDespite good sanitation, problems arise when the sanitation system is not working properly in case of e.g. leakage and backflow caused by blockages or dried out traps.", [["drainage systems", "TREATMENT", 43, 59], ["the sanitation system", "TREATMENT", 189, 210], ["e.g. leakage and backflow", "PROBLEM", 246, 271], ["blockages", "PROBLEM", 282, 291], ["dried out traps", "PROBLEM", 295, 310], ["drainage", "OBSERVATION", 43, 51], ["leakage", "OBSERVATION", 251, 258], ["blockages", "OBSERVATION", 282, 291]]], ["It is beyond proof that wastewater, sewages, or drains act as cradles for emerging new microorganisms with increasing ability to resist antibiotics and possibly armed with virulence factors obtained from other encountered species [47, 50, 51] .", [["virulence factors", "PROTEIN", 172, 189], ["drains", "TREATMENT", 48, 54], ["emerging new microorganisms", "PROBLEM", 74, 101], ["antibiotics", "TREATMENT", 136, 147], ["virulence factors", "PROBLEM", 172, 189]]], ["The cradles consist of microbial biofilm, where transfer of genes coding resistance and virulence is promoted [47, 62] .", [["biofilm", "ANATOMY", 33, 40], ["microbial biofilm", "TREATMENT", 23, 40], ["virulence", "PROBLEM", 88, 97], ["microbial biofilm", "OBSERVATION", 23, 40]]], ["The pressure for selection of resistant microbes is probably higher in healthcare settings due to the turnover of many sick patients shedding along with administered antibiotics down the drains.", [["patients", "ORGANISM", 124, 132], ["patients", "SPECIES", 124, 132], ["The pressure", "TEST", 0, 12], ["resistant microbes", "PROBLEM", 30, 48], ["antibiotics", "TREATMENT", 166, 177], ["the drains", "TREATMENT", 183, 193], ["pressure", "OBSERVATION_MODIFIER", 4, 12], ["resistant", "OBSERVATION_MODIFIER", 30, 39], ["microbes", "OBSERVATION", 40, 48], ["probably", "UNCERTAINTY", 52, 60], ["higher", "OBSERVATION_MODIFIER", 61, 67], ["drains", "OBSERVATION", 187, 193]]], ["Drains have been reported to be the source of several outbreaks.", [["Drains", "TREATMENT", 0, 6], ["several", "OBSERVATION_MODIFIER", 46, 53], ["outbreaks", "OBSERVATION", 54, 63]]], ["The threat of mortality rate equaling the pre-antibiotic era is immediate and not for future.", [["mortality rate", "TEST", 14, 28]]], ["If no efficient antibiotics, current infections can't be treated and sensitive interventions will not be possible to pursue.", [["infections", "DISEASE", 37, 47], ["efficient antibiotics", "TREATMENT", 6, 27], ["current infections", "PROBLEM", 29, 47], ["sensitive interventions", "TREATMENT", 69, 92]]], ["Therefore, preventive actions are urgent and must be taken to reduce infections causing us to focus on the fundamental need for a safe and maintained sanitation system.", [["infections", "DISEASE", 69, 79], ["infections", "PROBLEM", 69, 79]]]], "PMC7245234": [["INTRODUCTIONIn December 2019, a cluster of patients with pneumonia of unknown cause was linked to a seafood wholesale market in Wuhan, China.", [["pneumonia", "DISEASE", 57, 66], ["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["pneumonia", "PROBLEM", 57, 66], ["pneumonia", "OBSERVATION", 57, 66]]], ["1 Since then, the novel coronavirus disease 2019 (Covid-19) has rapidly spread across the world leading the World Health Organization (WHO) to declare a global pandemic on 11 March 2020.", [["coronavirus disease", "DISEASE", 24, 43], ["Covid-19", "CHEMICAL", 50, 58], ["coronavirus", "ORGANISM", 24, 35], ["coronavirus disease 2019 (Covid-19", "SPECIES", 24, 58], ["the novel coronavirus disease", "PROBLEM", 14, 43], ["Covid", "TEST", 50, 55], ["coronavirus disease", "OBSERVATION", 24, 43]]], ["The surge in the number of people seeking medical treatment has temporarily overwhelmed health services, leading to concerns regarding the allocation of scarce resources such as intensive care facilities.", [["people", "ORGANISM", 27, 33], ["people", "SPECIES", 27, 33], ["medical treatment", "TREATMENT", 42, 59]]], ["2,3", [["2,3", "CHEMICAL", 0, 3], ["2,3", "SIMPLE_CHEMICAL", 0, 3]]]], "0dea3dbd3c3150c866cb699f059bc90b92f8eafb": [["F\u00fcr St\u00e4dte, Gemeinden und teilweise auch ganze Regionen wird es immer wichtiger, ein f\u00fcr die jeweiligen Zielgruppen attraktives Profil beziehungsweise Image zu vermitteln, um im Wettbewerb zum Beispiel um Touristeninnen und Touristen, Unternehmen oder Arbeitnehmerinnen und Arbeitnehmer bestehen zu k\u00f6nnen.", [["Gemeinden und teilweise auch ganze Regionen wird es immer wichtiger, ein f\u00fcr die jeweiligen Zielgruppen attraktives Profil beziehungsweise Image zu vermitteln, um im Wettbewerb zum Beispiel um Touristeninnen und Touristen, Unternehmen oder Arbeitnehmerinnen und Arbeitnehmer bestehen zu k\u00f6nnen", "SPECIES", 12, 305]]], ["Allerdings sind Bem\u00fchungen im Markenmanagement auch immer mit einem relativ hohen Aufwand sowie in der Regel entsprechenden Kosten verbunden.", [["Bem\u00fchungen im Markenmanagement", "TREATMENT", 16, 46]]], ["Dar\u00fcber hinaus l\u00e4sst sich bei zahlreichen Markenmanagement-Bem\u00fchungen beobachten, dass ein falsches beziehngsweise stark reduziertes Verst\u00e4nd-nis des Themas Markenmanagement zugrunde gelegt wird und h\u00e4ufig keine klare Strategie formuliert wurde.", [["Dar\u00fcber hinaus l\u00e4sst sich bei zahlreichen Markenmanagement-Bem\u00fchungen beobachten, dass ein falsches beziehngsweise stark reduziertes Verst\u00e4nd-nis des Themas Markenmanagement zugrunde gelegt wird und h\u00e4ufig keine klare Strategie formuliert wurde", "SPECIES", 0, 244], ["sich bei zahlreichen Markenmanagement", "TREATMENT", 21, 58], ["Bem\u00fchungen beobachten", "TREATMENT", 59, 80], ["nis des Themas", "TREATMENT", 142, 156], ["zugrunde gelegt wird", "TREATMENT", 174, 194]]]], "144dc9ec07fe527c68d2b3d0e162bcec8421c2c3": [["It is estimated that 40 000 people die of suicide every year in the United States, and the global death toll is estimated to be at 800 000 (WHO, 2014) .", [["death", "DISEASE", 98, 103], ["people", "ORGANISM", 28, 34], ["people", "SPECIES", 28, 34]]], ["The World Health Organization predicts close to one million deaths by the year 2030, contributing to a projected 1.4% of all deaths worldwide (World Health Organization, 2011) .", [["deaths", "DISEASE", 60, 66], ["deaths", "DISEASE", 125, 131]]], ["The actual numbers may be far higher, as suicidal deaths tend to be typically under reported because of societal taboos and criminalization of suicide in certain societies.INTRODUCTIONSuicide attempts may, likewise, be grossly underestimated because of poor reporting and insufficient data collection.", [["deaths", "DISEASE", 50, 56], ["suicidal deaths", "PROBLEM", 41, 56], ["societal taboos", "TREATMENT", 104, 119], ["insufficient data collection", "PROBLEM", 272, 300]]], ["Twenty or more suicide attempts occur for every one death by suicide, suggesting that suicide attempts are more frequent than suicide itself (Bertolote et al, 2010) .", [["death", "DISEASE", 52, 57]]], ["Suicide attempts are currently the best predictor of completed suicide, which indicates that proper reporting and close monitoring of the individuals who attempt suicide may serve to prevent future suicides.", [["Suicide", "DISEASE", 0, 7], ["suicide", "TREATMENT", 162, 169]]], ["To this effect, Da Cruz et al determined that over 40% of individuals who died by suicide visited the emergency department at least once in the 12 months before death; with 28% of them visiting on more than three occasions.", [["death", "DISEASE", 161, 166], ["individuals", "ORGANISM", 58, 69]]], ["Death by suicide followed soon after the last emergency department visit in the group of frequent attempters compared with other attenders (Da Cruz et al, 2011) .", [["Death", "DISEASE", 0, 5]]], ["This critically underscores the insufficiency of existing methods of suicide risk assessment, demonstrated by failure to identify high-risk individuals despite repeated visits to the emergency department before death.INTRODUCTIONThere are also some consistent gender differences in suicidal behavior that are important to note.", [["death", "DISEASE", 211, 216], ["suicidal behavior", "DISEASE", 282, 299], ["suicide risk assessment", "TEST", 69, 92], ["high-risk individuals", "PROBLEM", 130, 151], ["insufficiency", "OBSERVATION", 32, 45]]], ["In many countries, including the United States, male-completed suicides outnumber females-completed ones with a rati\u00f5 3 : 1, although women are more likely to experience suicidal ideation to a higher degree than men (SAMHSA, 2013) .", [["suicidal ideation", "DISEASE", 170, 187], ["women", "ORGANISM", 134, 139], ["men", "ORGANISM", 212, 215], ["women", "SPECIES", 134, 139], ["men", "SPECIES", 212, 215], ["suicidal ideation", "PROBLEM", 170, 187]]], ["Men are also likely to employ more violent methods of suicide than women (Canetto and Sakinofsky, 1998) .", [["Men", "ORGANISM", 0, 3], ["women", "ORGANISM", 67, 72], ["Men", "SPECIES", 0, 3], ["women", "SPECIES", 67, 72]]], ["Both suicide deaths and attempts are acts of extreme psychological despair, and constitute a profound emotional burden to both the family and relatives of the victims.", [["deaths", "DISEASE", 13, 19], ["Both suicide deaths", "PROBLEM", 0, 19], ["extreme psychological despair", "PROBLEM", 45, 74], ["a profound emotional burden", "PROBLEM", 91, 118]]], ["In essence, there is a great need to develop diagnostic methods, which include behavioral and biological indicators for reliable and timely identification of risk factors that may lead to suicidal behavior.CLINICAL ASPECTS OF SUICIDALITYSuicide is defined as an intentional act of taking one's life by engaging in self-directed injurious behavior.", [["suicidal behavior", "DISEASE", 188, 205], ["diagnostic methods", "TEST", 45, 63], ["risk factors", "PROBLEM", 158, 170], ["suicidal behavior", "PROBLEM", 188, 205]]], ["Suicidal ideation and suicide attempts are suicidal behavior that may manifest as standalone events or precipitate a completed suicide (Crosby et al, 2011) .", [["Suicidal ideation", "DISEASE", 0, 17], ["suicidal behavior", "DISEASE", 43, 60], ["Suicidal ideation", "PROBLEM", 0, 17], ["suicide attempts", "PROBLEM", 22, 38], ["suicidal behavior", "PROBLEM", 43, 60]]], ["Several theories have been proposed to model suicide risk, each taking into account etiological and phenotypic variability that is associated with suicide.", [["phenotypic variability", "PROBLEM", 100, 122], ["phenotypic variability", "OBSERVATION", 100, 122]]], ["They are categorized into risk factors that predispose (distal factors) and precipitate suicidal event (proximal factors).", [["suicidal event (proximal factors", "PROBLEM", 88, 120]]], ["Proximal factors are typically associated with neuropsychiatric pathology and may be precipitated by stressful life events (Mann, 2003) .", [["Proximal factors", "PROBLEM", 0, 16], ["neuropsychiatric pathology", "PROBLEM", 47, 73]]], ["Psychiatric disorders and the risk for suicidal behavior has been a topic of intense study given that~90% of suicide completers are diagnosed with some form of psychiatric illness including major depressive disorder (MDD) and substance abuse disorders (Arsenault-Lapierre et al, 2004) .", [["Psychiatric disorders", "DISEASE", 0, 21], ["suicidal behavior", "DISEASE", 39, 56], ["psychiatric illness", "DISEASE", 160, 179], ["major depressive disorder", "DISEASE", 190, 215], ["MDD", "DISEASE", 217, 220], ["substance abuse disorders", "DISEASE", 226, 251], ["Psychiatric disorders", "PROBLEM", 0, 21], ["suicidal behavior", "PROBLEM", 39, 56], ["intense study", "TEST", 77, 90], ["psychiatric illness", "PROBLEM", 160, 179], ["major depressive disorder", "PROBLEM", 190, 215], ["substance abuse disorders", "PROBLEM", 226, 251]]], ["Behavioral traits such as impulsivity and aggressive behavior may also contribute to the risk of suicidal behavior, specifically in adolescents or young adults.", [["impulsivity", "DISEASE", 26, 37], ["aggressive behavior", "DISEASE", 42, 61], ["suicidal behavior", "DISEASE", 97, 114], ["adolescents", "SPECIES", 132, 143], ["Behavioral traits", "PROBLEM", 0, 17], ["impulsivity", "PROBLEM", 26, 37], ["aggressive behavior", "PROBLEM", 42, 61], ["suicidal behavior", "PROBLEM", 97, 114]]], ["These traits are often co-morbid with different psychiatric disorders such as bipolar disorders and substance abuse disorders (Brent et al, 1994; Cuomo et al, 2008; McGirr et al, 2008) .CLINICAL ASPECTS OF SUICIDALITYFamilial transmission and early life adversity (ELA) are distal events associated with suicide risk (Mann, 2003; Moscicki, 1994) .", [["psychiatric disorders", "DISEASE", 48, 69], ["bipolar disorders", "DISEASE", 78, 95], ["substance abuse disorders", "DISEASE", 100, 125], ["ELA", "DISEASE", 265, 268], ["different psychiatric disorders", "PROBLEM", 38, 69], ["bipolar disorders", "PROBLEM", 78, 95], ["substance abuse disorders", "PROBLEM", 100, 125], ["SUICIDALITYFamilial transmission", "PROBLEM", 206, 238], ["distal events", "PROBLEM", 274, 287]]], ["Physical or sexual abuse and parental neglect are significantly associated with suicidal risk (Brezo et al, 2008) .", [["Physical or sexual abuse", "DISEASE", 0, 24], ["parental neglect", "DISEASE", 29, 45], ["parental neglect", "PROBLEM", 29, 45]]], ["The association between ELA and suicide risk in these individuals is strongly supported by the changes in several downstream factors, including epigenetic changes, hypothalamic-pituitary-adrenal (HPA) axis activation and neuronal plasticity, informed to a large extent by animal studies and post-mortem studies (Labonte et al, 2013; Labonte et al, 2012; McGowan et al, 2009; Roth et al, 2011) .CLINICAL ASPECTS OF SUICIDALITYFamily history of suicidal behavior has also been identified as a risk factor.", [["neuronal", "ANATOMY", 221, 229], ["suicidal behavior", "DISEASE", 443, 460], ["ELA", "GENE_OR_GENE_PRODUCT", 24, 27], ["hypothalamic-pituitary-adrenal", "GENE_OR_GENE_PRODUCT", 164, 194], ["HPA", "GENE_OR_GENE_PRODUCT", 196, 199], ["neuronal", "CELL", 221, 229], ["downstream factors", "PROTEIN", 114, 132], ["the changes in several downstream factors", "PROBLEM", 91, 132], ["epigenetic changes", "PROBLEM", 144, 162], ["hypothalamic-pituitary-adrenal (HPA) axis activation", "PROBLEM", 164, 216], ["animal studies", "TEST", 272, 286], ["post-mortem studies", "TEST", 291, 310], ["suicidal behavior", "PROBLEM", 443, 460], ["pituitary", "ANATOMY", 177, 186], ["adrenal", "ANATOMY", 187, 194], ["neuronal plasticity", "OBSERVATION", 221, 240]]], ["In a registry-based study, Tidemalm et al (2011) assessed suicides in probands of individuals who died by suicide, and determined that the risk does run in families and is influenced by both genetic and shared environmental factors.", [["individuals", "ORGANISM", 82, 93], ["based study", "TEST", 14, 25]]], ["Given that suicidal behavior is strongly associated with psychiatric disorders, Brent et al examined suicidal behavior and psychopathology among probands of adolescent suicide victims.", [["suicidal behavior", "DISEASE", 11, 28], ["psychiatric disorders", "DISEASE", 57, 78], ["suicidal behavior", "DISEASE", 101, 118], ["psychopathology", "DISEASE", 123, 138], ["suicide victims", "DISEASE", 168, 183], ["suicidal behavior", "PROBLEM", 11, 28], ["psychiatric disorders", "PROBLEM", 57, 78], ["suicidal behavior", "PROBLEM", 101, 118], ["psychopathology", "PROBLEM", 123, 138], ["adolescent suicide victims", "PROBLEM", 157, 183]]], ["They observed that the rates of suicide attempts were higher in relatives of adolescent suicide victims even after controlling for familial rates of psychopathology, suggesting that familial transmission of suicide is discrete from psychopathology (Brent et al, 1996) .CLINICAL ASPECTS OF SUICIDALITYSubstance abuse is also considered a risk factor for suicidal behavior.", [["suicide victims", "DISEASE", 88, 103], ["psychopathology", "DISEASE", 149, 164], ["psychopathology", "DISEASE", 232, 247], ["suicidal behavior", "DISEASE", 353, 370], ["psychopathology", "PROBLEM", 149, 164], ["psychopathology", "PROBLEM", 232, 247], ["suicidal behavior", "PROBLEM", 353, 370]]], ["The risk for suicide is much higher in individuals with substance abuse disorder compared with general population (Wilcox et al, 2004) .", [["substance abuse disorder", "DISEASE", 56, 80], ["suicide", "PROBLEM", 13, 20], ["substance abuse disorder", "PROBLEM", 56, 80]]], ["However, the majority of individuals with substance abuse issues are often diagnosed with other psychiatric conditions, a confounding factor which must be kept in perspective (Treatment.", [["substance abuse", "DISEASE", 42, 57], ["psychiatric", "DISEASE", 96, 107], ["other psychiatric conditions", "PROBLEM", 90, 118], ["a confounding factor", "PROBLEM", 120, 140]]], ["Conditions, such as early childhood trauma and posttraumatic stress disorders (PTSDs), often co-occur with substance abuse and their ability to confer suicide risk has also been explored.", [["trauma", "DISEASE", 36, 42], ["posttraumatic stress disorders", "DISEASE", 47, 77], ["PTSDs", "DISEASE", 79, 84], ["substance abuse", "DISEASE", 107, 122], ["early childhood trauma", "PROBLEM", 20, 42], ["posttraumatic stress disorders", "PROBLEM", 47, 77]]], ["Roy (2003) assessed the association between childhood trauma and suicide attempts in individuals with substance abuse and determined that in these individuals, suicide attempts were associated with childhood trauma.", [["trauma", "DISEASE", 54, 60], ["substance abuse", "DISEASE", 102, 117], ["trauma", "DISEASE", 208, 214], ["childhood trauma", "PROBLEM", 44, 60], ["childhood trauma", "PROBLEM", 198, 214]]], ["Furthermore, Price et al (2004) found that drug dependence was associated with PTSD and suicidal behavior in a cohort of Vietnam veterans assessed over a period of 25 years.", [["drug dependence", "DISEASE", 43, 58], ["PTSD", "DISEASE", 79, 83], ["suicidal behavior", "DISEASE", 88, 105], ["drug dependence", "PROBLEM", 43, 58], ["PTSD", "PROBLEM", 79, 83], ["suicidal behavior", "PROBLEM", 88, 105]]], ["Overall, suicidal behavior may manifest as a consequence of interaction between early life events, traits such as aggression and impulsivity, and psychiatric illness.INFLAMMATION AND SYMPTOMS OF SUICIDALITYAberrations in inflammatory cytokines have been reported in several neuropsychiatric conditions, including MDD, schizophrenia, and bipolar disorders (Dowlati et al, 2010; Miller et al, 2011; Munkholm et al, 2013) .", [["suicidal behavior", "DISEASE", 9, 26], ["aggression", "DISEASE", 114, 124], ["impulsivity", "DISEASE", 129, 140], ["psychiatric illness", "DISEASE", 146, 165], ["MDD", "DISEASE", 313, 316], ["schizophrenia", "DISEASE", 318, 331], ["bipolar disorders", "DISEASE", 337, 354], ["inflammatory cytokines", "PROTEIN", 221, 243], ["suicidal behavior", "PROBLEM", 9, 26], ["early life events", "PROBLEM", 80, 97], ["impulsivity", "PROBLEM", 129, 140], ["psychiatric illness", "PROBLEM", 146, 165], ["INFLAMMATION", "PROBLEM", 166, 178], ["SYMPTOMS", "PROBLEM", 183, 191], ["SUICIDALITYAberrations", "PROBLEM", 195, 217], ["inflammatory cytokines", "PROBLEM", 221, 243], ["MDD", "PROBLEM", 313, 316], ["schizophrenia", "PROBLEM", 318, 331], ["bipolar disorders", "PROBLEM", 337, 354], ["inflammatory", "OBSERVATION_MODIFIER", 221, 233], ["schizophrenia", "OBSERVATION", 318, 331]]], ["Mechanistically, it is known that inflammation can trigger depressive symptoms and is associated with suicidality based on studies involving patients who receive interferon (IFN)-based or interleukin-2 (IL-2) immuno-therapy (Buter et al, 1993; Capuron et al, 2004; Dieperink et al, 2004; Janssen et al, 1994; Renault et al, 1987) .", [["inflammation", "DISEASE", 34, 46], ["depressive symptoms", "DISEASE", 59, 78], ["suicidality", "DISEASE", 102, 113], ["IFN", "CHEMICAL", 174, 177], ["patients", "ORGANISM", 141, 149], ["interferon", "GENE_OR_GENE_PRODUCT", 162, 172], ["interleukin-2", "GENE_OR_GENE_PRODUCT", 188, 201], ["IL-2", "GENE_OR_GENE_PRODUCT", 203, 207], ["interferon", "PROTEIN", 162, 172], ["IFN", "PROTEIN", 174, 177], ["patients", "SPECIES", 141, 149], ["inflammation", "PROBLEM", 34, 46], ["depressive symptoms", "PROBLEM", 59, 78], ["suicidality", "PROBLEM", 102, 113], ["studies", "TEST", 123, 130], ["interferon (IFN)", "TREATMENT", 162, 178], ["interleukin-2 (IL", "TREATMENT", 188, 205], ["immuno-therapy", "TREATMENT", 209, 223], ["inflammation", "OBSERVATION", 34, 46]]], ["It is well established that~30-45% of patients receiving IFN treatment develop depressive-like symptoms during the course of therapy, with a proportion of them experiencing these symptoms long after therapy has ceased (Meyers et al, 1991; Miyaoka et al, 1999) .", [["IFN", "CHEMICAL", 57, 60], ["depressive-like symptoms", "DISEASE", 79, 103], ["patients", "ORGANISM", 38, 46], ["IFN", "PROTEIN", 57, 60], ["patients", "SPECIES", 38, 46], ["IFN treatment", "TREATMENT", 57, 70], ["depressive-like symptoms", "PROBLEM", 79, 103], ["therapy", "TREATMENT", 125, 132], ["these symptoms", "PROBLEM", 173, 187], ["therapy", "TREATMENT", 199, 206]]], ["Moreover, healthy volunteers who receive injections of lipopolysaccharide (LPS), a bacterial endotoxin, which induces a strong inflammatory response in the periphery as well as in the central nervous system, experience depressive symptoms (Yirmiya et al, 2000) .", [["periphery", "ANATOMY", 156, 165], ["central nervous system", "ANATOMY", 184, 206], ["lipopolysaccharide", "CHEMICAL", 55, 73], ["LPS", "CHEMICAL", 75, 78], ["endotoxin", "CHEMICAL", 93, 102], ["depressive symptoms", "DISEASE", 219, 238], ["volunteers", "ORGANISM", 18, 28], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 55, 73], ["LPS", "SIMPLE_CHEMICAL", 75, 78], ["central nervous system", "ANATOMICAL_SYSTEM", 184, 206], ["lipopolysaccharide (LPS", "TREATMENT", 55, 78], ["a bacterial endotoxin", "PROBLEM", 81, 102], ["a strong inflammatory response in the periphery", "PROBLEM", 118, 165], ["depressive symptoms", "PROBLEM", 219, 238], ["bacterial endotoxin", "OBSERVATION", 83, 102], ["strong", "OBSERVATION_MODIFIER", 120, 126], ["inflammatory", "OBSERVATION", 127, 139], ["periphery", "ANATOMY_MODIFIER", 156, 165], ["central", "ANATOMY_MODIFIER", 184, 191], ["nervous system", "ANATOMY", 192, 206]]], ["However, questions arise as to whether inflammation contributes to symptoms of suicidality or merely exists as an epiphenomenon in patients who are considered 'primary psychiatric patients'.", [["inflammation", "DISEASE", 39, 51], ["suicidality", "DISEASE", 79, 90], ["psychiatric", "DISEASE", 168, 179], ["patients", "ORGANISM", 131, 139], ["patients", "ORGANISM", 180, 188], ["patients", "SPECIES", 131, 139], ["patients", "SPECIES", 180, 188], ["inflammation", "PROBLEM", 39, 51], ["symptoms", "PROBLEM", 67, 75], ["suicidality", "PROBLEM", 79, 90]]], ["Moreover, are there individuals in whom inflammation is particularly pronounced and is associated with a specific symptom profile?", [["inflammation", "DISEASE", 40, 52], ["inflammation", "PROBLEM", 40, 52], ["a specific symptom profile", "PROBLEM", 103, 129], ["inflammation", "OBSERVATION", 40, 52]]], ["Several studies indicate that inflammation may be particularly pronounced in patients who experience suicidality ( Figure 1 ; Table 1 ).", [["inflammation", "DISEASE", 30, 42], ["suicidality", "DISEASE", 101, 112], ["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85], ["Several studies", "TEST", 0, 15], ["inflammation", "PROBLEM", 30, 42], ["suicidality", "PROBLEM", 101, 112], ["inflammation", "OBSERVATION", 30, 42]]], ["An early study found that patients with a history of suicide attempts have increased blood levels of the soluble IL-2 receptors compared with healthy controls (Nassberger and Traskman-Bendz, 1993) .", [["blood", "ANATOMY", 85, 90], ["patients", "ORGANISM", 26, 34], ["blood", "ORGANISM_SUBSTANCE", 85, 90], ["IL-2 receptors", "GENE_OR_GENE_PRODUCT", 113, 127], ["soluble IL-2 receptors", "PROTEIN", 105, 127], ["patients", "SPECIES", 26, 34], ["An early study", "TEST", 0, 14], ["suicide attempts", "PROBLEM", 53, 69], ["increased blood levels", "PROBLEM", 75, 97], ["the soluble IL", "TREATMENT", 101, 115]]], ["This was followed by two post-mortem studies, which independently provided evidence of increased inflammation in the brains of suicide victims.", [["brains", "ANATOMY", 117, 123], ["inflammation", "DISEASE", 97, 109], ["brains", "ORGAN", 117, 123], ["two post-mortem studies", "TEST", 21, 44], ["increased inflammation", "PROBLEM", 87, 109], ["evidence of", "UNCERTAINTY", 75, 86], ["increased", "OBSERVATION_MODIFIER", 87, 96], ["inflammation", "OBSERVATION", 97, 109], ["brains", "ANATOMY", 117, 123]]], ["First, Tonelli et al (2008) reported elevated mRNA transcripts of IL-4 and IL-13 in the orbitofrontal cortex of suicide victims.", [["orbitofrontal cortex", "ANATOMY", 88, 108], ["IL-4", "GENE_OR_GENE_PRODUCT", 66, 70], ["IL-13", "GENE_OR_GENE_PRODUCT", 75, 80], ["orbitofrontal cortex", "MULTI-TISSUE_STRUCTURE", 88, 108], ["mRNA transcripts", "RNA", 46, 62], ["IL-4", "PROTEIN", 66, 70], ["IL-13", "PROTEIN", 75, 80], ["elevated mRNA transcripts", "PROBLEM", 37, 62], ["IL", "TEST", 66, 68], ["IL", "TEST", 75, 77], ["orbitofrontal cortex", "ANATOMY", 88, 108]]], ["Subsequently, Steiner et al (2008) demonstrated increased microgliosis, indicative of an enhanced inflammation, in suicide victims with a diagnosis of depression and schizophrenia.", [["microgliosis", "DISEASE", 58, 70], ["inflammation", "DISEASE", 98, 110], ["depression", "DISEASE", 151, 161], ["schizophrenia", "DISEASE", 166, 179], ["increased microgliosis", "PROBLEM", 48, 70], ["an enhanced inflammation", "PROBLEM", 86, 110], ["depression", "PROBLEM", 151, 161], ["schizophrenia", "PROBLEM", 166, 179], ["increased", "OBSERVATION_MODIFIER", 48, 57], ["microgliosis", "OBSERVATION", 58, 70], ["indicative of", "UNCERTAINTY", 72, 85], ["enhanced", "OBSERVATION_MODIFIER", 89, 97], ["inflammation", "OBSERVATION", 98, 110], ["depression", "OBSERVATION", 151, 161], ["schizophrenia", "OBSERVATION", 166, 179]]], ["These initial findings were supported by a study from our group, showing elevated levels of IL-6 in the cerebrospinal fluid (CSF) of recent suicide attempters.", [["cerebrospinal fluid", "ANATOMY", 104, 123], ["IL-6", "GENE_OR_GENE_PRODUCT", 92, 96], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 104, 123], ["CSF", "ORGANISM_SUBSTANCE", 125, 128], ["IL-6", "PROTEIN", 92, 96], ["a study", "TEST", 41, 48], ["elevated levels of IL", "PROBLEM", 73, 94], ["the cerebrospinal fluid", "TEST", 100, 123], ["recent suicide attempters", "PROBLEM", 133, 158], ["elevated", "OBSERVATION_MODIFIER", 73, 81], ["cerebrospinal fluid", "ANATOMY", 104, 123]]], ["In addition, we observed that IL-6 levels in these patients correlated with the severity of depression as assessed by Montgomery-Asberg Depression Rating Scale (Lindqvist et al, 2009) .", [["depression", "DISEASE", 92, 102], ["IL-6", "GENE_OR_GENE_PRODUCT", 30, 34], ["patients", "ORGANISM", 51, 59], ["IL-6", "PROTEIN", 30, 34], ["patients", "SPECIES", 51, 59], ["depression", "PROBLEM", 92, 102]]], ["A previous study had found lower CSF levels of neuroprotective IL-8 levels in suicide attempters compared with healthy controls, confirming dysregulation of the immune system in suicidal patients (Isung et al, 2012) .", [["immune system", "ANATOMY", 161, 174], ["suicide attempters", "DISEASE", 78, 96], ["suicidal", "DISEASE", 178, 186], ["CSF", "GENE_OR_GENE_PRODUCT", 33, 36], ["IL-8", "GENE_OR_GENE_PRODUCT", 63, 67], ["patients", "ORGANISM", 187, 195], ["IL-8", "PROTEIN", 63, 67], ["patients", "SPECIES", 187, 195], ["A previous study", "TEST", 0, 16], ["lower CSF levels", "PROBLEM", 27, 43], ["neuroprotective IL", "TREATMENT", 47, 65], ["dysregulation of the immune system", "PROBLEM", 140, 174]]], ["Since then, we found that decreased IL-8 levels were specific to patients with anxiety and identified the presence of a single-nucleotide polymorphism in the promoter region of the IL-8 gene, which predicted more severe anxiety in the suicide attempters (Janelidze et al, 2015) .", [["anxiety", "DISEASE", 79, 86], ["anxiety", "DISEASE", 220, 227], ["suicide attempters", "DISEASE", 235, 253], ["IL-8", "GENE_OR_GENE_PRODUCT", 36, 40], ["patients", "ORGANISM", 65, 73], ["IL-8", "GENE_OR_GENE_PRODUCT", 181, 185], ["IL-8", "PROTEIN", 36, 40], ["promoter region", "DNA", 158, 173], ["IL-8 gene", "DNA", 181, 190], ["patients", "SPECIES", 65, 73], ["decreased IL-8 levels", "PROBLEM", 26, 47], ["anxiety", "PROBLEM", 79, 86], ["a single-nucleotide polymorphism", "PROBLEM", 118, 150], ["severe anxiety", "PROBLEM", 213, 227], ["decreased", "OBSERVATION_MODIFIER", 26, 35], ["severe", "OBSERVATION_MODIFIER", 213, 219]]], ["Interestingly, O'Donovan et al (2013) demonstrated that increased inflammation correlated with the degree of suicidal ideation in patients with depression, even after controlling for active suicide attempts and degree of depressive symptoms.", [["inflammation", "DISEASE", 66, 78], ["suicidal ideation", "DISEASE", 109, 126], ["depression", "DISEASE", 144, 154], ["depressive symptoms", "DISEASE", 221, 240], ["patients", "ORGANISM", 130, 138], ["patients", "SPECIES", 130, 138], ["increased inflammation", "PROBLEM", 56, 78], ["suicidal ideation", "PROBLEM", 109, 126], ["depression", "PROBLEM", 144, 154], ["active suicide attempts", "PROBLEM", 183, 206], ["depressive symptoms", "PROBLEM", 221, 240], ["increased", "OBSERVATION_MODIFIER", 56, 65], ["inflammation", "OBSERVATION", 66, 78]]], ["Limited post-mortem data on teenage suicide victims also points to the association between inflammation and suicide.", [["inflammation", "DISEASE", 91, 103], ["inflammation", "PROBLEM", 91, 103], ["suicide", "PROBLEM", 108, 115], ["inflammation", "OBSERVATION", 91, 103]]], ["Pandey et al (2012) reported that post-mortem brain tissue from teenage suicide victims had increased mRNA and protein levels of IL-1\u03b2, IL-6, and tumor necrosis factor alpha (TNF-\u03b1) in certain cortical regions (Brodmann area 10).", [["brain tissue", "ANATOMY", 46, 58], ["cortical regions", "ANATOMY", 193, 209], ["Brodmann area", "ANATOMY", 211, 224], ["necrosis", "DISEASE", 152, 160], ["brain tissue", "TISSUE", 46, 58], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 129, 134], ["IL-6", "GENE_OR_GENE_PRODUCT", 136, 140], ["tumor necrosis factor alpha", "GENE_OR_GENE_PRODUCT", 146, 173], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 175, 180], ["cortical regions", "MULTI-TISSUE_STRUCTURE", 193, 209], ["IL-6", "PROTEIN", 136, 140], ["tumor necrosis factor alpha", "PROTEIN", 146, 173], ["TNF-\u03b1", "PROTEIN", 175, 180], ["post-mortem brain tissue", "PROBLEM", 34, 58], ["increased mRNA", "PROBLEM", 92, 106], ["protein levels", "TEST", 111, 125], ["IL", "TEST", 129, 131], ["IL", "TEST", 136, 138], ["tumor necrosis factor alpha", "PROBLEM", 146, 173], ["TNF", "TEST", 175, 178], ["brain tissue", "ANATOMY", 46, 58], ["tumor", "OBSERVATION_MODIFIER", 146, 151], ["necrosis", "OBSERVATION", 152, 160], ["alpha", "OBSERVATION_MODIFIER", 168, 173], ["cortical", "ANATOMY_MODIFIER", 193, 201], ["regions", "ANATOMY_MODIFIER", 202, 209], ["Brodmann", "ANATOMY_MODIFIER", 211, 219]]], ["More studies are clearly needed to support the relationship between inflammation and suicidality in youth, as suggested by a recent meta-analysis (Kim et al, 2014) .", [["inflammation", "DISEASE", 68, 80], ["suicidality", "DISEASE", 85, 96], ["inflammation", "PROBLEM", 68, 80], ["suicidality", "PROBLEM", 85, 96], ["inflammation", "OBSERVATION", 68, 80]]], ["Together, these studies suggest that suicidal individuals may have an inflammatory signature irrespective of their primary diagnoses and other underlying conditions.", [["individuals", "ORGANISM", 46, 57], ["these studies", "TEST", 10, 23], ["suicidal individuals", "PROBLEM", 37, 57], ["an inflammatory signature", "PROBLEM", 67, 92], ["other underlying conditions", "PROBLEM", 137, 164], ["inflammatory", "OBSERVATION", 70, 82]]], ["However, there are studies that also report a decrease in cytokine levels in suicidal individuals (Clark et al, 2016; Gabbay et al, 2009) .", [["cytokine", "PROTEIN", 58, 66], ["a decrease in cytokine levels in suicidal individuals", "PROBLEM", 44, 97], ["decrease", "OBSERVATION_MODIFIER", 46, 54]]], ["Although some of these discrepancies may be attributed to differences in sample size, study design, and relevant controls, it is critical to acknowledge the complexity of drawing definitive conclusions, while controlling for diverse confounding factors such as medication history, post-mortem tissue integrity, past psychiatric and substance abuse history, and previous suicide attempts.", [["tissue", "ANATOMY", 293, 299], ["psychiatric", "DISEASE", 316, 327], ["substance abuse", "DISEASE", 332, 347], ["tissue", "TISSUE", 293, 299], ["study design", "TEST", 86, 98], ["diverse confounding factors", "PROBLEM", 225, 252], ["post-mortem tissue integrity", "PROBLEM", 281, 309], ["may be attributed to", "UNCERTAINTY", 37, 57], ["size", "OBSERVATION_MODIFIER", 80, 84]]], ["In this context, meta-analyses provide a formal, qualitative assessment of previously published studies, which can then be used to derive conclusions.", [["qualitative assessment", "TEST", 49, 71], ["previously published studies", "TEST", 75, 103]]], ["In one such metaanalysis study that assessed changes in inflammatory cytokines in blood, CSF, and post-mortem tissue of suicidal individuals, Black et al found a robust association between increased suicidality and plasma levels of IL-1\u03b2 and IL-6.", [["blood", "ANATOMY", 82, 87], ["post-mortem tissue", "ANATOMY", 98, 116], ["plasma", "ANATOMY", 215, 221], ["suicidality", "DISEASE", 199, 210], ["blood", "ORGANISM_SUBSTANCE", 82, 87], ["CSF", "ORGANISM_SUBSTANCE", 89, 92], ["post-mortem tissue", "TISSUE", 98, 116], ["plasma", "ORGANISM_SUBSTANCE", 215, 221], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 232, 237], ["IL-6", "GENE_OR_GENE_PRODUCT", 242, 246], ["inflammatory cytokines", "PROTEIN", 56, 78], ["IL-1\u03b2", "PROTEIN", 232, 237], ["IL-6", "PROTEIN", 242, 246], ["one such metaanalysis study", "TEST", 3, 30], ["inflammatory cytokines in blood, CSF", "PROBLEM", 56, 92], ["suicidal individuals", "PROBLEM", 120, 140], ["Black et al", "PROBLEM", 142, 153], ["increased suicidality", "PROBLEM", 189, 210], ["plasma levels", "TEST", 215, 228], ["IL", "TEST", 232, 234], ["inflammatory", "OBSERVATION_MODIFIER", 56, 68], ["blood", "ANATOMY", 82, 87], ["CSF", "ANATOMY", 89, 92]]], ["These changes were significant to distinguish psychiatric patients with suicidality from psychiatric patients without suicidality and healthy controls.", [["psychiatric", "DISEASE", 46, 57], ["suicidality", "DISEASE", 72, 83], ["psychiatric", "DISEASE", 89, 100], ["suicidality", "DISEASE", 118, 129], ["patients", "ORGANISM", 58, 66], ["patients", "ORGANISM", 101, 109], ["patients", "SPECIES", 58, 66], ["patients", "SPECIES", 101, 109], ["suicidality", "PROBLEM", 72, 83], ["suicidality", "PROBLEM", 118, 129]]], ["They also found increased IL-1\u03b2 and IL-6 in post-mortem brain tissue from suicide completers and reported that reduced CSF levels of IL-8 were associated with suicidal behavior (Black and Miller, 2015) .INFLAMMATION AND SYMPTOMS OF SUICIDALITYIn an interesting study, Torres-Platas et al (2014) showed that depressed individuals who committed suicide have a greater proportion of activated microglia in the anterior cingulate cortex white matter compared with subjects without psychiatric disorders who died from other causes.", [["brain tissue", "ANATOMY", 56, 68], ["microglia", "ANATOMY", 390, 399], ["anterior cingulate cortex white matter", "ANATOMY", 407, 445], ["suicidal behavior", "DISEASE", 159, 176], ["depressed", "DISEASE", 307, 316], ["psychiatric disorders", "DISEASE", 477, 498], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 26, 31], ["IL-6", "GENE_OR_GENE_PRODUCT", 36, 40], ["brain tissue", "TISSUE", 56, 68], ["CSF", "GENE_OR_GENE_PRODUCT", 119, 122], ["IL-8", "GENE_OR_GENE_PRODUCT", 133, 137], ["individuals", "ORGANISM", 317, 328], ["microglia", "CELL", 390, 399], ["anterior cingulate cortex", "MULTI-TISSUE_STRUCTURE", 407, 432], ["IL-1\u03b2", "PROTEIN", 26, 31], ["IL-6", "PROTEIN", 36, 40], ["CSF", "PROTEIN", 119, 122], ["IL-8", "PROTEIN", 133, 137], ["activated microglia", "CELL_TYPE", 380, 399], ["increased IL", "PROBLEM", 16, 28], ["reduced CSF levels of IL", "PROBLEM", 111, 135], ["suicidal behavior", "PROBLEM", 159, 176], ["INFLAMMATION", "PROBLEM", 203, 215], ["SYMPTOMS", "PROBLEM", 220, 228], ["an interesting study", "TEST", 246, 266], ["depressed individuals", "PROBLEM", 307, 328], ["activated microglia in the anterior cingulate cortex white matter", "PROBLEM", 380, 445], ["psychiatric disorders", "PROBLEM", 477, 498], ["increased", "OBSERVATION_MODIFIER", 16, 25], ["IL", "OBSERVATION_MODIFIER", 26, 28], ["brain tissue", "ANATOMY", 56, 68], ["greater", "OBSERVATION_MODIFIER", 358, 365], ["activated microglia", "OBSERVATION", 380, 399], ["anterior", "ANATOMY_MODIFIER", 407, 415], ["cingulate cortex", "ANATOMY", 416, 432]]], ["The same group also had specific microglial phenotypes that were associated with concurrent increases in vascular density and increased expression of perivascular macrophage markers.", [["microglial", "ANATOMY", 33, 43], ["vascular", "ANATOMY", 105, 113], ["perivascular macrophage", "ANATOMY", 150, 173], ["microglial", "CELL", 33, 43], ["vascular", "MULTI-TISSUE_STRUCTURE", 105, 113], ["perivascular macrophage", "CELL", 150, 173], ["perivascular macrophage markers", "PROTEIN", 150, 181], ["specific microglial phenotypes", "PROBLEM", 24, 54], ["concurrent increases in vascular density", "PROBLEM", 81, 121], ["increased expression of perivascular macrophage markers", "PROBLEM", 126, 181], ["microglial phenotypes", "OBSERVATION", 33, 54], ["increases", "OBSERVATION_MODIFIER", 92, 101], ["vascular", "ANATOMY", 105, 113], ["density", "OBSERVATION", 114, 121], ["increased", "OBSERVATION_MODIFIER", 126, 135], ["expression", "OBSERVATION_MODIFIER", 136, 146], ["perivascular", "ANATOMY_MODIFIER", 150, 162], ["macrophage markers", "OBSERVATION", 163, 181]]], ["Schnieder et al (2014) reported similar findings, where they observed increased density of perivascular cells in prefrontal cortex white matter of suicide victims.", [["perivascular cells", "ANATOMY", 91, 109], ["prefrontal cortex white matter", "ANATOMY", 113, 143], ["perivascular cells", "CELL", 91, 109], ["prefrontal cortex", "MULTI-TISSUE_STRUCTURE", 113, 130], ["perivascular cells", "CELL_TYPE", 91, 109], ["increased density of perivascular cells", "PROBLEM", 70, 109], ["increased", "OBSERVATION_MODIFIER", 70, 79], ["density", "OBSERVATION", 80, 87], ["perivascular cells", "ANATOMY", 91, 109], ["prefrontal cortex", "ANATOMY", 113, 130]]], ["It is known that peripheral cytokines can be trafficked into the CNS either through regions with limited blood-brain barrier (BBB) permeability, such as the circumventricular organs and the choroid plexus, or through a compromised BBB (Dantzer et al, 2008) , which has been reported to be leaky in suicidal individuals (Bayard-Burfield et al, 1996; Falcone et al, 2010; Ventorp et al, 2016) .", [["CNS", "ANATOMY", 65, 68], ["blood-brain barrier", "ANATOMY", 105, 124], ["BBB", "ANATOMY", 126, 129], ["circumventricular organs", "ANATOMY", 157, 181], ["choroid plexus", "ANATOMY", 190, 204], ["CNS", "ANATOMICAL_SYSTEM", 65, 68], ["brain barrier", "TISSUE", 111, 124], ["BBB", "MULTI-TISSUE_STRUCTURE", 126, 129], ["circumventricular organs", "ORGAN", 157, 181], ["choroid plexus", "MULTI-TISSUE_STRUCTURE", 190, 204], ["BBB", "MULTI-TISSUE_STRUCTURE", 231, 234], ["peripheral cytokines", "PROTEIN", 17, 37], ["peripheral cytokines", "PROBLEM", 17, 37], ["peripheral", "ANATOMY_MODIFIER", 17, 27], ["cytokines", "OBSERVATION", 28, 37], ["CNS", "ANATOMY", 65, 68], ["brain", "ANATOMY", 111, 116], ["circumventricular organs", "ANATOMY", 157, 181], ["choroid plexus", "ANATOMY", 190, 204]]], ["In line with these findings, Wohleb et al demonstrated increased peripheral myeloid cell trafficking into perivascular spaces and specific brain regions using a repeated social defeat stress model.", [["peripheral myeloid cell", "ANATOMY", 65, 88], ["perivascular spaces", "ANATOMY", 106, 125], ["brain", "ANATOMY", 139, 144], ["peripheral myeloid cell", "CELL", 65, 88], ["perivascular spaces", "IMMATERIAL_ANATOMICAL_ENTITY", 106, 125], ["brain", "ORGAN", 139, 144], ["increased peripheral myeloid cell trafficking into perivascular spaces and specific brain regions", "PROBLEM", 55, 152], ["a repeated social defeat stress model", "TREATMENT", 159, 196], ["increased", "OBSERVATION_MODIFIER", 55, 64], ["peripheral myeloid cell trafficking", "OBSERVATION", 65, 100], ["perivascular", "ANATOMY_MODIFIER", 106, 118], ["brain", "ANATOMY", 139, 144], ["regions", "ANATOMY_MODIFIER", 145, 152]]], ["These changes were further accompanied by microglial activation and induction of anxiety-like behavior.", [["microglial", "ANATOMY", 42, 52], ["anxiety", "DISEASE", 81, 88], ["microglial", "CELL", 42, 52], ["microglial activation", "PROBLEM", 42, 63], ["anxiety", "PROBLEM", 81, 88], ["microglial activation", "OBSERVATION", 42, 63]]], ["This suggests an active role for peripheral myeloid cells in altering neuroimmune response and behavior (Wohleb et al, 2013) .", [["peripheral myeloid cells", "ANATOMY", 33, 57], ["peripheral myeloid cells", "CELL", 33, 57], ["peripheral myeloid cells", "CELL_TYPE", 33, 57], ["peripheral myeloid cells", "PROBLEM", 33, 57], ["active", "OBSERVATION_MODIFIER", 17, 23], ["peripheral myeloid cells", "OBSERVATION", 33, 57]]], ["Certain behavioral traits, such as impulsivity and aggression, have been found to confer a greater degree of suicide risk (Brent et al, 1994; McGirr et al, 2008) .", [["aggression", "DISEASE", 51, 61], ["Certain behavioral traits", "PROBLEM", 0, 25]]], ["Clinical studies also indicate a relationship between inflammation and traits of aggression and impulsivity (Coccaro et al, 2014; Isung et al, 2014; Mommersteeg et al, 2008; Suarez et al, 2002) .", [["inflammation", "DISEASE", 54, 66], ["aggression", "DISEASE", 81, 91], ["impulsivity", "DISEASE", 96, 107], ["Clinical studies", "TEST", 0, 16], ["inflammation", "PROBLEM", 54, 66], ["aggression", "PROBLEM", 81, 91], ["impulsivity", "PROBLEM", 96, 107], ["inflammation", "OBSERVATION", 54, 66]]], ["For example, in individuals with personality disorders, elevated TNF-\u03b1 and C-reactive protein (CRP) are associated with aggressive traits (Coccaro, 2006) .", [["personality disorders", "DISEASE", 33, 54], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 65, 70], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 75, 93], ["CRP", "GENE_OR_GENE_PRODUCT", 95, 98], ["TNF-\u03b1", "PROTEIN", 65, 70], ["C-reactive protein", "PROTEIN", 75, 93], ["CRP", "PROTEIN", 95, 98], ["personality disorders", "PROBLEM", 33, 54], ["elevated TNF", "PROBLEM", 56, 68], ["C-reactive protein", "PROBLEM", 75, 93], ["CRP", "TEST", 95, 98], ["reactive", "OBSERVATION_MODIFIER", 77, 85], ["aggressive", "OBSERVATION_MODIFIER", 120, 130]]], ["Recently, the same group demonstrated that plasma CRP and IL-6 levels are associated with aggressive behavior in individuals diagnosed with intermittent explosive disorders (Coccaro et al, 2014) .", [["plasma", "ANATOMY", 43, 49], ["aggressive behavior", "DISEASE", 90, 109], ["intermittent explosive disorders", "DISEASE", 140, 172], ["plasma", "ORGANISM_SUBSTANCE", 43, 49], ["CRP", "GENE_OR_GENE_PRODUCT", 50, 53], ["IL-6", "GENE_OR_GENE_PRODUCT", 58, 62], ["CRP", "PROTEIN", 50, 53], ["IL-6", "PROTEIN", 58, 62], ["plasma CRP", "TEST", 43, 53], ["IL", "TEST", 58, 60], ["aggressive behavior", "PROBLEM", 90, 109], ["intermittent explosive disorders", "PROBLEM", 140, 172], ["associated with", "UNCERTAINTY", 74, 89], ["aggressive", "OBSERVATION_MODIFIER", 90, 100]]], ["A study on suicide attempters by Isung et al (2014) found that plasma IL-6 levels were positively correlated with impulsivity trait and with violent suicide attempt methods.INFLAMMATION AND SYMPTOMS OF SUICIDALITYThe above-mentioned studies provide evidence that suicidal behavior is associated with the changes in cytokine profiles in peripheral blood as well as in the brain.", [["plasma", "ANATOMY", 63, 69], ["peripheral blood", "ANATOMY", 336, 352], ["brain", "ANATOMY", 371, 376], ["suicidal behavior", "DISEASE", 263, 280], ["plasma", "ORGANISM_SUBSTANCE", 63, 69], ["IL-6", "GENE_OR_GENE_PRODUCT", 70, 74], ["peripheral blood", "ORGANISM_SUBSTANCE", 336, 352], ["brain", "ORGAN", 371, 376], ["cytokine", "PROTEIN", 315, 323], ["A study", "TEST", 0, 7], ["plasma IL", "TEST", 63, 72], ["impulsivity trait", "PROBLEM", 114, 131], ["violent suicide attempt methods", "PROBLEM", 141, 172], ["INFLAMMATION", "PROBLEM", 173, 185], ["SYMPTOMS", "PROBLEM", 190, 198], ["SUICIDALITY", "PROBLEM", 202, 213], ["The above-mentioned studies", "TEST", 213, 240], ["suicidal behavior", "PROBLEM", 263, 280], ["the changes in cytokine profiles in peripheral blood", "PROBLEM", 300, 352], ["SUICIDALITY", "OBSERVATION", 202, 213], ["cytokine profiles", "OBSERVATION", 315, 332], ["peripheral", "ANATOMY_MODIFIER", 336, 346], ["blood", "ANATOMY", 347, 352], ["brain", "ANATOMY", 371, 376]]], ["In addition, it is important to determine whether such changes are specific for suicidal behavior, independent of underlying psychiatric diagnosis.", [["suicidal behavior", "DISEASE", 80, 97], ["psychiatric", "DISEASE", 125, 136], ["suicidal behavior", "PROBLEM", 80, 97]]], ["It is also of interest to assess whether similar or different degrees of inflammatory changes are found among individuals with suicidal ideation as well as among suicide attempters and completers.", [["suicidal ideation", "DISEASE", 127, 144], ["suicide attempters", "DISEASE", 162, 180], ["inflammatory changes", "PROBLEM", 73, 93], ["suicidal ideation", "PROBLEM", 127, 144], ["different degrees", "OBSERVATION_MODIFIER", 52, 69], ["inflammatory", "OBSERVATION", 73, 85]]], ["Addressing this, Janelidze et al (2011) observed plasma IL-6 and TNF-\u03b1 levels to be elevated in suicidal depressed individuals compared with non-suicidal depressed individuals and healthy controls, suggesting that suicidal individuals may have a unique cytokine profile among depressive patients.", [["plasma", "ANATOMY", 49, 55], ["suicidal depressed", "DISEASE", 96, 114], ["depressed", "DISEASE", 154, 163], ["depressive", "DISEASE", 276, 286], ["plasma", "ORGANISM_SUBSTANCE", 49, 55], ["IL-6", "GENE_OR_GENE_PRODUCT", 56, 60], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 65, 70], ["individuals", "ORGANISM", 223, 234], ["patients", "ORGANISM", 287, 295], ["plasma IL-6", "PROTEIN", 49, 60], ["TNF", "PROTEIN", 65, 68], ["cytokine", "PROTEIN", 253, 261], ["patients", "SPECIES", 287, 295], ["plasma IL", "TEST", 49, 58], ["TNF-\u03b1 levels", "TEST", 65, 77], ["elevated", "PROBLEM", 84, 92], ["suicidal depressed individuals", "PROBLEM", 96, 126], ["non-suicidal depressed individuals", "PROBLEM", 141, 175], ["suicidal individuals", "PROBLEM", 214, 234]]], ["Supporting this, O'Donovan et al (2013) found that a higher degree of suicidal ideation was associated with an increased inflammatory index in patients independent of the degree of depressive symptoms.", [["suicidal ideation", "DISEASE", 70, 87], ["depressive symptoms", "DISEASE", 181, 200], ["patients", "ORGANISM", 143, 151], ["patients", "SPECIES", 143, 151], ["suicidal ideation", "PROBLEM", 70, 87], ["an increased inflammatory index", "PROBLEM", 108, 139], ["depressive symptoms", "PROBLEM", 181, 200], ["increased", "OBSERVATION_MODIFIER", 111, 120], ["inflammatory index", "OBSERVATION", 121, 139]]], ["These findings are in line with an early hallmark study, showing increased microglial density in schizophrenic and depressed suicide completers, although not in patients from the same diagnostic groups that died from other causes, stressing that the inflammatory changes might be specific to suicidality across diagnostic boundaries (Steiner et al, 2008) .NEUROIMMUNOLOGICAL MECHANISMS INVOLVED IN SUICIDAL BEHAVIORInflammatory cytokines can be synthesized in the central nervous system or enter the brain from the periphery via different mechanisms, including compromised BBB.", [["microglial", "ANATOMY", 75, 85], ["central nervous system", "ANATOMY", 464, 486], ["brain", "ANATOMY", 500, 505], ["BBB", "ANATOMY", 573, 576], ["schizophrenic", "DISEASE", 97, 110], ["depressed", "DISEASE", 115, 124], ["suicidality", "DISEASE", 292, 303], ["microglial", "CELL", 75, 85], ["patients", "ORGANISM", 161, 169], ["central nervous system", "ANATOMICAL_SYSTEM", 464, 486], ["brain", "ORGAN", 500, 505], ["periphery", "IMMATERIAL_ANATOMICAL_ENTITY", 515, 524], ["BBB", "MULTI-TISSUE_STRUCTURE", 573, 576], ["cytokines", "PROTEIN", 428, 437], ["patients", "SPECIES", 161, 169], ["an early hallmark study", "TEST", 32, 55], ["increased microglial density in schizophrenic and depressed suicide completers", "PROBLEM", 65, 143], ["the inflammatory changes", "PROBLEM", 246, 270], ["SUICIDAL BEHAVIORInflammatory cytokines", "PROBLEM", 398, 437], ["increased", "OBSERVATION_MODIFIER", 65, 74], ["microglial density", "OBSERVATION", 75, 93], ["schizophrenic", "OBSERVATION_MODIFIER", 97, 110], ["depressed", "OBSERVATION_MODIFIER", 115, 124], ["inflammatory", "OBSERVATION", 250, 262], ["central", "ANATOMY_MODIFIER", 464, 471], ["nervous system", "ANATOMY", 472, 486], ["brain", "ANATOMY", 500, 505], ["periphery", "ANATOMY_MODIFIER", 515, 524]]], ["We have previously shown that suicide attempters have an increased BBB permeability, which is associated with increased CSF levels of glycosaminoglycan hyaluronic acid, which is a ligand for CD44 and is indicative of increased neuroinflammation (Ventorp et al, 2016) .NEUROIMMUNOLOGICAL MECHANISMS INVOLVED IN SUICIDAL BEHAVIOROne of the mechanisms, which could be responsible for the observed increase in inflammatory cytokine levels, is activation of the Toll-like receptors (TLRs).", [["BBB", "ANATOMY", 67, 70], ["suicide attempters", "DISEASE", 30, 48], ["glycosaminoglycan", "CHEMICAL", 134, 151], ["hyaluronic acid", "CHEMICAL", 152, 167], ["neuroinflammation", "DISEASE", 227, 244], ["BBB", "TISSUE", 67, 70], ["CSF", "GENE_OR_GENE_PRODUCT", 120, 123], ["glycosaminoglycan hyaluronic acid", "SIMPLE_CHEMICAL", 134, 167], ["CD44", "GENE_OR_GENE_PRODUCT", 191, 195], ["Toll-like receptors", "GENE_OR_GENE_PRODUCT", 457, 476], ["TLRs", "GENE_OR_GENE_PRODUCT", 478, 482], ["CSF", "PROTEIN", 120, 123], ["CD44", "PROTEIN", 191, 195], ["inflammatory cytokine", "PROTEIN", 406, 427], ["Toll-like receptors", "PROTEIN", 457, 476], ["TLRs", "PROTEIN", 478, 482], ["an increased BBB permeability", "PROBLEM", 54, 83], ["increased CSF levels of glycosaminoglycan hyaluronic acid", "PROBLEM", 110, 167], ["CD44", "PROBLEM", 191, 195], ["increased neuroinflammation", "PROBLEM", 217, 244], ["the observed increase in inflammatory cytokine levels", "PROBLEM", 381, 434], ["increased", "OBSERVATION_MODIFIER", 57, 66], ["BBB permeability", "OBSERVATION", 67, 83], ["increased", "OBSERVATION_MODIFIER", 110, 119], ["CSF levels", "OBSERVATION", 120, 130], ["hyaluronic acid", "OBSERVATION", 152, 167], ["indicative of", "UNCERTAINTY", 203, 216], ["increased", "OBSERVATION_MODIFIER", 217, 226], ["neuroinflammation", "OBSERVATION", 227, 244], ["increase", "OBSERVATION_MODIFIER", 394, 402], ["inflammatory cytokine levels", "OBSERVATION", 406, 434]]], ["TLRs have a critical role in regulating innate immune response and facilitating immune function in the event of infection (Hanke and Kielian, 2011) .", [["infection", "DISEASE", 112, 121], ["TLRs", "GENE_OR_GENE_PRODUCT", 0, 4], ["TLRs", "PROTEIN", 0, 4], ["infection", "PROBLEM", 112, 121], ["infection", "OBSERVATION", 112, 121]]], ["They are widely expressed in different cell types of the CNS and are identified to have diverse functions, from cognition to memory (Okun et al, 2010; Okun et al, 2011) .", [["cell", "ANATOMY", 39, 43], ["CNS", "ANATOMY", 57, 60], ["cell", "CELL", 39, 43], ["CNS", "ANATOMICAL_SYSTEM", 57, 60], ["different cell types", "OBSERVATION", 29, 49]]], ["In the only study to date on suicidal subjects, Pandey et al (2014) , concluded that, irrespective of psychiatric diagnoses, mRNA and protein levels of TLR3 and TLR4 were consistently dysregulated in suicide victims (depressed and non-depressed).", [["psychiatric", "DISEASE", 102, 113], ["depressed", "DISEASE", 217, 226], ["non-depressed", "DISEASE", 231, 244], ["TLR3", "GENE_OR_GENE_PRODUCT", 152, 156], ["TLR4", "GENE_OR_GENE_PRODUCT", 161, 165], ["TLR3", "PROTEIN", 152, 156], ["TLR4", "PROTEIN", 161, 165], ["psychiatric diagnoses", "PROBLEM", 102, 123], ["mRNA and protein levels", "TEST", 125, 148], ["TLR3", "TEST", 152, 156], ["TLR4", "TEST", 161, 165], ["depressed", "PROBLEM", 217, 226]]], ["Although preliminary, this study, for the first time, demonstrated the role of TLRs in suicide.NEUROIMMUNOLOGICAL MECHANISMS INVOLVED IN SUICIDAL BEHAVIORInflammatory cytokines may promote suicidal behavior by several mechanisms.", [["suicidal behavior", "DISEASE", 189, 206], ["TLRs", "GENE_OR_GENE_PRODUCT", 79, 83], ["TLRs", "PROTEIN", 79, 83], ["cytokines", "PROTEIN", 167, 176], ["this study", "TEST", 22, 32], ["SUICIDAL BEHAVIORInflammatory cytokines", "TREATMENT", 137, 176], ["suicidal behavior", "PROBLEM", 189, 206]]], ["Additional mechanisms by which cytokines may contribute to the pathophysiology of suicidal behavior include activation of the kynurenine pathway of tryptophan catabolism, dysregulation of the HPA axis and alterations in monoamine metabolism, as described below.NEUROIMMUNOLOGICAL MECHANISMS INVOLVED IN SUICIDAL BEHAVIORThe kynurenine pathway consists of a series of enzymes involved in the metabolism of the essential amino acid, tryptophan.", [["suicidal behavior", "DISEASE", 82, 99], ["kynurenine", "CHEMICAL", 126, 136], ["tryptophan", "CHEMICAL", 148, 158], ["kynurenine", "CHEMICAL", 324, 334], ["amino acid", "CHEMICAL", 419, 429], ["tryptophan", "CHEMICAL", 431, 441], ["kynurenine", "CHEMICAL", 126, 136], ["tryptophan", "CHEMICAL", 148, 158], ["monoamine", "CHEMICAL", 220, 229], ["kynurenine", "CHEMICAL", 324, 334], ["amino acid", "CHEMICAL", 419, 429], ["tryptophan", "CHEMICAL", 431, 441], ["kynurenine", "SIMPLE_CHEMICAL", 126, 136], ["tryptophan", "SIMPLE_CHEMICAL", 148, 158], ["monoamine", "SIMPLE_CHEMICAL", 220, 229], ["kynurenine", "SIMPLE_CHEMICAL", 324, 334], ["amino acid", "AMINO_ACID", 419, 429], ["tryptophan", "SIMPLE_CHEMICAL", 431, 441], ["cytokines", "PROTEIN", 31, 40], ["enzymes", "PROTEIN", 367, 374], ["suicidal behavior", "PROBLEM", 82, 99], ["tryptophan catabolism", "PROBLEM", 148, 169], ["dysregulation of the HPA axis", "PROBLEM", 171, 200], ["alterations in monoamine metabolism", "PROBLEM", 205, 240], ["The kynurenine pathway", "TEST", 320, 342], ["a series of enzymes", "TEST", 355, 374], ["HPA axis", "ANATOMY", 192, 200], ["monoamine metabolism", "OBSERVATION", 220, 240], ["amino acid", "OBSERVATION", 419, 429]]], ["The pathway is active in the periphery as well as in the central nervous system.", [["periphery", "ANATOMY", 29, 38], ["central nervous system", "ANATOMY", 57, 79], ["central nervous system", "ANATOMICAL_SYSTEM", 57, 79], ["active", "OBSERVATION_MODIFIER", 15, 21], ["periphery", "ANATOMY_MODIFIER", 29, 38], ["central", "ANATOMY_MODIFIER", 57, 64], ["nervous system", "ANATOMY", 65, 79]]], ["The initial step in metabolism of tryptophan into kynurenine is catalyzed by indoleamine 2,3-dioxygenase (IDO) or tryptophan 2,3-dioxygenase (TDO).", [["tryptophan", "CHEMICAL", 34, 44], ["kynurenine", "CHEMICAL", 50, 60], ["indoleamine 2,3-dioxygenase", "CHEMICAL", 77, 104], ["tryptophan", "CHEMICAL", 114, 124], ["tryptophan", "CHEMICAL", 34, 44], ["kynurenine", "CHEMICAL", 50, 60], ["indoleamine", "CHEMICAL", 77, 88], ["tryptophan", "CHEMICAL", 114, 124], ["tryptophan", "AMINO_ACID", 34, 44], ["kynurenine", "SIMPLE_CHEMICAL", 50, 60], ["indoleamine 2,3-dioxygenase", "GENE_OR_GENE_PRODUCT", 77, 104], ["IDO", "GENE_OR_GENE_PRODUCT", 106, 109], ["tryptophan 2,3-dioxygenase", "SIMPLE_CHEMICAL", 114, 140], ["TDO", "SIMPLE_CHEMICAL", 142, 145], ["indoleamine 2,3-dioxygenase", "PROTEIN", 77, 104], ["IDO", "PROTEIN", 106, 109], ["tryptophan 2,3-dioxygenase", "PROTEIN", 114, 140], ["TDO", "PROTEIN", 142, 145], ["tryptophan into kynurenine", "TREATMENT", 34, 60], ["tryptophan", "TREATMENT", 114, 124]]], ["Kynurenine is further broken down into highly neuroactive compounds such as quinolinic acid (QUIN) and kynurenic acid (KYNA).", [["Kynurenine", "CHEMICAL", 0, 10], ["quinolinic acid", "CHEMICAL", 76, 91], ["QUIN", "CHEMICAL", 93, 97], ["kynurenic acid", "CHEMICAL", 103, 117], ["KYNA", "CHEMICAL", 119, 123], ["Kynurenine", "CHEMICAL", 0, 10], ["quinolinic acid", "CHEMICAL", 76, 91], ["QUIN", "CHEMICAL", 93, 97], ["kynurenic acid", "CHEMICAL", 103, 117], ["KYNA", "CHEMICAL", 119, 123], ["Kynurenine", "SIMPLE_CHEMICAL", 0, 10], ["quinolinic acid", "SIMPLE_CHEMICAL", 76, 91], ["QUIN", "SIMPLE_CHEMICAL", 93, 97], ["kynurenic acid", "SIMPLE_CHEMICAL", 103, 117], ["KYNA", "SIMPLE_CHEMICAL", 119, 123], ["Kynurenine", "TREATMENT", 0, 10], ["quinolinic acid (QUIN)", "TREATMENT", 76, 98], ["kynurenic acid (KYNA)", "TREATMENT", 103, 124]]], ["Inflammatory cytokines such as IFN-\u03b3, IL-6, IL-1\u03b2, and TNF-\u03b1 are potent activators of IDO and/or TDO (Kim et al, 2012; Mandi and Vecsei, 2012; Schwieler et al, 2015; Taylor and Feng, 1991; Urata et al, 2014) .", [["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 31, 36], ["IL-6", "GENE_OR_GENE_PRODUCT", 38, 42], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 44, 49], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 55, 60], ["IDO", "GENE_OR_GENE_PRODUCT", 86, 89], ["TDO", "GENE_OR_GENE_PRODUCT", 97, 100], ["Inflammatory cytokines", "PROTEIN", 0, 22], ["IFN-\u03b3, IL-6, IL-1\u03b2", "PROTEIN", 31, 49], ["TNF", "PROTEIN", 55, 58], ["IDO", "PROTEIN", 86, 89], ["Inflammatory cytokines", "PROBLEM", 0, 22], ["IFN", "TEST", 31, 34], ["IL", "TEST", 38, 40], ["IL", "TEST", 44, 46], ["TNF", "TEST", 55, 58], ["IDO", "TEST", 86, 89]]], ["QUIN is one of the neuroactive metabolite that is synthesized in microglia.", [["microglia", "ANATOMY", 65, 74], ["QUIN", "CHEMICAL", 0, 4], ["QUIN", "CHEMICAL", 0, 4], ["QUIN", "SIMPLE_CHEMICAL", 0, 4], ["microglia", "CELL", 65, 74], ["microglia", "CELL_TYPE", 65, 74], ["neuroactive metabolite", "OBSERVATION", 19, 41], ["microglia", "ANATOMY", 65, 74]]], ["QUIN is a selective N-methyl-Daspartic acid (NMDA) receptor agonist and acts via activation of the NR1+NR2A and NR1+NR2B NMDA receptor subunits (de Carvalho et al, 1996) .", [["QUIN", "CHEMICAL", 0, 4], ["N-methyl-Daspartic acid", "CHEMICAL", 20, 43], ["NMDA", "CHEMICAL", 45, 49], ["NMDA", "CHEMICAL", 121, 125], ["QUIN", "CHEMICAL", 0, 4], ["N-methyl-Daspartic acid", "CHEMICAL", 20, 43], ["NMDA", "CHEMICAL", 45, 49], ["NMDA", "CHEMICAL", 121, 125], ["QUIN", "SIMPLE_CHEMICAL", 0, 4], ["N-methyl-Daspartic acid", "SIMPLE_CHEMICAL", 20, 43], ["NMDA", "SIMPLE_CHEMICAL", 45, 49], ["NR1+NR2A", "GENE_OR_GENE_PRODUCT", 99, 107], ["NR1+NR2B NMDA receptor", "GENE_OR_GENE_PRODUCT", 112, 134], ["NR1", "PROTEIN", 99, 102], ["NR2A", "PROTEIN", 103, 107], ["NR1", "PROTEIN", 112, 115], ["NR2B NMDA receptor subunits", "PROTEIN", 116, 143], ["a selective N-methyl-Daspartic acid (NMDA) receptor agonist", "TREATMENT", 8, 67], ["the NR1", "TREATMENT", 95, 102], ["NR2B NMDA receptor subunits", "TREATMENT", 116, 143]]], ["In addition to NMDA receptor activation, QUIN also inhibits astrocytic uptake of glutamate by inhibiting glutamine synthetase and increases neuronal glutamate release (Tavares et al, 2002) .", [["astrocytic", "ANATOMY", 60, 70], ["neuronal", "ANATOMY", 140, 148], ["NMDA", "CHEMICAL", 15, 19], ["QUIN", "CHEMICAL", 41, 45], ["glutamate", "CHEMICAL", 81, 90], ["glutamine", "CHEMICAL", 105, 114], ["glutamate", "CHEMICAL", 149, 158], ["NMDA", "CHEMICAL", 15, 19], ["QUIN", "CHEMICAL", 41, 45], ["glutamate", "CHEMICAL", 81, 90], ["glutamine", "CHEMICAL", 105, 114], ["glutamate", "CHEMICAL", 149, 158], ["NMDA", "SIMPLE_CHEMICAL", 15, 19], ["QUIN", "SIMPLE_CHEMICAL", 41, 45], ["astrocytic", "IMMATERIAL_ANATOMICAL_ENTITY", 60, 70], ["glutamate", "SIMPLE_CHEMICAL", 81, 90], ["glutamine synthetase", "GENE_OR_GENE_PRODUCT", 105, 125], ["neuronal", "CELL", 140, 148], ["glutamate", "SIMPLE_CHEMICAL", 149, 158], ["NMDA receptor", "PROTEIN", 15, 28], ["glutamine synthetase", "PROTEIN", 105, 125], ["NMDA receptor activation", "TREATMENT", 15, 39], ["astrocytic uptake of glutamate", "PROBLEM", 60, 90], ["inhibiting glutamine synthetase", "TREATMENT", 94, 125], ["neuronal glutamate release", "TREATMENT", 140, 166]]], ["KYNA, on the other hand, blocks the cholinergic \u03b17 nicotinic receptor and antagonizes the glycine site of the NMDA receptor (Hilmas et al, 2001; Stone, 1993) .", [["KYNA", "CHEMICAL", 0, 4], ["glycine", "CHEMICAL", 90, 97], ["NMDA", "CHEMICAL", 110, 114], ["KYNA", "CHEMICAL", 0, 4], ["glycine", "CHEMICAL", 90, 97], ["NMDA", "CHEMICAL", 110, 114], ["KYNA", "SIMPLE_CHEMICAL", 0, 4], ["\u03b17 nicotinic receptor", "GENE_OR_GENE_PRODUCT", 48, 69], ["glycine", "AMINO_ACID", 90, 97], ["NMDA receptor", "GENE_OR_GENE_PRODUCT", 110, 123], ["cholinergic \u03b17 nicotinic receptor", "PROTEIN", 36, 69], ["NMDA receptor", "PROTEIN", 110, 123], ["KYNA", "TEST", 0, 4], ["the cholinergic \u03b17 nicotinic receptor", "TREATMENT", 32, 69], ["antagonizes the glycine site", "TREATMENT", 74, 102], ["Stone", "OBSERVATION", 145, 150]]], ["KYNA also antagonizes \u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor, which has been implicated in the pathophysiology of depression and in the mechanism of action of several antidepressant drugs (Freudenberg et al, 2015; Schwarcz et al, 2012) .", [["KYNA", "CHEMICAL", 0, 4], ["\u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid", "CHEMICAL", 22, 74], ["AMPA", "CHEMICAL", 76, 80], ["depression", "DISEASE", 144, 154], ["antidepressant", "CHEMICAL", 197, 211], ["KYNA", "CHEMICAL", 0, 4], ["\u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid", "CHEMICAL", 22, 74], ["AMPA", "CHEMICAL", 76, 80], ["KYNA", "SIMPLE_CHEMICAL", 0, 4], ["\u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid", "SIMPLE_CHEMICAL", 22, 74], ["AMPA", "SIMPLE_CHEMICAL", 76, 80], ["KYNA", "TEST", 0, 4], ["\u03b1-amino", "TEST", 22, 29], ["hydroxy", "TREATMENT", 32, 39], ["methyl", "TREATMENT", 42, 48], ["isoxazolepropionic acid (AMPA) receptor", "TREATMENT", 51, 90], ["depression", "PROBLEM", 144, 154], ["several antidepressant drugs", "TREATMENT", 189, 217], ["depression", "OBSERVATION", 144, 154]]], ["We found QUIN levels in CSF of suicide attempters to be two to three times higher than in healthy controls with no change in KYNA levels.", [["QUIN", "CHEMICAL", 9, 13], ["KYNA", "CHEMICAL", 125, 129], ["QUIN", "CHEMICAL", 9, 13], ["KYNA", "CHEMICAL", 125, 129], ["QUIN", "SIMPLE_CHEMICAL", 9, 13], ["CSF", "ORGANISM_SUBSTANCE", 24, 27], ["KYNA", "SIMPLE_CHEMICAL", 125, 129], ["QUIN levels", "TEST", 9, 20], ["suicide attempters", "PROBLEM", 31, 49], ["change in KYNA levels", "PROBLEM", 115, 136], ["QUIN levels", "OBSERVATION", 9, 20], ["no", "UNCERTAINTY", 112, 114], ["change", "OBSERVATION_MODIFIER", 115, 121]]], ["Interestingly, in the same study, QUIN levels positively correlated with IL-6 in CSF, indicating that the activation of the kynurenine pathway in these patients was associated with an active inflammatory state.", [["QUIN", "CHEMICAL", 34, 38], ["kynurenine", "CHEMICAL", 124, 134], ["QUIN", "CHEMICAL", 34, 38], ["kynurenine", "CHEMICAL", 124, 134], ["QUIN", "SIMPLE_CHEMICAL", 34, 38], ["IL-6", "GENE_OR_GENE_PRODUCT", 73, 77], ["CSF", "GENE_OR_GENE_PRODUCT", 81, 84], ["kynurenine", "SIMPLE_CHEMICAL", 124, 134], ["patients", "ORGANISM", 152, 160], ["IL-6", "PROTEIN", 73, 77], ["patients", "SPECIES", 152, 160], ["the same study", "TEST", 18, 32], ["QUIN levels", "TEST", 34, 45], ["IL", "TEST", 73, 75], ["the kynurenine pathway", "PROBLEM", 120, 142], ["an active inflammatory state", "PROBLEM", 181, 209], ["active", "OBSERVATION_MODIFIER", 184, 190], ["inflammatory", "OBSERVATION", 191, 203]]], ["The increase in QUIN was also correlated with the suicidal intent in this cohort of patients (Erhardt et al, 2013) .", [["QUIN", "CHEMICAL", 16, 20], ["QUIN", "CHEMICAL", 16, 20], ["QUIN", "SIMPLE_CHEMICAL", 16, 20], ["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 84, 92], ["The increase in QUIN", "PROBLEM", 0, 20], ["the suicidal intent", "PROBLEM", 46, 65], ["increase", "OBSERVATION_MODIFIER", 4, 12], ["QUIN", "OBSERVATION", 16, 20]]], ["Furthermore, to determine whether QUIN levels remain elevated over time, we measured CSF QUIN for two continuous years after an initial suicide attempt.", [["QUIN", "CHEMICAL", 34, 38], ["QUIN", "CHEMICAL", 89, 93], ["QUIN", "CHEMICAL", 34, 38], ["QUIN", "CHEMICAL", 89, 93], ["QUIN", "SIMPLE_CHEMICAL", 34, 38], ["CSF", "GENE_OR_GENE_PRODUCT", 85, 88], ["QUIN", "SIMPLE_CHEMICAL", 89, 93], ["QUIN levels", "TEST", 34, 45], ["elevated", "PROBLEM", 53, 61], ["CSF QUIN", "TEST", 85, 93], ["an initial suicide attempt", "TREATMENT", 125, 151], ["elevated", "OBSERVATION", 53, 61]]], ["Not only did we find QUIN to be elevated over 2 years, we also observed that high levels of IL-6 and lower KYNA in the same patient group correlated with the severity of suicidal ideation and depressive symptoms (Bay-Richter et al, 2015) .", [["QUIN", "CHEMICAL", 21, 25], ["KYNA", "CHEMICAL", 107, 111], ["suicidal ideation", "DISEASE", 170, 187], ["depressive symptoms", "DISEASE", 192, 211], ["QUIN", "CHEMICAL", 21, 25], ["KYNA", "CHEMICAL", 107, 111], ["QUIN", "SIMPLE_CHEMICAL", 21, 25], ["IL-6", "GENE_OR_GENE_PRODUCT", 92, 96], ["KYNA", "SIMPLE_CHEMICAL", 107, 111], ["patient", "ORGANISM", 124, 131], ["IL-6", "PROTEIN", 92, 96], ["patient", "SPECIES", 124, 131], ["QUIN", "PROBLEM", 21, 25], ["IL", "TEST", 92, 94], ["lower KYNA", "PROBLEM", 101, 111], ["suicidal ideation", "PROBLEM", 170, 187], ["depressive symptoms", "PROBLEM", 192, 211], ["lower KYNA", "ANATOMY", 101, 111]]], ["Interestingly, a post-mortem study found increased QUIN immunoreactivity in suicidal depressed patients seemingly in agreement with our findings (Steiner et al, 2011) .", [["QUIN", "CHEMICAL", 51, 55], ["suicidal depressed", "DISEASE", 76, 94], ["QUIN", "CHEMICAL", 51, 55], ["QUIN", "SIMPLE_CHEMICAL", 51, 55], ["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 95, 103], ["a post-mortem study", "TEST", 15, 34], ["increased QUIN immunoreactivity", "PROBLEM", 41, 72], ["increased", "OBSERVATION_MODIFIER", 41, 50], ["QUIN immunoreactivity", "OBSERVATION", 51, 72]]], ["In the same study, certain regions of the anterior cingulate cortex in suicide victims reportedly contained higher density of QUIN-positive microglia.", [["anterior cingulate cortex", "ANATOMY", 42, 67], ["microglia", "ANATOMY", 140, 149], ["QUIN", "CHEMICAL", 126, 130], ["QUIN", "CHEMICAL", 126, 130], ["anterior cingulate cortex", "MULTI-TISSUE_STRUCTURE", 42, 67], ["QUIN", "SIMPLE_CHEMICAL", 126, 130], ["microglia", "CELL", 140, 149], ["QUIN-positive microglia", "CELL_LINE", 126, 149], ["the same study", "TEST", 3, 17], ["QUIN-positive microglia", "PROBLEM", 126, 149], ["anterior", "ANATOMY_MODIFIER", 42, 50], ["cingulate cortex", "ANATOMY", 51, 67], ["higher density", "OBSERVATION_MODIFIER", 108, 122], ["positive microglia", "OBSERVATION", 131, 149]]], ["However, a follow-up study found a decrease in the number of QUIN reactive microglia in the hippocampi from the same suicide victims (Busse et al, 2015) .", [["microglia", "ANATOMY", 75, 84], ["hippocampi", "ANATOMY", 92, 102], ["QUIN", "CHEMICAL", 61, 65], ["QUIN", "CHEMICAL", 61, 65], ["QUIN", "SIMPLE_CHEMICAL", 61, 65], ["microglia", "CELL", 75, 84], ["hippocampi", "ORGAN", 92, 102], ["microglia", "CELL_TYPE", 75, 84], ["a follow-up study", "TEST", 9, 26], ["a decrease", "PROBLEM", 33, 43], ["QUIN reactive microglia in the hippocampi", "PROBLEM", 61, 102], ["decrease", "OBSERVATION_MODIFIER", 35, 43], ["QUIN", "OBSERVATION", 61, 65], ["reactive microglia", "OBSERVATION", 66, 84], ["hippocampi", "ANATOMY", 92, 102]]], ["These findings suggest that certain brain regions may be more sensitive to inflammatory insult, which might have contributed to specific differences in the localization of QUIN reactive microglia in the brains of suicide victims.", [["brain", "ANATOMY", 36, 41], ["microglia", "ANATOMY", 186, 195], ["brains", "ANATOMY", 203, 209], ["QUIN", "CHEMICAL", 172, 176], ["QUIN", "CHEMICAL", 172, 176], ["brain", "ORGAN", 36, 41], ["QUIN", "SIMPLE_CHEMICAL", 172, 176], ["microglia", "CELL", 186, 195], ["brains", "ORGAN", 203, 209], ["microglia", "CELL_TYPE", 186, 195], ["certain brain regions", "PROBLEM", 28, 49], ["inflammatory insult", "PROBLEM", 75, 94], ["QUIN reactive microglia", "PROBLEM", 172, 195], ["inflammatory", "OBSERVATION_MODIFIER", 75, 87], ["reactive microglia", "OBSERVATION", 177, 195]]], ["On the other hand, plasma KYNA has been previously shown to be reduced in depressed patients, although neither QUIN nor cytokine levels were profiled in these patients (Myint et al, 2007) .", [["plasma", "ANATOMY", 19, 25], ["KYNA", "CHEMICAL", 26, 30], ["depressed", "DISEASE", 74, 83], ["QUIN", "CHEMICAL", 111, 115], ["KYNA", "CHEMICAL", 26, 30], ["QUIN", "CHEMICAL", 111, 115], ["plasma", "ORGANISM_SUBSTANCE", 19, 25], ["KYNA", "SIMPLE_CHEMICAL", 26, 30], ["patients", "ORGANISM", 84, 92], ["QUIN", "SIMPLE_CHEMICAL", 111, 115], ["patients", "ORGANISM", 159, 167], ["cytokine", "PROTEIN", 120, 128], ["patients", "SPECIES", 84, 92], ["patients", "SPECIES", 159, 167], ["plasma KYNA", "TEST", 19, 30], ["QUIN nor cytokine levels", "TEST", 111, 135], ["reduced", "OBSERVATION_MODIFIER", 63, 70], ["depressed", "OBSERVATION_MODIFIER", 74, 83]]], ["Interestingly, we found a twofold increase in CSF QUIN/KYNA ratio in suicide attempters compared with healthy controls.", [["QUIN", "CHEMICAL", 50, 54], ["KYNA", "CHEMICAL", 55, 59], ["suicide attempters", "DISEASE", 69, 87], ["QUIN", "CHEMICAL", 50, 54], ["KYNA", "CHEMICAL", 55, 59], ["CSF", "GENE_OR_GENE_PRODUCT", 46, 49], ["QUIN", "SIMPLE_CHEMICAL", 50, 54], ["KYNA", "SIMPLE_CHEMICAL", 55, 59], ["a twofold increase in CSF QUIN/KYNA ratio", "PROBLEM", 24, 65], ["twofold", "OBSERVATION_MODIFIER", 26, 33], ["increase", "OBSERVATION_MODIFIER", 34, 42], ["CSF QUIN", "OBSERVATION", 46, 54]]], ["KYNA, being an NMDA receptor antagonist, may induce a net positive effect on NMDA receptor signaling leading to aberrant glutamate signaling (Erhardt et al, 2013) .NEUROIMMUNOLOGICAL MECHANISMS INVOLVED IN SUICIDAL BEHAVIOREvidence suggests that the dysregulation of the kynurenine pathway might be more pronounced in depressed individuals with suicidality than depressed patients without suicidal behavior.", [["KYNA", "CHEMICAL", 0, 4], ["NMDA", "CHEMICAL", 15, 19], ["NMDA", "CHEMICAL", 77, 81], ["glutamate", "CHEMICAL", 121, 130], ["kynurenine", "CHEMICAL", 271, 281], ["depressed", "DISEASE", 318, 327], ["suicidality", "DISEASE", 345, 356], ["depressed", "DISEASE", 362, 371], ["suicidal behavior", "DISEASE", 389, 406], ["KYNA", "CHEMICAL", 0, 4], ["NMDA", "CHEMICAL", 15, 19], ["NMDA", "CHEMICAL", 77, 81], ["glutamate", "CHEMICAL", 121, 130], ["kynurenine", "CHEMICAL", 271, 281], ["KYNA", "SIMPLE_CHEMICAL", 0, 4], ["NMDA", "SIMPLE_CHEMICAL", 15, 19], ["NMDA receptor", "GENE_OR_GENE_PRODUCT", 77, 90], ["glutamate", "SIMPLE_CHEMICAL", 121, 130], ["kynurenine", "SIMPLE_CHEMICAL", 271, 281], ["patients", "ORGANISM", 372, 380], ["NMDA receptor", "PROTEIN", 77, 90], ["patients", "SPECIES", 372, 380], ["KYNA", "TEST", 0, 4], ["an NMDA receptor antagonist", "TREATMENT", 12, 39], ["a net positive effect", "PROBLEM", 52, 73], ["NMDA receptor signaling", "TREATMENT", 77, 100], ["aberrant glutamate signaling", "PROBLEM", 112, 140], ["the dysregulation of the kynurenine pathway", "PROBLEM", 246, 289], ["suicidality", "PROBLEM", 345, 356], ["suicidal behavior", "PROBLEM", 389, 406], ["aberrant", "OBSERVATION_MODIFIER", 112, 120], ["glutamate signaling", "OBSERVATION", 121, 140]]], ["Sublette et al (2011) were the first to demonstrate that blood kynurenine levels are elevated in suicide attempters compared with a depressed-only control group.", [["blood", "ANATOMY", 57, 62], ["kynurenine", "CHEMICAL", 63, 73], ["suicide attempters", "DISEASE", 97, 115], ["depressed", "DISEASE", 132, 141], ["kynurenine", "CHEMICAL", 63, 73], ["blood", "ORGANISM_SUBSTANCE", 57, 62], ["kynurenine", "SIMPLE_CHEMICAL", 63, 73], ["blood kynurenine levels", "TEST", 57, 80], ["elevated", "PROBLEM", 85, 93], ["a depressed", "PROBLEM", 130, 141], ["elevated", "OBSERVATION_MODIFIER", 85, 93]]], ["Interestingly, Dahl et al (2015) also reported that depressive episodes in MDD patients are not associated with an increase in plasma kynurenine metabolite levels, despite the presence of elevated cytokine levels in these individuals.", [["plasma", "ANATOMY", 127, 133], ["depressive episodes", "DISEASE", 52, 71], ["MDD", "DISEASE", 75, 78], ["kynurenine", "CHEMICAL", 134, 144], ["kynurenine", "CHEMICAL", 134, 144], ["patients", "ORGANISM", 79, 87], ["plasma", "ORGANISM_SUBSTANCE", 127, 133], ["kynurenine", "SIMPLE_CHEMICAL", 134, 144], ["cytokine", "PROTEIN", 197, 205], ["patients", "SPECIES", 79, 87], ["depressive episodes in MDD", "PROBLEM", 52, 78], ["an increase in plasma kynurenine metabolite levels", "PROBLEM", 112, 162], ["elevated cytokine levels", "PROBLEM", 188, 212], ["depressive", "OBSERVATION_MODIFIER", 52, 62], ["elevated", "OBSERVATION_MODIFIER", 188, 196], ["cytokine levels", "OBSERVATION", 197, 212]]], ["In addition, it should be noted that certain metabolites do not freely cross the BBB, and it might, therefore, be of importance to study the CSF levels of metabolites when determining their correlation to neuropsychiatric symptoms (Schwarcz et al, 2012) .NEUROIMMUNOLOGICAL MECHANISMS INVOLVED IN SUICIDAL BEHAVIORSo far, only a few studies have compared suicidal depressed individuals with non-suicidal depressive individuals, trying to assess whether the biological changes of these two groups are different or, perhaps, similar but differing in magnitude.", [["BBB", "ANATOMY", 81, 84], ["neuropsychiatric symptoms", "DISEASE", 205, 230], ["depressed", "DISEASE", 364, 373], ["depressive", "DISEASE", 404, 414], ["BBB", "MULTI-TISSUE_STRUCTURE", 81, 84], ["CSF", "GENE_OR_GENE_PRODUCT", 141, 144], ["the CSF levels", "TEST", 137, 151], ["neuropsychiatric symptoms", "PROBLEM", 205, 230], ["a few studies", "TEST", 327, 340], ["suicidal depressed individuals", "PROBLEM", 355, 385], ["non-suicidal depressive individuals", "PROBLEM", 391, 426]]], ["Indeed, a multitude of papers have shown that patients with depression display inflammation (Dowlati et al, 2010; Howren et al, 2009; Liu et al, 2012; Valkanova et al, 2013) and the exact same mechanisms (inflammation and activation of the kynurenine pathway) are proposed as the mechanism of depression (particularly of inflammationinduced depression) (Dantzer and Walker, 2014; Maes et al, 2011; Myint et al, 2012; Reus et al, 2015) .", [["depression", "DISEASE", 60, 70], ["inflammation", "DISEASE", 79, 91], ["inflammation", "DISEASE", 205, 217], ["kynurenine", "CHEMICAL", 240, 250], ["depression", "DISEASE", 293, 303], ["depression", "DISEASE", 341, 351], ["kynurenine", "CHEMICAL", 240, 250], ["patients", "ORGANISM", 46, 54], ["kynurenine", "SIMPLE_CHEMICAL", 240, 250], ["patients", "SPECIES", 46, 54], ["depression", "PROBLEM", 60, 70], ["inflammation", "PROBLEM", 79, 91], ["inflammation", "PROBLEM", 205, 217], ["the kynurenine pathway", "TREATMENT", 236, 258], ["depression", "PROBLEM", 293, 303], ["inflammationinduced depression", "PROBLEM", 321, 351], ["Walker", "TREATMENT", 366, 372], ["inflammation", "OBSERVATION", 79, 91]]], ["Evidence at this point is scarce, but indicates that the inflammatory changes and generation of kynurenine neurotoxic metabolites are, at least, more pronounced in suicidal individuals (Janelidze et al, 2011; O'Donovan et al, 2013; Sublette et al, 2011) .", [["kynurenine", "CHEMICAL", 96, 106], ["neurotoxic", "DISEASE", 107, 117], ["kynurenine", "CHEMICAL", 96, 106], ["kynurenine", "SIMPLE_CHEMICAL", 96, 106], ["the inflammatory changes", "PROBLEM", 53, 77], ["kynurenine neurotoxic metabolites", "PROBLEM", 96, 129], ["scarce", "OBSERVATION", 26, 32], ["inflammatory", "OBSERVATION", 57, 69], ["pronounced", "OBSERVATION_MODIFIER", 150, 160]]], ["It is difficult to determine from the available studies whether these changes are actually unique to patients with suicidal ideation or behavior.", [["suicidal ideation", "DISEASE", 115, 132], ["patients", "ORGANISM", 101, 109], ["patients", "SPECIES", 101, 109], ["the available studies", "TEST", 34, 55], ["suicidal ideation", "PROBLEM", 115, 132]]], ["The reason is that studies on depressive patients frequently do not attempt to distinguish between suicidal and non-suicidal patients.", [["depressive", "DISEASE", 30, 40], ["patients", "ORGANISM", 41, 49], ["patients", "ORGANISM", 125, 133], ["patients", "SPECIES", 41, 49], ["patients", "SPECIES", 125, 133], ["suicidal and non-suicidal patients", "PROBLEM", 99, 133]]], ["Patients with a certain degree of suicidal ideation are often included among the non-suicidal depressive individuals.", [["suicidal ideation", "DISEASE", 34, 51], ["depressive", "DISEASE", 94, 104], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["suicidal ideation", "PROBLEM", 34, 51], ["the non-suicidal depressive individuals", "PROBLEM", 77, 116]]], ["Additional studies on this topic are highly warranted in the future.NEUROIMMUNOLOGICAL MECHANISMS INVOLVED IN SUICIDAL BEHAVIORIn addition to the kynurenine pathway activation, inflammatory cytokines can also induce the changes in monoamine metabolism as well as in the HPA axis (Oquendo et al, 2014) .", [["kynurenine", "CHEMICAL", 146, 156], ["kynurenine", "CHEMICAL", 146, 156], ["monoamine", "CHEMICAL", 231, 240], ["kynurenine", "SIMPLE_CHEMICAL", 146, 156], ["monoamine", "SIMPLE_CHEMICAL", 231, 240], ["inflammatory cytokines", "PROTEIN", 177, 199], ["Additional studies", "TEST", 0, 18], ["the kynurenine pathway activation", "TREATMENT", 142, 175], ["inflammatory cytokines", "PROBLEM", 177, 199], ["the changes in monoamine metabolism", "PROBLEM", 216, 251], ["monoamine metabolism", "OBSERVATION", 231, 251]]], ["Cytokine administration in both animals and humans is known to activate the HPA axis (Dunn, 2000) .", [["Cytokine", "GENE_OR_GENE_PRODUCT", 0, 8], ["humans", "ORGANISM", 44, 50], ["Cytokine", "PROTEIN", 0, 8], ["humans", "SPECIES", 44, 50], ["humans", "SPECIES", 44, 50], ["Cytokine administration", "TREATMENT", 0, 23]]], ["IFN-\u03b1 used in the treatment of hepatitis C is a potent activator of the HPA axis as it causes increases in cortisol and adrenocorticotropic hormone levels within several hours of the treatment.", [["IFN-\u03b1", "CHEMICAL", 0, 5], ["hepatitis C", "DISEASE", 31, 42], ["cortisol", "CHEMICAL", 107, 115], ["cortisol", "CHEMICAL", 107, 115], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 0, 5], ["hepatitis C", "ORGANISM", 31, 42], ["cortisol", "SIMPLE_CHEMICAL", 107, 115], ["adrenocorticotropic hormone", "GENE_OR_GENE_PRODUCT", 120, 147], ["IFN", "PROTEIN", 0, 3], ["IFN", "TREATMENT", 0, 3], ["hepatitis C", "PROBLEM", 31, 42], ["increases in cortisol and adrenocorticotropic hormone levels", "PROBLEM", 94, 154], ["the treatment", "TREATMENT", 179, 192], ["hepatitis", "OBSERVATION", 31, 40], ["increases", "OBSERVATION_MODIFIER", 94, 103]]], ["HPA axis activation also correlates with the onset of depressive symptoms in patients who undergo interferon therapy compared with those who do not (Capuron et al, 2003) .", [["depressive symptoms", "DISEASE", 54, 73], ["patients", "ORGANISM", 77, 85], ["interferon", "GENE_OR_GENE_PRODUCT", 98, 108], ["interferon", "PROTEIN", 98, 108], ["patients", "SPECIES", 77, 85], ["HPA axis activation", "PROBLEM", 0, 19], ["depressive symptoms", "PROBLEM", 54, 73], ["interferon therapy", "TREATMENT", 98, 116]]], ["The serotonin system is one of the most widely studied neurotransmitter systems in depressive disorders (Vaswani et al, 2003) and its dysregulation by inflammatory cytokines could be one of the mechanisms underlying suicidal ideation and behavior (Oquendo et al, 2014) .", [["serotonin", "CHEMICAL", 4, 13], ["depressive disorders", "DISEASE", 83, 103], ["suicidal ideation", "DISEASE", 216, 233], ["serotonin", "CHEMICAL", 4, 13], ["serotonin", "SIMPLE_CHEMICAL", 4, 13], ["inflammatory cytokines", "PROTEIN", 151, 173], ["depressive disorders", "PROBLEM", 83, 103], ["inflammatory cytokines", "PROBLEM", 151, 173], ["suicidal ideation", "PROBLEM", 216, 233], ["serotonin system", "OBSERVATION", 4, 20], ["most widely", "OBSERVATION_MODIFIER", 35, 46], ["inflammatory", "OBSERVATION_MODIFIER", 151, 163]]], ["IL-1\u03b2 and TNF-\u03b1 have been shown to enhance the expression and activation of serotonin transporters in cell lines via a p38 mitogen-activated protein kinase pathway (Mossner et al, 1998; Ramamoorthy et al, 1995; Zhu et al, 2006; Zhu et al, 2005) .", [["cell lines", "ANATOMY", 102, 112], ["serotonin", "CHEMICAL", 76, 85], ["serotonin", "CHEMICAL", 76, 85], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 0, 5], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 10, 15], ["serotonin transporters", "GENE_OR_GENE_PRODUCT", 76, 98], ["cell lines", "CELL", 102, 112], ["p38 mitogen-activated protein kinase", "GENE_OR_GENE_PRODUCT", 119, 155], ["IL-1\u03b2", "PROTEIN", 0, 5], ["TNF-\u03b1", "PROTEIN", 10, 15], ["serotonin transporters", "PROTEIN", 76, 98], ["cell lines", "CELL_LINE", 102, 112], ["p38 mitogen-activated protein kinase", "PROTEIN", 119, 155], ["IL", "TEST", 0, 2], ["TNF", "TEST", 10, 13], ["serotonin transporters", "TREATMENT", 76, 98], ["cell lines", "TREATMENT", 102, 112], ["a p38 mitogen", "TEST", 117, 130], ["activated protein kinase pathway", "TREATMENT", 131, 163]]], ["Acute IL-6 administration is also known to increase serotonin release in rat striatum (Zhang et al, 2001) .", [["striatum", "ANATOMY", 77, 85], ["serotonin", "CHEMICAL", 52, 61], ["serotonin", "CHEMICAL", 52, 61], ["IL-6", "GENE_OR_GENE_PRODUCT", 6, 10], ["serotonin", "SIMPLE_CHEMICAL", 52, 61], ["rat", "ORGANISM", 73, 76], ["striatum", "MULTI-TISSUE_STRUCTURE", 77, 85], ["rat", "SPECIES", 73, 76], ["Acute IL-6 administration", "TREATMENT", 0, 25], ["serotonin release in rat striatum", "PROBLEM", 52, 85]]], ["Alterations in cytokineinduced serotonin metabolism have also been reported.", [["serotonin", "CHEMICAL", 31, 40], ["serotonin", "CHEMICAL", 31, 40], ["cytokineinduced", "GENE_OR_GENE_PRODUCT", 15, 30], ["serotonin", "SIMPLE_CHEMICAL", 31, 40], ["Alterations in cytokineinduced serotonin metabolism", "PROBLEM", 0, 51], ["serotonin metabolism", "OBSERVATION", 31, 51]]], ["5-hydroxyl indole acetic acid (5-HIAA), a metabolic product of serotonin, has been shown to be elevated following LPS injections in rodent models of depression (O'Connor et al, 2009 ).", [["5-hydroxyl indole acetic acid", "CHEMICAL", 0, 29], ["5-HIAA", "CHEMICAL", 31, 37], ["serotonin", "CHEMICAL", 63, 72], ["LPS", "CHEMICAL", 114, 117], ["depression", "DISEASE", 149, 159], ["5-hydroxyl indole acetic acid", "CHEMICAL", 0, 29], ["5-HIAA", "CHEMICAL", 31, 37], ["serotonin", "CHEMICAL", 63, 72], ["5-hydroxyl indole acetic acid", "SIMPLE_CHEMICAL", 0, 29], ["5-HIAA", "SIMPLE_CHEMICAL", 31, 37], ["serotonin", "SIMPLE_CHEMICAL", 63, 72], ["LPS", "SIMPLE_CHEMICAL", 114, 117], ["hydroxyl indole acetic acid", "TEST", 2, 29], ["LPS injections", "TREATMENT", 114, 128], ["depression", "PROBLEM", 149, 159], ["elevated", "OBSERVATION_MODIFIER", 95, 103]]], ["Thus, inflammatory cytokines can influence a variety of neurotransmitter functions, ranging from synthesis to inducing changes directly at the receptor level.UPSTREAM TRIGGERS OF SUICIDALITYThe rates of suicidal behavior in individuals affected by conditions that involve the immune system are generally higher than in individuals with somatic conditions that do not increase inflammation.", [["immune system", "ANATOMY", 276, 289], ["suicidal behavior", "DISEASE", 203, 220], ["inflammation", "DISEASE", 376, 388], ["immune system", "ANATOMICAL_SYSTEM", 276, 289], ["inflammatory cytokines", "PROTEIN", 6, 28], ["inflammatory cytokines", "PROBLEM", 6, 28], ["suicidal behavior", "PROBLEM", 203, 220], ["somatic conditions", "PROBLEM", 336, 354], ["increase inflammation", "PROBLEM", 367, 388], ["inflammatory", "OBSERVATION_MODIFIER", 6, 18], ["increase", "OBSERVATION_MODIFIER", 367, 375], ["inflammation", "OBSERVATION", 376, 388]]], ["For example,~1% of adolescents with hemophilia, a genetic condition that does not involve inflammation, have previously attempted suicide compared with 7% of adolescents with thalassemia major, a condition that is often characterized by the presence of chronic vascular inflammatory state (Ghanizadeh and Baligh-Jahromi, 2009; Ghanizadeh et al, 2006) .", [["vascular", "ANATOMY", 261, 269], ["hemophilia", "DISEASE", 36, 46], ["inflammation", "DISEASE", 90, 102], ["thalassemia major", "DISEASE", 175, 192], ["adolescents", "ORGANISM", 19, 30], ["vascular", "MULTI-TISSUE_STRUCTURE", 261, 269], ["adolescents", "SPECIES", 19, 30], ["hemophilia", "PROBLEM", 36, 46], ["a genetic condition", "PROBLEM", 48, 67], ["inflammation", "PROBLEM", 90, 102], ["thalassemia major", "PROBLEM", 175, 192], ["chronic vascular inflammatory state", "PROBLEM", 253, 288], ["hemophilia", "OBSERVATION", 36, 46], ["inflammation", "OBSERVATION", 90, 102], ["chronic", "OBSERVATION_MODIFIER", 253, 260], ["vascular", "ANATOMY", 261, 269], ["inflammatory", "OBSERVATION", 270, 282]]], ["It is also known that MDD is more prevalent in patients afflicted with conditions characterized by chronic inflammation (such as cardiovascular diseases, type 2 diabetes, and rheumatoid arthritis) than in the general population (Steptoe, 2007) .AUTOIMMUNE DISORDERSMultiple sclerosis (MS) is a chronic inflammatory neurological disorder characterized by sensory and motor loss, cognitive impairment, blindness, and fatigue.", [["cardiovascular", "ANATOMY", 129, 143], ["neurological", "ANATOMY", 315, 327], ["MDD", "DISEASE", 22, 25], ["inflammation", "DISEASE", 107, 119], ["cardiovascular diseases", "DISEASE", 129, 152], ["type 2 diabetes", "DISEASE", 154, 169], ["rheumatoid arthritis", "DISEASE", 175, 195], ["DISORDERSMultiple sclerosis", "DISEASE", 256, 283], ["MS", "DISEASE", 285, 287], ["neurological disorder", "DISEASE", 315, 336], ["sensory and motor loss", "DISEASE", 354, 376], ["cognitive impairment", "DISEASE", 378, 398], ["blindness", "DISEASE", 400, 409], ["fatigue", "DISEASE", 415, 422], ["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 47, 55], ["MDD", "PROBLEM", 22, 25], ["chronic inflammation", "PROBLEM", 99, 119], ["cardiovascular diseases", "PROBLEM", 129, 152], ["type 2 diabetes", "PROBLEM", 154, 169], ["rheumatoid arthritis", "PROBLEM", 175, 195], ["AUTOIMMUNE DISORDERSMultiple sclerosis", "PROBLEM", 245, 283], ["a chronic inflammatory neurological disorder", "PROBLEM", 292, 336], ["sensory and motor loss", "PROBLEM", 354, 376], ["cognitive impairment", "PROBLEM", 378, 398], ["blindness", "PROBLEM", 400, 409], ["fatigue", "PROBLEM", 415, 422], ["more prevalent", "OBSERVATION_MODIFIER", 29, 43], ["chronic", "OBSERVATION_MODIFIER", 99, 106], ["inflammation", "OBSERVATION", 107, 119], ["rheumatoid arthritis", "OBSERVATION", 175, 195], ["sclerosis", "OBSERVATION", 274, 283], ["chronic", "OBSERVATION_MODIFIER", 294, 301], ["inflammatory", "OBSERVATION_MODIFIER", 302, 314], ["neurological disorder", "OBSERVATION", 315, 336], ["sensory", "OBSERVATION_MODIFIER", 354, 361], ["motor loss", "OBSERVATION", 366, 376], ["blindness", "OBSERVATION", 400, 409]]], ["Patients with MS report high rates of depression reaching~40% in these patients (Chwastiak et al, 2002) .", [["MS", "DISEASE", 14, 16], ["depression", "DISEASE", 38, 48], ["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 71, 79], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 71, 79], ["depression", "PROBLEM", 38, 48]]], ["In a subset of MS patients with no history of psychiatric illness, treatment with IFN-\u03b3 worsens depressive symptoms and induces suicidal ideation or attempts (Benros et al, 2011; Chwastiak et al, 2002; Fragoso et al, 2010) .", [["MS", "DISEASE", 15, 17], ["psychiatric illness", "DISEASE", 46, 65], ["IFN-\u03b3", "CHEMICAL", 82, 87], ["depressive symptoms", "DISEASE", 96, 115], ["suicidal ideation", "DISEASE", 128, 145], ["patients", "ORGANISM", 18, 26], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 82, 87], ["IFN", "PROTEIN", 82, 85], ["patients", "SPECIES", 18, 26], ["psychiatric illness", "PROBLEM", 46, 65], ["treatment", "TREATMENT", 67, 76], ["IFN", "TREATMENT", 82, 85], ["depressive symptoms", "PROBLEM", 96, 115], ["suicidal ideation", "PROBLEM", 128, 145]]], ["Death by suicide may account for at least 15% of mortality in MS populations (Sadovnick et al, 1991) .", [["Death", "DISEASE", 0, 5], ["MS", "DISEASE", 62, 64]]], ["Another study determined an increased risk for suicide completion in a Swedish cohort of MS patients (Fredrikson et al, 2003) .", [["MS", "DISEASE", 89, 91], ["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 92, 100], ["Another study", "TEST", 0, 13], ["suicide completion", "TREATMENT", 47, 65], ["increased", "OBSERVATION_MODIFIER", 28, 37]]], ["A similar study in a smaller cohort of Danish MS patients identified a twofold increase in risk of death by suicide compared with the general population, with the greatest risk in the first year following diagnosis (Bronnum-Hansen et al, 2005) .", [["MS", "DISEASE", 46, 48], ["death", "DISEASE", 99, 104], ["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57], ["A similar study", "TEST", 0, 15], ["death", "PROBLEM", 99, 104], ["increase", "OBSERVATION_MODIFIER", 79, 87]]], ["Systemic lupus erythematosus (SLE) is another autoimmune disorder predominantly affecting women of reproductive age.", [["Systemic lupus erythematosus", "DISEASE", 0, 28], ["SLE", "DISEASE", 30, 33], ["autoimmune disorder", "DISEASE", 46, 65], ["women", "ORGANISM", 90, 95], ["women", "SPECIES", 90, 95], ["Systemic lupus erythematosus", "PROBLEM", 0, 28], ["SLE", "PROBLEM", 30, 33], ["another autoimmune disorder", "PROBLEM", 38, 65], ["lupus erythematosus", "OBSERVATION", 9, 28], ["autoimmune", "OBSERVATION_MODIFIER", 46, 56]]], ["About 17-71% of SLE patients present with psychiatric symptoms (Wekking, 1993) .", [["SLE", "DISEASE", 16, 19], ["psychiatric", "DISEASE", 42, 53], ["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["psychiatric symptoms", "PROBLEM", 42, 62]]], ["Prevalence of depression is estimated to be fourfold higher in SLE patients compared with non-SLE patients with at least 75% of SLE patients being diagnosed with depression during their lifetime (Palagini et al, 2013) .", [["depression", "DISEASE", 14, 24], ["SLE", "DISEASE", 63, 66], ["non-SLE", "DISEASE", 90, 97], ["SLE", "DISEASE", 128, 131], ["depression", "DISEASE", 162, 172], ["patients", "ORGANISM", 67, 75], ["patients", "ORGANISM", 98, 106], ["patients", "ORGANISM", 132, 140], ["patients", "SPECIES", 67, 75], ["patients", "SPECIES", 98, 106], ["patients", "SPECIES", 132, 140], ["depression", "PROBLEM", 14, 24], ["depression", "PROBLEM", 162, 172], ["depression", "OBSERVATION", 14, 24]]], ["Interestingly, the presence of anti-NR1 antibodies has been consistently reported in the CSF of SLE patients and correlates positively with their neuropsychiatric symptoms (Arinuma et al, 2008; Fragoso-Loyo et al, 2008; Gono et al, 2011; Lapteva et al, 2006; Yoshio et al, 2006) .", [["SLE", "DISEASE", 96, 99], ["anti-NR1 antibodies", "GENE_OR_GENE_PRODUCT", 31, 50], ["CSF", "ORGANISM_SUBSTANCE", 89, 92], ["patients", "ORGANISM", 100, 108], ["anti-NR1 antibodies", "PROTEIN", 31, 50], ["patients", "SPECIES", 100, 108], ["anti-NR1 antibodies", "PROBLEM", 31, 50], ["their neuropsychiatric symptoms", "PROBLEM", 140, 171]]], ["As mentioned above, NR1 is a subunit of the ionotropic glutamate NMDA receptor (Perez-Otano et al, 2001) .", [["glutamate", "CHEMICAL", 55, 64], ["NMDA", "CHEMICAL", 65, 69], ["glutamate", "CHEMICAL", 55, 64], ["NMDA", "CHEMICAL", 65, 69], ["NR1", "GENE_OR_GENE_PRODUCT", 20, 23], ["glutamate NMDA receptor", "GENE_OR_GENE_PRODUCT", 55, 78], ["NR1", "PROTEIN", 20, 23], ["ionotropic glutamate NMDA receptor", "PROTEIN", 44, 78]]], ["Examining a Chinese population of SLE patients, Pan et al reported a 34% prevalence of suicidal ideation, with lower estimates ranging from 8 to 12% reported in other SLE populations across the world (Ishikura et al, 2001; Xie et al, 2012; Zakeri et al, 2012) .", [["SLE", "DISEASE", 34, 37], ["suicidal ideation", "DISEASE", 87, 104], ["SLE", "DISEASE", 167, 170], ["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46], ["suicidal ideation", "PROBLEM", 87, 104]]], ["It is unclear if suicidal thoughts in these patients manifest as a consequence of the disease or from an underlying psychiatric condition or both.INFECTIONSInfections induce inflammation, and, as such, may activate the above-mentioned neuroinflammatory mechanisms leading to depression and suicidal symptoms.", [["suicidal thoughts", "DISEASE", 17, 34], ["psychiatric", "DISEASE", 116, 127], ["inflammation", "DISEASE", 174, 186], ["depression", "DISEASE", 275, 285], ["suicidal symptoms", "DISEASE", 290, 307], ["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52], ["suicidal thoughts", "PROBLEM", 17, 34], ["the disease", "PROBLEM", 82, 93], ["an underlying psychiatric condition", "PROBLEM", 102, 137], ["INFECTIONSInfections", "PROBLEM", 146, 166], ["inflammation", "PROBLEM", 174, 186], ["neuroinflammatory mechanisms", "PROBLEM", 235, 263], ["depression", "PROBLEM", 275, 285], ["suicidal symptoms", "PROBLEM", 290, 307], ["unclear if", "UNCERTAINTY", 6, 16], ["inflammation", "OBSERVATION", 174, 186]]], ["Certain infections may be particularly strong triggers of neuroinflammation, as they invade the central nervous system, and such neurotrophic pathogens include herpes viruses, human HIV, and possibly hepatitis C virus.", [["central nervous system", "ANATOMY", 96, 118], ["infections", "DISEASE", 8, 18], ["neuroinflammation", "DISEASE", 58, 75], ["herpes viruses", "DISEASE", 160, 174], ["human HIV, and possibly hepatitis C", "DISEASE", 176, 211], ["central nervous system", "ANATOMICAL_SYSTEM", 96, 118], ["herpes viruses", "ORGANISM", 160, 174], ["human", "ORGANISM", 176, 181], ["HIV", "ORGANISM", 182, 185], ["hepatitis C virus", "ORGANISM", 200, 217], ["human", "SPECIES", 176, 181], ["HIV", "SPECIES", 182, 185], ["hepatitis C virus", "SPECIES", 200, 217], ["human", "SPECIES", 176, 181], ["HIV", "SPECIES", 182, 185], ["hepatitis C virus", "SPECIES", 200, 217], ["Certain infections", "PROBLEM", 0, 18], ["neuroinflammation", "PROBLEM", 58, 75], ["such neurotrophic pathogens", "PROBLEM", 124, 151], ["herpes viruses", "PROBLEM", 160, 174], ["human HIV", "PROBLEM", 176, 185], ["hepatitis C virus", "PROBLEM", 200, 217], ["infections", "OBSERVATION", 8, 18], ["neuroinflammation", "OBSERVATION", 58, 75], ["central", "ANATOMY_MODIFIER", 96, 103], ["nervous system", "ANATOMY", 104, 118], ["herpes viruses", "OBSERVATION", 160, 174], ["possibly", "UNCERTAINTY", 191, 199]]], ["The prevalence of MDD, suicidal ideation, and attempted suicides in HIV patients is reported to be up to 27.2%, 31%, and 32.7%, respectively (Serafini et al, 2015) .", [["MDD", "DISEASE", 18, 21], ["suicidal ideation", "DISEASE", 23, 40], ["HIV", "DISEASE", 68, 71], ["HIV", "ORGANISM", 68, 71], ["patients", "ORGANISM", 72, 80], ["HIV", "SPECIES", 68, 71], ["patients", "SPECIES", 72, 80], ["HIV", "SPECIES", 68, 71], ["MDD", "PROBLEM", 18, 21], ["suicidal ideation", "PROBLEM", 23, 40]]], ["Chronic hepatitis C patients also display a higher prevalence of depression and suicide risk compared with the general population (Lucaciu and Dumitrascu, 2015) .", [["Chronic hepatitis C", "DISEASE", 0, 19], ["depression", "DISEASE", 65, 75], ["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["Chronic hepatitis C", "PROBLEM", 0, 19], ["depression", "PROBLEM", 65, 75], ["suicide risk", "PROBLEM", 80, 92], ["hepatitis", "OBSERVATION", 8, 17], ["higher prevalence", "OBSERVATION_MODIFIER", 44, 61], ["depression", "OBSERVATION", 65, 75]]], ["Alavi et al (2012) found that, before treatment, 36% of chronic hepatitis C patients suffer from major depression and 18% endure a moderate-to-severe suicide risk.", [["chronic hepatitis C", "DISEASE", 56, 75], ["depression", "DISEASE", 103, 113], ["suicide", "DISEASE", 150, 157], ["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["treatment", "TREATMENT", 38, 47], ["chronic hepatitis C", "PROBLEM", 56, 75], ["major depression", "PROBLEM", 97, 113], ["severe suicide risk", "PROBLEM", 143, 162], ["chronic", "OBSERVATION_MODIFIER", 56, 63], ["hepatitis", "OBSERVATION", 64, 73], ["moderate", "OBSERVATION_MODIFIER", 131, 139]]], ["A study by Okusaga et al (2011) found higher seropositivity for influenza B virus in patients with a history of suicide attempt, whereas seropositivity for all three types of viruses (influenza A, B, and coronaviruses) was associated with the history of mood disorders.", [["influenza B", "DISEASE", 64, 75], ["influenza A, B, and coronaviruses", "DISEASE", 184, 217], ["mood disorders", "DISEASE", 254, 268], ["influenza B virus", "ORGANISM", 64, 81], ["patients", "ORGANISM", 85, 93], ["influenza A", "ORGANISM", 184, 195], ["B", "GENE_OR_GENE_PRODUCT", 197, 198], ["coronaviruses", "ORGANISM", 204, 217], ["influenza B virus", "SPECIES", 64, 81], ["patients", "SPECIES", 85, 93], ["influenza B virus", "SPECIES", 64, 81], ["A study", "TEST", 0, 7], ["higher seropositivity", "PROBLEM", 38, 59], ["influenza B virus", "PROBLEM", 64, 81], ["suicide attempt", "PROBLEM", 112, 127], ["viruses (influenza A, B, and coronaviruses", "PROBLEM", 175, 217], ["mood disorders", "PROBLEM", 254, 268], ["viruses", "OBSERVATION", 175, 182]]], ["Recently, the onset of de novo depression has been associated with the higher levels of cytomegalovirus IgG antibodies with the odds of incident depression being three times greater in individuals with antibody levels in the highest quartile (Simanek et al, 2014) .", [["depression", "DISEASE", 31, 41], ["depression", "DISEASE", 145, 155], ["cytomegalovirus", "ORGANISM", 88, 103], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 104, 118], ["cytomegalovirus IgG antibodies", "PROTEIN", 88, 118], ["de novo depression", "PROBLEM", 23, 41], ["cytomegalovirus IgG antibodies", "PROBLEM", 88, 118], ["incident depression", "PROBLEM", 136, 155], ["antibody levels", "TEST", 202, 217], ["cytomegalovirus", "OBSERVATION", 88, 103]]], ["Certain neurotrophic pathogens are not only capable of inducing inflammation but might manipulate the host neurons in very specific ways to trigger a behavioral response.", [["neurons", "ANATOMY", 107, 114], ["inflammation", "DISEASE", 64, 76], ["neurons", "CELL", 107, 114], ["host neurons", "CELL_TYPE", 102, 114], ["Certain neurotrophic pathogens", "PROBLEM", 0, 30], ["inducing inflammation", "PROBLEM", 55, 76], ["neurotrophic", "OBSERVATION_MODIFIER", 8, 20], ["pathogens", "OBSERVATION", 21, 30], ["inflammation", "OBSERVATION", 64, 76]]], ["Toxoplasma gondii is a common protozoan parasite that establishes latency in the muscle and brain (Henriquez et al, 2009) .", [["muscle", "ANATOMY", 81, 87], ["brain", "ANATOMY", 92, 97], ["Toxoplasma gondii", "DISEASE", 0, 17], ["Toxoplasma gondii", "ORGANISM", 0, 17], ["muscle", "ORGAN", 81, 87], ["brain", "ORGAN", 92, 97], ["Toxoplasma gondii", "SPECIES", 0, 17], ["Toxoplasma gondii", "SPECIES", 0, 17], ["Toxoplasma gondii", "PROBLEM", 0, 17], ["a common protozoan parasite", "PROBLEM", 21, 48], ["common", "OBSERVATION_MODIFIER", 23, 29], ["protozoan", "OBSERVATION_MODIFIER", 30, 39], ["parasite", "OBSERVATION", 40, 48], ["latency", "OBSERVATION_MODIFIER", 66, 73], ["muscle", "ANATOMY", 81, 87], ["brain", "ANATOMY", 92, 97]]], ["Infection in humans is frequently asymptomatic and can occur, for example, after consumption of undercooked meat infected with parasitic oocysts.", [["meat", "ANATOMY", 108, 112], ["oocysts", "ANATOMY", 137, 144], ["Infection", "DISEASE", 0, 9], ["undercooked meat infected", "DISEASE", 96, 121], ["parasitic oocysts", "DISEASE", 127, 144], ["humans", "ORGANISM", 13, 19], ["meat", "ORGANISM_SUBDIVISION", 108, 112], ["humans", "SPECIES", 13, 19], ["humans", "SPECIES", 13, 19], ["Infection", "PROBLEM", 0, 9], ["parasitic oocysts", "PROBLEM", 127, 144], ["infected", "OBSERVATION_MODIFIER", 113, 121], ["parasitic oocysts", "OBSERVATION", 127, 144]]], ["The host immune response CD4 + and CD8 + T cells are responsible for keeping the parasite under control and relatively quiescent in the central nervous system (Gazzinelli et al, 1992) .", [["CD4 + and CD8 + T cells", "ANATOMY", 25, 48], ["central nervous system", "ANATOMY", 136, 158], ["CD4", "GENE_OR_GENE_PRODUCT", 25, 28], ["CD8", "GENE_OR_GENE_PRODUCT", 35, 38], ["central nervous system", "ANATOMICAL_SYSTEM", 136, 158], ["CD4 + and CD8 + T cells", "CELL_TYPE", 25, 48], ["The host immune response", "TEST", 0, 24], ["CD4", "TEST", 25, 28], ["CD8", "TEST", 35, 38], ["T cells", "PROBLEM", 41, 48], ["quiescent", "OBSERVATION_MODIFIER", 119, 128], ["central", "ANATOMY_MODIFIER", 136, 143], ["nervous system", "ANATOMY", 144, 158]]], ["Interestingly, latent T. gondii infection has been identified as a risk factor for suicide and suicide attempts (Arling et al, 2009; Ling et al, 2011) .", [["T. gondii infection", "DISEASE", 22, 41], ["T. gondii", "ORGANISM", 22, 31], ["T. gondii", "SPECIES", 22, 31], ["T. gondii", "SPECIES", 22, 31], ["latent T. gondii infection", "PROBLEM", 15, 41], ["suicide", "PROBLEM", 83, 90], ["latent", "OBSERVATION_MODIFIER", 15, 21], ["T.", "OBSERVATION_MODIFIER", 22, 24], ["gondii infection", "OBSERVATION", 25, 41]]], ["Reactivation of infection has also been associated with traits such as aggression and impulsivity, two behavioral endophenotypes associated with suicidal behavior (Cook et al, 2015) .", [["infection", "DISEASE", 16, 25], ["aggression", "DISEASE", 71, 81], ["impulsivity", "DISEASE", 86, 97], ["suicidal behavior", "DISEASE", 145, 162], ["infection", "PROBLEM", 16, 25], ["impulsivity", "PROBLEM", 86, 97], ["two behavioral endophenotypes", "PROBLEM", 99, 128], ["suicidal behavior", "PROBLEM", 145, 162], ["infection", "OBSERVATION", 16, 25]]], ["Proposed mechanisms underlying T. gondii-associated behavioral changes include alterations in immune response as well as dysfunction associated with dopaminergic neurotransmission.", [["T. gondii-associated behavioral changes", "PROBLEM", 31, 70], ["alterations in immune response", "PROBLEM", 79, 109], ["dysfunction", "PROBLEM", 121, 132], ["dopaminergic neurotransmission", "TREATMENT", 149, 179], ["immune response", "OBSERVATION", 94, 109]]], ["In rodents, for example, infection with T. gondii elicits release of IFN-\u03b3, IL-12, IL-8, and TNF-\u03b1 primarily by cells of the innate immune system (Miller et al, 2009) .", [["cells", "ANATOMY", 112, 117], ["infection", "DISEASE", 25, 34], ["T. gondii", "ORGANISM", 40, 49], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 69, 74], ["IL-12", "GENE_OR_GENE_PRODUCT", 76, 81], ["IL-8", "GENE_OR_GENE_PRODUCT", 83, 87], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 93, 98], ["cells", "CELL", 112, 117], ["IFN", "PROTEIN", 69, 72], ["IL-8", "PROTEIN", 83, 87], ["TNF", "PROTEIN", 93, 96], ["\u03b1", "PROTEIN", 97, 98], ["T. gondii", "SPECIES", 40, 49], ["T. gondii", "SPECIES", 40, 49], ["infection", "PROBLEM", 25, 34], ["T. gondii elicits", "TEST", 40, 57], ["IFN", "TEST", 69, 72], ["IL", "TEST", 76, 78], ["IL", "TEST", 83, 85], ["TNF", "TEST", 93, 96], ["infection", "OBSERVATION", 25, 34]]], ["Recently, using a rodent model of T. gondii infection, Notarangelo et al (2014) showed that brain kynurenine and QUIN levels are persistently elevated in infected animals.", [["brain", "ANATOMY", 92, 97], ["T. gondii infection", "DISEASE", 34, 53], ["kynurenine", "CHEMICAL", 98, 108], ["QUIN", "CHEMICAL", 113, 117], ["kynurenine", "CHEMICAL", 98, 108], ["QUIN", "CHEMICAL", 113, 117], ["T. gondii", "ORGANISM", 34, 43], ["brain", "ORGAN", 92, 97], ["kynurenine", "SIMPLE_CHEMICAL", 98, 108], ["QUIN", "SIMPLE_CHEMICAL", 113, 117], ["T. gondii", "SPECIES", 34, 43], ["T. gondii", "SPECIES", 34, 43], ["T. gondii infection", "PROBLEM", 34, 53], ["brain kynurenine", "TEST", 92, 108], ["QUIN levels", "TEST", 113, 124], ["persistently elevated", "PROBLEM", 129, 150], ["infection", "OBSERVATION", 44, 53], ["brain", "ANATOMY", 92, 97], ["kynurenine", "OBSERVATION", 98, 108], ["persistently", "OBSERVATION_MODIFIER", 129, 141], ["elevated", "OBSERVATION_MODIFIER", 142, 150], ["infected", "OBSERVATION_MODIFIER", 154, 162]]], ["Moreover, the T. gondii genome encodes for tyrosine hydroxylase, a rate-limiting enzyme in the synthesis of dopamine, wherein it catalyzes the conversion of tyrosine into L-DOPA (Gaskell et al, 2009 ).", [["tyrosine", "CHEMICAL", 43, 51], ["dopamine", "CHEMICAL", 108, 116], ["tyrosine", "CHEMICAL", 157, 165], ["L-DOPA", "CHEMICAL", 171, 177], ["tyrosine", "CHEMICAL", 43, 51], ["dopamine", "CHEMICAL", 108, 116], ["tyrosine", "CHEMICAL", 157, 165], ["L-DOPA", "CHEMICAL", 171, 177], ["T. gondii", "ORGANISM", 14, 23], ["tyrosine hydroxylase", "GENE_OR_GENE_PRODUCT", 43, 63], ["dopamine", "SIMPLE_CHEMICAL", 108, 116], ["tyrosine", "AMINO_ACID", 157, 165], ["L-DOPA", "SIMPLE_CHEMICAL", 171, 177], ["T. gondii genome", "DNA", 14, 30], ["tyrosine hydroxylase", "PROTEIN", 43, 63], ["T. gondii", "SPECIES", 14, 23], ["T. gondii", "SPECIES", 14, 23], ["tyrosine hydroxylase", "TREATMENT", 43, 63], ["a rate", "TEST", 65, 71], ["dopamine", "TREATMENT", 108, 116], ["tyrosine into L-DOPA", "TREATMENT", 157, 177]]], ["Using T. Gondii-infected mice, Prandovsky et al showed that increased dopamine staining was restricted to tissue cysts containing the parasite.", [["tissue cysts", "ANATOMY", 106, 118], ["dopamine", "CHEMICAL", 70, 78], ["dopamine", "CHEMICAL", 70, 78], ["mice", "ORGANISM", 25, 29], ["dopamine", "SIMPLE_CHEMICAL", 70, 78], ["tissue cysts", "TISSUE", 106, 118], ["mice", "SPECIES", 25, 29], ["mice", "SPECIES", 25, 29], ["Prandovsky et al", "TREATMENT", 31, 47], ["increased dopamine staining", "PROBLEM", 60, 87], ["tissue cysts", "PROBLEM", 106, 118], ["increased", "OBSERVATION_MODIFIER", 60, 69], ["dopamine staining", "OBSERVATION", 70, 87], ["to tissue", "OBSERVATION_MODIFIER", 103, 112], ["cysts", "OBSERVATION", 113, 118], ["parasite", "OBSERVATION_MODIFIER", 134, 142]]], ["They also observed increased dopamine release in response to T. gondii infection (Prandovszky et al, 2011) .", [["dopamine", "CHEMICAL", 29, 37], ["T. gondii infection", "DISEASE", 61, 80], ["dopamine", "CHEMICAL", 29, 37], ["dopamine", "SIMPLE_CHEMICAL", 29, 37], ["T. gondii", "ORGANISM", 61, 70], ["T. gondii", "SPECIES", 61, 70], ["T. gondii", "SPECIES", 61, 70], ["increased dopamine release", "TREATMENT", 19, 45], ["T. gondii infection", "PROBLEM", 61, 80], ["increased", "OBSERVATION_MODIFIER", 19, 28], ["dopamine release", "OBSERVATION", 29, 45], ["gondii infection", "OBSERVATION", 64, 80]]], ["Together, the biological effects of T. gondii might include increases in ................................................................................................................................................ the levels of pro-inflammatory cytokines, QUIN, and dopamine, thus altering both glutamatergic and dopaminergic neurotransmission.TRAUMATIC BRAIN INJURYTraumatic brain injury (TBI) results from sudden trauma to the brain.", [["brain", "ANATOMY", 380, 385], ["brain", "ANATOMY", 433, 438], ["QUIN", "CHEMICAL", 260, 264], ["dopamine", "CHEMICAL", 270, 278], ["brain injury", "DISEASE", 380, 392], ["TBI", "DISEASE", 394, 397], ["sudden trauma to the brain", "DISEASE", 412, 438], ["QUIN", "CHEMICAL", 260, 264], ["dopamine", "CHEMICAL", 270, 278], ["T. gondii", "ORGANISM", 36, 45], ["QUIN", "SIMPLE_CHEMICAL", 260, 264], ["dopamine", "SIMPLE_CHEMICAL", 270, 278], ["brain", "ORGAN", 380, 385], ["brain", "ORGAN", 433, 438], ["pro-inflammatory cytokines", "PROTEIN", 232, 258], ["T. gondii", "SPECIES", 36, 45], ["T. gondii", "SPECIES", 36, 45], ["T. gondii", "PROBLEM", 36, 45], ["pro-inflammatory cytokines", "TREATMENT", 232, 258], ["QUIN", "TREATMENT", 260, 264], ["dopamine", "TREATMENT", 270, 278], ["TRAUMATIC BRAIN INJURYTraumatic brain injury", "PROBLEM", 348, 392], ["sudden trauma to the brain", "PROBLEM", 412, 438], ["dopaminergic neurotransmission", "OBSERVATION", 317, 347], ["BRAIN", "ANATOMY", 358, 363], ["INJURYTraumatic", "ANATOMY_MODIFIER", 364, 379], ["brain", "ANATOMY", 380, 385], ["injury", "OBSERVATION", 386, 392], ["brain", "ANATOMY", 433, 438]]], ["Immune system activation following TBI usually occurs as a secondary event and further worsens existing neuro-degeneration and other neurological impairments following initial trauma.", [["Immune system", "ANATOMY", 0, 13], ["neurological", "ANATOMY", 133, 145], ["TBI", "DISEASE", 35, 38], ["neuro-degeneration", "DISEASE", 104, 122], ["neurological impairments", "DISEASE", 133, 157], ["trauma", "DISEASE", 176, 182], ["Immune system activation", "PROBLEM", 0, 24], ["TBI", "PROBLEM", 35, 38], ["a secondary event", "PROBLEM", 57, 74], ["further worsens existing neuro-degeneration", "PROBLEM", 79, 122], ["other neurological impairments", "PROBLEM", 127, 157], ["initial trauma", "PROBLEM", 168, 182]]], ["The neuroinflammation is characterized by microglial activation and release of inflammatory factors such as IL-1\u03b2, TNF-\u03b1, and IFN-\u03b3 (Block and Hong, 2005) .", [["microglial", "ANATOMY", 42, 52], ["neuroinflammation", "DISEASE", 4, 21], ["microglial", "CELL", 42, 52], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 108, 113], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 115, 120], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 126, 131], ["inflammatory factors", "PROTEIN", 79, 99], ["IL-1\u03b2", "PROTEIN", 108, 113], ["TNF", "PROTEIN", 115, 118], ["IFN", "PROTEIN", 126, 129], ["The neuroinflammation", "PROBLEM", 0, 21], ["microglial activation", "PROBLEM", 42, 63], ["inflammatory factors", "PROBLEM", 79, 99], ["IL", "TEST", 108, 110], ["TNF", "TEST", 115, 118], ["neuroinflammation", "OBSERVATION", 4, 21], ["microglial activation", "OBSERVATION", 42, 63], ["inflammatory", "OBSERVATION_MODIFIER", 79, 91]]], ["In a study involving the largest cohort of TBI patients (two million controls and 200 000 Swedish TBI patients), it was determined that those with TBI are three times more likely to die of suicide than controls (Fazel et al, 2014) .", [["TBI", "DISEASE", 43, 46], ["TBI", "DISEASE", 98, 101], ["TBI", "DISEASE", 147, 150], ["patients", "ORGANISM", 47, 55], ["patients", "ORGANISM", 102, 110], ["patients", "SPECIES", 47, 55], ["patients", "SPECIES", 102, 110], ["a study", "TEST", 3, 10], ["TBI", "PROBLEM", 147, 150], ["largest", "OBSERVATION_MODIFIER", 25, 32]]], ["To determine whether increases in inflammatory mediators are associated with TBI, Jeungst and colleagues measured TNF-\u03b1 levels in serum and CSF of TBI patients 6 and 12 months following initial injury.", [["serum", "ANATOMY", 130, 135], ["TBI", "DISEASE", 77, 80], ["TBI", "DISEASE", 147, 150], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 114, 119], ["serum", "ORGANISM_SUBSTANCE", 130, 135], ["CSF", "ORGANISM_SUBSTANCE", 140, 143], ["patients", "ORGANISM", 151, 159], ["inflammatory mediators", "PROTEIN", 34, 56], ["TNF", "PROTEIN", 114, 117], ["patients", "SPECIES", 151, 159], ["inflammatory mediators", "PROBLEM", 34, 56], ["TBI", "PROBLEM", 77, 80], ["TNF", "TEST", 114, 117], ["levels in serum", "TEST", 120, 135], ["TBI patients", "TEST", 147, 159], ["initial injury", "PROBLEM", 186, 200], ["increases", "OBSERVATION_MODIFIER", 21, 30], ["inflammatory", "OBSERVATION", 34, 46], ["injury", "OBSERVATION", 194, 200]]], ["Not only did elevated TNF-\u03b1 levels correlate with TBI but they also found positive correlations between TNF-\u03b1 levels and disinhibition (a behavioral proxy for impulsivity), as well as disinhibition and suicidal ideation at various time points.", [["TBI", "DISEASE", 50, 53], ["suicidal ideation", "DISEASE", 202, 219], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 22, 27], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 104, 109], ["TNF", "PROTEIN", 22, 25], ["TNF", "PROTEIN", 104, 107], ["elevated TNF", "PROBLEM", 13, 25], ["TBI", "PROBLEM", 50, 53], ["TNF", "TEST", 104, 107], ["disinhibition", "PROBLEM", 121, 134], ["impulsivity", "PROBLEM", 159, 170], ["disinhibition and suicidal ideation", "PROBLEM", 184, 219], ["elevated", "OBSERVATION_MODIFIER", 13, 21], ["TNF", "OBSERVATION", 22, 25]]], ["Thus, they found an alternative rational for the etiology of TBI, involving immune activation and increase in cognitive deficits associated with impulse control and suicidal behavior (Juengst et al, 2014) .", [["TBI", "DISEASE", 61, 64], ["cognitive deficits", "DISEASE", 110, 128], ["suicidal behavior", "DISEASE", 165, 182], ["TBI", "PROBLEM", 61, 64], ["immune activation", "PROBLEM", 76, 93], ["increase in cognitive deficits", "PROBLEM", 98, 128], ["impulse control and suicidal behavior", "PROBLEM", 145, 182], ["TBI", "OBSERVATION", 61, 64], ["increase", "OBSERVATION_MODIFIER", 98, 106]]], ["A study by Mackay et al (2006) found an increase in activation of the kynurenine pathway, which was sustained for at least 1 year (and possibly longer) following TBI.", [["kynurenine", "CHEMICAL", 70, 80], ["TBI", "DISEASE", 162, 165], ["kynurenine", "CHEMICAL", 70, 80], ["kynurenine", "SIMPLE_CHEMICAL", 70, 80], ["A study", "TEST", 0, 7], ["the kynurenine pathway", "TREATMENT", 66, 88], ["TBI", "PROBLEM", 162, 165], ["increase", "OBSERVATION_MODIFIER", 40, 48], ["possibly longer", "UNCERTAINTY", 135, 150]]], ["Meanwhile, another study determined that during the first year after mild-to-severe TBI, suicidal ideation was present in 25% of patients (Mackelprang et al, 2014) .", [["TBI", "DISEASE", 84, 87], ["suicidal ideation", "DISEASE", 89, 106], ["patients", "ORGANISM", 129, 137], ["patients", "SPECIES", 129, 137], ["another study", "TEST", 11, 24], ["mild-to-severe TBI", "PROBLEM", 69, 87], ["suicidal ideation", "PROBLEM", 89, 106]]], ["These long-lasting effects of the TBI could be, in part, responsible for the increased risk of suicidality observed in veterans (Brenner et al, 2011) .VITAMIN D DEFICIENCYLow levels of vitamin D have been linked with MDD and other psychiatric illnesses (Kjaergaard et al, 2011) , and recent studies have begun to explore its role in suicidal behavior.", [["TBI", "DISEASE", 34, 37], ["suicidality", "DISEASE", 95, 106], ["vitamin D", "CHEMICAL", 185, 194], ["MDD", "DISEASE", 217, 220], ["psychiatric illnesses", "DISEASE", 231, 252], ["suicidal behavior", "DISEASE", 333, 350], ["vitamin D", "CHEMICAL", 185, 194], ["vitamin D", "SIMPLE_CHEMICAL", 185, 194], ["the TBI", "PROBLEM", 30, 37], ["suicidality", "PROBLEM", 95, 106], ["VITAMIN D DEFICIENCYLow levels", "TEST", 151, 181], ["vitamin D", "TREATMENT", 185, 194], ["MDD", "PROBLEM", 217, 220], ["other psychiatric illnesses", "PROBLEM", 225, 252], ["recent studies", "TEST", 284, 298], ["suicidal behavior", "PROBLEM", 333, 350], ["TBI", "OBSERVATION", 34, 37], ["suicidality", "OBSERVATION", 95, 106]]], ["Umhau et al (2013) investigated vitamin D status in a cohort of active duty military service professional and found that low levels of vitamin D correlate with increased suicide risk.", [["vitamin D", "CHEMICAL", 32, 41], ["vitamin D", "CHEMICAL", 135, 144], ["vitamin D", "CHEMICAL", 32, 41], ["vitamin D", "CHEMICAL", 135, 144], ["vitamin D", "SIMPLE_CHEMICAL", 32, 41], ["vitamin D", "SIMPLE_CHEMICAL", 135, 144], ["vitamin D status", "TREATMENT", 32, 48], ["vitamin D", "TREATMENT", 135, 144], ["increased suicide risk", "PROBLEM", 160, 182]]], ["Although it is still unclear how vitamin D is associated with suicidal behavior, it is plausible that its immune-modulatory functions might have a role.", [["vitamin D", "CHEMICAL", 33, 42], ["suicidal behavior", "DISEASE", 62, 79], ["vitamin D", "CHEMICAL", 33, 42], ["vitamin D", "SIMPLE_CHEMICAL", 33, 42], ["suicidal behavior", "PROBLEM", 62, 79]]], ["1,25-dihydroxyvitamin D3 attenuates immune response by suppressing the effects of IL-2 and IFN-\u03b3, produced by Th1 cells, subsequently preventing the activation and proliferation of T-cell populations (Cippitelli and Santoni, 1998) .", [["Th1 cells", "ANATOMY", 110, 119], ["T-cell", "ANATOMY", 181, 187], ["1,25-dihydroxyvitamin D3", "CHEMICAL", 0, 24], ["1,25-dihydroxyvitamin D3", "CHEMICAL", 0, 24], ["1,25-dihydroxyvitamin D3", "SIMPLE_CHEMICAL", 0, 24], ["IL-2", "GENE_OR_GENE_PRODUCT", 82, 86], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 91, 96], ["Th1 cells", "CELL", 110, 119], ["T-cell populations", "CELL", 181, 199], ["IL", "PROTEIN", 82, 84], ["IFN-\u03b3", "PROTEIN", 91, 96], ["Th1 cells", "CELL_TYPE", 110, 119], ["T-cell populations", "CELL_TYPE", 181, 199], ["dihydroxyvitamin D3 attenuates immune response", "TREATMENT", 5, 51], ["IL", "TEST", 82, 84], ["IFN", "TREATMENT", 91, 94], ["Th1 cells", "OBSERVATION", 110, 119]]], ["Furthermore, vitamin D also inhibits the release of cytokines such as IL-6 and TNF-\u03b1 from human monocytes .", [["monocytes", "ANATOMY", 96, 105], ["vitamin D", "CHEMICAL", 13, 22], ["vitamin D", "CHEMICAL", 13, 22], ["vitamin D", "SIMPLE_CHEMICAL", 13, 22], ["IL-6", "GENE_OR_GENE_PRODUCT", 70, 74], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 79, 84], ["human", "ORGANISM", 90, 95], ["monocytes", "CELL", 96, 105], ["cytokines", "PROTEIN", 52, 61], ["IL-6", "PROTEIN", 70, 74], ["TNF", "PROTEIN", 79, 82], ["human monocytes", "CELL_TYPE", 90, 105], ["human", "SPECIES", 90, 95], ["human", "SPECIES", 90, 95], ["vitamin D", "TREATMENT", 13, 22], ["cytokines", "TEST", 52, 61], ["IL", "TEST", 70, 72], ["TNF", "TEST", 79, 82]]], ["Grudet et al compared vitamin D levels in suicide attempters, non-suicidal depressed patients, and healthy individuals, and found that suicidal patients had significantly lower levels of vitamin D, compared with the other groups, and that 58% of the suicide attempters were severely vitamin D deficient.", [["vitamin D", "CHEMICAL", 22, 31], ["suicide attempters", "DISEASE", 42, 60], ["depressed", "DISEASE", 75, 84], ["suicidal", "DISEASE", 135, 143], ["vitamin D", "CHEMICAL", 187, 196], ["vitamin D", "CHEMICAL", 283, 292], ["vitamin D", "CHEMICAL", 22, 31], ["vitamin D", "CHEMICAL", 187, 196], ["vitamin D", "CHEMICAL", 283, 292], ["vitamin D", "SIMPLE_CHEMICAL", 22, 31], ["patients", "ORGANISM", 85, 93], ["patients", "ORGANISM", 144, 152], ["vitamin D", "SIMPLE_CHEMICAL", 187, 196], ["vitamin D", "SIMPLE_CHEMICAL", 283, 292], ["patients", "SPECIES", 85, 93], ["patients", "SPECIES", 144, 152], ["vitamin D levels", "TEST", 22, 38], ["non-suicidal depressed patients", "PROBLEM", 62, 93], ["vitamin D", "TREATMENT", 187, 196], ["the suicide attempters", "PROBLEM", 246, 268], ["severely vitamin D deficient", "PROBLEM", 274, 302]]], ["Lower vitamin D levels also correlated with elevated levels of inflammatory cytokines in the suicidal and depressive patients (Grudet et al, 2014) .THERAPYSeveral clinical trials have found that ketamine robustly decreases depressive and suicidal symptoms in as little as 40 min with effects lasting for several weeks (DiazGranados et al, 2010; Larkin and Beautrais, 2011; Price and Mathew, 2015; Price et al, 2009; Zarate et al, 2012) .", [["vitamin D", "CHEMICAL", 6, 15], ["depressive", "DISEASE", 106, 116], ["ketamine", "CHEMICAL", 195, 203], ["depressive and suicidal symptoms", "DISEASE", 223, 255], ["vitamin D", "CHEMICAL", 6, 15], ["ketamine", "CHEMICAL", 195, 203], ["vitamin D", "SIMPLE_CHEMICAL", 6, 15], ["patients", "ORGANISM", 117, 125], ["ketamine", "SIMPLE_CHEMICAL", 195, 203], ["inflammatory cytokines", "PROTEIN", 63, 85], ["patients", "SPECIES", 117, 125], ["Lower vitamin D levels", "TEST", 0, 22], ["elevated levels", "PROBLEM", 44, 59], ["inflammatory cytokines", "PROBLEM", 63, 85], ["the suicidal and depressive patients", "PROBLEM", 89, 125], ["ketamine", "TREATMENT", 195, 203], ["depressive", "PROBLEM", 223, 233], ["suicidal symptoms", "PROBLEM", 238, 255], ["inflammatory cytokines", "OBSERVATION", 63, 85]]], ["Animal studies also showed that ketamine is capable of reducing depressive effects in LPS-injected mice, which exhibit activation of the kynurenine pathway in the brain through IDO induction (O'Connor et al, 2009; Walker et al, 2013) .", [["brain", "ANATOMY", 163, 168], ["ketamine", "CHEMICAL", 32, 40], ["depressive", "DISEASE", 64, 74], ["LPS", "CHEMICAL", 86, 89], ["kynurenine", "CHEMICAL", 137, 147], ["ketamine", "CHEMICAL", 32, 40], ["kynurenine", "CHEMICAL", 137, 147], ["ketamine", "SIMPLE_CHEMICAL", 32, 40], ["LPS", "SIMPLE_CHEMICAL", 86, 89], ["mice", "ORGANISM", 99, 103], ["kynurenine", "SIMPLE_CHEMICAL", 137, 147], ["brain", "ORGAN", 163, 168], ["IDO", "GENE_OR_GENE_PRODUCT", 177, 180], ["IDO", "PROTEIN", 177, 180], ["mice", "SPECIES", 99, 103], ["Animal studies", "TEST", 0, 14], ["ketamine", "TREATMENT", 32, 40], ["reducing depressive effects in LPS", "PROBLEM", 55, 89], ["brain", "ANATOMY", 163, 168]]], ["As ketamine is an NMDA receptor antagonist, its observed beneficial effects could be due to its competing action with neurotoxic QUIN, an NMDA receptor agonist.", [["ketamine", "CHEMICAL", 3, 11], ["NMDA", "CHEMICAL", 18, 22], ["neurotoxic", "DISEASE", 118, 128], ["QUIN", "CHEMICAL", 129, 133], ["NMDA", "CHEMICAL", 138, 142], ["ketamine", "CHEMICAL", 3, 11], ["NMDA", "CHEMICAL", 18, 22], ["QUIN", "CHEMICAL", 129, 133], ["NMDA", "CHEMICAL", 138, 142], ["ketamine", "SIMPLE_CHEMICAL", 3, 11], ["NMDA", "SIMPLE_CHEMICAL", 18, 22], ["QUIN", "SIMPLE_CHEMICAL", 129, 133], ["NMDA", "SIMPLE_CHEMICAL", 138, 142], ["ketamine", "TREATMENT", 3, 11], ["an NMDA receptor antagonist", "TREATMENT", 15, 42], ["neurotoxic QUIN", "TREATMENT", 118, 133], ["an NMDA receptor agonist", "TREATMENT", 135, 159]]], ["In addition, ketamine can be metabolized in vivo via P450 enzymes to produce various metabolites, some of which are biologically active, such as (2R, 6R)-hydroxynorketamine (HNK), and mediate antidepressant effects by activation of AMPA receptors (Zanos et al, 2016) .", [["ketamine", "CHEMICAL", 13, 21], ["(2R, 6R)-hydroxynorketamine", "CHEMICAL", 145, 172], ["antidepressant", "CHEMICAL", 192, 206], ["AMPA", "CHEMICAL", 232, 236], ["ketamine", "CHEMICAL", 13, 21], ["(2R, 6R)-hydroxynorketamine", "CHEMICAL", 145, 172], ["HNK", "CHEMICAL", 174, 177], ["AMPA", "CHEMICAL", 232, 236], ["ketamine", "SIMPLE_CHEMICAL", 13, 21], ["P450 enzymes", "GENE_OR_GENE_PRODUCT", 53, 65], ["(2R, 6R)-hydroxynorketamine", "SIMPLE_CHEMICAL", 145, 172], ["HNK", "SIMPLE_CHEMICAL", 174, 177], ["AMPA", "SIMPLE_CHEMICAL", 232, 236], ["P450 enzymes", "PROTEIN", 53, 65], ["AMPA receptors", "PROTEIN", 232, 246], ["ketamine", "TREATMENT", 13, 21], ["P450 enzymes", "TEST", 53, 65], ["various metabolites", "PROBLEM", 77, 96], ["hydroxynorketamine", "TREATMENT", 154, 172], ["AMPA receptors", "TREATMENT", 232, 246], ["active", "OBSERVATION_MODIFIER", 129, 135]]], ["Currently, there are several ongoing clinical trials investigating whether repeated administration or different doses of ketamine are able to increase its efficacy in various psychiatric disorders (US National Institute of Health, 2016).THERAPYAnother drug with therapeutic potential to treat MDD and suicidal behavior includes 4-chloro-kynurenine (4-Cl-KYN), which is a brain-penetrating prodrug of 7-chloro-kynurenic acid, and works by blocking the glycine co-agonist site of the NMDA receptor.", [["brain", "ANATOMY", 371, 376], ["ketamine", "CHEMICAL", 121, 129], ["psychiatric disorders", "DISEASE", 175, 196], ["MDD", "DISEASE", 293, 296], ["suicidal behavior", "DISEASE", 301, 318], ["4-chloro-kynurenine", "CHEMICAL", 328, 347], ["4-Cl-KYN", "CHEMICAL", 349, 357], ["7-chloro-kynurenic acid", "CHEMICAL", 400, 423], ["glycine", "CHEMICAL", 451, 458], ["NMDA", "CHEMICAL", 482, 486], ["ketamine", "CHEMICAL", 121, 129], ["4-chloro-kynurenine", "CHEMICAL", 328, 347], ["4-Cl-KYN", "CHEMICAL", 349, 357], ["7-chloro-kynurenic acid", "CHEMICAL", 400, 423], ["glycine", "CHEMICAL", 451, 458], ["NMDA", "CHEMICAL", 482, 486], ["ketamine", "SIMPLE_CHEMICAL", 121, 129], ["4-chloro-kynurenine", "SIMPLE_CHEMICAL", 328, 347], ["4-Cl-KYN", "SIMPLE_CHEMICAL", 349, 357], ["brain", "ORGAN", 371, 376], ["7-chloro-kynurenic acid", "SIMPLE_CHEMICAL", 400, 423], ["NMDA receptor", "GENE_OR_GENE_PRODUCT", 482, 495], ["glycine co-agonist site", "PROTEIN", 451, 474], ["NMDA receptor", "PROTEIN", 482, 495], ["repeated administration", "TREATMENT", 75, 98], ["ketamine", "TREATMENT", 121, 129], ["various psychiatric disorders", "PROBLEM", 167, 196], ["MDD", "PROBLEM", 293, 296], ["suicidal behavior", "PROBLEM", 301, 318], ["4-chloro-kynurenine", "TREATMENT", 328, 347], ["brain", "ANATOMY", 371, 376]]], ["4-Cl-KYN exerts similar antidepressant effects of ketamine, but not side effects in animal models (Zanos et al, 2015) .", [["4-Cl", "CHEMICAL", 0, 4], ["KYN", "CHEMICAL", 5, 8], ["antidepressant", "CHEMICAL", 24, 38], ["ketamine", "CHEMICAL", 50, 58], ["4-Cl-KYN", "CHEMICAL", 0, 8], ["ketamine", "CHEMICAL", 50, 58], ["4-Cl-KYN", "SIMPLE_CHEMICAL", 0, 8], ["ketamine", "SIMPLE_CHEMICAL", 50, 58], ["ketamine", "TREATMENT", 50, 58]]], ["Interestingly, these beneficial moodaltering effects are contingent on the activity of AMPA receptors, suggesting an important relationship between NMDA and AMPA receptors in generating antidepressant response.", [["AMPA", "CHEMICAL", 87, 91], ["NMDA", "CHEMICAL", 148, 152], ["AMPA", "CHEMICAL", 157, 161], ["antidepressant", "CHEMICAL", 186, 200], ["AMPA", "CHEMICAL", 87, 91], ["NMDA", "CHEMICAL", 148, 152], ["AMPA", "CHEMICAL", 157, 161], ["AMPA", "SIMPLE_CHEMICAL", 87, 91], ["NMDA", "SIMPLE_CHEMICAL", 148, 152], ["AMPA", "SIMPLE_CHEMICAL", 157, 161], ["AMPA receptors", "PROTEIN", 87, 101], ["AMPA receptors", "PROTEIN", 157, 171], ["AMPA receptors", "TREATMENT", 87, 101], ["NMDA and AMPA receptors", "TREATMENT", 148, 171]]], ["There is, currently, an ongoing clinical trial testing the antidepressant effects of 4-Cl-KYN in MDD patients (US National Institute of Health, 2016).THERAPYAnother potentially promising pharmacological target is glycogen synthase kinase-3 (GSK3), which raises the levels of pro-inflammatory cytokines and, thus, is thought to promote the development of aggression and depressive symptoms, which are closely linked to development of suicidality (Beurel and Jope, 2014) .", [["antidepressant", "CHEMICAL", 59, 73], ["4-Cl-KYN", "CHEMICAL", 85, 93], ["MDD", "DISEASE", 97, 100], ["glycogen", "CHEMICAL", 213, 221], ["aggression", "DISEASE", 354, 364], ["depressive symptoms", "DISEASE", 369, 388], ["suicidality", "DISEASE", 433, 444], ["4-Cl-KYN", "CHEMICAL", 85, 93], ["4-Cl-KYN", "SIMPLE_CHEMICAL", 85, 93], ["patients", "ORGANISM", 101, 109], ["glycogen synthase kinase-3", "GENE_OR_GENE_PRODUCT", 213, 239], ["GSK3", "GENE_OR_GENE_PRODUCT", 241, 245], ["glycogen synthase kinase-3", "PROTEIN", 213, 239], ["GSK3", "PROTEIN", 241, 245], ["pro-inflammatory cytokines", "PROTEIN", 275, 301], ["patients", "SPECIES", 101, 109], ["an ongoing clinical trial testing", "TEST", 21, 54], ["glycogen synthase kinase", "TEST", 213, 237], ["pro-inflammatory cytokines", "PROBLEM", 275, 301], ["aggression", "PROBLEM", 354, 364], ["depressive symptoms", "PROBLEM", 369, 388], ["suicidality", "PROBLEM", 433, 444], ["pro-inflammatory cytokines", "OBSERVATION", 275, 301]]], ["Administration of lithium, which exhibits anti-inflammatory effects through inhibition of GSK3, has been found effective in decreasing depressive-like and aggressive behavior in animal models (Beurel and Jope, 2014) and reducing suicidal attempts and suicide completion in patients with bipolar as well as unipolar depression (Baldessarini et al, 2006; Guzzetta et al, 2007) .THERAPYOther potential drug targets include cyclooxygenase-2 (COX-2) inhibitors, which are selective nonsteroidal anti-inflammatory drugs.", [["lithium", "CHEMICAL", 18, 25], ["depressive-like and aggressive behavior", "DISEASE", 135, 174], ["suicidal attempts", "DISEASE", 229, 246], ["bipolar", "DISEASE", 287, 294], ["unipolar depression", "DISEASE", 306, 325], ["lithium", "CHEMICAL", 18, 25], ["lithium", "SIMPLE_CHEMICAL", 18, 25], ["GSK3", "GENE_OR_GENE_PRODUCT", 90, 94], ["patients", "ORGANISM", 273, 281], ["cyclooxygenase-2", "GENE_OR_GENE_PRODUCT", 420, 436], ["COX-2", "GENE_OR_GENE_PRODUCT", 438, 443], ["nonsteroidal anti-inflammatory drugs", "SIMPLE_CHEMICAL", 477, 513], ["GSK3", "PROTEIN", 90, 94], ["patients", "SPECIES", 273, 281], ["lithium", "TREATMENT", 18, 25], ["anti-inflammatory effects through inhibition of GSK3", "PROBLEM", 42, 94], ["decreasing depressive-like and aggressive behavior", "PROBLEM", 124, 174], ["suicide completion", "TREATMENT", 251, 269], ["bipolar", "TREATMENT", 287, 294], ["unipolar depression", "PROBLEM", 306, 325], ["cyclooxygenase-2 (COX-2) inhibitors", "TREATMENT", 420, 455], ["selective nonsteroidal anti-inflammatory drugs", "TREATMENT", 467, 513], ["anti-inflammatory effects", "OBSERVATION", 42, 67], ["effective", "OBSERVATION_MODIFIER", 111, 120], ["decreasing", "OBSERVATION_MODIFIER", 124, 134], ["depressive", "OBSERVATION", 135, 145], ["aggressive", "OBSERVATION_MODIFIER", 155, 165], ["anti-inflammatory drugs", "OBSERVATION", 490, 513]]], ["Several recent meta-analyses of randomized controlled trials (RCTs) have found a COX-2 inhibitor celecoxib to be an effective add-on treatment for unipolar depression as celecoxib decreases depression severity and increases remission rates (Faridhosseini et al, 2014; Na et al, 2014) .", [["celecoxib", "CHEMICAL", 97, 106], ["unipolar depression", "DISEASE", 147, 166], ["celecoxib", "CHEMICAL", 170, 179], ["depression", "DISEASE", 190, 200], ["celecoxib", "CHEMICAL", 97, 106], ["celecoxib", "CHEMICAL", 170, 179], ["COX-2", "GENE_OR_GENE_PRODUCT", 81, 86], ["celecoxib", "SIMPLE_CHEMICAL", 97, 106], ["celecoxib", "SIMPLE_CHEMICAL", 170, 179], ["randomized controlled trials (RCTs", "TREATMENT", 32, 66], ["a COX-2 inhibitor celecoxib", "TREATMENT", 79, 106], ["treatment", "TREATMENT", 133, 142], ["unipolar depression", "PROBLEM", 147, 166], ["celecoxib", "TREATMENT", 170, 179], ["depression severity", "PROBLEM", 190, 209]]], ["A RCT conducted by Nery et al (2008) has found that adjunctive treatment with celecoxib is able to produce a rapid antidepressant effect in bipolar disorder patients during depressive or mixed phases.", [["celecoxib", "CHEMICAL", 78, 87], ["antidepressant", "CHEMICAL", 115, 129], ["bipolar disorder", "DISEASE", 140, 156], ["depressive", "DISEASE", 173, 183], ["celecoxib", "CHEMICAL", 78, 87], ["celecoxib", "SIMPLE_CHEMICAL", 78, 87], ["patients", "ORGANISM", 157, 165], ["patients", "SPECIES", 157, 165], ["A RCT", "TEST", 0, 5], ["adjunctive treatment", "TREATMENT", 52, 72], ["celecoxib", "TREATMENT", 78, 87], ["a rapid antidepressant effect in bipolar disorder", "PROBLEM", 107, 156], ["depressive or mixed phases", "PROBLEM", 173, 199]]], ["Infliximab, which is a monoclonal antibody against TNF-\u03b1, has also shown some antidepressant effects, as it is able to decrease depressive symptoms in patients with treatment-resistant depression and elevated levels of plasma inflammatory biomarkers (Raison et al, 2013) .", [["plasma", "ANATOMY", 219, 225], ["Infliximab", "CHEMICAL", 0, 10], ["antidepressant", "CHEMICAL", 78, 92], ["depressive symptoms", "DISEASE", 128, 147], ["depression", "DISEASE", 185, 195], ["Infliximab", "SIMPLE_CHEMICAL", 0, 10], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 51, 56], ["patients", "ORGANISM", 151, 159], ["plasma", "ORGANISM_SUBSTANCE", 219, 225], ["monoclonal antibody", "PROTEIN", 23, 42], ["TNF-\u03b1", "PROTEIN", 51, 56], ["patients", "SPECIES", 151, 159], ["Infliximab", "TREATMENT", 0, 10], ["a monoclonal antibody", "TEST", 21, 42], ["TNF", "TEST", 51, 54], ["depressive symptoms", "PROBLEM", 128, 147], ["treatment", "TREATMENT", 165, 174], ["resistant depression", "PROBLEM", 175, 195], ["elevated levels of plasma inflammatory biomarkers", "PROBLEM", 200, 249], ["some", "OBSERVATION_MODIFIER", 73, 77], ["antidepressant effects", "OBSERVATION", 78, 100]]], ["A new, recently started RCT will evaluate the effect of adjunctively administrated infliximab on bipolar I and II depression (US National Institute of Health, 2016).", [["infliximab", "CHEMICAL", 83, 93], ["bipolar I and II depression", "DISEASE", 97, 124], ["infliximab", "SIMPLE_CHEMICAL", 83, 93], ["infliximab", "TREATMENT", 83, 93], ["bipolar I and II depression", "PROBLEM", 97, 124], ["new", "OBSERVATION_MODIFIER", 2, 5]]], ["Other clinical studies have shown that infliximab and etanercept, another TNF-\u03b1 blocker, are capable of improving symptoms of depression in patients with various inflammatory conditions (Ersozlu-Bozkirli et al, 2015; Ertenli et al, 2012; Gelfand et al, 2008; Minderhoud et al, 2007; Tookman et al, 2008) .THERAPYMinocycline, which is a broad-range tetracycline antibiotic capable of decreasing microglial activation, is another promising treatment for depressive symptoms.", [["microglial", "ANATOMY", 394, 404], ["infliximab", "CHEMICAL", 39, 49], ["etanercept", "CHEMICAL", 54, 64], ["depression", "DISEASE", 126, 136], ["THERAPYMinocycline", "CHEMICAL", 305, 323], ["tetracycline", "CHEMICAL", 348, 360], ["depressive symptoms", "DISEASE", 452, 471], ["THERAPYMinocycline", "CHEMICAL", 305, 323], ["tetracycline", "CHEMICAL", 348, 360], ["infliximab", "SIMPLE_CHEMICAL", 39, 49], ["etanercept", "SIMPLE_CHEMICAL", 54, 64], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 74, 79], ["patients", "ORGANISM", 140, 148], ["THERAPYMinocycline", "SIMPLE_CHEMICAL", 305, 323], ["tetracycline", "SIMPLE_CHEMICAL", 348, 360], ["microglial", "CELL", 394, 404], ["TNF", "PROTEIN", 74, 77], ["patients", "SPECIES", 140, 148], ["Other clinical studies", "TEST", 0, 22], ["infliximab", "TREATMENT", 39, 49], ["etanercept", "TREATMENT", 54, 64], ["another TNF-\u03b1 blocker", "TREATMENT", 66, 87], ["improving symptoms", "PROBLEM", 104, 122], ["depression", "PROBLEM", 126, 136], ["various inflammatory conditions", "PROBLEM", 154, 185], ["THERAPYMinocycline", "TREATMENT", 305, 323], ["a broad-range tetracycline antibiotic", "TREATMENT", 334, 371], ["decreasing microglial activation", "PROBLEM", 383, 415], ["depressive symptoms", "PROBLEM", 452, 471], ["infliximab", "OBSERVATION", 39, 49], ["depression", "OBSERVATION", 126, 136], ["inflammatory", "OBSERVATION_MODIFIER", 162, 174], ["decreasing", "OBSERVATION_MODIFIER", 383, 393], ["microglial activation", "OBSERVATION", 394, 415]]], ["Preliminary data from an open-label study of patients with MDD suggest that adjunctive minocycline treatment is able to reduce the severity of depressive and psychotic symptoms (Miyaoka et al, 2012) .", [["MDD", "DISEASE", 59, 62], ["minocycline", "CHEMICAL", 87, 98], ["depressive", "DISEASE", 143, 153], ["psychotic symptoms", "DISEASE", 158, 176], ["minocycline", "CHEMICAL", 87, 98], ["patients", "ORGANISM", 45, 53], ["minocycline", "SIMPLE_CHEMICAL", 87, 98], ["patients", "SPECIES", 45, 53], ["Preliminary data", "TEST", 0, 16], ["an open-label study", "TEST", 22, 41], ["MDD", "PROBLEM", 59, 62], ["adjunctive minocycline treatment", "TREATMENT", 76, 108], ["depressive and psychotic symptoms", "PROBLEM", 143, 176]]], ["Currently, ongoing RCTs are investigating the effect of minocycline add-on treatment for the management of depressive symptoms in patients with treatment-resistant depression (Husain et al, 2015) , MDD (Dean et al, 2014) , and bipolar depression (Savitz et al, 2012) .THERAPYOther anti-inflammatory drugs with therapeutic promise in the treatment of depressive and suicidal symptoms include those targeting cytokine IL-6 and its biological function.", [["minocycline", "CHEMICAL", 56, 67], ["depressive symptoms", "DISEASE", 107, 126], ["depression", "DISEASE", 164, 174], ["MDD", "DISEASE", 198, 201], ["bipolar depression", "DISEASE", 227, 245], ["depressive", "DISEASE", 350, 360], ["suicidal symptoms", "DISEASE", 365, 382], ["minocycline", "CHEMICAL", 56, 67], ["minocycline", "SIMPLE_CHEMICAL", 56, 67], ["patients", "ORGANISM", 130, 138], ["IL-6", "GENE_OR_GENE_PRODUCT", 416, 420], ["cytokine IL-6", "PROTEIN", 407, 420], ["patients", "SPECIES", 130, 138], ["ongoing RCTs", "TREATMENT", 11, 23], ["minocycline", "TREATMENT", 56, 67], ["treatment", "TREATMENT", 75, 84], ["the management", "TREATMENT", 89, 103], ["depressive symptoms", "PROBLEM", 107, 126], ["treatment", "TREATMENT", 144, 153], ["resistant depression", "PROBLEM", 154, 174], ["bipolar depression", "PROBLEM", 227, 245], ["THERAPYOther anti-inflammatory drugs", "TREATMENT", 268, 304], ["therapeutic promise", "TREATMENT", 310, 329], ["depressive and suicidal symptoms", "PROBLEM", 350, 382], ["those targeting cytokine IL", "TREATMENT", 391, 418], ["anti-inflammatory drugs", "OBSERVATION", 281, 304]]], ["An example of such drug is tocilizumab, a monoclonal anti-IL-6 receptor antibody that works by preventing the IL-6 ligand from binding to the IL-6 receptors.", [["tocilizumab", "CHEMICAL", 27, 38], ["tocilizumab", "SIMPLE_CHEMICAL", 27, 38], ["anti-IL-6 receptor", "GENE_OR_GENE_PRODUCT", 53, 71], ["IL-6", "GENE_OR_GENE_PRODUCT", 110, 114], ["IL-6 receptors", "GENE_OR_GENE_PRODUCT", 142, 156], ["monoclonal anti-IL-6 receptor antibody", "PROTEIN", 42, 80], ["IL-6 ligand", "PROTEIN", 110, 121], ["IL-6 receptors", "PROTEIN", 142, 156], ["tocilizumab", "TREATMENT", 27, 38], ["a monoclonal anti-IL-6 receptor antibody", "TREATMENT", 40, 80]]], ["Previous studies have found that tocilizumab is able to effectively treat several inflammatory and autoimmune diseases (Choy et al, 2002; Fonseka et al, 2015; Ito et al, 2004 ) and a recently initiated RCT will access the ability of tocilizumab to decrease depressive symptomology in treatment-resistant depression (US National Institute of Health, 2016).", [["tocilizumab", "CHEMICAL", 33, 44], ["autoimmune diseases", "DISEASE", 99, 118], ["tocilizumab", "CHEMICAL", 233, 244], ["depressive symptomology", "DISEASE", 257, 280], ["depression", "DISEASE", 304, 314], ["tocilizumab", "SIMPLE_CHEMICAL", 33, 44], ["tocilizumab", "SIMPLE_CHEMICAL", 233, 244], ["Previous studies", "TEST", 0, 16], ["tocilizumab", "TREATMENT", 33, 44], ["several inflammatory and autoimmune diseases", "PROBLEM", 74, 118], ["tocilizumab", "TREATMENT", 233, 244], ["depressive symptomology", "PROBLEM", 257, 280], ["resistant depression", "PROBLEM", 294, 314], ["tocilizumab", "OBSERVATION", 33, 44], ["inflammatory", "OBSERVATION_MODIFIER", 82, 94]]], ["A more recently developed drug is the human anti-IL-6 monoclonal antibody-sirukumab.", [["sirukumab", "CHEMICAL", 74, 83], ["human", "ORGANISM", 38, 43], ["anti-IL-6", "GENE_OR_GENE_PRODUCT", 44, 53], ["sirukumab", "SIMPLE_CHEMICAL", 74, 83], ["human anti-IL-6 monoclonal antibody", "PROTEIN", 38, 73], ["human", "SPECIES", 38, 43], ["human", "SPECIES", 38, 43], ["the human anti-IL", "TEST", 34, 51]]], ["In previous studies, sirukumab was able to decrease inflammatory symptoms in patients with rheumatoid arthritis (Smolen et al, 2014; Tanaka and Martin Mola, 2014 ).", [["sirukumab", "CHEMICAL", 21, 30], ["rheumatoid arthritis", "DISEASE", 91, 111], ["sirukumab", "CHEMICAL", 21, 30], ["sirukumab", "SIMPLE_CHEMICAL", 21, 30], ["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85], ["previous studies", "TEST", 3, 19], ["inflammatory symptoms", "PROBLEM", 52, 73], ["rheumatoid arthritis", "PROBLEM", 91, 111], ["inflammatory", "OBSERVATION_MODIFIER", 52, 64], ["rheumatoid arthritis", "OBSERVATION", 91, 111]]], ["An ongoing RCT will assess the efficacy and safety of an add-on sirukumab treatment in MDD patients (US National Institute of Health, 2016).THERAPYPentoxifylline is a phosphodiesterase inhibitor, which, among other effects, decreases the expression of proinflammatory cytokines such as TNF-\u03b1, IL-1, and IL-6 in blood cells (Ferrari et al, 2010; Gonzalez-Espinoza et al, 2012; Neuner et al, 1994; Pollice et al, 2001) .", [["blood cells", "ANATOMY", 311, 322], ["sirukumab", "CHEMICAL", 64, 73], ["MDD", "DISEASE", 87, 90], ["THERAPYPentoxifylline", "CHEMICAL", 140, 161], ["sirukumab", "CHEMICAL", 64, 73], ["THERAPYPentoxifylline", "CHEMICAL", 140, 161], ["sirukumab", "SIMPLE_CHEMICAL", 64, 73], ["patients", "ORGANISM", 91, 99], ["THERAPYPentoxifylline", "SIMPLE_CHEMICAL", 140, 161], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 286, 291], ["IL-1", "GENE_OR_GENE_PRODUCT", 293, 297], ["IL-6", "GENE_OR_GENE_PRODUCT", 303, 307], ["blood cells", "CELL", 311, 322], ["proinflammatory cytokines", "PROTEIN", 252, 277], ["TNF", "PROTEIN", 286, 289], ["IL-1", "PROTEIN", 293, 297], ["IL-6", "PROTEIN", 303, 307], ["blood cells", "CELL_TYPE", 311, 322], ["patients", "SPECIES", 91, 99], ["An ongoing RCT", "TEST", 0, 14], ["sirukumab treatment", "TREATMENT", 64, 83], ["THERAPYPentoxifylline", "TREATMENT", 140, 161], ["a phosphodiesterase inhibitor", "TREATMENT", 165, 194], ["proinflammatory cytokines", "TEST", 252, 277], ["TNF", "TEST", 286, 289], ["IL", "TEST", 293, 295], ["IL", "TEST", 303, 305]]], ["Although it has also been shown to decrease depressive-like behavior in animal models (Bah et al, 2011; Elgarf et al, 2014) , whether it can be replicated in humans has not yet been determined.", [["depressive-like behavior", "DISEASE", 44, 68], ["humans", "ORGANISM", 158, 164], ["humans", "SPECIES", 158, 164], ["humans", "SPECIES", 158, 164], ["depressive-like behavior", "PROBLEM", 44, 68], ["decrease", "OBSERVATION_MODIFIER", 35, 43], ["depressive", "OBSERVATION", 44, 54]]], ["A recently started RCT will attempt to shed some light, as it will explore whether pentoxifylline is able to reduce depressive symptoms, as well as improve artery function, in older primary care patients (US National Institute of Health, 2016).THERAPYMost of the above-mentioned anti-inflammatory treatments are in the process of being tested for their effectiveness as anti-depressive action.", [["artery", "ANATOMY", 156, 162], ["pentoxifylline", "CHEMICAL", 83, 97], ["depressive symptoms", "DISEASE", 116, 135], ["pentoxifylline", "CHEMICAL", 83, 97], ["pentoxifylline", "SIMPLE_CHEMICAL", 83, 97], ["artery", "MULTI-TISSUE_STRUCTURE", 156, 162], ["patients", "ORGANISM", 195, 203], ["patients", "SPECIES", 195, 203], ["pentoxifylline", "TREATMENT", 83, 97], ["depressive symptoms", "PROBLEM", 116, 135], ["anti-inflammatory treatments", "TREATMENT", 279, 307], ["anti-depressive action", "TREATMENT", 370, 392], ["artery", "ANATOMY", 156, 162], ["anti-inflammatory treatments", "OBSERVATION", 279, 307]]], ["As discussed in the above sections of this review, irrespective of psychiatric condition, suicidal patients and those at increased suicidal risk often display pronounced inflammatory changes and, therefore, might benefit from anti-inflammatory therapies.", [["psychiatric", "DISEASE", 67, 78], ["suicidal", "DISEASE", 90, 98], ["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107], ["psychiatric condition", "PROBLEM", 67, 88], ["increased suicidal risk", "PROBLEM", 121, 144], ["pronounced inflammatory changes", "PROBLEM", 159, 190], ["anti-inflammatory therapies", "TREATMENT", 226, 253], ["pronounced", "OBSERVATION_MODIFIER", 159, 169], ["inflammatory", "OBSERVATION", 170, 182]]], ["Unfortunately, suicidal patients are frequently excluded from the initial phase of investigation due to the safety concerns.", [["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32]]], ["Thus, whether the mentioned anti-inflammatory treatments could be additionally used as effective therapies for suicidal behavior remains to be studied in well-designed clinical trials.CONCLUSIONSMounting evidence implicates dysregulation of the immune system in pathophysiology of suicidality.", [["immune system", "ANATOMY", 245, 258], ["suicidal behavior", "DISEASE", 111, 128], ["suicidality", "DISEASE", 281, 292], ["anti-inflammatory treatments", "TREATMENT", 28, 56], ["effective therapies", "TREATMENT", 87, 106], ["suicidal behavior", "PROBLEM", 111, 128], ["dysregulation of the immune system", "PROBLEM", 224, 258], ["suicidality", "PROBLEM", 281, 292], ["immune system", "OBSERVATION", 245, 258]]], ["The potential upstream triggers of suicidal behavior include various inflammatory conditions (TBI, vitamin deficiency, autoimmune disorders, and infections), which, through raised levels of inflammatory mediators, can cause dysregulation of the kynurenine pathway of tryptophan catabolism, hyperactivation of the HPA axis, and alterations in monoamine metabolism in the patients.", [["suicidal behavior", "DISEASE", 35, 52], ["TBI", "DISEASE", 94, 97], ["vitamin deficiency", "DISEASE", 99, 117], ["autoimmune disorders", "DISEASE", 119, 139], ["infections", "DISEASE", 145, 155], ["kynurenine", "CHEMICAL", 245, 255], ["tryptophan", "CHEMICAL", 267, 277], ["kynurenine", "CHEMICAL", 245, 255], ["tryptophan", "CHEMICAL", 267, 277], ["monoamine", "CHEMICAL", 342, 351], ["vitamin", "SIMPLE_CHEMICAL", 99, 106], ["kynurenine", "SIMPLE_CHEMICAL", 245, 255], ["tryptophan", "SIMPLE_CHEMICAL", 267, 277], ["monoamine", "SIMPLE_CHEMICAL", 342, 351], ["patients", "ORGANISM", 370, 378], ["inflammatory mediators", "PROTEIN", 190, 212], ["patients", "SPECIES", 370, 378], ["suicidal behavior", "PROBLEM", 35, 52], ["various inflammatory conditions", "PROBLEM", 61, 92], ["TBI", "PROBLEM", 94, 97], ["vitamin deficiency", "PROBLEM", 99, 117], ["autoimmune disorders", "PROBLEM", 119, 139], ["infections", "PROBLEM", 145, 155], ["inflammatory mediators", "PROBLEM", 190, 212], ["tryptophan catabolism", "PROBLEM", 267, 288], ["hyperactivation of the HPA axis", "PROBLEM", 290, 321], ["alterations in monoamine metabolism", "PROBLEM", 327, 362], ["inflammatory", "OBSERVATION_MODIFIER", 69, 81], ["inflammatory", "OBSERVATION_MODIFIER", 190, 202], ["HPA axis", "ANATOMY", 313, 321], ["monoamine metabolism", "OBSERVATION", 342, 362]]], ["These neurobiological effects might cause profound changes in emotion and behavior, which could ultimately lead to suicide in vulnerable individuals.", [["profound changes in emotion and behavior", "PROBLEM", 42, 82], ["suicide in vulnerable individuals", "PROBLEM", 115, 148]]], ["More studies are needed to further characterize the interconnection between upstream triggers of inflammation, downstream mediators, and predisposition factors, which, in the presence of inflammation, confer resilience or vulnerability towards development of suicidality.CONCLUSIONSCurrently, anti-inflammatory treatments, initially approved for other conditions, are being tested in depressive individuals.", [["inflammation", "DISEASE", 97, 109], ["inflammation", "DISEASE", 187, 199], ["suicidality", "DISEASE", 259, 270], ["depressive", "DISEASE", 384, 394], ["downstream mediators", "PROTEIN", 111, 131], ["predisposition factors", "PROTEIN", 137, 159], ["More studies", "TEST", 0, 12], ["inflammation", "PROBLEM", 97, 109], ["predisposition factors", "PROBLEM", 137, 159], ["inflammation", "PROBLEM", 187, 199], ["suicidality", "PROBLEM", 259, 270], ["anti-inflammatory treatments", "TREATMENT", 293, 321], ["depressive individuals", "PROBLEM", 384, 406], ["inflammation", "OBSERVATION", 97, 109], ["inflammation", "OBSERVATION", 187, 199], ["anti-inflammatory treatments", "OBSERVATION", 293, 321]]], ["Although for safety concerns, actively suicidal individuals and those at increased suicide risk are excluded from such clinical trials, it may be of key importance to include suicidal individuals in the future as this patient group exhibits the most pronounced inflammatory changes, likely to respond to treatment.", [["individuals", "ORGANISM", 48, 59], ["patient", "ORGANISM", 218, 225], ["patient", "SPECIES", 218, 225], ["actively suicidal individuals", "PROBLEM", 30, 59], ["increased suicide risk", "PROBLEM", 73, 95], ["suicidal individuals", "PROBLEM", 175, 195], ["the most pronounced inflammatory changes", "PROBLEM", 241, 281], ["treatment", "TREATMENT", 304, 313], ["most pronounced", "OBSERVATION_MODIFIER", 245, 260], ["inflammatory", "OBSERVATION", 261, 273]]], ["Ketamine, an NMDA receptor antagonist, which might counteract some of the actions of the kynurenine pathway metabolites, is being specifically tested in suicidal individuals.CONCLUSIONSIn the future, it may prove to be advantageous to target additional signaling and regulatory mechanisms involved in neuroinflammation.", [["Ketamine", "CHEMICAL", 0, 8], ["NMDA", "CHEMICAL", 13, 17], ["kynurenine", "CHEMICAL", 89, 99], ["neuroinflammation", "DISEASE", 301, 318], ["Ketamine", "CHEMICAL", 0, 8], ["NMDA", "CHEMICAL", 13, 17], ["kynurenine", "CHEMICAL", 89, 99], ["Ketamine", "SIMPLE_CHEMICAL", 0, 8], ["NMDA", "SIMPLE_CHEMICAL", 13, 17], ["kynurenine", "SIMPLE_CHEMICAL", 89, 99], ["Ketamine", "TREATMENT", 0, 8], ["an NMDA receptor antagonist", "TREATMENT", 10, 37], ["neuroinflammation", "PROBLEM", 301, 318]]], ["Such targets could include TLRs, activation of which regulates the production of proinflammatory cytokines, as some studies have found some abnormalities in brain and blood TLRs' levels in depressed and suicidal patients (Pandey et al, 2014; Wu et al, 2015) .", [["brain", "ANATOMY", 157, 162], ["blood", "ANATOMY", 167, 172], ["depressed", "DISEASE", 189, 198], ["suicidal", "DISEASE", 203, 211], ["TLRs", "GENE_OR_GENE_PRODUCT", 27, 31], ["brain", "ORGAN", 157, 162], ["blood", "ORGANISM_SUBSTANCE", 167, 172], ["TLRs", "GENE_OR_GENE_PRODUCT", 173, 177], ["patients", "ORGANISM", 212, 220], ["TLRs", "PROTEIN", 27, 31], ["proinflammatory cytokines", "PROTEIN", 81, 106], ["patients", "SPECIES", 212, 220], ["proinflammatory cytokines", "PROBLEM", 81, 106], ["some studies", "TEST", 111, 123], ["some abnormalities in brain and blood TLRs' levels", "PROBLEM", 135, 185], ["depressed and suicidal patients", "PROBLEM", 189, 220], ["brain", "ANATOMY", 157, 162], ["depressed", "OBSERVATION_MODIFIER", 189, 198]]], ["Another target could be regulation of the balance between Th1 and Th2-type T-cell populations, as several studies have found an imbalance of these cell types and their corresponding cytokines in the blood of MDD patients with suicidality (Huang and Lee, 2007; Kim et al, 2008; Mendlovic et al, 1999) .CONCLUSIONSAltogether, as neuroinflammation is gradually becoming more accepted as a cause of behavioral symptoms in suicidal individuals, a wide range of novel treatment options, targeting either upstream or downstream factors in the inflammatory cascade, are showing promise to help affected patients.", [["Th2-type T-cell", "ANATOMY", 66, 81], ["cell", "ANATOMY", 147, 151], ["blood", "ANATOMY", 199, 204], ["MDD", "DISEASE", 208, 211], ["suicidality", "DISEASE", 226, 237], ["neuroinflammation", "DISEASE", 327, 344], ["Th1", "GENE_OR_GENE_PRODUCT", 58, 61], ["Th2", "GENE_OR_GENE_PRODUCT", 66, 69], ["cell", "CELL", 147, 151], ["blood", "ORGANISM_SUBSTANCE", 199, 204], ["patients", "ORGANISM", 212, 220], ["patients", "ORGANISM", 595, 603], ["Th1 and Th2-type T-cell populations", "CELL_TYPE", 58, 93], ["cytokines", "PROTEIN", 182, 191], ["patients", "SPECIES", 212, 220], ["patients", "SPECIES", 595, 603], ["Th1", "TEST", 58, 61], ["several studies", "TEST", 98, 113], ["these cell types", "PROBLEM", 141, 157], ["suicidality", "PROBLEM", 226, 237], ["neuroinflammation", "PROBLEM", 327, 344], ["behavioral symptoms in suicidal individuals", "PROBLEM", 395, 438], ["novel treatment options", "TREATMENT", 456, 479], ["the inflammatory cascade", "PROBLEM", 532, 556], ["balance", "OBSERVATION_MODIFIER", 42, 49], ["type T-cell populations", "OBSERVATION", 70, 93], ["imbalance", "OBSERVATION", 128, 137], ["cell types", "OBSERVATION", 147, 157], ["inflammatory", "OBSERVATION_MODIFIER", 536, 548]]], ["As such, the future for development of novel therapies in psychiatry looks brighter than in decades.FUNDING AND DISCLOSURELB was supported by the National Institute of Mental Health (NIMH) (MH104622) and Van Andel Research Institute internal grants.", [["novel therapies", "TREATMENT", 39, 54]]]], "PMC5902693": [["A recent systematic review identified taxonomy of Twitter as a tool for health research, including content analysis, surveillance, engagement, recruitment, intervention, and network analysis [5].", [["content analysis", "TEST", 99, 115], ["surveillance", "TEST", 117, 129], ["intervention", "TREATMENT", 156, 168], ["network analysis", "TEST", 174, 190]]], ["Prior research found Twitter users engaged in communication pertinent to infectious diseases, such as Ebola [6,7], measles [8], Middle East Respiratory Syndrome [9], and Zika [10,11].", [["infectious diseases", "DISEASE", 73, 92], ["Ebola", "DISEASE", 102, 107], ["measles", "DISEASE", 115, 122], ["Middle East Respiratory Syndrome", "DISEASE", 128, 160], ["Ebola", "ORGANISM", 102, 107], ["Middle East Respiratory Syndrome", "PROBLEM", 128, 160], ["Middle", "ANATOMY_MODIFIER", 128, 134], ["Respiratory Syndrome", "OBSERVATION", 140, 160]]], ["The Centers for Disease Control and Prevention (CDC) encourages the strategic use of Twitter to disseminate CDC health information and engage with individuals and partners [12].", [["Disease Control", "TREATMENT", 16, 31]]], ["CDC uses Twitter as part of their overall health communication strategies [13,14], uses Twitter chats to engage Twitter users on specific health topics [15-17], and publicizes public health events and publications via Twitter [18].IntroductionAdvanced molecular detection (AMD) harnesses the power of next-generation genomic sequencing, high-performance computing, and epidemiology to study pathogens.", [["AMD", "DISEASE", 273, 276], ["next-generation genomic sequencing", "TREATMENT", 301, 335]]], ["CDC uses AMD technologies to identify emerging pathogens, improve vaccines, make food safer, develop faster tests, and connect information from public health investigations with genomic data from pathogens to understand how infections spread [19].IntroductionThe Office of Advanced Molecular Detection (OAMD) in the National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), CDC, promotes open sharing of scientific data through publicly accessible platforms and added Twitter () as a communication channel in May 2015.", [["AMD", "DISEASE", 9, 12], ["infections", "DISEASE", 224, 234], ["Infectious Diseases", "DISEASE", 358, 377], ["AMD technologies", "TREATMENT", 9, 25], ["emerging pathogens", "PROBLEM", 38, 56], ["vaccines", "TREATMENT", 66, 74], ["faster tests", "TEST", 101, 113], ["Zoonotic", "OBSERVATION_MODIFIER", 349, 357], ["Infectious", "OBSERVATION", 358, 368]]], ["OAMD uses Twitter to promote free exchange of information and interactivity between CDC infectious disease programs and partners in federal and state agencies, academia, and professional organizations, as well as the general public.", [["infectious disease", "DISEASE", 88, 106], ["academia", "PROBLEM", 160, 168]]], ["OAMD noted the value of Twitter in March 2016, when a tweet regarding CDC\u2019s submission of genomic sequence data to a publicly accessible database led to a global discussion on Elizabethkingia anophelis and a subsequent international partnership to investigate this rare bacterium [20].IntroductionIn this case study, we analyzed the Twitter handle to divulge information regarding followers and popular tweet content.", [["OAMD", "DISEASE", 0, 4], ["Elizabethkingia anophelis", "ORGANISM", 176, 201], ["Elizabethkingia anophelis", "SPECIES", 176, 201], ["Elizabethkingia anophelis", "SPECIES", 176, 201], ["this rare bacterium", "PROBLEM", 260, 279], ["this case study", "TEST", 300, 315]]], ["Here, we address 3 research questions (RQ):IntroductionThis case study enables us to understand how a CDC Twitter account communicates scientific information to its followers, and provides health communicators with information for future enhancement of their Twitter communication.Data ::: MethodsData were retrieved via Twitter Search Application Programming Interface and downloaded to a server at Athens, Georgia, USA.", [["MethodsData", "TREATMENT", 290, 301]]], ["Data on favorites, followers, followings, and tweets, including retweet count, were downloaded by November 21, 2016.", [["retweet count", "TEST", 64, 77]]], ["A protocol for analysis was created and approved for use by OAMD.Data ::: MethodsCDC encourages the strategic use of Twitter to disseminate CDC health information and engage with individuals and partners.", [["A protocol for analysis", "TEST", 0, 23]]], ["All tweets posted by are cleared internally by OAMD scientific and communication staff or cross-cleared with scientific and communication staff in other CDC programs that are conducting AMD-related activities.Manual Coding ::: MethodsFirst, we manually categorized \u2019s followers into 6 categories specified by OAMD:Manual Coding ::: MethodsNext, we manually categorized \u2019s tweets into 6 categories specified by OAMD:Manual Coding ::: MethodsThen, we manually determined whether photos or videos, or their links, were attached to the tweets.", [["AMD", "DISEASE", 186, 189], ["Methods", "TREATMENT", 433, 440]]], ["We also manually coded whether a tweet was an original tweet posted by or it was a retweet by of a tweet originally posted by other Twitter users.Manual Coding ::: MethodsA total of 10% random samples of original tweets posted by (68/682), \u2019s retweets of other Twitter users\u2019 tweets (9/86), and followers of (81/809) were double-coded by 2 independent coders, and the inter-rater reliability is substantial (\u03ba=.749, .757, and .839, respectively) [22].Statistical Analysis ::: MethodsStatistical analysis was conducted in R 3.3.1 (R Core Team, R Foundation for Statistical Computing, Vienna, Austria) via RStudio 0.99.903 (RStudio, Inc., Boston, MA).", [["the inter-rater reliability", "TEST", 364, 391], ["MethodsStatistical analysis", "TEST", 476, 503], ["RStudio", "TEST", 604, 611], ["substantial", "OBSERVATION_MODIFIER", 395, 406]]], ["For negative binomial regression models, we used glm.nb() in MASS package.", [["glm.nb", "PROTEIN", 49, 55], ["MASS package", "TREATMENT", 61, 73], ["binomial regression", "OBSERVATION", 13, 32]]], ["For hurdle models, we used hurdle() in pscl package [23].Statistical Analysis ::: MethodsWe stratified the corpus of tweets into 2 subcorpora (original tweets and tweets of other Twitter users retweeted by ).", [["corpus", "ANATOMY", 107, 113], ["hurdle() in pscl package", "TREATMENT", 27, 51]]], ["Regression models were then applied to each subcorpus to compute the probability ratios, to evaluate whether sharing images or videos (or their links) increased the probability of a tweet being retweeted, and whether contents might be a confounder or an effect modifier.", [["Regression models", "TEST", 0, 17]]], ["Negative binomial regression models were used, as the retweet frequency was overdispersed.", [["binomial regression", "OBSERVATION", 9, 28]]], ["Negative binomial regression models took into account data points that were zeros.", [["binomial regression models", "PROBLEM", 9, 35], ["binomial regression", "OBSERVATION", 9, 28]]], ["A hurdle model is a model with 2 components: (1) a hurdle component for zero versus positive counts and (2) a truncated count component for positive counts [23].", [["zero versus positive counts", "PROBLEM", 72, 99], ["a truncated count component", "TEST", 108, 135], ["positive counts", "PROBLEM", 140, 155]]], ["In our hurdle models, the default binomial distribution (logistic regression) was used for the hurdle component; a truncated negative binomial distribution was chosen for the count component, given the overdispersion of the data.Original Tweets by ::: MethodsFor the original tweet subcorpus, we performed model selection between 5 different statistical models.", [["the hurdle component", "PROBLEM", 91, 111], ["a truncated negative binomial distribution", "PROBLEM", 113, 155], ["the count component", "TEST", 171, 190], ["Methods", "TREATMENT", 252, 259], ["model selection", "TREATMENT", 306, 321], ["binomial distribution", "OBSERVATION", 34, 55], ["negative", "OBSERVATION_MODIFIER", 125, 133], ["binomial distribution", "OBSERVATION", 134, 155]]], ["We started with a Poisson regression model with both the variable for photo or video attachment (Media) and the content variable (Content) as predictor variables and retweet count as the outcome variable (Model A).", [["a Poisson regression model", "TREATMENT", 16, 42], ["photo or video attachment (Media", "TREATMENT", 70, 102], ["retweet count", "TEST", 166, 179]]], ["Due to overdispersion of the retweet count data, we explored the use of negative binomial regression models (Models B and C) and the hurdle models (Models D and E), and we explored whether content is a confounder by comparing models that include both Media and Content (Models B and D) and those that only include the Media predictor (Models C and E), through likelihood ratio tests and Akaike Information Criterion (AIC).Retweets by ::: MethodsWe constructed 2 negative binomial regression models.", [["the retweet count data", "TEST", 25, 47], ["likelihood ratio tests", "TEST", 360, 382]]], ["Model F included both Media and Content variables as predictors; Model G included Media only.Ethics Approval ::: MethodsThis study was approved (H15083) by Georgia Southern University\u2019s Institutional Review Board under the B2 exempt category because of the fact that the social media posts analyzed in this study are considered publicly observable behavior.Availability of Data and Material ::: MethodsThe datasets used and/or analyzed during this study are available from the corresponding author on reasonable request.Findings ::: ResultsAs of November 21, 2016, had published 768 tweets, of which 88.8% (682/768) were original and 11.2% (86/768) were \u2019s retweets of other Twitter users\u2019 tweets. had 809 followers, and it followed 195 Twitter accounts.", [["Methods", "TREATMENT", 113, 120], ["This study", "TEST", 120, 130], ["this study", "TEST", 302, 312], ["Methods", "TREATMENT", 395, 402], ["this study", "TEST", 443, 453]]], ["There were 37 likes.Followers ::: ResultsAmong the 809 followers, 26.0% (210/809) were individual health professionals, 11.6% (94/809) nongovernmental organizations, 3.3% (27/809) government agencies\u2019 accounts, 3.3% (27/809) accounts of media organizations and journalists, and 0.9% (7/809) academic journals.", [["nongovernmental organizations", "TEST", 135, 164]]], ["In addition, 54.9% (444/809) of the followers did not fall under any prespecified categories.Content ::: ResultsApproximately half of \u2019s tweets (360/768, 46.9%) referred to the CDC AMD website and research that was taking place during that time; of these tweets, the majority (354/360, 98.3%) were original tweets (Table 1).", [["AMD", "DISEASE", 181, 184]]], ["Nearly 1 in 5 (135/768, 17.6%) tweets referred to publications of CDC AMD scientists (usually their abstracts on PubMed), of which all, except 2 (133/135, 98.5%), were original tweets.", [["AMD", "DISEASE", 70, 73]]], ["For example, 1 tweet promoted an exhibition in the CDC Museum: \u201cJoin us this Thu, Feb 4, 6-8 pm, to see AMD in action in Museum\u2019s opening of Places & Spaces: Mapping Science. https://t.co/Wp3eZVleUe.\u201d", [["AMD", "DISEASE", 104, 107], ["AMD", "CHEMICAL", 104, 107]]], ["(February 2, 2016; Tweet ID: 694581586566717440); another highlighted the program\u2019s annual science event, AMD Day: \u201cThanks to state partners and all who attended #AMDDay2016. \u201d", [["AMD", "DISEASE", 106, 109]]], ["For example, the most retweeted tweet in our dataset of 768 tweets was about the Google Doodle on scientist Antoine van Leeuwenhoek.", [["tweet", "CANCER", 32, 37]]], ["Regarding photos or videos attached to tweets, 43% (333/768) of the tweets contained photos or videos, whereas the remaining 57% (435/768) did not.Retweets ::: ResultsFor the subcorpus with original tweets, the results of our model selection process are presented in Table 2.", [["our model selection process", "TREATMENT", 222, 249]]], ["A likelihood ratio test between Model A (Poisson regression) and Model B (negative binomial regression) gave a significant result (\u03c721=259.7, P<.001), indicating that Model B, with a higher log-likelihood, fit the data better.", [["A likelihood ratio test", "TEST", 0, 23], ["Poisson regression", "TEST", 41, 59]]], ["A likelihood ratio test between Model B (negative binomial regression with \u201cContent\u201d as confounder) and Model C (negative binomial regression without \u201cContent\u201d) found that there was no significant difference in their log-likelihood (\u03c725=9.3, P=.10).", [["A likelihood ratio test", "TEST", 0, 23], ["Model C (negative binomial regression", "PROBLEM", 104, 141], ["likelihood", "TEST", 221, 231], ["P", "TEST", 242, 243], ["no", "UNCERTAINTY", 182, 184], ["significant", "OBSERVATION_MODIFIER", 185, 196], ["difference", "OBSERVATION_MODIFIER", 197, 207]]], ["The simple model (Model C) had a lower AIC score and was therefore preferred.Retweets ::: ResultsGiven the excess of zeros in the data, we explored the hurdle models as aforementioned.", [["a lower AIC score", "PROBLEM", 31, 48], ["simple model", "OBSERVATION_MODIFIER", 4, 16]]], ["A likelihood ratio test between Model D (hurdle model with \u201cContent\u201d as confounder; Table 3) and Model E (hurdle model without \u201cContent\u201d; Table 4) found that there was no significant difference in their log-likelihood (\u03c7210=17.9, P=.06).", [["A likelihood ratio test", "TEST", 0, 23], ["P", "TEST", 230, 231], ["no", "UNCERTAINTY", 168, 170], ["significant", "OBSERVATION_MODIFIER", 171, 182], ["difference", "OBSERVATION_MODIFIER", 183, 193]]], ["With a lower AIC score, Model E was therefore preferred (Table 2).", [["a lower AIC score", "PROBLEM", 5, 22], ["lower", "ANATOMY_MODIFIER", 7, 12]]], ["Finally, a likelihood ratio test between Model C (negative binomial model) and Model E (hurdle model) found that there was no significant difference in their log-likelihood (\u03c722=0.7, P=.70).", [["a likelihood ratio test", "TEST", 9, 32], ["Model C", "TEST", 41, 48], ["P", "TEST", 183, 184], ["no", "UNCERTAINTY", 123, 125], ["significant", "OBSERVATION_MODIFIER", 126, 137], ["difference", "OBSERVATION_MODIFIER", 138, 148]]], ["As Model C has a lower AIC, we chose Model C as the final model for the subcorpus of original Twitter content posted by (Table 2).Retweets ::: ResultsAn original tweet from sharing images or videos (or their links) had 37% more retweets (Model C: probability ratio=1.374, 95% CI 1.129-1.674, P=.002) than that of an original tweet that did not share images or videos (or their links; Table 3).", [["a lower AIC", "PROBLEM", 15, 26], ["probability ratio", "TEST", 247, 264], ["CI", "TEST", 276, 278], ["P", "TEST", 292, 293]]], ["We observed no significant difference between the content categories, except for the miscellaneous category that has 36% more retweets than tweets referred to the CDC AMD website (Model B: probability ratio=1.355, 95% CI 1.035-1.778, P=.03; Model D: probability ratio=1.501, 95% CI 1.046-2.153, P=.03).Retweets ::: ResultsRegarding tweets retweeted by , we did not observe any significant difference in the retweet count between different contents in Model F (negative binomial regression model with both Media and Content variables).", [["AMD", "DISEASE", 167, 170], ["the miscellaneous category", "PROBLEM", 81, 107], ["probability ratio", "TEST", 189, 206], ["CI", "TEST", 218, 220], ["P", "TEST", 234, 235], ["probability ratio", "TEST", 250, 267], ["CI", "TEST", 279, 281], ["P", "TEST", 295, 296], ["the retweet count", "TEST", 403, 420], ["no", "UNCERTAINTY", 12, 14], ["significant", "OBSERVATION_MODIFIER", 15, 26], ["difference", "OBSERVATION", 27, 37], ["significant", "OBSERVATION_MODIFIER", 377, 388], ["difference", "OBSERVATION", 389, 399]]], ["A likelihood ratio test between Model F and Model G (negative binomial regression model with and without Content variables) found no significant difference between the two (\u03c725=8.2, P=.14).", [["A likelihood ratio test", "TEST", 0, 23], ["Model G", "TEST", 44, 51], ["Content variables", "TEST", 105, 122], ["P", "TEST", 182, 183], ["no", "UNCERTAINTY", 130, 132], ["significant", "OBSERVATION_MODIFIER", 133, 144], ["difference", "OBSERVATION", 145, 155]]], ["We could not reject the null hypothesis that content was not a confounder, and we therefore selected Model G that was simpler and had a lower AIC (Table 4).", [["the null hypothesis", "PROBLEM", 20, 39], ["a lower AIC", "TREATMENT", 134, 145]]], ["There was no difference in the retweet count between a tweet sharing photos or images (or their links) and one that did not (Model G: probability ratio=0.825, 95% CI 0.508-1.369, P=.44; Table 5).Principal Findings ::: DiscussionThe AMD program uses Twitter to communicate its accomplishments, provide updates on activities, and share scientific data.", [["AMD", "DISEASE", 232, 235], ["the retweet count", "TEST", 27, 44], ["probability ratio", "TEST", 134, 151], ["CI", "TEST", 163, 165], ["P", "TEST", 179, 180], ["no", "UNCERTAINTY", 10, 12], ["difference", "OBSERVATION_MODIFIER", 13, 23]]], ["This study confirms OAMD\u2019s experience that original tweets containing images or videos (or their links) created for the Twitter profile received more retweets.", [["This study", "TEST", 0, 10]]], ["Our case study of a Twitter handle specializing in communicating public health applications of AMD provides concrete evidence that informs public health communication in practice.Principal Findings ::: DiscussionAs of November 2016, 54.9% (444/809) of \u2019s followers did not belong to any of the prespecified categories.", [["AMD", "DISEASE", 95, 98]]], ["The a priori\u2013defined categories were categories of target audience specified in OAMD\u2019s existing communication strategies.", [["communication strategies", "TREATMENT", 96, 120]]], ["Further research will investigate who these people are.", [["people", "ORGANISM", 44, 50], ["people", "SPECIES", 44, 50]]], ["By identifying followers who retweeted \u2019s tweets, may engage them for help disseminating information across Twitter.Principal Findings ::: DiscussionOur study found that 51.9% (354/682) of original tweets from directed users to the website of OAMD.", [["OAMD", "DISEASE", 243, 247], ["OAMD", "CANCER", 243, 247], ["DiscussionOur study", "TEST", 139, 158]]], ["Our study also found that did tweet on topics other than the prespecified content categories, by both tweeting their own tweets and retweeting others\u2019 tweets.", [["Our study", "TEST", 0, 9]]], ["It showed scientific and event information not captured in the prespecified content categories defined by OAMD, but that were deemed relevant to their followers by OAMD at an ad hoc basis.", [["OAMD", "CANCER", 164, 168]]], ["Future research into the tweets in the miscellaneous category would help OAMD detail these tweets and develop new content categories for the playbook of their routine communication strategies.In the Context of the Literature ::: DiscussionPrevious research has identified factors that contributed to more retweets.", [["their routine communication strategies", "TREATMENT", 153, 191]]], ["Soboleva et al noted that hashtags and retweet requests were associated with higher retweet rates, whereas URL links and mentions were associated with lower rates of retweeting [26].In the Context of the Literature ::: DiscussionIn this study, we focused on the effect of attaching images or videos to tweets on their retweet frequency, in particular, tweets tweeted by .", [["this study", "TEST", 232, 242]]], ["According to Soboleva and colleagues [26], images can increase the effect of advertisements partly because they can convey meanings not expressed via words.", [["images", "TEST", 43, 49]]], ["Prior studies on the effect of links to visual cues on retweet frequency using Twitter data collected in 2011 had conflicting results [27,28].", [["Prior studies", "TEST", 0, 13], ["Twitter data", "TEST", 79, 91]]], ["However, another study that analyzed tweets from 2009 to 2012, drawn from 298 Twitter profiles operated by 100 top brands, found that links to photos or videos increased the likelihood of a tweet being retweeted [29].", [["another study", "TEST", 9, 22]]], ["A more recent study analyzing 2014 Twitter data posted by 32 major commercial brands found that photos were consistently associated with higher retweet rates across 3 industries under study (automobile, fast-moving consumer goods, and luxury) [26].", [["A more recent study", "TEST", 0, 19]]], ["Nevertheless, the same study found that the industry of the brand was an effect modifier for the effect of videos on retweet rates (significant increase in retweet probability for luxury brands, but insignificant effect for the other 2 industries) [26].", [["the same study", "TEST", 14, 28], ["videos on retweet rates", "TEST", 107, 130], ["significant", "OBSERVATION_MODIFIER", 132, 143], ["increase", "OBSERVATION_MODIFIER", 144, 152]]], ["In a retrospective observational study, the effect of attaching visual cues to a tweet on its retweet frequency was found to vary across cycles of original tweets with hashtags #CDCGrandRounds and #VitalSigns.", [["a retrospective observational study", "TEST", 3, 38], ["attaching visual cues", "PROBLEM", 54, 75], ["hashtags #CDCGrandRounds", "TREATMENT", 168, 192]]], ["The probability ratios of retweet frequency of tweets with visual cues as compared to tweets without visual cues ranged from less than 1 to as high as 34, depending on the topic of the specific CDC Grand Round event or Vital Signs publication [31].", [["visual cues", "TEST", 59, 70], ["visual cues", "TEST", 101, 112]]], ["Further evidence was provided by Can et al who identified certain features of an image that were positively correlated with retweet count [25].", [["an image", "TEST", 78, 86], ["retweet count", "TEST", 124, 137]]], ["Consistent with prior findings, this study on adds evidence to a growing literature that attaching visual cues to tweets will increase their retweet frequency, and this practice may enhance Twitter users\u2019 engagement with health communication messages promoted by medical and public health professionals.Limitations ::: DiscussionOur study is limited to its cross-sectional design and to 1 CDC Twitter profile.", [["this study", "TEST", 32, 42], ["DiscussionOur study", "TEST", 319, 338]]], ["The strength of this study is that we manually coded and statistically analyzed the entire corpus of tweets published by .", [["corpus", "ANATOMY", 91, 97], ["this study", "TEST", 16, 26]]], ["Although our study follows the protocol defined a priori, it lacks the ability to classify 55% of the followers and 80% of contents retweeted by that did not fall into any of the prespecified categories.", [["our study", "TEST", 9, 18]]], ["We also did not analyze specific visual features of the photos or videos (as in [25]) that were beyond the scope of our study.", [["our study", "TEST", 116, 125]]], ["There were other potential confounders or effect modifiers [26] that were not included in our study.", [["effect modifiers", "PROBLEM", 42, 58], ["our study", "TEST", 90, 99]]], ["Given the nature of this study as an observational study, we cannot rule out the possibility of residual confounding by other factors.Conclusions ::: DiscussionAs part of its communication strategies, OAMD includes its Twitter handle, , as one of its communication channels to its audience.", [["this study", "TEST", 20, 30], ["an observational study", "TEST", 34, 56], ["residual confounding by other factors", "PROBLEM", 96, 133]]], ["This study underscored the importance of including visual information to build engagements with tweets.", [["This study", "TEST", 0, 10]]], ["Following on this brief study conducted in mid-November of 2016, OAMD increased its use of visual cues for tweets, including photos and graphs, and we have seen steady engagement rates during the subsequent 12 months.Conclusions ::: DiscussionOn the basis of anecdotal evidence that Twitter is used highly in the biotechnology and biomedical industries, OAMD decided to use this mechanism to target these audiences.", [["this brief study", "TEST", 13, 29], ["photos and graphs", "TEST", 125, 142]]], ["Further investigation is needed to identify the 55% of \u2019s followers who did not belong to any of the prespecified categories in this study.", [["Further investigation", "TEST", 0, 21], ["this study", "TEST", 128, 138]]], ["However, a more in-depth study or survey is necessary to determine their interest in .", [["a more in-depth study", "TEST", 9, 30]]]], "43f3b3e2af86af484ab7aae55ad9b2354e4a14eb": [["IntroductionIn 2003, Hong Kong was profoundly affected by an unknown communicable disease entitled \"severe acute respiratory syndrome\" (SARS). e outbreak originated in a hospital and then spread to the wider community. e disease took the lives of 286 Hong Kong citizens and 774 people worldwide.", [["communicable disease", "DISEASE", 69, 89], ["acute respiratory syndrome", "DISEASE", 107, 133], ["SARS", "DISEASE", 136, 140], ["people", "ORGANISM", 278, 284], ["people", "SPECIES", 278, 284], ["an unknown communicable disease", "PROBLEM", 58, 89], ["severe acute respiratory syndrome", "PROBLEM", 100, 133], ["severe", "OBSERVATION_MODIFIER", 100, 106], ["acute", "OBSERVATION_MODIFIER", 107, 112], ["respiratory syndrome", "OBSERVATION", 113, 133], ["disease", "OBSERVATION", 221, 228]]], ["Furthermore, in 2004, the Hong Kong government established the Centre for Health Protection (CHP), a similar entity as the US's Centers for Disease Control and Prevention (CDC).Introductione CHP aims to effectively prevent and control diseases in Hong Kong, in collaboration with both national and international stakeholders.", [["the US", "TEST", 119, 125], ["Disease Control", "TREATMENT", 140, 155], ["control diseases", "PROBLEM", 227, 243]]], ["Since the beginning of CHP, the agency has devised numerous guidelines and publications for health workers and the general public in order to prevent the spread of communicable diseases and promote healthy living.", [["communicable diseases", "DISEASE", 164, 185], ["health workers", "TREATMENT", 92, 106], ["communicable diseases", "PROBLEM", 164, 185]]], ["Following the SARS outbreak in Hong Kong, proper hand hygiene has been widely promoted in multiple contexts, focusing on the instances when hands should be washed as well as the duration and technique of handwashing. e worldwide public health agencies have asserted that proper hand hygiene can control the spread of communicable diseases from the common cold to the life-threatening severe acute respiratory syndrome, as well as fight against the rise in antibiotic resistance.", [["hand", "ANATOMY", 49, 53], ["hand", "ANATOMY", 278, 282], ["SARS", "DISEASE", 14, 18], ["communicable diseases", "DISEASE", 317, 338], ["acute respiratory syndrome", "DISEASE", 391, 417], ["hand", "ORGANISM_SUBDIVISION", 49, 53], ["hands", "ORGANISM_SUBDIVISION", 140, 145], ["hand", "ORGANISM_SUBDIVISION", 278, 282], ["communicable diseases", "PROBLEM", 317, 338], ["threatening severe acute respiratory syndrome", "PROBLEM", 372, 417], ["antibiotic resistance", "TREATMENT", 456, 477], ["severe", "OBSERVATION_MODIFIER", 384, 390], ["acute", "OBSERVATION_MODIFIER", 391, 396], ["respiratory syndrome", "OBSERVATION", 397, 417], ["antibiotic resistance", "OBSERVATION", 456, 477]]], ["Systematic reviews also show that insufficient washing of hands increases food-borne illness outbreaks and diarrheal diseases [2, 3] .", [["food-borne illness", "DISEASE", 74, 92], ["diarrheal diseases", "DISEASE", 107, 125], ["hands", "ORGANISM_SUBDIVISION", 58, 63], ["Systematic reviews", "TEST", 0, 18], ["diarrheal diseases", "PROBLEM", 107, 125]]], ["However, there are few studies that evaluate the compliance of Hong Kong people in this area or the effectiveness of their handwashing after 15 years of health education on this topic. us, these are the main topics of interest for this study.Literature Reviewthe effectiveness of handwashing and alcohol-based hand sanitizers. e majority of handwashing and hygiene studies typically focused on healthcare providers and students, while few studies targeted the general public. e common areas of focus for these studies included the length of time spent handwashing, missed areas, common situations where handwashing was warranted, compliance with guidelines, and the relationship between demographic data and hand cleanliness.Literature ReviewFor instance, in the US, Monk-Tuner et al. reported that only 10% of their 313 participants washed their hands for 15 seconds or longer.", [["hand", "ANATOMY", 310, 314], ["hand", "ANATOMY", 708, 712], ["alcohol", "CHEMICAL", 296, 303], ["alcohol", "CHEMICAL", 296, 303], ["people", "ORGANISM", 73, 79], ["alcohol", "SIMPLE_CHEMICAL", 296, 303], ["hand", "ORGANISM_SUBDIVISION", 310, 314], ["hand", "ORGANISM_SUBDIVISION", 708, 712], ["participants", "ORGANISM", 821, 833], ["people", "SPECIES", 73, 79], ["participants", "SPECIES", 821, 833], ["few studies", "TEST", 19, 30], ["health education", "TREATMENT", 153, 169], ["this study", "TEST", 231, 241], ["hygiene studies", "TEST", 357, 372], ["these studies", "TEST", 504, 517], ["demographic data", "TEST", 687, 703], ["the US", "TEST", 759, 765]]], ["A observational study conducted by Michigan State University researchers also revealed that, among 3,749 people, the average washing times for men and women are 6.27 and 7.07 seconds, respectively, even though the CDC has been advocating the proper method for handwashing since 2012 [6] .Literature ReviewIn Turkey, Ergin et al. reported that 27% of 303 university students washed their hands just 4 times per day. ey found that the main reason for students not washing their hands on a more regular basis was due to the belief that there was no need to do so. ey also found that female participants scored significantly higher in knowledge, skills, and practices of hand hygiene [7] .", [["hand", "ANATOMY", 667, 671], ["people", "ORGANISM", 105, 111], ["men", "ORGANISM", 143, 146], ["women", "ORGANISM", 151, 156], ["hand", "ORGANISM_SUBDIVISION", 667, 671], ["people", "SPECIES", 105, 111], ["men", "SPECIES", 143, 146], ["women", "SPECIES", 151, 156], ["participants", "SPECIES", 587, 599], ["A observational study", "TEST", 0, 21]]], ["In Kenya, Curtis et al. also found that handwashing after using the toilet was the most common instance of hand hygiene [9, 10] .Literature ReviewAlso, previous studies have identified that gender, age, employment status, and educational level are the factors that affect an individual's hand-hygiene practices.", [["hand", "ANATOMY", 107, 111], ["hand", "ANATOMY", 288, 292], ["hand", "ORGANISM_SUBDIVISION", 107, 111], ["hand", "ORGANISM_SUBDIVISION", 288, 292], ["the toilet", "TREATMENT", 64, 74], ["previous studies", "TEST", 152, 168]]], ["In the US, Anderson et al., Berry et al., Edwards et al., and Vanyolos et al. found that female participants washed their hands significantly more than male participants; in Korea, Park et al. also found this to be true [11] [12] [13] [14] .", [["participants", "ORGANISM", 96, 108], ["[11] [12] [13] [14]", "SIMPLE_CHEMICAL", 220, 239], ["participants", "SPECIES", 96, 108], ["participants", "SPECIES", 157, 169]]], ["Burnett found that an increase in age was linked to improved perceptions of hand-hygiene practices [16] .", [["hand", "ANATOMY", 76, 80], ["hand", "ORGANISM_SUBDIVISION", 76, 80], ["increase", "OBSERVATION_MODIFIER", 22, 30]]], ["Lau et al. found that factors such as age, employment status, and perceived local outbreaks of SARS were related to adopting good handhygiene practices for the protection of oneself and others [17] .", [["SARS", "DISEASE", 95, 99], ["SARS", "PROBLEM", 95, 99], ["et al", "OBSERVATION", 4, 9]]], ["In contrast, Pan et al. found that the number of areas of the hands that were neglected during handwashing had no correlation with the demographic data (gender, age, or profession) of participants; they also found no significant relationship between the duration of handwashing and the number of missed areas [18] .", [["Pan", "PROTEIN", 13, 16], ["participants", "SPECIES", 184, 196], ["number", "OBSERVATION_MODIFIER", 39, 45], ["areas", "ANATOMY_MODIFIER", 49, 54], ["hands", "ANATOMY", 62, 67]]], ["Some studies have revealed that exposure to proper hand-hygiene practices through mass media and the availability of handwashing facilities affect general handwashing practice [9, 10, 13] .Literature ReviewRegarding the effectiveness of handwashing, Szil\u00e1gyi et al. and Vanyolos et al. used fluorescent hand gel with ultraviolet (UV) light to assess the nursing and medical students' quality of handwashing [12, 19] . e results showed that women wash their hands better than men, with nurses displaying the best handwashing practices.", [["hand", "ANATOMY", 51, 55], ["women", "ORGANISM", 440, 445], ["men", "ORGANISM", 475, 478], ["women", "SPECIES", 440, 445], ["men", "SPECIES", 475, 478], ["Some studies", "TEST", 0, 12], ["mass media", "TREATMENT", 82, 92], ["fluorescent hand gel", "TREATMENT", 291, 311], ["ultraviolet (UV)", "TREATMENT", 317, 333]]], ["When comparing different age groups, participants aged 40-49 performed the best overall. e most common missed areas were the fingernails and wrists [19] .", [["fingernails", "ANATOMY", 125, 136], ["wrists", "ANATOMY", 141, 147], ["fingernails", "ORGANISM_SUBDIVISION", 125, 136], ["participants", "SPECIES", 37, 49], ["fingernails", "ANATOMY", 125, 136], ["wrists", "ANATOMY", 141, 147]]], ["A similar procedure using visual assessment was carried out by Kampf et al., and the results showed that the palms and fingertips were usually quite thoroughly cleaned [20] .", [["palms", "ANATOMY", 109, 114], ["fingertips", "ANATOMY", 119, 129], ["palms", "ORGANISM_SUBDIVISION", 109, 114], ["fingertips", "ORGANISM_SUBDIVISION", 119, 129], ["A similar procedure", "TREATMENT", 0, 19], ["visual assessment", "TEST", 26, 43], ["the palms and fingertips", "PROBLEM", 105, 129], ["palms", "ANATOMY", 109, 114], ["fingertips", "ANATOMY", 119, 129]]], ["In another study, Kampf et al. used gel containing UV-sensitive dye [21] .", [["UV", "CHEMICAL", 51, 53], ["another study", "TEST", 3, 16], ["gel containing UV", "TREATMENT", 36, 53]]], ["Participants were asked to apply this gel to their hands and then wash them under running water.", [["Participants", "SPECIES", 0, 12]]], ["A graphical assessment technique was then used to assess the missed areas by evaluating the absence of the UV dye.Literature Reviewe tools used in this study make reference to the above-mentioned literature.Literature ReviewIn Hong Kong, the CHP advocates proper handwashing practice to the public aligned with the CDC in the United States, the National Health Service (NHS) in the United Kingdom, the Public Health Agency of Canada, and the Global Handwashing Partnership which includes washing one's hands with water and soap before and after at least eight specific situations; the process comprises six steps over seven areas of both hands for no less than 20 seconds [22] .", [["hands", "ORGANISM_SUBDIVISION", 502, 507], ["A graphical assessment technique", "TEST", 0, 32], ["the UV dye", "TREATMENT", 103, 113], ["this study", "TEST", 147, 157], ["UV dye", "OBSERVATION", 107, 113]]], ["In 2014, the CHP conducted a handhygiene survey. e results revealed that although Hong Kong people had a good understanding of hand hygiene, 6% of them reported that they did not wash their hands after using the toilet, and less than a third washed their hands after touching public equipment or installations.", [["hand", "ANATOMY", 127, 131], ["people", "ORGANISM", 92, 98], ["hand", "ORGANISM_SUBDIVISION", 127, 131], ["people", "SPECIES", 92, 98]]], ["Recently, Lee et al. developed an observational checklist in order to assess foreign domestic workers' handwashing practices in Hong Kong [23] .", [["an observational checklist", "TEST", 31, 57]]], ["None of the participants rubbed their hands for 20 seconds or more, and none of the participants rubbed all areas of their hands.", [["hands", "ORGANISM_SUBDIVISION", 123, 128], ["participants", "SPECIES", 12, 24], ["participants", "SPECIES", 84, 96], ["hands", "ANATOMY", 123, 128]]], ["Moreover, a study was also conducted in a local hospital in relation to the compliance of healthcare professionals with the WHO's \"My 5 Moments for Hand Hygiene\" guidelines. e frequency of hand-hygiene practices was measured, but the quality of the practices was not evaluated.", [["hand", "ANATOMY", 189, 193], ["hand", "ORGANISM_SUBDIVISION", 189, 193], ["a study", "TEST", 10, 17], ["hand", "ANATOMY", 189, 193]]], ["Of the 13,694 situations in which hand hygiene should have been practiced in a unit with 21 healthcare professionals, including nurses, physiotherapists, and healthcare assistants, the compliance rate was 35.1%.", [["hand", "ANATOMY", 34, 38], ["hand", "ORGANISM_SUBDIVISION", 34, 38], ["the compliance rate", "TEST", 181, 200]]], ["Lower rates of compliance were noted from 12:00 p.m. to 14:00 p.m.", [["compliance", "OBSERVATION", 15, 25]]], ["(21.3%, 95% CI: 17.2-25.3), as well as among nurses who shared their badges with others (23.7%, 95% CI: 17.8-29.6) [24] .", [["CI", "TEST", 12, 14], ["CI", "TEST", 100, 102]]], ["Among the above-mentioned local studies, none of them was able to unveil the overall effectiveness of handwashing, and a comprehensive and in-depth exploration of hand-hygiene practices among Hong Kong people is neglected [25] . erefore, this study was designed to fill this gap, and the following research questions were developed:Literature Review(1) What are the most common instances of handwashing among Hong Kong adults?Literature Review(2) How long do Hong Kong adults spend washing their hands? (3) What areas are most commonly missed in handwashing? (4) How many of the participants have received proper hand-hygiene information, and what are the common information resources? (5) What are the differences between independent variables, common missed areas, and handwashing instances? (6) What is the relationship between independent variables, common missed areas, and handwashing instances?Methods.is study used a cross-sectional survey with convenience sampling, and behavioural observations were conducted from January to March in 2018.", [["hand", "ANATOMY", 163, 167], ["hand", "ANATOMY", 613, 617], ["hand", "ORGANISM_SUBDIVISION", 163, 167], ["people", "ORGANISM", 202, 208], ["participants", "ORGANISM", 579, 591], ["people", "SPECIES", 202, 208], ["participants", "SPECIES", 579, 591], ["local studies", "TEST", 26, 39], ["this study", "TEST", 238, 248], ["Methods.is study", "TEST", 901, 917], ["a cross-sectional survey", "TEST", 923, 947], ["convenience sampling", "TEST", 953, 973], ["behavioural observations", "TEST", 979, 1003], ["hand", "ANATOMY", 163, 167]]], ["Before conducting this study, ethical approval was obtained from the research ethics committee of a local higher-education institute in Hong Kong. e ethical committee reference number is NUR/SRC/20171220/016.Venue and Participants.Given that the target population was Hong Kong adults and that public handwashing facilities were required, this study was conducted in several public barbecue sites in three different territories of Hong Kong (i.e., Hong Kong Island, Kowloon, and the New Territories) in order to broaden the scope of this study.", [["Participants", "SPECIES", 218, 230], ["this study", "TEST", 18, 28], ["this study", "TEST", 339, 349], ["this study", "TEST", 533, 543]]], ["Barbeque sites were chosen as areas to recruit participants because spacious handwashing facilities with touchless faucets and sinks were provided in an outdoor washing area. e participants were the visitors to the barbecue sites whose age \u226518, mentally sound Hong Kong residents, and those who were able to communicate with Cantonese as Cantonese is the mother tongue of Hong Kong people.", [["tongue", "ANATOMY", 362, 368], ["tongue", "ORGAN", 362, 368], ["people", "ORGANISM", 382, 388], ["participants", "SPECIES", 47, 59], ["participants", "SPECIES", 177, 189], ["people", "SPECIES", 382, 388], ["Barbeque sites", "TREATMENT", 0, 14], ["touchless faucets", "TREATMENT", 105, 122]]], ["Participants who had experience working in healthcare settings and those with artificial nails, irremovable hand accessories, or a disability in both hands were excluded from this study.Materials.A survey was carried out by face-to-face interviews at the barbecue sites. e participants were required to report their demographic information, instances of handwashing, and their sources of handwashing information.Materials.3.4.", [["hand", "ANATOMY", 108, 112], ["disability", "DISEASE", 131, 141], ["nails", "ORGANISM_SUBDIVISION", 89, 94], ["hand", "ORGANISM_SUBDIVISION", 108, 112], ["barbecue sites", "DNA", 255, 269], ["Participants", "SPECIES", 0, 12], ["participants", "SPECIES", 273, 285], ["artificial nails", "TREATMENT", 78, 94], ["irremovable hand accessories", "TREATMENT", 96, 124], ["a disability in both hands", "PROBLEM", 129, 155], ["this study", "TEST", 175, 185], ["A survey", "TEST", 196, 204]]], ["Procedure.", [["Procedure", "TREATMENT", 0, 9]]], ["First, information sheets were given to the participants.", [["participants", "SPECIES", 44, 56]]], ["After obtaining informed consent from them, the participants were asked to rub Glo Germ gel in their hands.", [["participants", "ORGANISM", 48, 60], ["hands", "ORGANISM_SUBDIVISION", 101, 106], ["participants", "SPECIES", 48, 60], ["hands", "ANATOMY", 101, 106]]], ["After the rater confirmed that both hands were fully covered by the gel, the participants were asked to wash their hands under running water in a way that was typical for them.", [["hands", "ORGANISM_SUBDIVISION", 36, 41], ["participants", "SPECIES", 77, 89]]], ["When the participants were washing their hands, the rater stood far behind them and recorded the time it took them to complete the process.", [["participants", "ORGANISM", 9, 21], ["participants", "SPECIES", 9, 21]]], ["After the participants had washed their hands, a portable, rechargeable black box with 10 watts of UV light was used to assess the residual fluorescent stains on the hands of the participants. e rater then recorded the results.Research Design and Analysis.", [["participants", "SPECIES", 10, 22], ["participants", "SPECIES", 179, 191], ["a portable", "TEST", 47, 57], ["rechargeable black box", "TREATMENT", 59, 81], ["UV light", "TREATMENT", 99, 107], ["the residual fluorescent stains", "PROBLEM", 127, 158], ["Research Design and Analysis", "TEST", 227, 255], ["residual", "OBSERVATION", 131, 139], ["fluorescent stains", "OBSERVATION", 140, 158]]], ["International BusinessMachine (IBM) Statistical Product and Service Solutions (SPSS) for Windows version 24.0 (IBM Corp, 2016) was used for data analysis. e situations in which participants would commonly wash their hands, demographic data, and the duration of handwashing were analyzed by using descriptive statistics of frequency count, mean, and standard deviation.", [["participants", "ORGANISM", 177, 189], ["participants", "SPECIES", 177, 189], ["data analysis", "TEST", 140, 153], ["demographic data", "TEST", 223, 239], ["frequency count", "TEST", 322, 337], ["mean", "TEST", 339, 343]]], ["To compare the continuous data between the missed areas and variables in demographic data, independent t-test and one-way ANOVA were used.", [["the continuous data", "TEST", 11, 30], ["demographic data", "TEST", 73, 89], ["independent t-test", "TEST", 91, 109]]], ["Linear and multiple logistic regressions were used to examine the relationship between variables in demographic data, duration of handwashing, and coverage of missed areas during handwashing.", [["Linear and multiple logistic regressions", "PROBLEM", 0, 40], ["demographic data", "TEST", 100, 116], ["handwashing", "TREATMENT", 130, 141], ["multiple", "OBSERVATION_MODIFIER", 11, 19], ["logistic regressions", "OBSERVATION", 20, 40]]], ["Variables were presented as regression coefficients. e odds ratio was adjusted with corresponding 95% confidence intervals and p values. e statistical significance of p < 0.05 was taken into account.", [["p values", "TEST", 127, 135]]], ["All statistical tests were two-tailed.ResultsEventually, 190 (94 males and 96 females) valid data were collected from the barbeque sites in three main regions of Hong Kong, comprising 47 (25%) participants from Hong Kong Island, 59 (31%) from Kowloon, and 84 (44%) from the New Territories. e ratio of the number of participants in these three geographical areas was similar to the total population distribution of Hong Kong. e characteristics of the samples are shown in Table 1 .Handwashing Survey.e leaflet devised by the CHP advises Hong Kong people to wash their hands in at least 8 different instances. ey are as follows: (1) after handling vomitus or faecal matter, (2) after using the toilet, (3) before and after visiting hospitals or residential care homes or caring for the sick, (4) after contact with animals or pets, (5) before eating or handling food, (6) after coughing or sneezing, (7) after touching public installations or equipment, and (8) before touching eyes, nose, and mouth.", [["samples", "ANATOMY", 451, 458], ["faecal matter", "ANATOMY", 658, 671], ["eyes", "ANATOMY", 977, 981], ["nose", "ANATOMY", 983, 987], ["mouth", "ANATOMY", 993, 998], ["people", "ORGANISM", 547, 553], ["eyes", "ORGAN", 977, 981], ["nose", "ORGANISM_SUBDIVISION", 983, 987], ["mouth", "ORGANISM_SUBDIVISION", 993, 998], ["participants", "SPECIES", 193, 205], ["participants", "SPECIES", 316, 328], ["people", "SPECIES", 547, 553], ["All statistical tests", "TEST", 0, 21], ["valid data", "TEST", 87, 97], ["Kowloon", "TEST", 243, 250], ["the samples", "TEST", 447, 458], ["handling vomitus or faecal matter", "PROBLEM", 638, 671], ["coughing", "PROBLEM", 877, 885], ["sneezing", "PROBLEM", 889, 897], ["touching eyes, nose, and mouth", "PROBLEM", 968, 998], ["New", "OBSERVATION_MODIFIER", 274, 277], ["Territories", "OBSERVATION_MODIFIER", 278, 289], ["number", "OBSERVATION_MODIFIER", 306, 312], ["faecal matter", "ANATOMY", 658, 671], ["nose", "ANATOMY", 983, 987], ["mouth", "ANATOMY", 993, 998]]], ["Among the 190 participants of this study, half (52.6%) washed their hands in 5 of the 8 instances and only 3 participants (1.6%) washed their hands in all 8 instances. e results showed that more than half of the participants washed their hands after handling vomitus or faecal matter (91.1%), after using the toilet (87.4%), before and after visiting a hospital or a residential care home or caring for the sick (72.6%), after having contact with animals or pets (61.6%), and before eating or handling food (58.4%).", [["faecal matter", "ANATOMY", 270, 283], ["participants", "ORGANISM", 212, 224], ["faecal", "ORGANISM_SUBDIVISION", 270, 276], ["participants", "SPECIES", 14, 26], ["participants", "SPECIES", 109, 121], ["participants", "SPECIES", 212, 224], ["this study", "TEST", 30, 40], ["handling vomitus or faecal matter", "PROBLEM", 250, 283], ["the toilet", "TREATMENT", 305, 315]]], ["In contrast, less than half of the participants washed their hands after coughing or sneezing (48.4%), after touching public installations or equipment (16.8%), and before touching their eyes, nose, and mouth (12.1%) (Figure 1 ).Handwashing Survey.Using an independent t-test and an analysis of variance (ANOVA) to compare the demographic data with handwashing instances, the results showed that the mean handwashing instances of participants with third-level education or above were significantly higher than those of participants who had primary-and secondary-level education only (p \u2264 0.001).Sources of Handwashing Information.Among the 190 participants, 84 (44.2%) received proper hand-hygiene information.", [["eyes", "ANATOMY", 187, 191], ["nose", "ANATOMY", 193, 197], ["mouth", "ANATOMY", 203, 208], ["hand", "ANATOMY", 685, 689], ["coughing", "DISEASE", 73, 81], ["sneezing", "DISEASE", 85, 93], ["participants", "ORGANISM", 35, 47], ["eyes", "ORGAN", 187, 191], ["nose", "ORGANISM_SUBDIVISION", 193, 197], ["mouth", "ORGANISM_SUBDIVISION", 203, 208], ["participants", "SPECIES", 35, 47], ["participants", "SPECIES", 430, 442], ["participants", "SPECIES", 519, 531], ["participants", "SPECIES", 644, 656], ["coughing", "PROBLEM", 73, 81], ["sneezing", "PROBLEM", 85, 93], ["an independent t-test", "TEST", 254, 275], ["an analysis", "TEST", 280, 291], ["the demographic data", "TEST", 323, 343], ["third-level education", "TREATMENT", 448, 469], ["eyes", "ANATOMY", 187, 191], ["nose", "ANATOMY", 193, 197], ["mouth", "ANATOMY", 203, 208]]], ["Given that this was an open-ended question, participants could list more than one resource. us, 106 resources were reported.", [["participants", "SPECIES", 44, 56]]], ["After grouping and categorising the resources, the result was revealed that the participants obtained information from the media (45%) and from schools (34%); relatively less information was obtained from hospitals (15%) and the workplace (12%).", [["participants", "SPECIES", 80, 92]]], ["Moreover, the instances of handwashing of those participants who received informed hand-hygiene information were significantly higher than those of participants who did not (p \u2264 0.001). us, the mean of the total missed areas was significantly higher in participants who did not receive information about proper hand hygiene than those who received it (p \ufffd 0.004).Duration of Handwashing.On average, the participants took 36.54 seconds (range \ufffd 10-120, SD \ufffd 18.57) to wash their hands. e majority of participants (86.8%) washed their hands for longer than 20 seconds, as advocated.Missed Areas.For each participant, a total of 86 anatomical areas were evaluated. e results showed that the fingertips (48.1%), medial area (30.5%), and back of the hand (28%) were the most commonly missed areas in terms of washing.", [["hand", "ANATOMY", 83, 87], ["hand", "ANATOMY", 311, 315], ["fingertips", "ANATOMY", 688, 698], ["medial area", "ANATOMY", 708, 719], ["back", "ANATOMY", 733, 737], ["hand", "ANATOMY", 745, 749], ["hand", "ORGANISM_SUBDIVISION", 311, 315], ["participants", "ORGANISM", 499, 511], ["fingertips", "ORGANISM_SUBDIVISION", 688, 698], ["hand", "ORGANISM_SUBDIVISION", 745, 749], ["participants", "SPECIES", 48, 60], ["participants", "SPECIES", 148, 160], ["participants", "SPECIES", 253, 265], ["participants", "SPECIES", 403, 415], ["participants", "SPECIES", 499, 511], ["participant", "SPECIES", 602, 613], ["the fingertips", "TEST", 684, 698], ["medial area", "TEST", 708, 719], ["hands", "ANATOMY", 478, 483], ["fingertips", "ANATOMY", 688, 698], ["medial", "OBSERVATION_MODIFIER", 708, 714], ["back", "ANATOMY", 733, 737], ["hand", "ANATOMY", 745, 749], ["washing", "OBSERVATION", 804, 811]]], ["Using an independent t-test and ANOVA to compare the differences between the demographic data and missed areas, we found that unemployed participants had significantly more missed areas than the other participants; the unemployed missed certain areas, including the back of the fingers (p \ufffd 0.014), palms (p \ufffd 0.007), back of the hand (p \ufffd 0.010), and medial areas (p \ufffd 0.003) ( Table 2 ).", [["fingers", "ANATOMY", 278, 285], ["palms", "ANATOMY", 299, 304], ["hand", "ANATOMY", 330, 334], ["medial areas", "ANATOMY", 352, 364], ["fingers", "ORGANISM_SUBDIVISION", 278, 285], ["palms", "ORGANISM_SUBDIVISION", 299, 304], ["hand", "ORGANISM_SUBDIVISION", 330, 334], ["participants", "SPECIES", 137, 149], ["participants", "SPECIES", 201, 213], ["an independent t-test", "TEST", 6, 27], ["the demographic data", "TEST", 73, 93], ["palms", "TEST", 299, 304], ["back", "ANATOMY", 266, 270], ["fingers", "ANATOMY", 278, 285], ["palms", "ANATOMY", 299, 304], ["back", "ANATOMY", 318, 322], ["hand", "ANATOMY", 330, 334], ["medial", "ANATOMY_MODIFIER", 352, 358]]], ["Fulltime university students also neglected the back of the fingers (p \ufffd 0.037).", [["fingers", "ORGANISM_SUBDIVISION", 60, 67], ["back", "ANATOMY", 48, 52], ["fingers", "ANATOMY", 60, 67]]], ["Blue-collar workers had significantly more missed areas, with the medial areas (p \ufffd 0.003) and the lateral areas (p \ufffd 0.005) of the hands being neglected.", [["medial areas", "ANATOMY", 66, 78], ["lateral areas", "ANATOMY", 99, 112], ["medial", "ANATOMY_MODIFIER", 66, 72], ["lateral", "ANATOMY_MODIFIER", 99, 106], ["hands", "ANATOMY", 132, 137]]], ["Moreover, the results showed that participants with thirdlevel education or above (M \ufffd 10.88, SD \ufffd 9.54) had significantly (p \ufffd 0.004) fewer total missed areas than those with primary-and secondary-level education only (M \ufffd 11.91, SD \ufffd 7.94).", [["participants", "SPECIES", 34, 46]]], ["Among the different age groups, the youngest age group performed significantly better than the older age groups over the front of the fingers (p \ufffd 0.038), the back of the fingers (p \ufffd 0.015), and the lateral side of the hand (p \ufffd 0.012 and 0.019).", [["fingers", "ANATOMY", 134, 141], ["fingers", "ANATOMY", 171, 178], ["hand", "ANATOMY", 220, 224], ["fingers", "ORGANISM_SUBDIVISION", 171, 178], ["hand", "ORGAN", 220, 224], ["fingers", "ANATOMY", 134, 141], ["back", "ANATOMY", 159, 163], ["fingers", "ANATOMY", 171, 178], ["lateral", "ANATOMY_MODIFIER", 200, 207], ["hand", "ANATOMY", 220, 224]]], ["In terms of the total missed areas, the youngest age group missed significantly fewer areas than the oldest (p \ufffd 0.046).Multiple Logistic Regression.Multiple logistic regression was used to examine the relationship between the demographic variables, total missed areas, and instances of handwashing. e results showed that age is the only significant predictor of the total missed areas. ose aged 30 and above tended to have 5 more missed areas than those aged 30 or below (p \ufffd 0.001, B \ufffd 4.933, 95% CI \ufffd 2.119-7.747).", [["Multiple Logistic Regression", "PROBLEM", 120, 148], ["Multiple logistic regression", "PROBLEM", 149, 177], ["B", "TEST", 484, 485], ["CI", "TEST", 499, 501], ["total", "OBSERVATION_MODIFIER", 16, 21], ["areas", "OBSERVATION_MODIFIER", 29, 34], ["significantly", "OBSERVATION_MODIFIER", 66, 79], ["fewer", "OBSERVATION_MODIFIER", 80, 85], ["areas", "OBSERVATION_MODIFIER", 86, 91], ["Logistic Regression", "OBSERVATION", 129, 148], ["significant", "OBSERVATION_MODIFIER", 338, 349], ["total", "OBSERVATION_MODIFIER", 367, 372]]], ["Considering the variables affecting the total number of instances of hand hygiene, the only significant predictor among the variables was the educational level of the participants. ose with only primary-and secondary-level education tended to have 1 more missed hand-hygiene instance than those whose educational levels were above the third level (p \ufffd 0.001, B \ufffd 1.003, 95% CI \ufffd 0.511-1.495).Research Implications.Although there is scant empirical evidence on the duration of handwashing for the general public, the key public health agencies around the world, such as CDC, NHS, Public Health Agency of Canada, and Global Handwashing Partnership, adopt the WHO's guideline for the healthcare providers as well as for the community use.", [["hand", "ANATOMY", 69, 73], ["hand", "ANATOMY", 262, 266], ["hand", "ORGANISM_SUBDIVISION", 69, 73], ["hand", "ORGANISM_SUBDIVISION", 262, 266], ["participants", "SPECIES", 167, 179], ["hand hygiene", "TREATMENT", 69, 81], ["educational levels", "TEST", 301, 319], ["CI", "TEST", 374, 376], ["scant", "OBSERVATION_MODIFIER", 432, 437]]], ["In our study, almost 90% of the participants completed their handwashing routine in 20 seconds or more. is contrasts with the studies conducted in the United States by Drankiewicz and Dundes, Shanks and Peteroy-Kelly, and Borchgrevink et al. [4] [5] [6] .Research Implications.In 2008, the WHO designed a handwashing leaflet, making reference to Taylor, who indicated that the fingertips, interdigital areas, thumbs, and wrists are the most commonly missed areas in handwashing [26] .", [["fingertips", "ANATOMY", 377, 387], ["interdigital areas", "ANATOMY", 389, 407], ["thumbs", "ANATOMY", 409, 415], ["wrists", "ANATOMY", 421, 427], ["participants", "ORGANISM", 32, 44], ["[4] [5] [6]", "SIMPLE_CHEMICAL", 242, 253], ["fingertips", "ORGANISM_SUBDIVISION", 377, 387], ["wrists", "ORGANISM_SUBDIVISION", 421, 427], ["participants", "SPECIES", 32, 44], ["our study", "TEST", 3, 12], ["the studies", "TEST", 122, 133], ["the fingertips, interdigital areas, thumbs, and wrists", "PROBLEM", 373, 427], ["fingertips", "ANATOMY", 377, 387], ["interdigital areas", "ANATOMY", 389, 407], ["thumbs", "ANATOMY", 409, 415], ["wrists", "ANATOMY", 421, 427]]], ["Pan et al. also found that the tips of the nails and the fingertips had the largest amount of residual florescent stains left after handwashing among healthcare workers in Taiwan [18] . e commonly missed areas among medical students in the study conducted by Vanyolos et al. was the first metacarpal, the proximal part of the palm (lateral), the distal phalanges, and the nail beds [12] .", [["nails", "ANATOMY", 43, 48], ["fingertips", "ANATOMY", 57, 67], ["metacarpal", "ANATOMY", 289, 299], ["palm", "ANATOMY", 326, 330], ["distal phalanges", "ANATOMY", 346, 362], ["nails", "PATHOLOGICAL_FORMATION", 43, 48], ["fingertips", "ORGANISM_SUBDIVISION", 57, 67], ["metacarpal", "MULTI-TISSUE_STRUCTURE", 289, 299], ["palm", "ORGANISM_SUBDIVISION", 326, 330], ["phalanges", "MULTI-TISSUE_STRUCTURE", 353, 362], ["residual florescent stains", "PROBLEM", 94, 120], ["the study", "TEST", 236, 245], ["tips", "OBSERVATION_MODIFIER", 31, 35], ["nails", "ANATOMY", 43, 48], ["fingertips", "ANATOMY", 57, 67], ["largest", "OBSERVATION_MODIFIER", 76, 83], ["amount", "OBSERVATION_MODIFIER", 84, 90], ["residual", "OBSERVATION_MODIFIER", 94, 102], ["florescent", "OBSERVATION", 103, 113], ["left", "ANATOMY_MODIFIER", 121, 125], ["first", "ANATOMY_MODIFIER", 283, 288], ["metacarpal", "ANATOMY", 289, 299], ["proximal", "ANATOMY_MODIFIER", 305, 313], ["palm", "ANATOMY", 326, 330], ["lateral", "ANATOMY_MODIFIER", 332, 339], ["distal", "ANATOMY_MODIFIER", 346, 352], ["phalanges", "ANATOMY", 353, 362], ["nail", "ANATOMY", 372, 376]]], ["In healthcare workers in\u0160kodov\u00e1 et al.'s study, the thumbs and fingertips were the most commonly missed areas [27, 28] .", [["fingertips", "ANATOMY", 63, 73], ["thumbs", "ORGANISM_SUBDIVISION", 52, 58], ["fingertips", "ORGANISM_SUBDIVISION", 63, 73], ["et al.'s study", "TEST", 32, 46], ["the thumbs and fingertips", "PROBLEM", 48, 73], ["thumbs", "ANATOMY", 52, 58], ["fingertips", "ANATOMY", 63, 73]]], ["In this study, the most frequently missed area was also the fingertips.", [["fingertips", "ANATOMY", 60, 70], ["fingertips", "ORGANISM_SUBDIVISION", 60, 70], ["this study", "TEST", 3, 13], ["fingertips", "ANATOMY", 60, 70]]], ["However, the medial aspect and back of the hand were the second and third most missed areas, respectively.", [["medial aspect", "ANATOMY", 13, 26], ["back", "ANATOMY", 31, 35], ["hand", "ANATOMY", 43, 47], ["medial aspect", "MULTI-TISSUE_STRUCTURE", 13, 26], ["hand", "ORGANISM_SUBDIVISION", 43, 47], ["medial", "OBSERVATION_MODIFIER", 13, 19], ["back", "ANATOMY_MODIFIER", 31, 35], ["hand", "ANATOMY", 43, 47], ["second", "OBSERVATION_MODIFIER", 57, 63], ["third", "ANATOMY_MODIFIER", 68, 73]]], ["Moreover, the interdigital area and the front and back of the fingers were the [2, 3, 6, [11] [12] [13] [14] 30] .Research Implications.In this study, we found that participants with higher educational levels had fewer missed areas, and they performed handwashing on a more regular basis; this is in contrast to the findings of Duggan et al. [15] .", [["interdigital area", "ANATOMY", 14, 31], ["[2, 3, 6, [11] [12] [13] [14] 30", "SIMPLE_CHEMICAL", 79, 111], ["participants", "SPECIES", 165, 177], ["the interdigital area", "TEST", 10, 31], ["this study", "TEST", 139, 149], ["interdigital", "OBSERVATION_MODIFIER", 14, 26], ["area", "OBSERVATION_MODIFIER", 27, 31], ["front", "ANATOMY_MODIFIER", 40, 45], ["back", "ANATOMY_MODIFIER", 50, 54], ["fingers", "ANATOMY", 62, 69]]], ["However, Curtis et al. in Kenya found that participants who had higher levels of education and literacy had a greater frequency of handwashing [9] . eir study also revealed that media exposure is an important determinant of the frequency of handwashing.", [["participants", "SPECIES", 43, 55], ["eir study", "TEST", 149, 158]]], ["In Korea, Park et al. reported that participants who received information about handwashing did wash their hands on a more frequent basis; this finding is in concordance with the finding presented in this study [6] .", [["participants", "SPECIES", 36, 48], ["this study", "TEST", 200, 210]]], ["Furthermore, Curtis et al. also reported that \"after defecation,\" \"before feeding a child,\" and \"before handling food\" were the most common situations in which participants washed their hands [9] .", [["participants", "SPECIES", 160, 172], ["defecation", "PROBLEM", 53, 63]]], ["Similar results were also found by Blanton et al. amongst caregivers in Kenyan schools [10] .Research Implications.is was also the case with Ergin et al. in relation to Turkish university students [7] . is study elicited the same results: \"after handling vomitus or faecal matter,\" \"before and after caring for the sick,\" and \"before eating or handling food\" are common situations in which Hong Kong people wash their hands.Research Implications.In relation to the association between age and handhygiene practices, we found that as age increases, handwashing becomes more neglected.", [["faecal matter", "ANATOMY", 266, 279], ["faecal", "ORGANISM_SUBDIVISION", 266, 272], ["people", "ORGANISM", 400, 406], ["hands", "ORGANISM_SUBDIVISION", 418, 423], ["people", "SPECIES", 400, 406], ["handling vomitus", "PROBLEM", 246, 262]]], ["However, Burnett highlighted that participants aged 55 years and older had good perceptions of hand hygiene, while the age group with the poorest perceptions was those under 26 years of age.", [["hand", "ANATOMY", 95, 99], ["participants", "ORGANISM", 34, 46], ["hand", "ORGANISM_SUBDIVISION", 95, 99], ["participants", "SPECIES", 34, 46]]], ["[16] e results of this study may be explained by the intense focus on hand-hygiene education in primary and/or secondary schools after the SARS attack in 2003 but relatively less in the community.Research Limitations.is study did have its limitations.", [["hand", "ANATOMY", 70, 74], ["SARS", "DISEASE", 139, 143], ["hand", "ORGANISM_SUBDIVISION", 70, 74], ["this study", "TEST", 18, 28], ["the SARS attack", "PROBLEM", 135, 150]]], ["One of these limitations is the potential unease felt by the participants that evolved by asking for ad hoc handwashing at the venue. erefore, the researcher did stand far behind the participants, and the participants were not informed that the time spent washing their hands was being recorded.", [["participants", "SPECIES", 61, 73], ["participants", "SPECIES", 183, 195], ["participants", "SPECIES", 205, 217]]], ["Given the researcher stayed far behind the participants, their compliance with the steps of handwashing could not be evaluated.", [["participants", "SPECIES", 43, 55]]], ["Besides, although the self-report survey is the fastest way to gather abundant data, this method cannot avoid social-desirability bias in which the participants wanted to \"be good,\" even though the survey is anonymous.", [["participants", "SPECIES", 148, 160]]], ["Furthermore, since most people had barbeque at sunny weekends only, suitable weather and period were quite short which limited the sample size.Conclusione results provide insights that will be useful for public health and primary-care professionals when reviewing health-promotion strategies for proper hand hygiene.", [["hand", "ANATOMY", 303, 307], ["people", "ORGANISM", 24, 30], ["hand", "ORGANISM_SUBDIVISION", 303, 307], ["people", "SPECIES", 24, 30], ["size", "OBSERVATION_MODIFIER", 138, 142]]], ["Although the sample size of this study was not large, this study and Pan et al.'s Taiwanese study found that the fingertips are the most commonly neglected areas [18] .", [["fingertips", "ANATOMY", 113, 123], ["fingertips", "ORGANISM_SUBDIVISION", 113, 123], ["this study", "TEST", 28, 38], ["this study", "TEST", 54, 64], ["Pan et al.'s Taiwanese study", "TEST", 69, 97], ["the fingertips", "PROBLEM", 109, 123], ["size", "OBSERVATION_MODIFIER", 20, 24], ["large", "OBSERVATION_MODIFIER", 47, 52], ["fingertips", "ANATOMY", 113, 123]]], ["Given that Taiwan and Hong Kong are located in the same region, it is worth investigating if similar results are found in other Asian countries. us, the reinforcement of fingertip washing is necessary for future handwashing practices.", [["fingertip", "ANATOMY", 170, 179], ["fingertip washing", "TREATMENT", 170, 187], ["handwashing practices", "TREATMENT", 212, 233]]], ["In addition, hand-hygiene education in schools seems to be quite effective; however, hand-hygiene education within the community seems inadequate, particularly for older adults and less well-educated groups.ConclusionAccording to the World Bank in 2018, the population density of Hong Kong increased from 6,587 people per square kilometre in 2007 to 7,040 in 2017, and it ranks as the fourth highest one in the world.", [["hand", "ANATOMY", 13, 17], ["hand", "ANATOMY", 85, 89], ["hand", "ORGANISM_SUBDIVISION", 85, 89], ["people", "SPECIES", 311, 317], ["hand", "ANATOMY", 13, 17]]], ["People live more closely together than before, and population will increase in the future.", [["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6]]], ["Since the outbreak of seasonal influenza and handfoot-mouth disease has been attacking Hong Kong frequently in recent years, the high population density of Hong Kong may exacerbate the risk of contracting communicable diseases through common contact surfaces such as door knobs, elevator buttons, handrails of escalators, and public transport.", [["influenza", "DISEASE", 31, 40], ["handfoot-mouth disease", "DISEASE", 45, 67], ["communicable diseases", "DISEASE", 205, 226], ["mouth", "ORGAN", 54, 59], ["seasonal influenza and handfoot", "PROBLEM", 22, 53], ["mouth disease", "PROBLEM", 54, 67], ["contracting communicable diseases", "PROBLEM", 193, 226], ["escalators", "TREATMENT", 310, 320], ["seasonal", "OBSERVATION_MODIFIER", 22, 30], ["influenza", "OBSERVATION", 31, 40], ["mouth", "ANATOMY", 54, 59], ["disease", "OBSERVATION", 60, 67]]], ["In addition to the effects of globalisation, other developed countries or cities with high population density may also be facing similar challenges. erefore, the public health and primary-care professionals may consider reviewing the protocol for proper hand hygiene and strategy of education and promotion and examine its effectiveness.Data AvailabilityAll the quantitative data used to support the findings of this study are available from the corresponding author upon request.Conflicts of Intereste authors declare that there are no conflicts of interest with respect to the research, authorship, and publication of this article.", [["hand", "ANATOMY", 254, 258], ["hand", "ORGANISM_SUBDIVISION", 254, 258], ["high population density", "PROBLEM", 86, 109], ["the protocol", "TREATMENT", 230, 242], ["proper hand hygiene", "TREATMENT", 247, 266], ["strategy of education", "TREATMENT", 271, 292], ["this study", "TEST", 412, 422], ["no", "UNCERTAINTY", 534, 536]]]], "3a4e09a68894826fba732719f8ff6f0cbc63b8a4": [["To the Editor,Recently, young COVID-19 patients have presented with erythematous and purpuric acral lesions similar to chilblains [1] [2] [3] .", [["purpuric acral lesions", "ANATOMY", 85, 107], ["chilblains", "CHEMICAL", 119, 129], ["patients", "ORGANISM", 39, 47], ["acral lesions", "PATHOLOGICAL_FORMATION", 94, 107], ["chilblains [1] [2] [3]", "SIMPLE_CHEMICAL", 119, 141], ["patients", "SPECIES", 39, 47], ["erythematous and purpuric acral lesions", "PROBLEM", 68, 107], ["chilblains", "TEST", 119, 129], ["erythematous", "OBSERVATION_MODIFIER", 68, 80], ["purpuric", "OBSERVATION_MODIFIER", 85, 93], ["acral", "ANATOMY", 94, 99], ["lesions", "OBSERVATION", 100, 107]]], ["Despite the scarcity of published cases, this topic has attracted significant mass media attention.", [["significant mass media attention", "PROBLEM", 66, 98], ["significant", "OBSERVATION_MODIFIER", 66, 77], ["mass", "OBSERVATION", 78, 82]]], ["4 Dermatologists have noted that more people than would be expected at this time of year are seeking medical attention for these chilblain-like lesions.", [["chilblain-like lesions", "ANATOMY", 129, 151], ["people", "ORGANISM", 38, 44], ["chilblain-like lesions", "CANCER", 129, 151], ["people", "SPECIES", 38, 44], ["these chilblain-like lesions", "PROBLEM", 123, 151], ["lesions", "OBSERVATION", 144, 151]]], ["Some have suggested that people presenting with this manifestation should be tested and isolated 2 .", [["people", "ORGANISM", 25, 31], ["people", "SPECIES", 25, 31]]], ["Determining the accuracy of this association is therefore crucial.To the Editor,To establish the real prevalence of COVID-19 in patients with acral skin lesions, we firstly evaluated all the cases of acral lesions presented in dermatology and paediatrics departments and family doctors' offices in an eastern Spanish region over a three-week period.", [["acral skin lesions", "ANATOMY", 142, 160], ["acral lesions", "ANATOMY", 200, 213], ["acral skin lesions", "DISEASE", 142, 160], ["acral lesions", "DISEASE", 200, 213], ["patients", "ORGANISM", 128, 136], ["acral skin lesions", "CANCER", 142, 160], ["acral lesions", "CANCER", 200, 213], ["patients", "SPECIES", 128, 136], ["COVID", "TEST", 116, 121], ["acral skin lesions", "PROBLEM", 142, 160], ["acral lesions", "PROBLEM", 200, 213], ["acral", "ANATOMY", 142, 147], ["skin", "ANATOMY", 148, 152], ["lesions", "OBSERVATION", 153, 160], ["acral", "ANATOMY", 200, 205], ["lesions", "OBSERVATION", 206, 213]]], ["Then we prospectively performed a SARS-CoV-2 PCR on nasopharyngeal aspirates taken from all available patients to determine whether their cutaneous manifestations were predictive of a positive result.To the Editor,To put our findings into context, we reviewed all the articles published before May 2020 concerning COVID-19 patients with cutaneous lesions.To the Editor,We evaluated 58 patients, whose characteristics are summarized in Table 1 .", [["nasopharyngeal aspirates", "ANATOMY", 52, 76], ["cutaneous", "ANATOMY", 138, 147], ["cutaneous lesions", "ANATOMY", 337, 354], ["cutaneous lesions", "DISEASE", 337, 354], ["nasopharyngeal aspirates", "MULTI-TISSUE_STRUCTURE", 52, 76], ["patients", "ORGANISM", 102, 110], ["patients", "ORGANISM", 323, 331], ["cutaneous lesions", "PATHOLOGICAL_FORMATION", 337, 354], ["patients", "ORGANISM", 385, 393], ["patients", "SPECIES", 102, 110], ["patients", "SPECIES", 323, 331], ["patients", "SPECIES", 385, 393], ["a SARS", "TEST", 32, 38], ["CoV-2 PCR", "TEST", 39, 48], ["nasopharyngeal aspirates", "TEST", 52, 76], ["their cutaneous manifestations", "PROBLEM", 132, 162], ["a positive result", "PROBLEM", 182, 199], ["cutaneous lesions", "PROBLEM", 337, 354], ["nasopharyngeal", "ANATOMY", 52, 66], ["aspirates", "OBSERVATION", 67, 76], ["cutaneous", "ANATOMY", 337, 346], ["lesions", "OBSERVATION", 347, 354]]], ["In most cases, lesions were chilblain-like.", [["lesions", "ANATOMY", 15, 22], ["lesions", "PATHOLOGICAL_FORMATION", 15, 22], ["lesions", "PROBLEM", 15, 22], ["lesions", "OBSERVATION", 15, 22]]], ["Fifteen patients had already been tested, and only one had a positive result: an 85-year-old man admitted for severe Covid-19 pneumonia.", [["pneumonia", "DISEASE", 126, 135], ["patients", "ORGANISM", 8, 16], ["man", "ORGANISM", 93, 96], ["patients", "SPECIES", 8, 16], ["man", "SPECIES", 93, 96], ["severe Covid-19 pneumonia", "PROBLEM", 110, 135], ["pneumonia", "OBSERVATION", 126, 135]]], ["He had an ulcer on a toe that was finally determined to be vascular in nature.To the Editor,We performed prospective PCR testing in 24 patients.", [["ulcer", "ANATOMY", 10, 15], ["toe", "ANATOMY", 21, 24], ["vascular", "ANATOMY", 59, 67], ["ulcer", "DISEASE", 10, 15], ["He", "ORGANISM", 0, 2], ["ulcer", "PATHOLOGICAL_FORMATION", 10, 15], ["toe", "ORGANISM_SUBDIVISION", 21, 24], ["vascular", "MULTI-TISSUE_STRUCTURE", 59, 67], ["patients", "ORGANISM", 135, 143], ["patients", "SPECIES", 135, 143], ["an ulcer on a toe", "PROBLEM", 7, 24], ["prospective PCR testing", "TEST", 105, 128], ["ulcer", "OBSERVATION", 10, 15], ["toe", "ANATOMY", 21, 24], ["vascular", "ANATOMY", 59, 67]]], ["All test results were negative.", [["All test results", "TEST", 0, 16], ["negative", "OBSERVATION", 22, 30]]], ["In total, then, PCR was negative in 38 patients and positive in a single patient whose lesion was very unlikely to be due to COVID-19.To the Editor,Our bibliography search returned 97 articles and we found 2 more through cross-references.", [["lesion", "ANATOMY", 87, 93], ["patients", "ORGANISM", 39, 47], ["patient", "ORGANISM", 73, 80], ["lesion", "CANCER", 87, 93], ["COVID-19", "DNA", 125, 133], ["patients", "SPECIES", 39, 47], ["patient", "SPECIES", 73, 80], ["PCR", "TEST", 16, 19], ["a single patient whose lesion", "PROBLEM", 64, 93], ["COVID", "TEST", 125, 130], ["Our bibliography search", "TEST", 148, 171], ["lesion", "OBSERVATION", 87, 93]]], ["Nine of these articles dealt with acral lesions specifically.", [["acral lesions", "ANATOMY", 34, 47], ["acral lesions", "CANCER", 34, 47], ["acral lesions", "PROBLEM", 34, 47], ["acral", "ANATOMY", 34, 39], ["lesions", "OBSERVATION", 40, 47]]], ["Their results are summarized in Table 2 .To the Editor,Data published in the literature are heterogeneous, as are the methods employed to collect them.", [["heterogeneous", "OBSERVATION", 92, 105]]], ["The first papers looked at cutaneous manifestations in patients with confirmed SARS-CoV-2 infection.", [["cutaneous", "ANATOMY", 27, 36], ["SARS-CoV-2 infection", "DISEASE", 79, 99], ["cutaneous", "ORGANISM_SUBDIVISION", 27, 36], ["patients", "ORGANISM", 55, 63], ["CoV-2", "ORGANISM", 84, 89], ["patients", "SPECIES", 55, 63], ["SARS-CoV-2", "SPECIES", 79, 89], ["SARS", "PROBLEM", 79, 83], ["CoV-2 infection", "PROBLEM", 84, 99], ["cutaneous", "ANATOMY", 27, 36], ["infection", "OBSERVATION", 90, 99]]], ["All rights reserved approach cannot reveal whether this dermatologic manifestation is a specific marker of SARS-CoV-2 infection, since patients without COVID-19 are not included.", [["SARS-CoV-2 infection", "DISEASE", 107, 127], ["SARS-CoV-2", "ORGANISM", 107, 117], ["patients", "ORGANISM", 135, 143], ["patients", "SPECIES", 135, 143], ["SARS-CoV", "SPECIES", 107, 115], ["this dermatologic manifestation", "PROBLEM", 51, 82], ["SARS", "PROBLEM", 107, 111], ["CoV", "PROBLEM", 112, 115], ["2 infection", "PROBLEM", 116, 127], ["COVID", "TEST", 152, 157], ["infection", "OBSERVATION", 118, 127]]], ["The other approach, which we have followed, is to analyse all patients with acral lesions.", [["acral lesions", "ANATOMY", 76, 89], ["patients", "ORGANISM", 62, 70], ["acral lesions", "CANCER", 76, 89], ["patients", "SPECIES", 62, 70], ["acral lesions", "PROBLEM", 76, 89], ["acral", "ANATOMY", 76, 81], ["lesions", "OBSERVATION", 82, 89]]], ["This can be done retrospectively, reporting on patients in the sample who have already been tested, or prospectively, performing the test on all available patients, regardless of whether they have symptoms.", [["patients", "ORGANISM", 47, 55], ["patients", "ORGANISM", 155, 163], ["patients", "SPECIES", 47, 55], ["patients", "SPECIES", 155, 163], ["the test", "TEST", 129, 137], ["symptoms", "PROBLEM", 197, 205]]], ["The retrospective method has a significant risk of confounding bias: due to the scarcity of COVID-19 tests 8 , they are usually reserved for patients with COVID-19-related symptoms, who are obviously more likely to test positive.Accepted ArticleAll previous studies including only patients with cutaneous acral lesions (summarized in table 2) have been retrospective, and only a minority of patients were tested.", [["cutaneous acral lesions", "ANATOMY", 295, 318], ["patients", "ORGANISM", 141, 149], ["patients", "ORGANISM", 281, 289], ["cutaneous acral lesions", "PATHOLOGICAL_FORMATION", 295, 318], ["patients", "ORGANISM", 391, 399], ["patients", "SPECIES", 141, 149], ["patients", "SPECIES", 281, 289], ["patients", "SPECIES", 391, 399], ["confounding bias", "PROBLEM", 51, 67], ["COVID", "TEST", 92, 97], ["COVID", "TEST", 155, 160], ["related symptoms", "PROBLEM", 164, 180], ["ArticleAll previous studies", "TEST", 238, 265], ["cutaneous acral lesions", "PROBLEM", 295, 318], ["cutaneous acral", "ANATOMY", 295, 310], ["lesions", "OBSERVATION", 311, 318]]], ["In total, 12 out of at least 49 tested patients were positive (24.5%).", [["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47]]], ["Combined with our results, they total 13 positives out of 88 tests (14.8%).", [["tests", "TEST", 61, 66]]], ["Our study suggests that acral skin lesions are not a specific marker of SARS-CoV-2 infection.", [["acral skin lesions", "ANATOMY", 24, 42], ["SARS-CoV-2 infection", "DISEASE", 72, 92], ["acral skin lesions", "CANCER", 24, 42], ["SARS-CoV-2", "ORGANISM", 72, 82], ["SARS-CoV", "SPECIES", 72, 80], ["Our study", "TEST", 0, 9], ["acral skin lesions", "PROBLEM", 24, 42], ["SARS", "PROBLEM", 72, 76], ["CoV-2 infection", "PROBLEM", 77, 92], ["acral", "OBSERVATION_MODIFIER", 24, 29], ["skin", "ANATOMY", 30, 34], ["lesions", "OBSERVATION", 35, 42], ["SARS", "OBSERVATION", 72, 76], ["infection", "OBSERVATION", 83, 92]]], ["Although larger prospective studies are needed, current evidence indicates that acral skin lesions should not be regarded as a sign of COVID-19 in otherwise asymptomatic patients.Accepted ArticleThis article is protected by copyright.", [["acral skin lesions", "ANATOMY", 80, 98], ["skin lesions", "DISEASE", 86, 98], ["acral skin lesions", "CANCER", 80, 98], ["patients", "ORGANISM", 170, 178], ["patients", "SPECIES", 170, 178], ["larger prospective studies", "TEST", 9, 35], ["acral skin lesions", "PROBLEM", 80, 98], ["COVID", "TEST", 135, 140], ["larger", "OBSERVATION_MODIFIER", 9, 15], ["acral", "OBSERVATION_MODIFIER", 80, 85], ["skin", "ANATOMY", 86, 90], ["lesions", "OBSERVATION", 91, 98]]]]}